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The Amphetamine Years is a history of psychostimulant drugs and their clinical 
applications in post-World War II American medicine. Comprising such well-known 
substances as the amphetamines (Benzedrine, Dexedrine), methylphenidate (Ritalin), and 
phenmetrazine (Preludin), this class of pharmaceuticals has been among the most widely 
consumed in the past half-century. Their therapeutic uses for a variety of indications such 
as depression, obesity, and attention-deficit/hyperactivity disorder (ADHD) in children, 
not to mention their relevance for a number of different medical specialties, reveals that 
psychostimulants have occupied an important, if underappreciated role in the practice of 
modern medicine. In this dissertation, I illuminate the various ways in which physicians, 
particularly psychiatrists, put these drugs to work in clinical practice. In short, I contend 
that physicians exploited the wide range of physiological and psychological effects of 
psychostimulants and made a place for them in different therapeutic settings, even ones 
characterized by competing views and theories about the workings of the human body 
and mind. 
My dissertation is distinguished by two prominent themes. First, I emphasize the 
clinician perspective as a vehicle for understanding the history of the psychostimulants, 
as well as related developments in psychiatry, pharmacotherapy, and the political 
economy of drugs, in the second half of the twentieth century. Scholars such Nicolas 
Rasmussen, David Courtwright, and Ilina Singh have elucidated the history of 
psychostimulants by emphasizing how pharmaceutical companies positioned their 





approach by studying clinicians, themselves, to further historical comprehension of the 
place of these pharmaceuticals within postwar medicine, society, and culture. Second, I 
advance the concept of “therapeutic versatility” to explain their historical trajectories. 
The complex set of psychological and physical effects these drugs produced made them 
ideal for a diverse range of therapeutic applications, which explains why they were 
embraced by many different medical specialties, why they were marketed by 
manufacturers for a variety of indications, and why they have enjoyed an enduring 
therapeutic lifespan, in spite of increasing efforts since the mid-1960s to regulate their 
availability and control their consumption. In addition to these two overarching themes, I 
advance five specific arguments in my dissertation. First, I contend that pharmaceutical 
markets were simultaneously created by the drug industry and clinicians. Pharmaceutical 
firms’ efforts to develop markets for their products have been well documented by 
historians, but in my dissertation, I underscore the role also played by clinicians in 
discerning drugs’ applications. Second, I argue that twentieth-century psychiatry’s 
conception of illness and therapeutics may not be served best by strictly dividing its 
history along lines of institutional and outpatient treatment. Third, I demonstrate how the 
use of psychostimulants by analytically oriented psychiatrists during the 1950s 
complicates historical notions of paradigm shift from a psychodynamic to biological 
orientation.  Psychotherapy and psychopharmacology were not competing paradigms; in 
practice, doctors often employed both. Fourth, I assert that an appreciation of 
psychiatrists’ empirical and eclectic approaches to the use of drugs is necessary to 
comprehend the rise of psychiatric pharmacotherapy in the postwar era. Finally, I contend 





psychostimulants and their extramedical consumption, it is necessary to conceive of a 
plurality of distinct “amphetamine cultures,” each characterized by a unique set of 
relationships between physician-prescribers, patient-consumers, pharmaceutical firms, 








 The Amphetamine Years is a history of psychostimulant drugs and their clinical 
applications in post-World War II American medicine. Comprising such well-known 
substances as the amphetamines (Benzedrine, Dexedrine), methylphenidate (Ritalin), and 
phenmetrazine (Preludin), this class of pharmaceuticals has been among the most widely 
consumed in the past half-century. Their therapeutic uses for a variety of indications, 
including depression, obesity, and attention-deficit/hyperactivity disorder (ADHD) in 
children, not to mention their relevance for a number of different medical specialties, 
reveals that psychostimulants have occupied an important, if underappreciated role in the 
practice of modern medicine. In this dissertation, I illuminate the myriad ways in which 
physicians, particularly psychiatrists, put these drugs to work in clinical practice. 
Clinicians exploited their wide array of effects and made a place for them in different 
therapeutic settings, even ones characterized by competing views and theories about the 
workings of the human body and mind.  
At the same time, I examine medicine’s relationship with the extramedical 
consumption and regulation of these drugs. The psychostimulants’ concomitant 
identification as drugs of abuse, as well as their association with “speed freaks,” dieting 
housewives, and doping athletes, suggests the ways in which American society has 
contended balancing the therapeutic benefits of drugs and their potential for harm. 
Proving that medical authority often speaks with more than one voice, clinicians played 





pharmaceuticals. In doing so, they grappled with establishing the hazards of stimulant 
consumption. Medical leaders also demonstrated concern about the role of 
pharmaceutical firms that relentlessly sought to expand markets for their products, as 
well as the federal government’s growing interest in regulating both industry and 
physician practices. In addition to my overriding interest in understanding how clinicians 
employed psychostimulants as therapeutic options, I endeavor to illuminate, if only 
dimly, one of the most complex issues of the last fifty years: the evolving relationship 
between pharmaceutical companies that produce drugs, the physicians who prescribe 
them, the patients who consume them, and the policymakers charged with regulating 
these practices. 
 Writing about the history of pharmaceuticals demands that we consider 
manufacturers, prescribers, consumers, and regulators. Scholars such as Nicolas 
Rasmussen, David Courtwright, and Ilina Singh have advanced historical comprehension 
of stimulants by emphasizing how pharmaceutical companies positioned their products in 
the medical marketplace.1 My dissertation takes a different, yet complementary approach 
by studying the clinicians themselves. In particular, I utilize the lens of physician 
experience and what I term “therapeutic versatility” to explain psychostimulants’ 
contribution to postwar medicine, society, and culture. Put another way, the complex set 
of psychological and physiological effects these drugs produced in their users rendered 
them ideal for a diverse range of applications. Their versatility explains why they were 
                                                
1 Nicolas Rasmussen, On Speed: The Many Lives of Amphetamine (New York: New York 
University Press, 2008); David Courtwright, Forces of Habit: Drugs and the Making of the Modern World 
(Cambridge, MA: Harvard University Press, 2001); Ilina Singh, “Bad Boys, Good Mothers, and the 
‘Miracle’ of Ritalin,” Science in Context 15, no. 4 (December 2002): 577-603; and Ilina Singh, “Not Just 
Naughty: 50 Years of Stimulant Advertising,” in Medicating Modern America: Prescription Drugs in 






embraced by many different medical specialties, why they were marketed by 
manufacturers for a variety of indications, and why they have enjoyed an enduring 
therapeutic lifespan, in spite of increasing efforts to regulate their availability and control 
their consumption.2 At the same time, I blur the boundaries that have characterized 
histories dealing with the therapeutic and illicit uses of these drugs. I do this by exploring 
the existence of distinct “amphetamine cultures” to provide a more nuanced 
understanding of the links between medical and extramedical consumption, as well as to 
explain the direction that efforts to deal with the latter took in the formulation of controls 
by policymakers during the 1970s.  
A Psychostimulant Primer 
Psychostimulants are a class of synthetic drugs that increase the activity of the 
central nervous system (CNS) and produce a wide array of physiological effects, of 
which, increased wakefulness and energy are the best known. Caffeine is a well-
recognized CNS stimulant found naturally in coffee, tea, cocoa, kola nuts, and other 
plants. Its effectiveness in combating drowsiness and enhancing alertness makes it the 
world’s most widely consumed psychoactive substance, with up to 90 percent of adults 
ingesting it daily in North America.3 While psychostimulants have some effects in 
                                                
2 For one discussion on the idea that pharmaceuticals have “lifespans,” see Sjaak van der Geest, 
Susan Reynolds Whyte, and Anita Hardon, “The Anthropology of Pharmaceuticals: A Biographical 
Approach,” Annual Review of Anthropology 25, no. 1 (October 1996): 153-178. The authors contend that 
pharmaceuticals have distinct phases, such as production, marketing, and prescription, which are 
comparable to the stages of life of organisms. Each phase, they contend, is characterized by different sets of 
agents, values, and ideas and should be also understood within its distinctive cultural and social context. 
 
3 For historical considerations on caffeine as a drug, see Brian Cowan, The Social Life of Coffee: 
The Emergence of the British Coffeehouse (New Haven, CT: Yale University Press, 2005); Mark 
Pendergrast, Uncommon Grounds: The History of Coffee and How It Transformed Our World (New York: 
Basic Books, 1999); and Bennett Alan Weinberg and Bonnie K. Bealer, The World of Caffeine: The 





common with caffeine, they are distinguished by greater potency, more complex effects 
on the body, and their synthetic rather than natural production.4  
 The best known psychostimulant is amphetamine, which refers to both a distinct 
compound and a class from which similar drugs have been derived. Amphetamines are 
chemically based on phenethylamine, a substance common in such foods as cheese, 
chocolate, and wine as a product of the microbial fermentation that results in their 
creation (see Figure 1.1). When consumed by eaters of these foods, the phenethylamine is 
usually passed through and removed from the body via the liver, where it and other 
dietary amines are degraded by the enzyme monoamine oxidase (MAO). Put simply, 
amphetamine is a synthetic derivative of phenethylamine whose only difference is a 
methyl group (-CH3) attached to the side chain.5 This single molecule makes a 
tremendous difference, however, because it prevents the MAO found in the liver from 
breaking down the phenethylamine. It is then able to enter the bloodstream and exert a 
variety of physiological effects upon the body and mind.6 
 
                                                
4 The similarity of amphetamine to caffeine provides a convenient reference for American and 
European readers, but an even better point of comparison to amphetamine is the drug khat (or qat). This 
plant, which is native to East Africa and the Arabian Peninsula, contains the amphetamine-like compound 
cathinone. Chewing its leaves provides users with sensations of euphoria and excitement, as well as a loss 
of appetite, that more closely mirrors the amphetamine experience. For more on the history of khat, see 
Courtwright, Forces of Habit, 55; John G. Kennedy, James Teague, and Lynn Fairbanks, “Qat Use in North 
Yemen and the Problem of Addiction: A Study in Medical Anthropology,” Culture, Medicine, and 
Psychiatry 4, no. 4 (December 1980): 311-344; and Ezekiel Gebissa, Leaf of Allah: Khat and Agricultural 
Transformation in Harerge, Ethiopia, 1875-1991 (Athens: Ohio University Press, 2004).  
 
5 The name “amphetamine” is actually a shortened version of the drug’s full chemical name, 
alpha-methylphenylethylamine. The name refers to the fact that the methyl group is attached to the alpha 
carbon on phenethylamine’s side chain. Amphetamine is alternately known by the chemical name beta-
phenyl-isopropylamine. 
 
6 My discussion of the chemical nature of the psychostimulants and their physiological effects is 
particularly indebted to Leslie Iversen, Speed, Ecstasy, Ritalin: The Science of Amphetamines (Oxford: 






Figure 1.1 – The basic molecular structure of phenethylamine and amphetamine, 
suggesting the similarities between the two. Note the methyl group on side chain of 




 The methyl group crucial to the formation of amphetamine can be attached to the 
side chain in both a left- or right-handed manner, resulting in two mirror image forms of 
amphetamine, or stereoisomers. When the mixture of left-handed and right-handed 
molecules is equal, then the form of amphetamine is a racemic mixture. This particular 
version is known as dl-amphetamine, which was the first form of amphetamine to be 
synthesized by British chemist Gordon Alles in 1929.7 The drug was subsequently 
introduced as Benzedrine by Smith, Kline & French (SKF) in 1933. Following this 
discovery, other isomers of amphetamine were soon isolated. The most important of these 
was the right-handed form, or dextro-isomer, which was more potent than the left-handed 
variant, or levo-isomer. Several years after the launch of Benzedrine, dextroamphetamine 
(or d-amphetamine) was first marketed by SKF as Dexedrine in 1937. Many other 
variants of this basic form are also possible. The addition of a second methyl chain to the 
nitrogen of the side chain results in the formation of methamphetamine, which is even 
more potent biologically than either Benzedrine or Dexedrine. Like the basic mixture of 
                                                
7 While Alles is given credit for initially discovering amphetamine’s effects on the body, as well 
as for patenting the drug, the Romanian chemist Lazăr Edeleanu synthesized it first in 1887. However, 
Edeleanu did not discern the medical applications of the drug, and it continues to be associated with Alles 





amphetamine (dl-amphetamine), methamphetamine also can be separated into two 
isomers, of which, the dextro-isomer (d-methamphetamine) is more powerful 
pharmacologically. An alteration to the benzene ring creates yet another variant, 
methylene-dioxy-methamphetamine (MDMA), better known by its street name “ecstasy” 
(see Figure 1.2). Using the basic chemical “scaffold” provided by the original 
phenethylamine molecule, an almost unlimited number of different compounds can be 
made. American chemists Alexander and Ann Shulgin were notable for their discovery of 
179 distinct phenethylamines that they synthesized and tested on themselves in order to 
document their psychotropic effects.8 
 
 
Figure 1.2 – The molecular structure of methamphetamine and MDMA.  
(Source: Author, redrawn from Iversen, Speed, Ecstasy, Ritalin, 6) 
 
 
 In addition to being a derivative of phenethylamine, amphetamine is chemically 
similar to a class of neurotransmitters known as catecholamines. These nervous system 
chemicals are synthesized primarily within the body from the amino acids phenylalanine 
(a molecular precursor of phenethylamine) and tyrosine. Amphetamine is closely related 
to two catecholamines in particular, dopamine and norepinephrine (see Figure 1.3). Best 
                                                
8 Alexander Shulgin and Ann Shulgin, PiHKAL: A Chemical Love Story (Berkeley, CA: 






known for its role as the brain’s “reward transmitter,” dopamine is one of the most 
studied chemicals in the body. Among its diverse functions within the brain, it plays an 
important role in regulating a person’s emotions and behavior. On the other hand, 
norepinephrine serves as both a hormone and neurotransmitter. It is responsible for 
activating the body’s “fight-or-flight” responses, such as increasing the heart rate, raising 
the blood pressure, and releasing glucose from energy stores. As neurotransmitters, 
dopamine and norepinephrine work by stimulating cellular receptors, which, in turn, are 
responsible for producing the physiological effects in question. 
 
 
Figure 1.3 – The molecular structure of dopamine and norepinephrine, compared to that 




Despite its similarity to dopamine, norepinephrine, and other neurotransmitters 
such as serotonin, amphetamine is unable to activate cellular receptors directly. Instead, 
the drug works by stimulating the release of natural neurotransmitters within the synaptic 
cleft, the gap between neurons (nerve cells) or neurons and other cells. The synaptic cleft 





commands between cells. Amphetamine works by boosting the amount of these 
chemicals within the synaptic cleft.9 For example, amphetamine’s increase of dopamine 
levels by inhibiting its reuptake partly explains the euphoria associated with the drug. 
Likewise, increased concentrations of dopamine caused by amphetamine have been 
linked to psychological dependency on the drug, due in part to dopamine’s association 
with the brain’s reinforcement of rewarding or pleasurable activities. Amphetamine’s 
increase of norepinephrine explains other physiological effects of the drug, such as 
increased pulse, faster breathing, and heightened energy. 
While numerous studies have established the various brain mechanisms involved 
in amphetamine responses, the effects of the drug on human mood and performance are 
quite complex. Alles immediately recognized the ability of amphetamine to alleviate 
fatigue and create a sense of confidence and euphoria. In scientific studies carried out 
after his discovery to discern the drug’s subjective effects, one report identified “a sense 
of well being [sic] and a feeling of exhilaration” and “lessened fatigue in reaction to 
work.”10 A 1938 study established how the drug increased a desire for work, made users 
believe it was easier to start or accomplish tasks, and enhanced general well-being, good 
humor, talkativeness, enthusiasm, and excitement, all with few adverse effects.11 These 
                                                
9 For an excellent visual depiction of amphetamine’s effect on boosting dopamine and 
norepinephrine levels within the synaptic cleft, see “The Mechanism of Action of Amphetamine (High 
Dose)” at [http://www.cnsforum.com/imagebank/item/Drug_amphet_high/default.aspx]. 
 
10 M. H. Nathanson, “The Central Action of Beta-aminopropylbenzene (Benzedrine): Clinical 
Observations,” Journal of the American Medical Association 108, no. 7 (February 13, 1937): 528-531. 
Among the phrases used by participants to describe the effects of amphetamine were “increased energy, felt 
as if I could not get to enough places fast enough”; “I have done things today I usually dislike but which I 
rather enjoyed doing today”; “the last hour and a half of work is usually an effort, today I felt fine”; “did 
not have my usual lethargic period after lunch”; “sense of well being, nothing seemed impossible of 
accomplishment”; “I wanted to stop and talk to everybody I met”; “I felt unusually friendly toward 
people”; “my spirits have been high all day, felt bubbling inside”; “I was able to organize my work quickly 






early reports discerned two key effects of amphetamine on users—a euphoric sensation 
and a concomitant ability to enhance work performance and increase cognitive ability. 
 While amphetamines are the best known of the psychostimulants, they are not the 
only ones. During the 1940s and 1950s, pharmaceutical companies discovered a variety 
of compounds with somewhat more complex chemical structures than the ones that 
comprised the early amphetamines. The best known of these was methylphenidate, 
synthesized in 1944 and introduced as Ritalin by Ciba in 1955.12 Like amphetamine, 
methylphenidate also exhibits several isometric forms, but it is the racemic version 
(again, an equal mixture of the dextro- and levo- forms) known as Ritalin.13 
 Ritalin was initially appreciated for its abilities to alleviate fatigue and stimulate 
mental and physical performance. Soon after its 1955 introduction, Ciba marketed the 
drug for chronic fatigue, lethargy, disturbed senile behavior, depression, and narcolepsy. 
As I discuss in this dissertation, many of these applications were eventually abandoned. 
Today, Ritalin is best known for its use in the management of ADHD in children and 
adolescents. It is still prescribed, though less commonly, as a treatment for narcolepsy. 
Methylphenidate bears a structural resemblance to amphetamine, particularly 
dextroamphetamine (see Figure 1.4). Like the amphetamines in general, it also functions 
as a dopamine and norepinephrine reuptake inhibitor. However, the drug is ten times less 
                                                                                                                                            
11 Poul Bahnsen, Erik Jacobsen, and Harriet Thesleff, “The Subjective Effects of Beta-
Phenylisopropylaminsulfate on Normal Adults,” Acta Medica Scandinavica 97 (1938), 89-131. 
 
12 Ciba, alternately rendered in all capital letters as CIBA, is an acronym for Chemische Industrie 
Basel (Chemical Industries Basel). However, use of the name as an acronym slowly began to disappear 
during the years of my study. Throughout this dissertation, I will use the form Ciba, which appears to have 
been in common use for much of the postwar era. See Chapter 2, note 39, for more on the early history of 
Ciba. 
 
13 As with amphetamine, the dextro-isomer of methylphenidate is the more potent of the two 
stereoisomers. During the early 2000s, Novartis (formerly Ciba-Geigy) introduced dextromethylphenidate 





potent than dextroamphetamine in terms of behavioral stimulation and its ability to 
promote catecholamine release in the brain. Nevertheless, this set of characteristics has 
given it therapeutic value for psychiatrists seeking a drug with qualities similar to 
amphetamine, but with somewhat less potency. As I note later, the positioning of 
methylphenidate’s effects between caffeine and amphetamine would serve as one of the 
drug’s major selling points. 
 
 
Figure 1.4 – Comparison of the molecular structure of methylphenidate and 
amphetamine. Note the similar chemical bonds (highlighted in bold) between the two 




Because they possess an ideal combination of water and fat solubility, 
psychostimulant drugs may be administered in a variety of ways. Based on Alles’s 
research, SKF first introduced the Benzedrine inhaler in 1933, in line with the drug’s 
original indication as a nasal decongestant (see Figures 1.5 and 1.6). The Benzedrine 
inhaler was a capped tube that contained a paper insert with 325 milligrams of an oily 
amphetamine base.14 For the next 15 years after its introduction, Benzedrine would be 
                                                
14 The Benzedrine inhalers originally contained 325 milligrams of the drug in the form of an oily, 
volatile base. The evaporative characteristic of the compound allowed the vapors to escape through an 





marketed as an over-the-counter cold remedy. Unfortunately, users who were drawn to 
the drug’s stimulating effects soon found a way to crack open the inhalers and swallow 
the paper inserts. The potentiated active agent found in the inhalers was 20 to 30 times 
greater than the average clinical dose of Benzedrine, and it delivered recreational users a 
more immediate and concentrated high than oral versions of the drug. Reports of inhaler 




Figure 1.5 – The original Benzedrine inhaler, introduced by SKF in 1933. (Source: 
Addiction Research Unit, SUNY-Buffalo) 
 
                                                                                                                                            
making it even easier to “crack” the inhalers to access the contents inside. In the 1940s, SKF reduced the 
dosage contained within the inhaler to 250 milligrams. 
  
15 On the early history of the Benzedrine inhaler, see Rasmussen, On Speed, chap. 2. For more on 
the inhaler’s abuse, see Courtwright, Forces of Habit, 78-80. Inhaler abuse was famously associated with 
the poets and novelists of the Beat Generation, particularly Jack Kerouac, William S. Burroughs, and Neal 
Cassady. These writers noted that their consumption of Benzedrine owed much to the creativity and 
productivity that the drug conferred. Kerouac wrote his most acclaimed novel On the Road in the span of 
three weeks while consuming massive quantities of Benzedrine. Likewise, Ginsberg penned “Howl” under 
the drug’s influence. However, “Bennie” soon revealed his dark side among the Beats. Burroughs’s wife 
Jean Vollmer wasted away as she consumed up to three Benzedrine inhalers a day. Later in life, Ginsberg 
would recant his use of stimulants when he became the voice of a new generation during the late 1960s. 






Figure 1.6 – A 1940s version of the Benzedrine inhaler. The plastic inhalers were 
commonly “cracked” by abusers who ingested the amphetamine-containing inserts. 




But the most common means of administering psychostimulants, particularly for 
medical applications, was and remains orally, through a measured dose dispensed in a 
tablet or capsule (see Figures 1.7 and 1.8). Alles patented the active salts of Benzedrine, 
and SKF introduced the first tablet form of the drug in 1936. Oral versions of other 
amphetamine drugs, such as Dexedrine and Dexamyl (a combination of 
dextroamphetamine and the barbiturate amobarbital) soon followed. Once swallowed, 
these drugs dissolve in the stomach and are absorbed into the body as they pass through 
the gut. The combination of water and fat solubility found in tablet and capsule forms of 
psychostimulants permit them to be easily absorbed into the body and to penetrate the 
blood-brain barrier. At the same time, oral administration allows the drug to be gradually 
released into the body and ensures a prolonged duration of action.  For medications such 
as Ritalin, where a single dosage may be required to last an entire school day, Ciba (now 
Novartis) has released sustained release (SR) and long acting (LA) versions.  These 
characteristics, not to mention the simplicity and convenience of a pill, have made oral 







Figure 1.7 – Dexedrine Spansule (10 mg.), manufactured by GlaxoSmithKline, formerly 
SKF. The Spansule was an extended release capsule introduced by SKF during the 1950s 





Figure 1.8 – Tablet of Ritalin (10 mg.), manufactured by Novartis, formerly Ciba-Geigy. 







More potent forms of the amphetamines and methylphenidate have been available 
in parenteral, or injectable, forms. Such versions are delivered directly into the 
bloodstream and persist in the body longer than their oral counterparts. As a result of 
their potency, as well as their implication in illicit use by addicts, intravenous forms of 
amphetamines and methylphenidate historically have been more tightly regulated. In 
many cases, their medical application in such forms has been discontinued.16  
Historiographical Context 
Establishing the Framework for Modern Pharmacotherapy and Psychiatry 
 As tools within the physician’s therapeutic armamentarium, drugs have been in 
near-constant use for thousands of years.17 Yet their effectiveness in treating disease is a 
more recent phenomenon.18 Prior to the twentieth century, drugs were valued more for 
their ability to produce a set of physiological effects, such as purging, vomiting, and the 
                                                
16 For example, Ciba-Geigy ceased production of injectable Ritalin in 1974. 
 
17 There exists no universal agreement of what constitutes a “drug.” However, a 1969 definition 
put forth by the World Health Organization provides a concise and useful standard: “any substance that, 
when taken into the living organism, may modify one or more of its functions.” See World Health 
Organization, WHO Expert Committee on Drug Dependence: Sixteenth Report (Geneva: World Health 
Organization, 1969), 6. A somewhat more legal definition of “drug” is provided by the U.S. Food & Drug 
Administration (FDA). As codified in the Federal Food, Drug & Cosmetic Act, drugs are “articles (other 
than food) intended to affect the structure or any function of the body of man or other animals” and 
“articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.” See 
Federal Food, Drug & Cosmetic Act, § 201(g)(1). This second definition suggests the medical orientation 
of many drugs. As Andrea Tone and Elizabeth Watkins have also noted: “Drugs are substances that alter 
the body in order to alleviate symptoms, help make a diagnosis, or promote health and well-being.” See 
Andrea Tone and Elizabeth Siegel Watkins, “Introduction,” in Medicating Modern America, 1. Even more 
specific are pharmaceutical drugs, which are generally distinguished by their industrialized processes of 
research and development, manufacture, distribution, and marketing.  
 
18 In the Epidemics, the ancient Greek physician Hippocrates claimed that medicine “consists in 
three things—the disease, the patient, and the physician.” In a response to this quote, Charles Rosenberg 
observed that one seeking an understanding of medicine should begin with disease. Yet the notion of 
disease is a very complex one, as it is more than simply less than optimum health. For Rosenberg, disease 
is simultaneously a “biological event, generation-specific repertoire of verbal constructs, occasion of 
legitimation for public policy, aspect of social role and individual identity, sanction for cultural values, 
structuring element in doctor-patient relations.” See Charles E. Rosenberg, “Framing Disease: Illness, 
Society, and History,” in Framing Disease: Studies in Cultural History, ed. Charles E. Rosenberg and Janet 





occasional alleviation of pain, than they were for the treatment of a particular disease.19 
Indeed, opium, ipecac, and mercury were the American physician’s drugs of choice 
during the eighteenth and nineteenth centuries. Physicians and patients alike prized these 
substances for their visible and predictable physiological effects as part of the paradigm 
of practice described by historian Charles Rosenberg.20 At the beginning of the 
nineteenth century, physicians still interpreted disease as the product of bodily 
disharmony, such as an imbalance between the body’s humours. Physicians did not treat 
specific diseases. Rather, they relied upon “heroic therapies” to restore balance and good 
health. That the Tennessee physician John Gunn advocated the routine use of the emetic 
ipecac to promote frequent “puking” in order to clean a patient’s system, but eschewed 
the use of medicines for particular diseases, suggests the role that drugs played in heroic 
therapies.21 Accompanying this holistic approach to the treatment of illness was a 
worldview common to both physicians and patients about the effectiveness of heroic 
medicine. While such therapies may appear unscientific today, and though they actually 
may have done more harm than good, these practices were accepted by patients who 
                                                
19 The idea of a single drug for a single disease, better known as a “magic bullet,” is a distinctively 
twentieth-century idea. Historically, it is associated with scientist Paul Erlich and his efforts to develop a 
cure for syphilis in which a drug would target the disease-causing bacterium without harming other 
organisms within the body. See Allan Brandt, No Magic Bullet: A Social History of Venereal Disease in the 
United States since 1880, expanded ed. (New York: Oxford University Press, 1987). By focusing on the 
social dimensions of sexually transmitted diseases, including AIDS, Brandt’s study complicates 
straightforward understandings regarding the attribution of disease to a single pathogen and its treatment to 
a selective therapy. 
 
20 Charles E. Rosenberg, “The Therapeutic Revolution: Medicine, Meaning, and Social Change in 
Nineteenth Century America,” in Explaining Epidemics and Other Studies in the History of Medicine 
(Cambridge: Cambridge University Press, 1992), 9-31. Rosenberg’s scholarship has been a pervasive 
influence on the history of medicine over the past several decades. For more on his strengths and 
weaknesses associated with his approach to the subject, see Naomi Rogers, “Explaining Everything?: The 
Power and Perils of Reading Rosenberg,” Journal of the History of Medicine and Allied Sciences 63, no. 4 
(October 2008): 423-434; and Nancy Tomes and Jeremy A. Greene, “Is There a Rosenberg School?” 
Journal of the History of Medicine and Allied Sciences 63, no. 4 (October 2008): 455-466. 
 





appreciated their visible effects and shared physicians’ understandings of the body and 
disease.22 
 The advent of the germ theory of disease, associated with German bacteriologist 
Robert Koch, provided a major impetus for change in understandings of illness and 
treatment.23 Termed the “therapeutic revolution” by Rosenberg, physicians and scientists 
at the end of the nineteenth century began to acknowledge the specificity of diseases, 
each caused by a particular pathogen and with a specific remedy. One major shift in the 
practice of medicine came with the emergence of public health regimes in the United 
States during this time, accompanied by an attendant rise in secularism and scientific 
discourse, to address epidemics such as cholera and typhoid.24 In the face of new 
discoveries about the cause of disease, another key transition in medicine occurred during 
the early twentieth century with the establishment of institutions and methodologies that 
improved the healing practices of individual physicians.25 One bounty of this new 
                                                
22 This is not to say that all drug-mediated therapies should be understood solely within the context 
of heroic medicine. For example, opium provided patients with appreciable relief from pain, and its use 
further contributed to the legitimacy of physicians during this time. For more on the transformation of 
therapeutics by physicians during the nineteenth century, see John Harley Warner, The Therapeutic 
Perspective: Medical Practice, Knowledge, and Identity in America, 1820-1885 (1986; reprint, Princeton, 
NJ: Princeton University Press, 1997). Warner elaborates on the broad principle of a “therapeutic 
revolution” outlined by Rosenberg, but he does diverge at various points, especially in his emphasis that 
changes were more evolutionary rather than revolutionary. Regarding drugs, Warner argues that heroic 
therapy was not used as frequently as believed. In addition, the decline in heroic therapy in the late 
nineteenth century was accompanied by a rise in palliative drug therapy, as well as physicians’ belief in 
relieving pain as the first indication of patient care.  
 
23 Much of the secondary literature on Koch’s life has been published in German. The leading 
biography in English remains Thomas D. Brock, Robert Koch: A Life in Medicine and Bacteriology (1988; 
reprint, Washington, DC: ASM Press, 1999).  
 
24 Charles E. Rosenberg, The Cholera Years: The United States in 1832, 1849, and 1866, 2nd ed. 
(Chicago: University of Chicago Press, 1987); Judith Walzer Leavitt, Typhoid Mary: Captive to the 
Public’s Health (Boston: Beacon Press, 1996); and Nancy Tomes, The Gospel of Germs: Men, Women, and 
the Microbe in American Life (Cambridge, MA: Harvard University Press, 1998). 
 
25 Harry M. Marks, The Progress of Experiment: Science and Therapeutic Reform in the United 





“rational therapeutics” was the development of new pharmaceuticals for treating illness 
and realizing a host of therapeutic goals. 
Late twentieth-century medicine has been characterized partly by the emergence 
of a plethora of new medications to treat illness. The discovery and subsequent mass 
production of penicillin and other antibiotics during the 1940s and 1950s provided 
medicine with its first means to eradicate diseases with a bacterial origin, including 
tuberculosis and syphilis.26 The introduction of these new pharmaceuticals was 
complemented during the Cold War era by the appearance of federally funded medical 
research programs, large-scale pharmaceutical firms (collectively referred to as “Big 
Pharma”), and governmental bodies designed to regulate them.27 As just one sign of the 
pharmaceutical industry’s medical and commercial influence since this development, 
consider that Americans paid almost $200 billion for prescription drugs in 2005 alone.28 
Consisting of institutions the historian of psychiatry David Healy has collectively termed 
                                                
26 Robert Bud, Penicillin: Triumph and Tragedy (New York: Oxford University Press, 2007); and 
Albert A. Elder, ed. The History of Penicillin Production (New York: American Institute of Chemical 
Engineers, 1970). Antecedents to penicillin also deserve mention. Salvarsan, discovered by Paul Erlich in 
1908, proved far superior to mercury compounds in the treatment of syphilis. Also, sulfonamides (sulfa 
drugs) were developed in the 1930s as forerunners to the antibiotics. See John E. Lesch, The First Miracle 
Drugs: How the Sulfa Drugs Transformed Medicine (New York: Oxford University Press, 2007). 
 
27 The historical development of “Big Pharma” has been described by numerous scholars, 
including Jonathan Liebenau, Medical Science and Medical Industry: The Formation of the American 
Pharmaceutical Industry (Baltimore: Johns Hopkins University Press, 1987); Louis Galambos with Jane 
Eliot Sewell, Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme, and Mulford, 
1895-1995 (Cambridge: Cambridge University Press, 1995); Nicolas Rasmussen, “The Commercial Drug 
Trial in Interwar America: Three Types of Clinician Collaborator,” in Bulletin of the History of Medicine 
75, no. 1 (Spring 2005): 50-80; Arthur A. Daemmrich, Pharmacopolitics: Drug Regulation in the United 
States and Germany (Chapel Hill: University of North Carolina Press, 2004); Alfred D. Chandler Jr., 
Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and 
Pharmaceutical Industries (Cambridge, MA: Harvard University Press, 2005), chap. 7-10; and Marks, The 
Progress of Experiment. Andrea Tone and Elizabeth Siegal Watkins also provide a very useful synopsis of 
major themes in American pharmaceutical history during the twentieth century. See Tone and Watkins, 
“Introduction,” in Tone and Watkins, Medicating Modern America, 1-17. 
 
28 Marcia Angell, The Truth about the Drug Companies: How They Deceive Us and What to Do 
About It (New York: Random House, 2004), 3; Greg Critser, Generation Rx: How Prescription Drugs Are 





the “medico-pharmaceutical complex,” the relationship between pharmaceutical firms 
that produce medications, medical practitioners who prescribe them, patients who 
consume them, and regulatory bodies charged with ensuring their safety and efficacy, has 
become an increasingly prominent feature of medicine since the end of World War II.29 
The place of “Big Pharma” in American medicine, society, and culture is no less germane 
today, either.30  
While many historians of medicine have been preoccupied with longstanding 
social issues such as race, class, and gender in the provision of health care or the 
relationship between physician and patient, historian Greg Higby has noted the 
development of a “new pharmaceutical history.” This emerging body of scholarship 
considers intersecting interests in the history of medicine, history of technology, business 
                                                
29 David Healy, The Antidepressant Era (Cambridge, MA: Harvard University Press, 1997), 7-42. 
Healy’s observations limit themselves mainly to the institutional components of drug development, 
marketing, and regulation. However, one might go further to suggest that pharmaceuticals embody many of 
the features of what historian Thomas Hughes has termed a “technological system.” Though a 
consideration of drugs as technologies is somewhat beyond the scope of this study, it is possible to argue 
that pharmaceutical products (i.e. drugs) are technological artifacts within a larger system of invention, 
innovation, and development, as well as production, consumption, and regulation. See Thomas P. Hughes, 
“The Evolution of Large Technological Systems,” in The Social Construction of Technological Systems, 
ed. Wiebe E. Bijker, Thomas P. Hughes, and Trevor Pinch (Cambridge, MA: MIT Press, 1987), 51-82. 
By and large, historians of medicine have generally not incorporated many of the concepts specific 
to the history of technology, yet medical historians can profit immensely from considering at least some of 
these ideas. Works that have attempted to integrate the two approaches include Keith Wailoo, Drawing 
Blood: Technology and Disease Identity in Twentieth-Century America (Baltimore: Johns Hopkins 
University Press, 1997); Joel D. Howell, Technology in the Hospital: Transforming Patient Care in the 
Early Twentieth Century (Baltimore: Johns Hopkins University Press, 1995); and Bettyann Holtzmann 
Kevles, Naked to the Bone: Medical Imaging in the Twentieth Century (New Brunswick, NJ: Rutgers 
University Press, 1997). 
 
30 For several excellent studies about the contemporary relationship between Big Pharma and the 
practice of medicine, see Merrill Goozner, The $800 Million Pill: The Truth Behind the Cost of New Drugs 
(Berkeley: University of California Press, 2004); Jerry Avorn, Powerful Medicines: The Benefits, Risks, 
and Costs of Prescription Drugs, rev. ed. (New York: Vintage, 2005); James Taggart, The World 
Pharmaceutical Industry (London: Routledge, 1993); Stuart O. Schweitzer, Pharmaceutical Economics 
and Policy (New York: Oxford University Press, 1997); William C. Bogner with Howard Thomas, Drugs 
to Market: Creating Value and Advantage in the Pharmaceutical Industry (New York: Pergamon, 1996); 
Anita McGahan, Greg Keller, and John F. McGuire, “The Pharmaceutical Industry in the 1990s,” Harvard 
Business School, Case #9-796-058, 1995, revised 1996; and John Abraham and Tim Reed, “Progress, 
Innovation and Regulatory Science in Drug Development: The Politics of International Standard Setting,” 





history and political economy, and cultural studies, to comprehend the postwar 
pharmaceutical enterprise and its relationship with medicine.31 
Developments in drug therapy during the postwar era included new medications 
for mental illness. Before the twentieth century, medical treatments for psychosis 
frequently met with limited success.32 In many cases, interventions at the societal level, 
such as institutionalization, predominated.33 By the twentieth century, however, 
psychiatry began to look toward bodily, or somatic, therapies for help. Despite the 
occasional success, such as the application of malarial fever therapy to treat 
neurosyphillis, most of these treatments had irresolute outcomes for physician and patient 
alike.34 In some cases, medical interventions such as psychosurgery incurred high human 
                                                
31 Gregory J. Higby, review of Medicating Modern America, by Tone and Watkins, eds., in 
Journal of American History 94, no. 4 (March 2008): 1323-1324. Further examples of leading historical 
studies in this vein are discussed below. 
 
32 Roy Porter, Madness: A Brief History (New York: Oxford University Press, 2003); Edward 
Shorter, A History of Psychiatry (New York: John Wiley & Sons, 1997); and David Healy, The Creation of 
Psychopharmacology (Cambridge, MA: Harvard University Press, 2002), 9-75. In a rejoinder to this view, 
Charles Rosenberg has observed that, despite its associations with twentieth century psychosomatic 
medicine, interest in the relationship between body and mind is considerably older. Moving away from 
specialized psychiatry and theological/metaphysical senses of mind and body, Rosenberg looked at 
everyday doctor-patient relationships to understand the nineteenth century construction of the neurosis 
concept as an outcome of the needs and circumstances of medical practice and the changing structure of 
etiological speculation between the mid-eighteenth and early twentieth centuries. See, Charles E. 
Rosenberg, “Body and Mind in the Nineteenth Century,” in Explaining Epidemics, 74-89. 
 
33 Gerald N. Grob, Mental Institutions in America: Social Policy to 1875 (New York: Free Press, 
1973); and Gerald N. Grob, Mental Illness and American Society, 1875-1940 (Princeton, NJ: Princeton 
University Press, 1983). 
 
34 If somewhat myopic in their interpretations, Garfield Tourney, “A History of Therapeutic 
Fashions in Psychiatry, 1800-1966,” American Journal of Psychiatry 124, no. 6 (December 1967): 784-
796; and Elliot S. Valenstein, Great and Desperate Cures: The Rise and Decline of Psychosurgery and 
Other Radical Treatments for Mental Illness (New York: Basic Books, 1986) are notable for their initial 
attempts to understand the history of bodily interventions for mental illness. In response to historical 
accounts that assess the somatic therapies of the early twentieth century as iterations on the path to modern 
biological psychiatry, critic Andrew Scull argued for the need to contextualize better these developments, 
observing that “historians have tended to pass over these innovations in embarrassed silence or to dismiss 
episodes of this sort as aberrations.” See, Andrew Scull, “Somatic Treatments and the Historiography of 
Psychiatry,” History of Psychiatry 5, no. 17 (March 1994), 9. Joel T. Braslow, Mental Ills and Bodily 
Cures: Psychiatric Treatment in the First Half of the Twentieth Century (Berkeley: University of California 





costs.35 Despite divergent interpretations of their efficacy and meaning for patients, 
somatic therapies in institutions in the first half of the twentieth century foreshadowed the 
future of psychiatry. In 1954, the major tranquilizer, or antipsychotic, chlorpromazine 
(Thorazine) was introduced in North America as the first effective drug in the treatment 
of schizophrenia. While chlorpromazine would eventually reveal its share of debilitating 
side effects in patients, the drug was a watershed in the treatment of psychosis and one 
that illustrated the intersecting developments in pharmacology and psychiatry.36 
The minor tranquilizers, or anxiolytics, and antidepressants that followed the 
initial major tranquilizers further revolutionized psychiatry’s back wards and private 
practices. Their increased use by psychiatrists meant that pharmacotherapy during the 
second half of the twentieth century superseded many of the bodily therapies used for the 
treatment of psychosis.37 And as historians such as Andrea Tone, Jonathan Metzl, David 
Herzberg, and David Healy have observed, the prescription of anxiolytics and 
antidepressants beginning in the 1950s would eventually displace psychoanalytic therapy 
in the treatment of neurosis, as well as engender a biological orientation for 
understanding anxiety and minor depression.38 It would be no understatement to say that 
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psychiatry, as it is now practiced in the early twenty-first century, is beholden more than 
ever to the pharmacological revolution that began just over a half-century ago. 
Situating the Psychostimulants 
 The psychostimulants are somewhat older than the major tranquilizers, minor 
tranquilizers, and antidepressants that transformed psychiatry during the 1950s. 
Benzedrine’s discovery in 1929 coincided with a larger effort to capitalize on the demand 
for synthetic derivatives of naturally occurring hormones. Particularly prized were 
adrenal hormones, especially for their action in raising blood pressure. In 1894, a team of 
British physiologists first identified the hormone as adrenaline. After a race to isolate and 
purify the hormone, an endeavor that resulted in a number of competing products, Parke, 
Davis & Company introduced Adrenalin in 1901, and it soon became the leading version 
of adrenaline on the market. Physicians treating shock appreciated its qualities as a 
“pressor” that raised blood pressure. Adrenalin also was valued for its ability to constrict 
blood vessels and was soon added to local anesthetics to help prevent hemorrhaging. 
Termed a “sympathomimetic” drug for how it mimicked the sympathetic nervous 
system’s actions on the body’s organs and muscles, Adrenalin’s advent inspired an 
enthusiastic search for similar drugs.39 The next important sympathomimetic to be 
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discovered was ephedrine, a derivative of the Chinese herb ma huang, or ephedra. The 
drug firm Eli Lilly introduced ephedrine to the market in the 1920s, and it became a 
massive success. While ephedrine had many of the pressor qualities of adrenaline, it also 
relaxed the bronchial passages and could be taken orally, making it a pioneering 
treatment for asthma. Due to the limited availability and high prices of the plant sources 
from which ephedrine was synthesized, demand outstripped supply and inspired a hunt 
for synthetic alternatives. While searching for derivatives of the drug that could be used 
as a nasal decongestant and bronchodilator, Gordon Alles discovered amphetamine.40  
The drug known today for its psychological properties began its therapeutic life 
very differently, yet the market for a nasal decongestant made the Benzedrine inhaler a 
bestseller. Alles was not oblivious to the broader potential of amphetamine. Nicolas 
Rasmussen has detailed how the threat of a patent dispute between Alles and SKF, whose 
products appeared to have been inspired by his findings, was transformed into a 
profitable alliance between the two parties. Alles subsequently isolated the active salts of 
amphetamine, which allowed the drug to be consumed orally. In 1937, the American 
Medical Association (AMA) approved the advertising of Benzedrine Sulfate for 
narcolepsy, postencephalitic Parkinsonism, and mild depression.41 The marketing of 
Benzedrine for depression coincides with Rasmussen’s broader observation about the 
significance of relationships between the pharmaceutical industry and academic clinical 
researchers during the interwar period. In the case of Benzedrine, SKF’s support of 
Harvard psychiatrist Abraham Meyerson played an important role in helping the 
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company to market the drug for a form of mild depression termed “anhedonia.”42 The 
indication of oral Benzedrine for depression propelled the drug to annual sales of 
$500,000 by 1941, about four percent of SKF’s total sales. 
 The outbreak of World War II only furthered amphetamine’s ascendance. 
American and British forces supplied upward of 180 million tablets of Benzedrine to 
their personnel, particularly aviators, to keep them alert during combat. About 15 percent 
of Army Air Force pilots used amphetamines during the war, many of them determining 
their own patterns of use rather than following official guidelines for consumption. 
Likewise, the Germans and Japanese supplied their personnel with methamphetamine.43 
Rasmussen has suggested that by war’s end, up to 16 million American servicemen had 
been exposed to the drug.44 
 Amphetamines exhibited no sign of decline after 1945, however. That same year, 
SKF’s sales of the drugs had quadrupled to $2 million, including $650,000 from the 
firm’s newest product, Dexedrine. The postwar era would see the drugs prescribed for an 
increasing number of indications, and amphetamines’ popularity would continue to soar. 
At the same time, their recreational consumption resulted in the emergence of what 
historian David Courtwright has termed “amphetamine democracies.”45 Their 
prominence in American society would become so entrenched by the 1970s that scholars 
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Lester Grinspoon and Peter Hedblom have called attention to the rise of the “speed 
culture.”46 My study focuses on this postwar era of clinical application and extramedical 
consumption.  
Key Themes and Arguments 
 My dissertation is distinguished by two prominent themes. First, I emphasize the 
clinician perspective as a vehicle for understanding the history of psychostimulants, as 
well as related developments in psychiatry, pharmacotherapy, and the political economy 
of drugs in the second half of the twentieth century. Second, I advance the concept of 
“therapeutic versatility” to explain psychostimulants’ multiple applications and their 
enduring shelf life in American medicine. These two themes allow me to craft a narrative 
that complements other scholars’ approaches and further illuminates the complex history 
of a class of pharmaceuticals recognized as important to the history of medicine. 
 In addition to these two central themes, I advance five specific arguments in my 
dissertation. First, I contend that drug manufacturers reacted to the ways in which 
physicians utilized their products and introduced new ones to exploit these potential 
indications. This responsiveness accompanied pharmaceutical firms’ established role of 
creating markets that physicians followed. Second, I argue that twentieth-century 
psychiatry’s conception of illness and therapy may not be served best by bifurcating its 
history along lines of institutional and outpatient therapeutic realms. The application of 
pharmacotherapy within both settings suggests they had more in common than their 
divergent histories would readily suggest. Third, I demonstrate how the widespread use 
of psychostimulants by analytically oriented psychiatrists during the 1950s complicates 
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historiographical notions of a paradigm shift from a psychodynamic to a biological 
orientation during the postwar era.47 Psychotherapy and psychopharmacology were not 
competing paradigms; in practice, doctors often employed both. Fourth, I assert that an 
appreciation of psychiatrists’ empirical and eclectic approaches to the use of drugs is 
necessary to comprehend the rise of pharmacotherapy in the postwar era. Finally, I 
contend that to understand the relationship between medical applications of 
psychostimulants and their extramedical consumption, it is necessary to conceive of a 
plurality of amphetamine cultures, each characterized by distinct relationships between 
physician-prescribers, patient-consumers, pharmaceutical firms, and political authorities. 
Emphasizing the Clinician Perspective 
The first theme of my dissertation involves my emphasis on the clinician 
perspective to illuminate the history of the psychostimulants. My approach parallels their 
study by Rasmussen in particular, who employed the pharmaceutical firm as his primary 
vehicle for understanding the history of amphetamines. While his history engaged myriad 
issues, it persuasively revealed how SKF responded to and even shaped the markets and 
indications for its amphetamine products. My inquiry is driven by a somewhat different 
concern. How did physicians interpret the medical applications of these drugs and make a 
place for them in their practices? By taking a “clinician-” rather than “industry-side” 
approach, my work provides a complementary perspective to his interpretation. Patients, 
pharmaceutical firms, regulators, and other key historical actors are important to my 
analysis. However, physician experiences provide a valuable lens for further clarifying 
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the history of psychostimulants, specifically, as well as the history of medicine, 
regulation, and pharmaceuticals, generally. 
“Therapeutic Versatility,” or the “Many Lives of Amphetamine” Redux 
  My dissertation is also informed by a second overarching theme. The historical 
trajectory of the psychostimulant drugs during the postwar era is best understood in the 
context of what I term therapeutic versatility. It was this characteristic that ultimately 
explains the variegated and enduring clinical applications of the psychostimulants. 
Rasmussen has also charted the “many lives of amphetamine.”48 Yet for all the narratives 
he uncovered, there are still others waiting to be illuminated. My dissertation exposes and 
analyzes a number of important, yet overlooked applications. 
 While the major tranquilizers have rightfully received much credit for 
revolutionizing institutional psychiatry during the 1950s, the role of other drugs such as 
Benzedrine, Dexedrine, and Ritalin as adjuncts to facilitate the use of novel 
antipsychotics has been obscured. As part of combination therapies to treat psychosis, the 
psychostimulants alleviated the untoward effects associated with the major tranquilizers, 
particularly lethargy, and enhanced their efficacy. In addition to their role in the treatment 
of psychoses such as schizophrenia, the drugs were deemed useful by psychiatrists in the 
management of major depression. Before the advent of the tricyclic antidepressants, 
stimulants such as Ritalin served to augment established somatic interventions such as 
electroconvulsive therapy (ECT). Documenting these ignored applications within the 
broader ambit of change in postwar American psychiatry, I advance understandings of 
stimulants’ therapeutic versatility. 
                                                





Even where the applications of these drugs are well understood, such as their 
indication for minor depression as early as the 1940s, there are still new facets to be 
revealed. Furthering the work done by Rasmussen in this area, I explore the use of 
pharmaceuticals by psychoanalytically oriented psychiatrists during the 1950s and 1960s. 
In particular, I demonstrate how these physicians turned to stimulants such as Ritalin, 
Dexedrine, and Methedrine to reduce patients’ inhibitions and intensify their emotional 
states in the process of administering a “talking cure.” Unlike in institutions, where the 
alleviation of visible symptoms and tangible results mattered most, psychiatrists in 
private practices often held different views of these drugs. Pharmaceuticals facilitated 
more open dialogues with patients, but they remained only adjuncts—the psychiatrist, not 
the drug, remained responsible for treatment. By taking a closer look at this and other 
applications that have passed unnoticed or have been discounted by historians, my 
dissertation contributes to our understanding of the “many lives” of psychostimulants. 
Pharmaceutical Industry Responsiveness to Clinician Practices 
 In addition to the themes that allow me to contribute to the scholarship regarding 
these drugs, I advance a set of arguments that engage, complicate, and contribute to the 
broader historical scholarship on psychiatry, pharmaceuticals, and the political economy 
of drug consumption in the postwar United States. First, I suggest how the 
pharmaceutical industry was responsive to the ways in which physicians utilized their 
medications. Scholarship by David Healy, Nicolas Rasmussen, and Jeremy Greene, 
among others, demonstrates the lead that pharmaceutical firms sometimes took in 





advertising and detailing.49 I do not discount the arguments of historians who have 
emphasized the industry’s role in directing the hand of the market. But I do conclude that 
firms were simultaneously receptive to physicians’ uses of their drugs and responded 
with new products to capitalize on these applications. 
Throughout this dissertation, I highlight the case of Ciba, the pharmaceutical firm 
that manufactured Ritalin. The company introduced the drug in 1955 with a set of initial 
indications and some basic supporting research. However, clinicians followed their own 
paths—driven by their experiences, needs, and therapeutic agendas—to discern how the 
drug would be used. Capitalizing on the findings of numerous psychiatrists during the 
mid-1950s, Ciba launched Serpatilin (a combination of methylphenidate and the 
antipsychotic drug reserpine) to harness what appeared to be a receptive market for 
combination therapies for schizophrenia and major depression. Likewise, when Ciba 
introduced Ritonic in 1959, the firm appears to have been responding to the reported 
experiences of physicians who tried combinations of amphetamines, vitamins, and 
hormones to increase the energy and quell the agitation of elderly patients who did not 
suffer from a specific disease. Eventually the company would take a more active role in 
directing the prescription of its products in the 1960s by indicating and advertising the 
drug for depression. But my research suggests that physician practices played a role in 
directing the early marketing trajectories that drugs such as Ritalin followed. 
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Blurring Boundaries between Institutional and Outpatient Psychiatry 
 In my discussion of the therapeutic versatility of psychostimulants, I alluded to 
their different applications in institutional and outpatient settings. Conventional 
interpretations have underscored the differences between these two modes of treatment as 
a defining characteristic of psychiatry for much of the twentieth century.50 This view has 
a certain basis in fact: patients suffering from the worst mental illnesses were frequently 
committed to mental hospitals where medical interventions commonly focused on the 
body. Collectively known as somatic therapies, these treatments included hydrotherapy, 
insulin coma therapy, malarial fever therapy, ECT, and psychosurgery.51 By contrast, 
outpatient psychiatry was concerned mainly with lesser mental ills collectively termed 
neurosis. For much of the century, psychiatrists approached “nerves” most visibly 
through the application of psychotherapy, a set of methods employed to elicit 
interpersonal rapport and establish a therapeutic relationship between clinician and 
patient. Perhaps the best-known form of psychotherapy in the 1950s was Freudian 
psychoanalysis, characterized by techniques such as free association and transference 
therapy to recover the repressed memories believed responsible for neurosis. The 
emergence of the minor tranquilizers and antidepressants during the 1950s and 1960s 
would have an important effect on outpatient psychiatry. Their increasing prescription, 
accompanied by biological models of mental illness and publications such as the third 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) that 
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privileged their use, would eventually overshadow psychodynamic approaches in private 
practice care.52 
 Yet such compartmentalization overlooks the fluidity that existed between the two 
modes of practice. Following examples set by historians Jonathan Sadowsky and Mical 
Raz, I contend that the application of psychostimulants as “adjuncts” that augmented 
existing psychiatric practices in both realms complicates the notion that these two 
therapeutic domains were separated by immutable boundaries.53 A case in point is the use 
of psychostimulants for depression. I explore how medications such as Ritalin were used 
as antidepressants in both institutional and outpatient settings, as well as how Ciba 
tailored its marketing efforts to capitalize on each. I also compare how clinicians 
experimented with Ritalin to discern efficacious pharmacotherapies for patients with 
psychosis at the same time that outpatient psychiatrists employed the drug to aid 
psychoanalysis. I concede that there were fundamental differences between the two 
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modes of practice. But by demonstrating the use of psychostimulants as adjuncts, I 
discern at least one commonality shared by institutional and outpatient psychiatry during 
the immediate postwar period. 
Complicating the Transition from Psychodynamic to Biological Psychiatry 
My dissertation also complicates historians’ understanding of the paradigm shift 
from a psychoanalytical orientation in outpatient psychiatry toward one that was 
biological and pharmacological in character. Historians such as Jonathan Metzl and 
Andrea Tone have alluded to the manner in which psychiatric medications for anxiety 
and depression were marketed to analytically oriented psychiatrists during the 1950s. 
However, little attention has been paid to psychiatrists who turned to stimulants to reduce 
patients’ inhibitions and intensify their emotional states for psychoanalysis. My study of 
this practice compounds historical accounts that have typically assumed that 
psychodynamic and pharmacological approaches were largely incompatible with one 
another, and it forces historians to reconsider the process of historical change within 
psychiatry during the postwar era. 
My dissertation problematizes the notion of a psychiatric paradigm shift in a 
second way. As the diagnostic category of depression broadened in the 1960s and 1970s 
to include a wider spectrum of symptoms alleged to affect the general population, 
psychostimulant drugs were often marketed for and prescribed to patients under the care 
of general practitioners rather than psychiatrists. Drugs such as Ritalin, like the 
antidepressants and anxiolytics, helped shift the practice of psychiatry from specialists to 
nonspecialists. Hence, their study tells historians much about professional dynamics and 





as psychiatric expertise. During the 1960s, physicians with no advanced training in 
psychiatry were targeted by drug companies as a new prescriber base for the treatment of 
depression.54 In doing so, pharmaceutical firms served as arbiters of expertise for 
psychostimulant drugs. New indications for psychostimulants were promoted in medical 
journal advertisements aimed at general practitioners, as well as industry-based 
publications such as the Physician’s Desk Reference (PDR). Such practices illustrate the 
role of pharmaceutical marketing in facilitating professional shifts and expanding the 
base of potential consumers for a drug.55 I look at the professional dynamics behind this 
“mainstreaming,” examining how psychiatrists reacted to the efforts of manufacturers 
such as Ciba to widen the prescriber and consumer base for its drugs during the 1960s 
and early 1970s. 
Empiricism and Its Role in Psychiatric Pharmacotherapy 
Throughout my dissertation, I emphasize the pragmatic and eclectic approaches 
taken by clinicians who prescribed psychostimulants. No example better illustrates my 
focus on empiricism than the way these drugs were applied within pediatric psychiatry. 
By the early 1960s, stimulants were established as a treatment for hyperkinetic disorder 
in children, later reclassified as ADHD. Scholars such as Ilina Singh, Rick Mayes, Adam 
Rafalovich, Andrew Lakoff, and Matthew Smith have charted the development of ADHD 
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as a diagnostic category, as well as the accompanying rise of a biological model for the 
disorder and its management with pharmacotherapy.56 However, much of the scholarship 
has explained this development as the result of competition between psychodynamic and 
biological orientations in psychiatry, in which the latter prevailed over the former. An 
alternate body of scholarship, most notably the work of Peter Conrad, has contended that 
the treatment of children with stimulants represented the medicalization of socially 
unacceptable behavior.57 Yet, neither of these interpretations necessarily matches the 
experiences of the physicians most responsible for the establishment of pediatric 
stimulant therapy. 
By contrast, my dissertation follows the clinical and pharmacological research 
that established pharmacotherapy as the preferred means for treating hyperkinesis. Rather 
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than parsing the rhetoric behind the causes and treatment of the disorder, or assuming that 
psychopharmacology triumphed in a clash of competing approaches toward children’s 
problems, I focus on how clinical researchers and practicing pediatric psychiatrists 
themselves approached the issue. It is worth noting that many clinicians who came to 
embrace stimulant therapies were initially uncertain about their potential efficacy. Yet, in 
the words of two psychiatrists, they were willing to attempt their use because of a “chief 
need…to improve a situation” in children’s behavioral problems.58 Emphasizing the 
therapeutic pragmatism of pediatric psychiatrists who established the efficacy of 
stimulant therapy for hyperkinesis, I examine the roles of such leading figures as Leon 
Eisenberg, C. Keith Conners, Gabrielle Weiss, and Donald and Rachel Klein in creating a 
space for pharmacotherapy among children. 
“Amphetamine Cultures” and Extramedical Consumption 
Published in 1975, Grinspoon and Hedblom’s The Speed Culture was the first 
major work to consider the history of amphetamines in a comprehensive manner. Their 
book had two major concerns: the medical application of amphetamines and the culture 
surrounding the extramedical and illicit use of the drugs. Written at a time when concern 
over amphetamine abuse in the United States was reaching a fevered pitch, Grinspoon 
and Hedblom’s greatest contribution was an attempt to address the tension between 
amphetamines’ potential as an efficacious addition to the therapeutic armamentarium of 
physicians and the drugs’ capability for great harm when misused. In the end, the authors 
were unable to legitimate the precarious balance and concluded that, socially and 
medically, amphetamines’ drawbacks outweighed their therapeutic benefits. In their final 
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summation on the consumption of amphetamines, Grinspoon and Hedblom observed, “To 
put it quite simply: our culture influences, encourages, and sometimes causes people to 
use amphetamines; and their behavior under the influence of these drugs often constitutes 
a caricature of the very society that produced it.”59  
Over three decades later, Rasmussen sought to explain how the amphetamines fit 
into the broader history of pharmaceuticals in the United States. Of particular interest was 
the common narrative in which many “miracle” drugs of the twentieth century, ranging 
from corticosteroids to benzodiazepines, were enthusiastically prescribed for illness, only 
to be found wanting later.60 Rasmussen highlighted the initial excitement surrounding the 
therapeutic possibilities of the amphetamines as antidepressants, performance enhancers, 
and diet aids. But he also documented how the therapeutic capabilities of Benzedrine, 
Dexedrine, and Dexamyl gave way to the horrors of speed junkies and crystal meth 
addicts. 
I accept these assertions about the downsides of amphetamine consumption. But 
there is a need to transcend, or at least complicate, the dichotomy that views the history 
of drugs solely in terms of a therapeutic “boom and bust.” I examine the extramedical 
consumption of amphetamines during the 1960s and 1970s by focusing on what I term 
amphetamine cultures, each with their own constituents, modes of use, and relationships 
with the medical establishment, regulatory authorities, and cultural brokers. For example, 
women who used Dexedrine to lose weight had a common set of experiences, 
expectations, and understandings indicative of a specific milieu in time. I argue that the 
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historical specificity of such cultures resulted in unique relationships with other key 
actors of drug consumption, manufacturing, marketing, and regulation in the United 
States, as well as shaped the historical trajectories each of these modes of use would take 
as controls on the extramedical use of these drugs were tightened through the 1970s. 
Sources and Methods 
 To excavate physician experiences, I consulted hundreds of relevant articles on 
the clinical use of psychostimulants during the timeframe of my study. Like many 
historical studies into the history of pharmacotherapy, the medical literature comprises 
the foundation for my study. I also made use of the archival collections of the American 
College of Neuropsychopharmacology (ACNP) at Vanderbilt University (recently 
relocated to the University of California, Los Angeles) and the American Institute for the 
History of Pharmacy (AIHP) at the University of Wisconsin. Among the collections of 
the ACNP, the papers of Dr. Heinz Lehmann proved particularly valuable, especially in 
comprehending Lehmann’s own response to controls on amphetamines during the 1970s. 
The AIHP’s archives provided me with access to materials on Ciba-Geigy that helped me 
understand its marketing of Ritalin during the 1950s and 1960s. Other collections, such 
as McGill University’s Osler Library Archives, further enriched this study. In addition, I 
made use of oral histories, especially for Chapters Three and Four of this dissertation. 
Several of these are published in the three volume series The Psychopharmacologists, 
edited by David Healy. These interviews provide a wealth of personal insights for 
historians of psychopharmacology. Many of the oral histories relevant to my topic, 





holdings.61 Finally, government documents, particularly Congressional hearings on the 
subject of drug regulation, controls on stimulant drugs, and concern over amphetamine 
consumption, are also integral to my analysis. Chapters Five and Six, in particular, profit 
from my use of these sources. 
Description of Chapters 
Chapter Two considers the place of psychostimulant drugs within the 
pharmacological revolution that took place in institutional psychiatry beginning in the 
mid-1950s. As analeptics that complemented the newly introduced major tranquilizers, 
psychostimulant drugs played an underappreciated role in this shift. Even if a minority 
approach, combination drug therapy conferred increased effectiveness on the major 
tranquilizers responsible for the treatment of psychosis and contributed further toward 
deinstitutionalization in the postwar era. As antidepressants or, to use the vernacular of 
the day, psychic mood energizers, psychostimulants likewise provided institutional 
psychiatrists with useful alternatives to involved somatic therapies such as ECT.  
Chapter Three reveals the role of psychostimulant drugs in outpatient psychiatry 
from the late 1940s to the late 1960s. It investigates the application of drugs by 
psychoanalytically oriented psychiatrists in the 1950s and 1960s. In particular, I examine 
how these physicians utilized Methedrine, Dexedrine, and Ritalin to improve 
psychoanalytic therapy. In addition, I discuss how pharmaceutical firms began marketing 
stimulants for conditions they termed “environmental depression” during the 1960s, 
mainly as a means to court general practitioners as a new set of prescribers for these 
drugs, as well as cultivate a wider base of consumer-patients. 
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 Chapter Four assesses the application of psychostimulant drugs in the 
management of hyperkinetic disorder during the postwar era. My primary concern is the 
discovery and establishment of pharmacotherapy with stimulants as a primary therapy for 
the disorder. I emphasize the empirical, even atheoretical, orientation of physicians who 
sought any means possible to improve children’s behavioral problems. Also important to 
the rise of pharmacotherapy for children during the 1960s were methods of qualitative 
and quantitative assessment that confirmed psychiatrists’ initial observations. 
In Chapter Five, I examine amphetamine cultures during the 1960s, a decade in 
which the extramedical uses of the drug soared. Looking at four cultures in particular—
“speed freaks” associated with the Haight-Ashbury district of San Francisco between 
1967 and 1969, diet pill users, truck drivers, and athletes—I conclude how the specificity 
of each of these cultures resulted in unique relationships with other players in drug 
consumption, manufacturing, marketing, and regulation in the United States, as well as 
shaped how authorities responded to extramedical consumption. Why, for example, 
would authorities be more likely to penalize the recreational use of the drug by teenagers 
living in Haight-Ashbury than they were to arrest an Indiana housewife who may have 
turned to diet drugs to give her more “pep”? The key to that assessment, I contend, 
involved how medical and political authorities defined and responded to sanctioned or 
legitimate uses. At the same time, I discuss how physicians became increasingly 
concerned during the 1960s about the potential dangers of amphetamine consumption. 
Part of the problem involved a definition of addiction rooted in a paradigm of physical 
dependency and associated with narcotics. Psychostimulants, by contrast, were 





Hence, they were identified initially as drugs of “habituation” rather than addiction. 
Debates by medical leaders during the early 1960s set the stage for a reappraisal of the 
safety, if not the efficacy, of amphetamines during the second half of the decade.  
Chapter Six considers how lawmakers, using the newly passed Controlled 
Substances Act as a platform, moved to tighten controls on amphetamines and other 
psychostimulant drugs during the early 1970s. Debates over the proper level of controls 
for psychostimulant drugs during the early 1970s focused on whether they should be 
controlled according to their legitimate medical applications, a position held by the FDA, 
or according to their potential for addiction and danger of being illegally diverted for 
illicit use, the preference of the Bureau of Narcotics and Dangerous Drugs (BNDD, to 
become the Drug Enforcement Administration, or DEA, in 1973). In contrast to those 
medical experts who supported the imposition of more stringent controls, I also consider 
how some leading physicians expressed opposition. 
My dissertation concludes with a brief look at clinical psychostimulant use since 
1980, particularly the staggering rise of these drugs to treat ADHD. But also notable have 
been failed attempts to revive their prescription for other indications, as the “Fen-Phen” 
debacle of the 1990s suggests. I end the dissertation by assessing the contributions this 










 As technologies, drugs are notable for the myriad roles they are capable of 
fulfilling, depending on both the user and the particular effect that is sought.1 The 
stimulating properties of Smith, Kline & French’s (SKF) Benzedrine led physicians and 
consumers to appreciate its potential for fighting fatigue, curing narcolepsy, and 
combating obesity. In their review of the medical literature in 1939, Edward C. 
Reifenstein, Jr. and Eugene Davidoff were able to quote 115 articles published in just 
three years, between 1935 and 1938, on the potential medical applications of 
Benzedrine.2 Less than a decade later, physician W. R. Bett reported a staggering 39 
indications for the drug.3 Pleasure seekers who cracked open Benzedrine inhalers to 
ingest their paper strips conferred notoriety upon them, but just as significant for the 
drug’s growing success were the efforts of SKF to discern medical applications for its 
                                                
1 In this case, a user can describe both a prescriber and a consumer of a drug. Sometimes, those 
individuals may be the same, such as a person treating himself or herself with an over-the-counter 
medication for the common cold. But frequently, they are different people. The issue of agency regarding 
the consumption of drugs is a long-standing one. As Senator Estes Kefauver famously remarked in his 1959 
hearings on drug markets, “The drug industry is unusual in that he who buys does not order, and he who 
orders does not buy.” His observation could be extended to cover the issue of consumption, as well. See 
Goozner, $800 Million Pill, 234. 
 
2 Edward C. Reifenstein Jr. and Eugene Davidoff, “Benzedrine Sulfate Therapy: The Present 
Status,” New York State Journal of Medicine 39 (January 1, 1939): 42-57. 
 
3 W. R. Bett, “Benzedrine Sulfate in Clinical Medicine: A Survey of the Literature,” Postgraduate 
Medical Journal 22 (August 1946): 205-218. Among the applications reported by Bett: epilepsy, 
Parkinson’s disease, schizophrenia, alcoholism, barbiturate intoxication, anesthetic overdose, morphine and 
codeine addiction, smoking (tobacco products), behavioral problems in children, enuresis, migraine 
headaches, heart block, multiple sclerosis, myasthenia gravis, myotonia (muscle rigidity), infantile cerebral 
palsy, urticardia, dysmenorrheal, colic, irradiation sickness, and hypotension. See also Courtwright, Forces 





amphetamine products and cultivate new markets.4 Policymakers and medical experts 
would eventually have to sort out legitimate uses from those deemed to be off-label, at 
best, and illicit, at worst. But what remains striking is how a single drug fulfilled many 
different needs by the people who used it. 
 The case of Benzedrine during the 1930s and 1940s was a harbinger for the use of 
other psychostimulant drugs during the second half of the twentieth century. This chapter 
takes up the issue of how a singular class of drugs fulfilled diverse clinical needs within 
institutional psychiatry. I use the example of Ritalin to demonstrate how medical 
professionals during the 1950s and 1960s discerned uses for this new stimulant. For some 
clinicians, Ritalin’s properties as an analeptic were most appreciated; for others, its 
potential as an antidepressant gained the drug new adherents. Moreover, I use Ritalin as a 
case to demonstrate the relationship between clinicians and the manufacturer in 
identifying and marketing new uses for the drug. While Ciba may have placed the drug 
on the market and provided rudimentary guidelines for use, physicians over the next two 
decades expanded the possibilities for the medication by reporting its efficacy in a 
number of settings.5 Ciba responded to the ways doctors used their drugs by altering their 
promotional efforts and introducing novel products to take advantage of these 
applications. Historians have demonstrated how drug firms cultivated markets for their 
products; however, it is also important to understand how clinicians simultaneously drove 
indications and influenced pharmaceutical marketing. 
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Institutional Psychiatry in the United States 
 Mental illness, whether termed psychiatric disorder, madness, insanity, or just 
“nerves,” has been a constant feature of the human condition. However, societies around 
the world have interpreted and reacted to this phenomenon in strikingly different ways. In 
Western societies, treatment of mental illness has remained under the purview of modern 
psychiatry since its emergence in Europe during the late eighteenth century.6 
 Without taking too reductionist a view of its professional heterogeneity and 
complexity, American psychiatry in the second half of the twentieth century essentially 
existed in two forms: institutional psychiatry that addressed the needs of mentally ill 
people unable to care for themselves within society, and outpatient psychiatry that tended 
to the relatively minor, everyday problems of patients in a private practice setting. Stated 
another way, institutional psychiatry concerned itself with psychoses; outpatient 
psychiatry focused on neuroses. In this chapter, I examine the first of these modes and the 
impact of psychostimulant drugs on its practice during the immediate postwar era. 
 Institutional psychiatry in the United States had its roots in the asylum movement 
of the early nineteenth century. Prior to the development of therapeutic asylums, care for 
the mentally ill was generally viewed as the responsibility of the family or community. In 
colonial America, the family often served as the primary source of care and support for 
                                                
6 Roy Porter’s Madness offers one of the best syntheses of Western views of mental illness. Porter 
begins his study by posing the fundamental question of whether mental illnesses are real diseases with 
biological bases, or whether they are social constructions reified by the medical establishment for 
professional purposes and by the public to explain and deal with intractable emotional and mental 
problems. While Porter does not satisfactorily resolve the issue in his book, he does provide an excellent 
summary of its history in the West, with a special emphasis on patient perspectives. To his credit, Porter 
avoids a positivist approach in his work, and takes a rather critical approach to such historically contentious 
issues such as the asylum and psychoanalysis. Nevertheless, he emphasizes that divisive therapies such as 
electroshock and psychosurgery represent attempts by well-meaning psychiatrists to provide therapeutic 
interventions for patients with few other options for a cure. On the balance, he also observes that many 
patients subject to the most invasive therapies were often denied agency and even powerless against 





those suffering from madness. Because insanity was not perceived as a social problem 
requiring public policies, communities often responded to the issue informally on an ad 
hoc basis. For example, town leaders frequently provided subsidies to alleviate the 
economic burdens placed on families caring for insane members. Townspeople also 
tended to adopt tolerant attitudes toward those mentally ill individuals considered part of 
the community and viewed as benign. For those perceived as a threat to public safety, 
communities reacted more aggressively. Confinement in jails or almshouses was one 
possibility; expulsion from the community, especially for those viewed as outsiders, was 
another. But in most cases, care for the mentally ill was a family matter in colonial 
America, with the community playing a limited, supporting role.7 
 The first half of the nineteenth century witnessed social and economic changes 
that altered the care of the mentally ill in the United States.8 The shift toward a more 
urban and industrial society in these decades heralded changes to the traditional family, 
as many of its functions, including education and care of dependent members, were 
                                                
7 Grob, Mad among Us, 5-22; Grob, Mental Institutions in America; and Mary Ann Jimenez, 
Changing Faces of Madness: Early American Attitudes and Treatment of the Insane (Hanover, NH: 
University Press of New England, for Brandeis University Press, 1987). In her survey of mental health care 
in New England between 1700 and 1840, Jimenez argues that there were essentially two distinct eras, 
colonial and post-revolutionary, regarding attitudes toward madness. The colonial era was defined by its 
Puritanical views on the subject. Prayer and fasting, rather than medical interventions, were the primary 
therapies. The post-revolutionary era was marked by an increasingly medical view on the subject, as the 
locus of therapy shifted from the family to the institution. Grob’s account of the colonial period is largely in 
accord with Jimenez’s, though he does stress nascent attempts at institutionalization, such as hospitals in 
Philadelphia and New York to address the needs of the insane. 
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transferred to new institutions such as schools and hospitals.9 The movement away from 
family economies toward wage labor jobs and the incipient erosion of community bonds 
meant that madness was no longer easily addressed in informal ways associated with 
communities where familiarity was paramount.10 Coinciding with the nascent 
urbanization and industrialization of this period was the introduction in the United States 
of a new conceptualization of madness and its management, rooted in the European 
Enlightenment of the mid- and late eighteenth centuries. Of particular note were the ideas 
of the French physician Philippe Pinel, best remembered for his therapeutic innovations 
in the treatment of the insane. Rejecting traditional means for dealing with mental illness, 
such as bleeding, corporal punishment, and confinement, Pinel pioneered what he termed 
traitement moral, which would later be known as “moral treatment” or “moral 
management” in the United States and England. The key to treating insanity, Pinel 
reasoned, lay in the power of a well-ordered asylum that could provide patients with an 
environment conducive toward effecting psychological changes to allow them to 
recover.11 
 The ideas of Pinel and his counterparts soon found their way across the Atlantic, 
where they crossed paths with the reform movements associated with the Second Great 
                                                
9 On the emergence of the hospital as an institution in the United States, see Charles E. Rosenberg, 
The Care of Strangers: The Rise of America’s Hospital System (1987; reprint, Baltimore: Johns Hopkins 
University Press, 1995). The modern hospital familiar to most readers, as an acute care facility, is mainly a 
product of the late nineteenth and twentieth centuries. However, Rosenberg stresses that many of the 
essential features of the institution were already discernable during the antebellum period. On the 
twentieth-century American hospital, see Rosemary Stevens, In Sickness and in Wealth: American 
Hospitals in the Twentieth Century, revised edition (Baltimore: Johns Hopkins University Press, 1999); and 
Morris J. Vogel, The Invention of the Modern Hospital: Boston, 1870-1930 (Chicago: University of 
Chicago Press, 1980). 
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Awakening of antebellum America. Private institutions such as McLean Asylum, 
Friends’ Asylum, and Hartford Retreat opened in the Northeast between 1811 and 1822. 
The establishment of these new institutions for the mentally ill was coupled with the 
ongoing development of psychiatry as a medical specialty during this same period. 
Indeed, the identity of the physicians who worked in these hospitals became inextricably 
linked with the notion that asylums were places where insanity could be cured and where 
medical expertise and discipline were paramount.12  
 Care for the mentally ill soon shifted from private to state-run facilities, and what 
had begun as small asylums were transformed into crowded, understaffed hospitals 
before the end of the nineteenth century. As historian Edward Shorter has observed of 
this phenomenon, asylums became “warehouses in which any hope of therapy was 
illusory.”13 The number of people confined to these institutions grew dramatically, some 
historians have contended, because the incidence of mental illness actually increased over 
the course of the century.14 The growth of the psychiatric population throughout the 
nation’s asylums and hospitals that began during the second half of the nineteenth 
century would persist until World War II and did not abate decisively until the 
deinstitutionalization movement of the postwar era.  
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14 Ibid., 62-63. The issue of whether mental illness became more prevalent during the nineteenth 
century has fueled one of most heated debates in the history of psychiatry. Historians commonly agree that 
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drinking-related psychosis was also more common during this era. However, vociferous debates have 
emerged on the subject of schizophrenia, typified by historian Edward Hare’s assertion that schizophrenia 
is relatively recent in origin and resulted in increased admissions to mental hospitals throughout the 
nineteenth century, as well as scholar Andrew Scull’s rejoinder that increasing numbers of people in 
institutions may be explained by expanding boundaries of what constituted mental illness and 
medicalization of certain behaviors as madness. For a deeper discussion on the history of neurosyphillis 





A case in point is the famous, or rather infamous, mental hospital in 
Milledgeville, Georgia. Approved by the Georgia General Assembly in 1837 and opened 
in Georgia’s then state capital in 1842, the “State Lunatic, Epileptic, and Idiot Asylum” 
coincided with many of the reform efforts that swept through Georgia and the nation 
during the antebellum period.15 During its earliest years, the asylum at Milledgeville 
adhered to the “institution as family” model espoused by its superintendent Dr. Thomas 
Green. Chief of a model therapeutic asylum, Green was renowned for dining with 
patients and eliminating patient restraints. However, the institution found itself 
increasingly strained by a rising population in the decades following the Civil War. As a 
sign of its increasing custodial function, the Milledgeville asylum in 1872 had a ratio of 
112 patients for every physician. In response to the new realities of a massive psychiatric 
population, abetted by Georgia communities’ practice of sending unwanted or 
problematic patients to the facility, the institution was renamed the Georgia State 
Sanitarium in 1897. The number of patients soared to over 10,000 by 1950, making it the 
largest mental hospital in the nation.16 Perhaps more odious was its reputation for insulin 
shock and electroconvulsive therapy (ECT) as means of discipline, the latter of which 
was nicknamed the “Georgia Power Cocktail.”17 Only with the advent of more 
efficacious pharmacological therapies beginning in the 1950s, as well as a move toward 
deinstitutionalization during the 1960s, did the number of committed patients begin to 
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17 For this more critical view, see Peter G. Cranford, But for the Grace of God: The Inside Story of 
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decrease. As a sign of a new decentralized model for treating the mentally ill in Georgia 
during the postwar era, the institution was renamed Central State Hospital in 1967. Yet 
the history of the Milledgeville institution is not so exceptional; rather, it is quite 
demonstrative of trends experienced by many state-run mental hospitals during the late 
nineteenth and early twentieth centuries.18 
 The first half of the twentieth century was marked by two major trends in the care 
of madness. First, there was a steep rise in the number of patients hospitalized for mental 
illness. Between 1903 and 1933, the population more than doubled in the United States, 
from 143,000 to 366,000.19 The overwhelming majority of these patients could be found 
in public institutions with 1,000 beds or more. A second development was the 
introduction of new somatic therapies. Some treatments, such as hydrotherapy, served 
ostensibly as a means to discipline patients. A handful of somatic therapies, such as the 
use of malarial fever therapy to treat neurosyphillis, were almost indisputable in their 
efficacy. Others, however, offered mixed results. While treatments such as insulin coma 
or Metrazol shock therapy may have provided some indication of efficacy to the 
clinicians who administered them, their benefits were often irresolute or took an 
incredible toll on the patient. No intervention was more illustrative of this reality than 
psychosurgery. Historian Jack Pressman notes that for many psychiatrists in the mid-
twentieth century, lobotomy represented “human salvage” to “reclaim – if just partially – 
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souls that otherwise would be forever consigned to the darkness of the nation’s 
asylums.”20 While Joel Braslow reminds historians that such therapies carried the onus of 
discipline as much as treatment, Pressman likewise emphasizes that psychosurgery must 
be remembered within the social, political, and even economic contexts within which it 
was performed. The procedure allowed many institutionalized patients to return home to 
their families and may have saved the taxpayers millions of dollars by alleviating them of 
the burden of “taxeaters” at a time when no other effective treatments were available for 
psychosis. Yet even proponent Walter Freeman cautioned that lobotomies were the “last 
resort” for patients due to the high toll they took on their bodies and minds.21  
Postwar Institutional Psychiatry and the Pharmacological Revolution 
 In most respects, care of the mentally ill on the eve of the Second World War 
appeared little different than it had a century earlier. Despite the introduction of somatic 
therapies during the first half of the twentieth century, they helped too few patients and 
proved ineffective at providing decisive cures for the remainder. Nor could such 
treatments alleviate overcrowded, understaffed mental hospitals throughout the nation. 
Historians of psychiatry have rightly described the period leading up to the conflict as the 
nadir of institutional psychiatry in America, a trough that had been a long time in the 
making. Following the war, psychiatric treatment would experience a profound 
transformation. 
 The seeds for change were sowed during the 1920s and 1930s, when reformers 
began to engage the state governments in charge of the hospitals and clamor for 
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substantive reform. Psychiatrists acting through their chief professional organization, the 
American Psychiatric Association (APA), began to push the issue of state regulation of 
mental hospitals. They were joined in this effort during the 1930s and 1940s by 
muckrakers who called attention to the severe institutional deficiencies and the terrible 
conditions in which many patients lived. The most famous of these crusaders included 
journalist Albert Deutsch, activist Mike Gorman, and novelist Mary Jane Ward, whose 
articles and books detailed the horrors of the nation’s worst mental hospitals while 
placing the blame for them at the feet of state governments.22 
 Notable as these nascent efforts at reform may have been, they were ultimately 
fruitless. Rather, it required the seismic political, scientific, and social shifts brought by 
the Second World War to realize lasting improvements in institutional psychiatry. 
Historian Gerald Grob has observed that the war was important for two reasons. First, the 
war altered the experiences of military psychiatrists by illustrating that psychiatric 
disorders were more pervasive than originally believed and for revealing the role that 
environmental factors—the stress of combat—played in their onset. Even more 
important, however, was the success of noninstitutional therapy in the management of 
soldiers suffering from mental breakdown. Victims of combat fatigue were frequently 
treated at company aid stations by military physicians, many of whom were surgeons 
trained in “first-aid psychiatry” by military psychiatric consultants. Emphasis was placed 
upon caring for psychiatric casualties in the field among their comrades, so that as many 
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as possible could return to service. The success of this technique and the experiences of 
psychiatrists who served in the military helped lay the groundwork for new approaches to 
civilian mental patients after the war. Rather than treat patients in an institutional setting 
such as the asylum or mental hospital, one that implied removing the person from society, 
emphasis was placed on caring for the patient within his community-at-large, where he 
could receive support from family and friends. This mode of psychiatry eventually 
became known as community psychiatry.23 
 A second outcome of World War II was the increased role of the federal 
government in setting policy, especially as it pertained to science and medicine. As the 
war against fascism gave way to the Cold War against communism, the involvement of 
the federal government in funding and directing medical research grew. Of particular 
importance to mental health care in the United States was the passage of the National 
Mental Health Act in 1946 and the formal establishment of the National Institute of 
Mental Health (NIMH) three years later. With these actions, the federal government 
became a primary driver for establishing new models of understanding and treating 
mental illness in the United States.24 
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 Accompanying the establishment of community-based care programs and the 
heightened role of federal policymaking was a third development: the rise of 
psychopharmacology and the introduction of new drugs to treat mental illness. In his 
survey of the postwar United States, historian James T. Patterson has called attention to 
the “grand expectations” that Americans had for this period. While the Cold War era was 
punctuated by the problems of political extremism associated with McCarthyism, 
ongoing racism amidst the Civil Rights Movement in the South, and a looming 
perception of conformity in America’s suburbs, Patterson also highlighted the social, 
political, and economic progress made in the decades following World War II.25 New 
drugs to treat illness were counted among the greatest successes of the era. 
Vannevar Bush, an engineer who had served as the head of the Office of 
Scientific Research and Development (OSRD) during World War II, best encapsulated 
the postwar enthusiasm for scientific, technological, and medical progress. With the 
dissolution of OSRD following the war, Bush pushed for a similar agency in the civilian 
realm. In his 1945 report to the President, Science: The Endless Frontier, Bush touted the 
need for basic research to continue technological progress. He dedicated Chapter 2 of his 
report, “The War against Disease,” specifically to the medical advances made during the 
war and to outlining the problems still facing the nation. Bush credited the role of new 
pharmaceuticals in helping to conquer diseases and called for additional research to 
support new drugs. At the same time, he pointed to an increase in mental disease as a 
clarion call for postwar medical science. According to Bush, approximately 7 million 
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Americans in 1945 were mentally ill, and they occupied more than one-third of the 
nation’s hospital beds, at a cost of $175 million a year. Without decisive intervention, this 
population would grow unchecked at the rate of 125,000 new inpatients per year.26  
Bush’s vision for a civilian equivalent of OSRD was eventually realized with the 
founding of the National Science Foundation (NSF) in 1950. As with the creation of 
NIMH a year earlier, the NSF’s establishment symbolized the increasing role of federal 
funding and policies to support science, technology, and medical research. This 
involvement, based partly in the optimism of scientific research to address social needs 
and partly as a response to threats posed by the expansion of communism, typified 
federal science policy during the Cold War era.27  
 In his study of the American medical profession, Paul Starr has contended that by 
the mid-twentieth century, the pharmaceutical industry had already become an essential 
part of the American medical system and key to the profession’s dominance.28 Historians 
from Robert Bud to Louis Galambos have pointed to the bounties of the pharmaceutical 
industry, beginning in earnest with the penicillin, as one of the most important 
developments of Cold War science and medicine.29 Antibiotics have deservedly received 
much of this attention because of the lives and limbs they saved during World War II, as 
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Printing Office, 1945), 13-16. 
 
27 For more on Vannevar Bush, see G. Paschal Zachary, Endless Frontier: Vannevar Bush, 
Engineer of the American Century, MIT Press ed. (Cambridge, MA: MIT Press, 1999). For more on 
science during World War II and the Cold War, more generally, see Stuart W. Leslie, The Cold War and 
American Science: The Military-Industrial-Academic Complex at MIT and Stanford (New York: Columbia 
University Press, 1993); and Thomas P. Hughes, Rescuing Prometheus: Four Monumental Projects that 
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well as the civilians they spared from infectious diseases in the years following the war. 
Psychiatry was also among those medical specialties that benefited most from the 
advances in pharmaceutical science. 
Developed by the French company Rhône-Poulenc and introduced to North 
America in 1954 by SKF as Thorazine, the antipsychotic drug chlorpromazine 
transformed therapeutics in psychiatry. As historian Edward Shorter has noted, its arrival 
heralded “the era of psychopharmacology.”30 Chlorpromazine was effective in the 
treatment of schizophrenia, which was arguably the most visible of the psychoses. While 
the medication did not cure institutionalized patients of their diseases, it alleviated their 
symptoms sufficiently enough that they were able to carry on relatively normal lives 
outside of hospitals.31 Though initially derided by some critics as nothing more than 
another sedative, chlorpromazine had a genuine calming and restorative effect on these 
hallucinating and deluded patients.32 In the years immediately following World War II, 
physicians attempted with varying degrees of success to use drugs such as barbiturates 
and amphetamines to alleviate the symptoms of their patients.33 But whatever misgivings 
critics held about chlorpromazine, it is clear that until its introduction, physicians were 
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33 Jacques S. Gottleib and Frank E. Coburn, “Psychopharmacologic Study of Schizophrenia and 
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often disappointed about other drugs’ lack of efficacy for treating their most serious 
cases. Within several years, chlorpromazine would be followed by other notable 
psychopharmaceuticals: the antipsychotic reserpine, the anxiolytic meprobamate, the 
tricyclic antidepressant imipramine, and the psychostimulant methylphenidate. The last 
of these drugs, marketed by Ciba as Ritalin, would play an underappreciated role in 
institutional psychiatry during the 1950s and 1960s.  
Enter, Ritalin: An Analeptic for Psychiatry 
The therapeutic effects of chlorpromazine fueled great enthusiasm for the drug 
and its administration to mentally ill patients, often without regard to specific diagnoses. 
Such efforts were aided by SKF, which lobbied state legislatures for the medication’s 
adoption in institutions.34 Even mental health activist Mike Gorman, who had fought for 
hospital reform in the late 1940s lent his support to the cause through the publication of 
his 1956 book Every Other Bed, which lamented that every other hospital bed in America 
was occupied by a psychiatric patient. Gorman touted the benefits of the new 
pharmacotherapies and called for their expanded use as a way to alleviate the burdens 
weighing down state mental hospitals.35 The role of the pharmaceutical industry, 
legislators, and even investigative journalists in promoting these new “wonder drugs” 
suggests a broader political economy of pharmacotherapy that was not limited to the 
physicians who prescribed medicines. Yet if there was immense enthusiasm among 
public proponents of chlorpromazine, it was apparent to clinicians in the back wards that 
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the drug was far from perfect. As two psychiatrists commented about the ubiquitous 
nature of chlorpromazine,  
shortly after the advent of tranquilizing agents as a therapeutic weapon in the new 
chemotherapy of severe mental states, particularly psychoses, it was noted that 
there was often an unpredictable aggravation of already existing and observable 
depressions, or even production of depressions where no such reaction had been 
observed clinically.36  
 
Looking around her own hospital in Whitfield, Mississippi, Dr. Veronica Pennington 
noted the varying effects of the drug on different patients: 
In our psychiatric hospital housing 4,500 patients, hundreds of patients have been 
returned to their homes as a result of the use of one or more ataraxics. More 
hyperkinetic, active, assaultive, noisy patients are represented in this group than 
any other type, leaving a residue of dull, inert, withdrawn, apathetic, depressed 
patients. The tranquilizing drugs frequently increase the inertia and lassitude of 
these patients and in many cases contribute to their retarded mental and physical 
activity.37 
 
While chlorpromazine worked wonders to release patients suffering from schizophrenia 
and mania, these afflicted groups represented only part of the psychiatric population, and 
the drug did little to help others suffering from conditions such as major depression. Even 
patients who benefitted most from the drug’s effects were subject to untoward effects 
such as listlessness and fatigue. 
To offset these side effects, clinicians such as Pennington sought other 
medications to help: “We therefore looked about for an analeptic to counterbalance the 
constitutional or drug induced lethargy and psychomotor retardation.”38 Psychiatrists first 
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prescribed amphetamines, most notably Benzedrine, as part of combination therapies for 
schizophrenics.  But they noted that the deleterious side-effects, including jitteriness and 
anxiety, tended to outweigh potential benefits. While amphetamines would continue to 
occupy a place in the treatment of depression, Ritalin’s entry into psychiatry in 1955 
could not have come at a better time for psychiatrists such as Pennington, who sought a 
milder stimulant to offset chlorpromazine’s adverse effects. 
Ritalin is the trademark name for methylphenidate, a stimulant of the central 
nervous system introduced by Ciba Pharmaceuticals and manufactured today by 
Novartis.39 In attempting to describe its effects and strength, researchers and clinicians 
during the 1950s and 1960s commonly noted that methylphenidate was “less potent than 
amphetamine but more so than caffeine.”40 From a contemporary vantage point, the 
situation of methylphenidate between caffeine and amphetamine is revealing. While 
caffeine is legal and unregulated in the United States and many other Western nations, 
amphetamines are now tightly controlled drugs. Now understood pharmacologically as an 
                                                                                                                                            
38 Pennington, “Phrenotropic Action,” 477. Analeptics here refer to central nervous system 
stimulants such as amphetamine or methylphenidate. 
 
39 Based in Basel, Switzerland, Ciba was originally established by Alexander Clavel in 1859 as a 
silk dyeing company. By the turn of the century, Ciba had produced its first pharmaceuticals, including 
Vioform, an antiseptic drug, and Salen, an anti-rheumatic agent. By the end of the First World War, the 
company had branched out to textiles and later plastics and insecticides. About the same time Ciba began 
operations, two other companies, Geigy and Sandoz, were also founded as dye producers in the same town. 
These three companies did not remain confined in Basel for long. All of them became multinational 
companies with branches in a number of countries, including the United States. Ciba, Geigy, and Sandoz 
had a number of reasons for this expansion, including the circumvention of patent laws and evasion of 
import duties and export taxes. In addition, developments taking place in German patent laws at the turn of 
the century, whereby the process of discovery rather than the end product was patented, were crucial in 
solidifying the interest of these companies in pharmaceuticals production. See Healy, Antidepressant Era, 
19. Perhaps the similar historical trajectories of Ciba, Geigy, and Sandoz and their proximity to one another 
help explain the companies’ mergers: first, as Ciba-Geigy in 1970, and later, with the addition of Sandoz, 
as Novartis in 1996. For some insights into Ciba-Geigy’s operations, see Ciba-Geigy, Ltd., Ciba-Geigy in 
the 1970s: Informal Portrait of an Industrial Organism (Basel: Function Information & Promotion, 1974). 
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amphetamine-like compound, methylphenidate is closely aligned with amphetamine in 
terms of its legal status as a controlled substance.41 
 In her own hospital, Pennington administered Ritalin to “dull, inert, untidy, mute, 
depressed, negativistic and catatonic” patients, for whom ECT and drugs such as 
chlorpromazine did not work.42 Ritalin, it was hoped, “would put positive qualities of 
vim, vigor and vitality into listless, lethargic, negative-quality individuals” who 
represented the hospital’s “treatment failures.”43 For a number of patients, Ritalin proved 
effective. One patient, C.B., was described by her doctors as, 
extravagan[t] in buying clothing that she would not wear. She preferred seclusion, 
was self-centered, had auditory hallucinations, thought that radio programs were 
directed toward her, and had many ideas of reference and persecutory illusions. 
She felt that she was being followed, that the telephone wires were tapped and 
Dictaphones were in her house. 
On our receiving ward she had not adjusted satisfactorily; was demanding 
and arrogant, would not associate with the other patients and was not cooperative 
in ward routine. She took no pride in her personal appearance and had many 
complaints about the way the hospital was managed; during interview she was 
sarcastic and evasive.44 
 
C.B. had not responded well to treatment, either. Frequent ECT sessions dislocated her 
jaw despite the precautions that her doctors had taken.45 Chlorpromazine by itself had no 
appreciable effect. Having no other recourse, C.B.’s doctors placed her on a combination 
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44 Ibid., 479. 
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of chlorpromazine and methylphenidate. The addition of Ritalin to her regimen seems to 
have helped: 
Within 8 weeks on this therapy she had improved to a state of apparent normalcy; 
she ate well without persuasion and gained weight, she took interest in her person 
and clothing and for the first time since admission eight years before she was 
smilingly pleasant, agreeable and cooperative. She participated in hospital work 
and in recreational activities and altogether seemed well adjusted, without further 
expression of delusional or hallucinatory trends.46 
 
After the “several visits required to convince her skeptical family of her improvement,” 
C.B. was discharged and reported to be “doing well” on a maintenance therapy of 
chlorpromazine and methylphenidate.47 As historians such as Braslow, Pressman, and 
Grob have observed, the patient’s ability to return home to her family had become a 
benchmark of successful treatment and desired therapeutic endpoint in postwar America. 
Thanks to the drug combination, clinicians appreciated how another bed was freed up in 
an overcrowded mental hospital, and policymakers touted how taxpayers were spared the 
expense of another ill mind to care for. 
 Another patient, V.S., had received a B.A. degree, remained single, and earned 
her living as a highly proficient secretary. She was first admitted in 1950 with a diagnosis 
of schizophrenia. Doctors gave chlorpromazine and meprobamate to V.S. but to no avail. 
Then Pennington prescribed her patient 80 milligrams of Ritalin twice a day: 
She showed definite improvement within a few days, and two months afterward 
was able to work full time as a secretary in my office. While she continues to 
walk slowly, she does not lie about as before, and her secretarial work is quick 
and accurate; in addition she is socially well adjusted in the hospital regime, keeps 
well groomed and apparently has no further hallucinations. She states that she 
feels more relaxed and is sleeping better.48 
                                                










The psychiatrist concluded that many of her patients had benefited from Ritalin therapy: 
“Improvement following Ritalin therapy ranged from better self-care to restoration to 
active and substantially better normal life outside the hospital. Verbalization was restored 
and/or normalized, and many patients reported feeling more ‘alive,’ ‘interested,’ or 
‘normal’ than [they had] for a long time.”49 
Pennington’s assessment of what constituted successful therapy for her patients 
suggests the complex set of assumptions held by psychiatrists. As Braslow noted in his 
study of psychiatrists who employed somatic therapies, the “therapeutic rationale” of 
clinicians, in which physicians constructed a particular condition as a disease and decided 
upon a particular outcome as a cure, was multifaceted in nature. A somatic intervention’s 
therapeutic goal could not necessarily be disaggregated from its elements of social 
management or discipline. As Pennington’s own case demonstrates, the complex set of 
assumptions held by somatically oriented psychiatrists did not disappear when clinicians 
turned to pharmacotherapy. On the one hand, Pennington’s own assumptions about the 
patient, including comments of “extravagance” and a lack of “pride in personal 
appearance,” surface in her case studies. Just as striking, however, is the genuine interest 
that doctors such as Pennington had in bettering their patients’ conditions. 
Ritalin as an Antidepressant 
 For readers in the early twenty-first century, no mental condition may be more 
prominent than depression. However, framing depression as a disorder has been one of 
the most contentious issues in psychiatry for centuries. Is depression a serious disease 
                                                
49 Pennington, “Phrenotropic Action,” 481. My account here focuses mainly on the qualitative 
effects that Ritalin had on Pennington’s patients, but she also considered quantitative measures of efficacy. 
See Veronica M. Pennington, “The Phrenotropic Action of Ritalin as Evaluated by an IBM Rating Scale,” 





limited to a small group of very ill people? Is it a wide-ranging and far-reaching disorder 
that affects millions? Is it both? Does depression even exist? These questions, all of 
which have been posed by historians of medicine and answered in a variety of ways, 
suggest the fluidity of depression as a concept, let alone a disorder requiring medical 
care.50 
 In response to scholarship crediting tricyclic antidepressants and monoamine 
oxidase inhibitors (MAOIs) as the first drugs that decisively treated depressive 
symptoms, historian Nicolas Rasmussen has deftly argued that amphetamine deserves to 
be considered as the first antidepressant.51 Shortly after the introduction of Benzedrine, 
SKF sought new clinical uses for the drug beyond its initial application as a nasal 
decongestant. Pivotal to the firm’s search for new markets were burgeoning relationships 
between the industry and clinical researchers during the interwar period. Companies such 
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as SKF commissioned studies at this time in order to discern new possibilities for their 
products. A partnership between the firm and the eminent neurologist and psychiatrist 
Abraham Meyerson was critical to Benzedrine’s successful marketing for depressive 
symptoms beginning in 1937. Rasmussen has observed how a depressive “symptom 
complex” termed “anhedonia” by Meyerson was shaped by the company into an 
indication of “depression.” Following the American Medical Association’s (AMA) 
approval, SKF proceeded to promote the drug for depressive symptoms in the 1940s.52 
 Rasmussen openly relies on an alternate interpretation of the history of psychiatry. 
The conventional reading of twentieth-century American psychiatry’s history holds that 
the advent of effective pharmacotherapies, beginning in earnest with chlorpromazine, 
ushered in a new era in which a biologically and pharmacologically oriented psychiatry 
effectively displaced the hegemony of “dynamic,” or psychoanalytically informed, 
psychiatry by the late 1960s.53 In reality, the process of change within psychiatry has 
been much more complicated, as Rasmussen has noted. Historian Jack Pressman has 
called attention to the myriad views that informed psychiatry during the 1930s and 1940s, 
and historian Joel Braslow reminds us that somatic approaches to mental illness co-
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existed with Freudian theories.54 An essential feature of this more nuanced interpretation 
of twentieth-century American psychiatry is the fact that somatic pragmatism always 
existed alongside various schools of thought. 
 The relevance of this more critical look at psychiatry for Rasmussen’s work, as 
well as for mine, has to do with how depression is defined and understood. Historian 
David Healy has argued that minor depression, as it is now diagnosed and treated, often 
with selective serotonin reuptake inhibitors (SSRIs) such as Prozac, Paxil, and Zoloft, is a 
relatively recent phenomenon, one that was solidified with a new classification for 
psychiatric disorders with the publication of the third edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-III) in 1980.55 Rasmussen argues that the 
marketing of Benzedrine in the 1940s for depressive symptoms suggests that the 
antidepressants are older than has been previously recognized. At issue is how 
psychiatrists and historians of medicine have chosen to define “depression.”  
Augmenting Rasmussen’s scholarship, I argue that psychiatrists in the 1950s and 
1960s turned to psychostimulants to manage a different form of depression historically 
known as melancholia, now generally referred to as “major depression.” In contrast to 
milder forms of depression now commonly treated, major depression is far less common. 
Before the 1957 advent of imipramine, the first tricyclic antidepressant used to treat 
major depression, ECT had proven beneficial in helping some patients.56 Despite its 
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usefulness, many psychiatrists conceded that ECT was feared by patients and opposed by 
a public that misunderstood the procedure.57 At the same time that Pennington published 
her study about the uses of Ritalin, David Morgan of the Mental Hospital in Kenmore, 
New South Wales, Australia, also mulled the potential of combining chlorpromazine with 
methylphenidate. The difference, however, was that Morgan was concerned with patients 
suffering from manic depression, for whom ECT had often been the only therapeutic 
option.58  
After adding Ritalin to his patients’ regimen of chlorpromazine, Morgan noted of 
one of them, “She has remained well since; she is bright, cheerful and cooperative,” 
while another had made a “continuous and uninterrupted improvement.”59 More striking 
to Morgan was the fact that a substantial number of his patients no longer required 
ECT.60 Contemplating this development, he compared the benefits that drugs and ECT 
had to offer. He believed the forms of treatment were complementary, and that each had 
unique strengths that made them appropriate for particular clinical needs: 
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[S]ome patients, when admitted to a mental hospital, are in such a shockingly 
debilitated condition that it becomes a matter of life and death to restore their 
internal chemical milieu to normal as rapidly as possible. To attain this end, it is 
most important to have the patients’ full cooperation, and in my experience this 
cooperation may be best obtained with electrotherapy. 
However, when the urgency is not paramount, then the use of 
chlorpromazine and “Ritalin” has many advantages. The patients do not fear 
taking tablets, whereas many are afraid of electrotherapy, even when it is given in 
combination with sedatives and muscle relaxants. Also, it is comforting to have an 
alternative to electrotherapy when one is treating an acutely depressed patient 
who has an advanced physical illness.61 
 
Morgan was acutely aware that ECT had a number of detractors, and he understood the 
need for some other means of treatment that would alleviate the anxieties of patients 
toward the procedure. Ritalin had demonstrated some effectiveness as an adjunct to ECT, 
but it was not replacement for the procedure in particularly acute situations. Nevertheless, 
Morgan was keen to recognize the antidepressant qualities of Ritalin and its potential as 
an adjunct. 
 Ritalin’s place in psychiatric institutions should also be considered in relation to 
the development of the tricyclic antidepressant imipramine.62 Geigy had pursued 
imipramine’s market potential under the pretense that it was a stimulant, suggesting the 
value then being placed on this class of drugs.63 Ritalin was not an antidepressant as it is 
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now understood today, but it fulfilled that role in the minds of those physicians who 
sought a way to alleviate their patients’ depressive symptoms. More to the point, Ritalin 
satisfied the needs of clinicians in the interim before the introduction of the first tricyclic 
antidepressants. In one of its first major applications, it had proven itself useful. As one 
group of psychiatrists noted, even after the first tricyclic antidepressants had been 
introduced for major depression,  
methylphenidate has a place in our armamentarium as a symptomatic treatment, 
an adjunctive treatment, and in some cases a definitive treatment, of depressive 
reactions of many types. At times it might serve as a useful stop-gap procedure 
while attitudinal barriers to E[C]T are being removed. At other times it might 
furnish the necessary motivational stimulus to convince the patient or his family 
that effective treatments are available and that hospitalization can be accepted. 
Again, before some other definitive treatment plan has had time to become 
effective, transient lifting of the depression with intravenous methylphenidate is 
indicated to facilitate some particular clinical or nursing procedure….In no way 
do we consider methylphenidate a disease-specific treatment but we see it as a 
useful CNS-stimulating drug, that is capable of counteracting the symptoms of 
depression....as a part of the total picture in many diagnostic categories.64 
 
In 1960, even as drugs such as imipramine were beginning to replace the combination of 
chlorpromazine-methylphenidate, Ritalin apparently still retained a place within the 
therapeutic armamentarium of psychiatrists treating major depression. Its value as an 
alternative therapy, especially for those patients too weak or resistant to ECT, made it 
clinically promising for some psychiatrists. 
 Aware of its successful use as an antidepressant for those patients suffering from 
the worst cases of mental illness, Ciba expanded this market by promoting Ritalin use 
within institutional psychiatry. A 1957 advertisement (see Figure 2.1) touted the 
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medication’s potential to bring schizophrenic patients “out of the corner” by 
“awaken[ing] [them] to reality.” Of particular interest was the way in which the drug was 
also indicated for “true depressives (negative, withdrawn, dull, listless, apathetic).” 
Another advertisement (see Figure 2.2) from around the same time also indicated 
Ritalin’s potential to treat “mild to moderate depressions” in both neurotic and psychotic 
patients.65 In its marketing of Ritalin for depression, Ciba appears to have relied 
especially on the initial clinical research efforts of John Ferguson, a Michigan 
psychiatrist who reported some of the earliest findings of the drug’s applications in the 
Journal of the American Medical Association (JAMA).66 
 
 
                                                
65 As I observe in the next chapter, the simultaneous indication of stimulants such as Ritalin for 
both psychosis and neurosis suggests some permeability between institutional and outpatient psychiatry 
during the immediate postwar era, especially where depression and its management were concerned. 
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Figure 2.1 – 1957 advertisement for Ritalin for schizophrenia and depression, “You can 
bring patients ‘out of the corner.’” (Source: March 1957 issue of Hospital and 






Figure 2.2 – 1956 advertisement for Ritalin for mild to moderate depression, “Arouse the 
depressed psychiatric patient.” (Source: November-December 1956 issue of 








Ciba’s Own Combination Drug: Serpatilin 
 While the combination of chlorpromazine and methylphenidate was touted as 
beneficial to those patients suffering from depressive states, other combination therapies 
also held promise. Just as SKF had introduced Thorazine onto the market, researchers at 
Ciba had managed to isolate an active salt in the Indian root Rauwolfia serpentina, which 
had been used for thousands of years to treat disorders ranging from hypertension to 
insanity. Ciba named the new compound reserpine, and one of the firm’s researchers,  
F. F. Yonkman, utilized the term “tranquilizer” to describe its effects. Psychiatrist Nathan 
Kline urged the company to support a large study of 710 patients to test its efficacy, and 
reserpine’s potential as an antipsychotic was soon realized.67  
  It did not take Ciba long to bring reserpine to market as Serpasil. Like 
chlorpromazine, reserpine proved effective in a number of patients suffering from 
psychosis, but it did little for those from depression. In April 1956, Dr. C. H. Carter 
published one of the first studies examining the combined effects of reserpine and 
methylphenidate. Among the functions Carter identified for methylphenidate was its 
ability to offset over-sedation from reserpine. He also noted methylphenidate’s 
counteraction of the “marked lethargy and dullness” that resulted from the high levels of 
anticonvulsants, as well as the symptoms of organic brain damage among 
institutionalized epileptics.68 Just as they had done with chlorpromazine, psychiatrists 
combined reserpine with methylphenidate to expand the therapeutic usefulness of this 
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latest antipsychotic. The difference, however, is that rather than combining Ritalin and 
Thorazine, drugs made by two different companies, clinicians were prescribing Ritalin 
and Serpasil, both products of Ciba. The company made the most of the opportunity to 
have Ritalin associated with their own Serpasil rather than SKF’s drug, and it went to 
great lengths to promote the combination of Ritalin and Serpasil in psychiatric use. Ciba 
Pharmaceutical Products’ Research Department even published several studies 
suggesting the potential of the combination therapy.69 
 That same year, Ciba introduced Serpatilin, the first of two known Ritalin 
combination drugs (See Figure 2.3). Marketed as a “new emotional stabilizer,” the drug 
was among the first to combine a major tranquilizer and stimulant: “With Serpatilin the 
calming, relaxing action of Serpasil releases patients from nervousness and stress, while 
the mood-lifting, antidepressant effect of Ritalin stimulates them gently and brightens 
their mental outlook.”70 The complementary action of the methylphenidate and reserpine 
contained in Serpatilin enabled the drug, its manufacturer claimed, to “lessen anxiety and 
tension and increase alertness; alleviate depression, nervousness, and chronic fatigue; lift 
mood gently and smoothly without letdown; promote desire to participate socially and 
improve behavior; maintain emotional stability and a sense of well-being.”71 That Ciba 
introduced Serpatilin so soon after Ritalin further suggests one of the predominant uses of 
methylphenidate during its earliest years. 
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Medizinische Wochenschrift 87, suppl. 14 (April 7, 1957): 370-374. 
 
70 “Serpatilin,” Physicians’ Desk Reference, 11th ed. (Oradell, NJ: Medical Economics, 1957), 442. 
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Figure 2.3 – 1956 advertisement for Serpatilin, “Stabilize the up and down patient.” 







One fascinating aspect about the history of Serpatilin, and one which 
foreshadowed the trajectory of Ritalin in the decade to come, involved its broadened 
indications during its brief market lifespan. Originally, the drug was intended for the 
most severe forms of psychiatric illness, especially “emotionally disturbed states marked 
by anxiety-tension, depression and lethargy, and chronic fatigue.”72 However, within five 
years of its introduction, Ciba marketed the drug for a variety of conditions, several of 
which fell outside the exclusive purview of psychiatry, including chronic fatigue and 
mild depression, lethargy, menopausal syndrome, and apathetic behavior.73 There exists 
no available evidence to suggest how such a repositioning of the drug may have taken 
place, but it does seem probable that the manufacturer played the leading role in 
widening the drug’s potential uses and increasing the likelihood that general practitioners 
and other specialists besides psychiatrists would prescribe it. This mainstreaming of 
Serpatilin was short-lived. By 1966, less than a decade after its introduction, Serpatilin 
had been removed from the market.74 The drug presumably had become the victim of 
better antipsychotics for the treatment of schizophrenia and related psychoses, as well as 
the introduction of the tricyclic antidepressants, which provided better symptomatic 
improvement for many patients suffering from major depression. 
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 Ciba’s receptivity to a tranquilizer-stimulant combination was not entirely novel, 
as evidenced by forerunners on the market. One notable example was Rauwidrine, a 
combination of amphetamine and Rauwolfia serpentina, introduced in the early 1950s by 
Riker Laboratories in Los Angeles.75 While one doctor in Glendale, California, observed 
that it might seem paradoxical to give a stimulant such as amphetamine to patients with 
anxiety and insomnia, he reasoned that the Rauwolfia content tended to counteract 
whatever unpleasant stimulation the amphetamine was capable of producing. Moreover, 
he suggested, “many patients manifest anxiety and insomnia as an outward expression of 
underlying depression. For such patients, the use of Rauwidrine to produce a lift in spirits 
and a new calm but buoyant mood is eminently logical.”76 To prove his point, he shared 
cases of multiple patients who had better “mental outlooks” and “improved spirits.” Even 
better, according to both patient and physician, was an enhanced ability to lose weight 
and combat obesity on the drug. Whether the case of Riker’s Rauwidrine mirrors that of 
Ciba’s Serpatilin is difficult to assess. But it does suggest the importance of combination 
drug therapies in psychiatric practice at this time, as well as pharmaceutical firms’ 
responsiveness to their potential. Even more striking is that the application of such 
combinations seemed equally germane to institutional psychiatry, where they augmented 
the effects of major tranquilizers, as well as outpatient psychiatry, where they apparently 
benefited patients with anxiety, minor depression, and insomnia. 
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Uppers for “Oldsters”: Stimulant Therapy for Geriatric Populations 
 By the mid-twentieth century, the infectious diseases that made infancy and 
childhood the most dangerous stages of life were still common, but the specter of death 
that accompanied measles, rubella, and other diseases had begun to fade. Child mortality 
declined and more Americans were reaching adulthood and surviving into old age. 
Historian Gerald Grob has noted that this phenomenon, termed the “second 
epidemiological transition” by demographers, had far-reaching consequences for 
American society and its health.77 Chief among these was the change in the age structure 
of the population and a new emphasis on treating the chronic degenerative diseases of 
adulthood and old age. Consider that in 1850, only four percent of the population was 
aged 60 or older, and in 1900, this figure had increased only slightly to six percent. 
However, by 1995, at least 17 percent of the population could be considered elderly. 
Such was the impact of this shift toward longer lifespans that cultural historian Howard 
Chudacoff has called attention to the emergence of “age consciousness,” especially as it 
related to the growing class of senior citizens.78 It probably comes as little surprise that 
such a profound demographic change was mirrored by the development of gerontology, 
the science of aging, and its attendant medical specialty, geriatrics.79 
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 In 1940, only 9 million Americans were 65 or older; authorities expected this 
figure to increase to 15.5 million Americans by 1960.80 Clinicians charged with treating 
these patients during this time had a wide variety of responses to this development. 
Consider one physician, who opined: 
In recent years it has become a paradoxical fact that medical achievement has 
increased rather than lessened one of our major health problems. Advances in 
surgical and medical techniques and the new knowledge resulting from biologic 
and pharmaceutical research has so extended the average life span tha[t] an ever-
increasing segment of our population is faced with the difficult mental and 
physical adjustments accompanying old age… 
The older personality is characterized by a lowered drive, and feelings of 
insecurity and inadequacy which frequently cause or aggravate the patient’s 
complaints. One of the primary purposes of any therapy directed toward the aged 
must be the alleviation of undesirable mental states.81 
 
In order to address emotional and mental problems faced by aging Americans, geriatric 
psychiatrists sought pharmacological aids for their patients. In 1944, Jacques Gottlieb, a 
psychiatrist at the Iowa Psychopathic Hospital and State University of Iowa’s College of 
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Medicine, documented his use of barbiturates to alleviate seniors’ tension and anxiety.82 
A few years later, clinicians reported success in using amphetamines such as Benzedrine 
to relieve mild depression and enhance mental alertness in their elderly patients.83 
 While some physicians might have prescribed both stimulants and depressants for 
the elderly, others harbored doubts. J. Leslie LeHew, a physician at the Masonic Home 
for the Aged in Guthrie, Oklahoma, expressed such reservations: “It has been [my] 
experience that these drugs, although occasionally helpful, are of very limited value in 
the treatment of the elderly. Amphetamines at times unduly increase nervousness and 
excitability; barbiturates often depress rather than sedate.”84 But even when voicing their 
concerns, physicians such as LeHew persisted in their belief that psychopharmacology 
would eventually help. The appearance of new combination drugs in the 1950s kept these 
hopes alive. 
 In 1950, SKF introduced Dexamyl, a combination drug containing 
dextroamphetamine (Dexedrine) and the barbiturate derivative amobarbital. In the 
immediate postwar era, the stimulant-depressant combination had received favorable 
attention for the treatment of depression.85 In one instance, a psychiatrist had described 
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his ability to treat 85 mildly depressed patients with Dexamyl.86 Mindful of these 
findings, LeHew prescribed the drug as a supportive, or supplemental, treatment for his 
patients who did not demonstrate overt signs or symptoms of mental illness. Over a year 
long period, patients were given one tablet of Dexamyl three times daily after meals. At 
the end of the period, 26 of the 36 patients experienced beneficial effects, while only 8 of 
the 28 patients taking a placebo experienced the same change. 
 On the surface, the mixture of amphetamine and barbiturate appeared to improve 
the health of the elderly patients who took them, but this perceived improvement was 
overshadowed by the fact that over half of the patients dropped out of the study within 
the first six months. The most common benefit was the alleviation of depression and an 
increase in sociability and activity resulting in “improved personal appearance and ability 
for self entertainment.”87 But at least one patient was made worse by a loss of appetite 
and a decrease in weight, which offset other improvements. Moreover, patients who 
dropped out of the study complained of gastrointestinal distress, poor appetite, backache, 
sleeplessness, nervousness, and hypertension. Despite some improvements from 
Dexamyl, LeHew had to contend with the fact that more than half of his patients stopped 
taking the drug because of unwanted side effects. 
 How might a physician have reconciled this apparent contradiction? LeHew 
thoughtfully considered the role of drugs in the lives of his patients:  
Actually, the medication seemed to be helping a few of the people who dropped 
from the study and, curiously enough, it seemed that this was the underlying 
reason for their discontinuing the medication. There are some old people who are 
afraid of health, who view their disabilities as something like accomplishments 
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entitling them to greater prestige, attention, and affection; and they tacitly resist 
anything that may threaten to deprive them of the bleak benefits of ill health. 
Obviously, no drug in itself can have a more than transient value for these 
patients. 
In this regard, it might be well to point out that any person’s ability to 
adjust does not depend alone on the numbers of years he has lived, but on the way 
he has lived his years. The ideal treatment of age, then, should begin in youth. 
Drugs cannot be expected to supply the answer to deep-seated personality 
problems—but they can help.88 
 
LeHew was sympathetic about the untoward effects the Dexamyl had produced in his 
elderly patients, but the frustrated physician also charged them with sabotaging their own 
therapy. If somewhat contradictory, LeHew at least understood that the drugs’ efficacy, 
or lack thereof, could only be explained when considering the broader milieu in which 
they were administered. At the same time, LeHew’s own reticence about administering 
Dexamyl to his patients, primarily because of the untoward effects of such a combination, 
suggests another issue just under the surface: the need for more efficacious therapies. 
Even if drugs could not “supply the answer” for patient’s problems, physicians remained 
enthusiastic about whatever assistance they might be able to provide. 
The Case of Ritonic 
 In November 1956, a special panel discussion on psychiatric drugs was sponsored 
by the American Geriatrics Society and American Academy of General Practice in New 
York. Led by psychiatrist Frank Ayd, Jr., and including other luminaries of the day such 
as Nathan Kline, the meeting considered the effect that new drugs, especially the major 
tranquilizers, were having on the management of mental disease in geriatric patients. 
While the panel discussion was clearly an outgrowth of the chlorpromazine and 
meprobamate revolutions, just as important was its implication about the role that 
medications could play in the management of aged patients. One such drug cited by Kline 
                                                





was Ritalin.89 Ayd also expressed an interest in the use of methylphenidate, and his work 
with the drug would play an important role in shaping its medical uses.90 
 In 1955, John Ferguson and William Funderburk of the Traverse City State 
Hospital in Michigan reported the story of a 76-year-old woman described as “talkative, 
wandering, disoriented, and confused,” and who “resisted help but was unable to help 
herself.”91 She had to be spoon-fed and soiled herself much of the time. On reserpine and 
methylphenidate, however, the woman’s condition began to improve as she “awaken[ed] 
to reality, showed a decrease in confusion, and started participating in off-ward 
activities.”92 Within six months of receiving these new drugs, the patient, who had been 
institutionalized since 1911, had ground parole and could go home or to a nursing home.  
This case was but one of many stories by Ferguson and Funderburk about the 
difference that Ritalin had made in their hospital. Under the drug’s influence, elderly 
patients “swamped” the staff beautician, bought toothbrushes, and asked for dental 
treatment. Destruction of furniture and clothes dropped 65 percent and mattress 
replacement was reduced by 75 percent. Nursing time for spoon feeding was “markedly 
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decreased” and attendance at hospital social functions increased 300 percent.93 “Our 
goal,” Ferguson and Funderburk related with a measure of pride, “was not so much the 
actual results to be obtained as it was an endeavor to help solve a great and ever-growing 
situation that faces the medical profession today, the socio-medical problems created by 
the extra years we, as doctors, have given mankind.”94 For the two researchers, 
methylphenidate and reserpine therapy provided general practitioners with the same 
powerful tool that aided psychiatrists in their bid to help patients in the institutional 
setting. Ferguson and Funderburk were explicit in their belief that these drugs “might 
make it possible for many senile older people to be cared for at home instead of having to 
go to institutions.”95 In reporting their findings, the researchers noted that if homes were 
available, 50 percent of their patients could be discharged.96 Just as important was 
Ferguson and Funderburk’s emphatic belief that general practitioners, especially family 
doctors, could prescribe the drug combination for their elderly patients, in order to 
forestall their need for nursing home care.97 
As much as Ritalin had influenced the outlooks of patients, it also affected how 
physicians understood their abilities and responsibilities as healers. Clinicians such as 
LeHew had frequently expressed uncertainty about what they could do to improve elderly 
patients’ health and quietly lamented the limits of their therapeutic capabilities. Such 
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attitudes contrasted with the sentiments of doctors such as Ferguson and Funderburk just 
a few years later. Ritalin’s application in the management of the elderly seemed 
prescient. Rather than treating a select number of patients with specific symptoms, the 
drug could be prescribed to an entire demographic suffering not necessarily from a 
particular disease but a set of symptoms that could be redefined as one. A recurring 
theme among those physicians writing about Ritalin’s utility was their observation that 
geriatric populations did not necessarily suffer from any specific disease.98 Their 
depression was tied to their advanced age and presumed deterioration of mind and 
body.99 These clinicians identified their patients as a population whose problems were not 
limited to the physiological, but also had elements of social or economic causation. 
Psychotropic drugs could be used not just to manage the symptoms of a disease, but also 
to restore a “sense of well-being” resulting from physical, social, and economic, 
repercussions of aging. For their patients with “no real organic disease,” Ritalin appeared 
to be an appropriate therapy.100 
For its part, Ciba appears to have understood this potential market for Ritalin. In 
many advertisements during the 1950s and 1960s, the firm made aged patients a 
particular focus.101 In one advertisement from 1957 (Figure 2.4), a visibly distressed, 
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older woman is promoted as a viable candidate for the drug in the treatment for 
depression. This particular ad was one among several published by Ciba as part of its late 
1950s “Ritalin Helps Brighten the Day” campaign. In another ad almost a decade later 
(Figure 2.5), seniors were still recognized by the manufacturer as patients for the drug. 
Indicated for “chronic fatigue that depresses and mild depression that fatigues,” the 1966 
advertisement for Ritalin depicted a listless older woman in the left panel, beset by a 
large pile of unpeeled potatoes. In the right panel, presumably after taking her 
medication, the same woman appears more content and energetic as she finishes peeling 
the potatoes.102 While it is necessary not to construe too much meaning from such ads, 
both depict how Ciba targeted the elderly as potential patients for Ritalin during the 
1950s and 1960s. 
 
                                                                                                                                            
may disclose one aspect of the complicated process in which markets are created, negotiated, and 
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Figure 2.4 – 1957 advertisement for Ritalin, “When Reassurance Is Not Enough…” 




Figure 2.5 – 1966 advertisement for Ritalin, “Relieves Chronic Fatigue that Depresses 
and Mild Depression that Fatigues.” (Source: 1966 issue of JAMA. The author thanks 





In 1959, the company introduced Ritonic for “patients who are losing their drive, 
alertness, vitality and zest for living because of the natural degenerative changes of 
advancing years.”103 A “new preparation designed to improve mood and maintain 
vitality,” each capsule of Ritonic contained Ritalin, B vitamins, and sex hormones (both 
testosterone and estrogen).104 Ritonic demonstrated how psychopharmacology was 
expanding into the newly developing geriatric market. Ciba’s efforts were mirrored by 
other companies. For example, SKF had similarly attempted to market Thorazine for 
senility during the mid- to late 1950s (see Figure 2.6). The marketing of two very 
different classes of drugs, a stimulant (Ritalin, Ritonic) and a major tranquilizer 
(Thorazine), for similar symptoms is striking, but not necessarily paradoxical. Each of the 
drugs produced effects considered desirable among physicians treating aging patients. 
Likewise, the marketing of pharmacologically opposing drugs for similar symptoms 
would continue, as I demonstrate in the next chapter. In this case, however, the 
emergence of Ritonic was part of a larger phenomenon of drug marketing for geriatric 
psychiatry. 
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Figure 2.6 – 1957 advertisement for Thorazine for elderly patients, “Doctor, what can 
you do for Pop?” (Source: June 1957 issue of Geriatrics. The author thanks Ben Hansen 




Another important development was the role of non-psychiatrists who 
increasingly prescribed drugs for newly defined “psychiatric” disorders of the elderly. 
For example, general practitioner Wesley Bare enthusiastically observed that Ritonic 
should “have a place in the armamentarium of the physician who sees even one aged 
patient.”105 Pharmaceutical company advertising in non-psychiatric journals further 
reflected the expansion of methylphenidate beyond the psychiatrist’s realm in the 
treatment of aging patients. 
Not all clinicians shared Bare’s enthusiasm for Ritonic, however. In 1966, two 
Texas physicians published their findings from a double-blind study of an unnamed 
vitamin-anabolic-stimulant mixture produced by Ciba (presumably Ritonic). They 
reasoned that a widespread belief that underweight geriatric patients would benefit from 
                                                





such tonics had never been subjected to rigorous testing. Such assumptions had “stood 
the test of time, extending from the days of the traveling medicine man to the age of 
television hucksters.”106 The two physicians did not necessarily view Ritonic as a quack 
product and, indeed, they praised some of its attributes, including the potential for 
methylphenidate to work as a psychic mood energizer for the elderly. While such a 
product streamlined the administration of several medications, they concluded that 
combination therapy should offer more therapeutic advantages than the “mere 
convenience of administration.”107 The researchers concluded that Ritonic offered no 
additional advantages over the individual administration of methylphenidate, vitamins, 
and hormones. In fact, such mixtures did not allow clinicians to customize the ingredients 
or their dosage to meet individual patient needs. Illustrative of Ritonic’s therapeutic 
inflexibility was the fact that the mixture contained similar amounts of estrogen and 
testosterone and did not take into account the hormonal differences between men and 
women. Physicians did not limit themselves to what Ciba placed on the market, however. 
The use of a dextroamphetamine and meprobamate combination by another group of 
physicians around the time demonstrates an ongoing experimental attitude by physicians 
seeking novel therapies for their patients.108  
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Medication Advantageous for Debilitated Geriatric Patients?” Journal of the American Geriatrics Society 




108 Arnold D. Krugman et al., “A Research Note: Effects of Dextro-Amphetamine and 
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Considering Combination Drug Therapy 
The use of psychostimulants as part of combination drug therapies was, in many 
ways, a defining characteristic of their use in institutional settings. In some cases, drugs 
such as Ritalin and Dexedrine were relegated to playing supporting roles. Yet 
psychiatrists who turned to these combinations acknowledged that they conferred a 
therapeutic efficacy that would have been unobtainable had just one drug been 
administered. While historians of psychopharmacology have rightly pointed to the 
revolution wrought by chlorpromazine and other major tranquilizers, they have paid scant 
attention to the role that drug combinations played in solidifying their effectiveness. 
 What made drug combinations useful to clinicians? In the treatment of psychosis, 
many clinicians noted that the untoward effects of chlorpromazine produced patients 
whose psychotic symptoms may have been alleviated, but at the expense of extreme 
fatigue. Hence, psychiatrists laboring to make their patients better “turned to the 
apparently paradoxical, but well-established therapeutic device of limiting the effect of 
one drug by administering its physiologic opposite, either simultaneously or 
consecutively.”109 In other cases, a drug such as chlorpromazine administered by itself 
appeared ineffective, but produced positive results when combined with amphetamine or 
methylphenidate. Such approaches to combination therapy also demonstrate how 
psychiatrists were imbued with a sense of pragmatism in their efforts to discern the best 
therapeutic options for their patients. 
Enthusiasm for combination therapies persisted even after newer drugs became 
available for the treatment of depression, anxiety, and other disorders. In the late 1960s, 
Dr. Heinz Lehmann and his research associates at the Douglas Hospital in Verdun, 
                                                





Quebec, undertook a study to determine how efficacious a combination of Dexedrine and 
Demerol, an opioid analgesic, were in the treatment of depression. Rather than targeting 
mild depression, Lehmann’s trial group was patients with “vital depression,” with 
depressed mood and feelings of hopelessness, worthlessness, and guilt. The doctors found 
that the combination helped most patients studied.110  
 Lehmann’s study is significant partly because it illustrates that although tricyclic 
antidepressants and MAOIs had been available for the treatment of serious depression 
beginning in the late 1950s, psychiatrists remained interested in psychostimulants for the 
treatment of depression. While identifying amphetamines specifically as stimulants of the 
central nervous system, they recognized that the drugs’ pharmacological effects had 
similarities to antidepressants. As drug companies began to seek new markets during the 
1960s, interest in older psychostimulants endured. 
 As the cases of Dexamyl, Serpatilin, and Ritonic demonstrate, pharmaceutical 
firms were not oblivious to potential markets for combination drugs. While it is unclear 
whether drug companies followed clinicians’ leads when introducing these new products, 
the cases of Serpatilin and Ritonic suggest that Ciba was receptive to the way in which 
their drugs were being utilized, and then developed combination products in response. In 
his consideration of Dexamyl, Rasmussen has likewise observed the role that clinical use 
of drug combinations played in marketing.111 While physicians may have been receptive 
to combining drugs in their practices, they did not necessarily embrace the integrated 
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Folder 31, International Neuropsychopharmacology Archives, American College of 
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products offered by pharmaceutical firms. As the case of Ritonic demonstrates, some 
physicians preferred the flexibility conferred by tailoring drugs and dosages individually 
for each patient. Nevertheless, the use of psychostimulants in institutional settings during 
these years suggests the importance of combination drug therapy as part of those 
practices.  
Industry Response to Clinician Practices 
 Scholars such as David Healy, Nicolas Rasmussen, and Jeremy Greene have 
discussed the efforts of pharmaceutical firms to shape the indications of their drugs to 
capitalize on potential markets. One of the best-known tools in these efforts has been the 
Physicians’ Desk Reference (PDR), first published in 1947 as a promotional and 
educational tool by firms for their products. While the first edition of the PDR was a 
mere 300 pages, by the 1960s, it had grown to over 1,000 pages.112 At over 3,000 pages, 
the most recent version (63rd edition, published in 2009) is more than ten times the size of 
the original.113 Accompanying the expansiveness of the PDR, however, has been its 
growing reputation as a source of information for prescribing physicians. What began as 
a means to position drugs in the medical marketplace has become a leading resource for 
physicians in understanding a drug’s indications. The PDR is but one example of how the 
pharmaceutical industry influenced physician practices; the use of “detail men” who have 
supplied physicians with information about their products is another well-documented 
practice.114 Taking into account historians’ observations of the active role played by 
                                                
112 My thanks to Jeremy Greene for this observation in Prescribing by Numbers, 22n3. 
 
113 Physicians’ Desk Reference, 63rd ed. (New York: Thomson-Reuters, 2009). 
 
114 Jeremy Greene, “Attention to ‘Details.’” See also, Tone, Age of Anxiety, 72-77, 125-155, for a 
discussion of how internal tensions existed within pharmaceutical firms over how best to promote their 





pharmaceutical firms in discerning potential markets for their drugs, my study of Ritalin 
suggests how firms likewise took advantage of the ways that clinicians used their 
products. 
 Immediately upon bringing Ritalin to market, Ciba touted its potential as an 
antagonist for barbiturate anesthesia (see Figure 2.7). Anesthesiologists were one of the 
earliest markets for Ritalin, based primarily on initial research that determined the drugs 
basic physiological effects on the body. Ritalin was not unique in this regard, as SKF 
similarly promoted Thorazine as a relaxant for surgery (see Figure 2.8). But 
accompanying this initial marketing by Ciba were investigations by inquisitive clinicians 
regarding other novel applications for the drug. Mindful of the established uses of 
amphetamines for weight loss, physicians probed the potential of methylphenidate for the 
medical management of obesity. Unfortunately, Ritalin did not prove to be as successful 
in this regard as SKF’s Dexedrine and Dexamyl.115 Nevertheless, these failures tell us 
much about the wide-ranging approach that clinical researchers took toward discovering 
novel applications for Ritalin during the 1950s. 
 
                                                                                                                                            
use detail men in order to promote the drug. After Berger retired from the company, Carter immediately 
resorted to detailing for Miltown. 
 
115 Oliver FitzGerald and L. G. McElearney, “Clinical Trial of Cafilon and Ritalin in the 






Figure 2.7 – Ciba advertisement for parenteral (intravenous) Ritalin for recovery from 






Figure 2.8 – SKF advertisement for Thorazine to prevent nausea during surgery, further 
suggesting myriad applications of psychotropic medications. (Source: Journal unknown. 






Not all applications turned out to be therapeutic dead-ends, however. The first reports 
about Ritalin’s potential for geriatric patients surfaced almost immediately after the drug 
reached market in 1955, and Ciba then moved to indicate and market Ritalin for older 
patients in 1957. The company went even further to introduce Ritonic in 1959, four years 
after Ferguson and Funderburk first reported on the efficacy of the drug for older 
patients. Likewise, Serpatilin reached market just after initial reports on the efficacy of 
methylphenidate and reserpine for mentally ill patients. New indications for Ritalin in the 
PDR and Ciba advertising during the 1950s and 1960s often emerged after their 
discussion in the clinical literature first, suggesting how firms were responsive to 
physician practices. 
 Conclusion 
 In this chapter, I call attention to how clinicians found a place for psychostimulant 
drugs in institutional psychiatry during the immediate postwar period. Using Ritalin as a 
case study, I conclude how these drugs served to counteract the untoward effects of the 
major tranquilizers credited as the first decisive therapies in the treatment of 
schizophrenia during the 1950s. While they may not have predominated in mental 
hospitals, these overlooked combination therapies extended the promises of efficacy to 
more patients than if chlorpromazine and reserpine had been used alone.116 In addition, I 
also demonstrate the position that psychostimulants held among clinicians who sought 
additional therapeutic options to alleviate the most severe forms of depression. When 
compared to established somatic therapies, stimulants were valued for their potential as 
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settings during these early years has been establishing how many physicians prescribed the drugs, or how 
many patients used them. Here, I have only been able to infer from the relevant literature that the use of 
these stimulants was established as a matter of practice, but not necessarily ubiquitous. I take up this issue 





adjuncts in dealing with patients either unwilling or incapable of undergoing treatments 
such as ECT. In both instances, stimulant pharmacotherapy demonstrated the pragmatism 
of psychiatrists as they utilized pharmaceuticals in ways that made sense to them and for 
their patients. At the same time, the uses of these drugs in institutional settings, especially 







Strange Couchfellows: Stimulants, Psychotherapy, and Depression in Outpatient 
Psychiatry 
 
During the same era in which institutional psychiatrists exploited the effects of 
psychostimulant medications to alleviate the symptoms of severe mental illness, 
outpatient psychiatrists contemplated the use of these drugs for patients and conditions of 
a different type. Private practice psychiatry, characterized during this time by its 
psychodynamic approach to neurosis, was also transformed by the pharmacological 
developments of the postwar era. Historians have called attention to how anxiolytics and 
antidepressants eventually displaced the dominance of Freudian “talk therapies.” Less 
appreciated, however, is how psychiatrists adapted stimulant drugs for use within the 
psychoanalytic paradigm. In this chapter, I discuss the neglected history of 
pharmacologic psychotherapy, documenting its brief heyday during the 1950s and its 
eventual dissolution by the end of the 1960s.1 
Introduction 
 Recent historical scholarship has emphasized how pharmacotherapy with 
anxiolytics and antidepressants superseded psychoanalysis as the primary form of 
                                                
1 Shorter calls attention to the problem of disentangling “psychotherapy” from “psychoanalysis” 
during the early and mid-twentieth centuries, claiming that at times “the analytic dog was wagging the 
therapeutic tail.” See Shorter, History of Psychiatry, 370n55. Though many of psychiatrists depicted in this 
chapter are practitioners of psychoanalysis and adherents of one of the traditions established by pioneers 
such as Sigmund Freud, Carl Jung, or Albert Adler, not all of them are. Some psychiatrists preferred a more 
generic form of talk therapy, referred to here as psychotherapy. In addition, not all psychoanalysts and 
psychotherapists were necessarily psychiatrists, but many of them were, as membership to the most 
prestigious societies related to these techniques was limited to physicians. Many patients might have 
received psychotherapy from psychologists, but it is important to remember that drug-mediated 
psychoanalysis and psychotherapy, as discussed in this chapter, was limited to psychiatrists. As physicians, 





therapeutics in postwar outpatient psychiatry. For some historians such as David Healy, 
this transition owed much to changing diagnostic categories that increased the number of 
people affected by depression and viewed disorders increasingly in biological rather than 
psychodynamic terms.2 In describing the rise of the “second biological psychiatry,” 
historian Edward Shorter has likewise emphasized the attenuation of a psychodynamic 
orientation toward mental illness during the postwar era.3 However, psychiatrists did not 
immediately discard talk therapies in favor of treatment exclusively with new “wonder 
drugs.” The process of change in outpatient psychiatry was gradual and even paradoxical.  
This chapter contributes to historical scholarship by investigating the use of drugs 
by psychoanalytically oriented psychiatrists during the 1950s and 1960s. Rather than 
challenging the old order, pharmacotherapy could be harnessed to preserve it, or even 
improve it, by expediting psychoanalysis. Psychiatrists were able to facilitate cathartic 
emotional responses in their patients that complemented transference therapies. 
                                                
2 Healy, Antidepressant Era. In The Antidepressant Era, one of Healy’s central observations 
relates to the fact that depression has never been a single unifying concept, and one that has become more 
fractured with the development and use of antidepressant drugs during the past 40 years. Before the 
antidepressants, depression, as it was then understood, was uncommon and considered a disorder of great 
severity. Healy suggests that the availability of antidepressants as part of the psychopharmacological 
revolution appropriately placed more attention on the illness and probably led to more effective 
recognition, diagnosis, and management of the disorder. However, Healy also h grave concerns that the 
widening diagnostic criteria of depression may involve the pharmaceutical industry’s marketing of not only 
the drugs but also the illness itself. It is also important to note that when dealing with depression, Healy 
harbors concerns over the reconceputalization of depression as a relatively common disorder, and one 
whose sufferers are overwhelmingly less likely to be found in institutional settings. This transition in the 
diagnosis of depression appears to underpins Healy’s study more than any other factor: “The common 
experience of depression lies somewhere midway between illness and disease, and the drugs themselves, 
the antidepressants, like somewhere between magic bullets and snake oil” (3-4). 
 
3 Shorter refers to the “second biological psychiatry” in A History of Psychiatry as the period 
between the 1950s and 1970s in which biologically-oriented psychiatry, which have relied upon somatic 
diagnoses for mental illness and pharmacotherapy for their treatment, displaced the psychoanalytic 
(Freudian) paradigm of psychiatric practice. Credit for this change belongs in large part, Shorter argues, to 
the successful introduction of chlorpromazine. The “first biological psychiatry” refers to a period in the late 
nineteenth and early twentieth centuries, in which psychiatrists led by Emil Kraeplin viewed psychiatric 
illness in biological terms. For Shorter, the period of psychoanalytic domination (at least in private 
practice—he acknowledges the role of somatic “alternatives” in institutions) represented a “hiatus” 
between the “first biological psychiatry” and “second biological psychiatry.” To his credit, Shorter also 





Stimulants such as Ritalin, Dexedrine, and Methedrine, in particular, were congruous 
with psychoanalytic practices because they induced effects that tended to enhance 
communication between the doctor and patient. Central to the transference therapy 
performed by these practitioners was a process known as abreaction. Abreaction is the 
expression and emotional discharge of unconscious material (as a repressed idea or 
emotion) by verbalization, especially in the presence of a therapist. With the assistance of 
drugs such as the psychostimulants, psychiatrists could abreact painful and traumatic 
experiences in their patients, revealing them as part of transference therapy and then 
inducing, both through the psychoanalytic interview and pharmacologically, a relief of 
tension. Pharmaceuticals facilitated these dialogues, but the therapeutic relationship 
between doctor and patient, not the drug that mediated it, received credit for the 
treatment. 
In addition to highlighting the application of drugs by psychiatrists not commonly 
associated with their use, I also examine the debates surrounding their place within 
psychoanalytic practice. Outpatient psychiatrists during the 1950s were often divided 
about the use of pharmaceuticals in their practices. Some openly opposed them on the 
grounds that they interfered with the doctor-patient relationship. But others 
enthusiastically embraced stimulants as a means to help cure anxious breadwinners and 
repressed housewives of their neuroses. Debates went far beyond whether drugs helped 
or hindered psychiatric practice, however, as psychiatrists contemplated what specific 
role they might play and the limits of their usefulness. Were they merely experimental 
tools, or might they be suitable for everyday practice? While their use constituted a 





the drugs in an effort to enhance their relationships with patients, better determine the 
causes of their problems, and discern the best course of treatment.  
 At the same time, there is a need to understand precisely why private practice 
psychiatrists felt it necessary or, at the very least, thought it useful to introduce drugs into 
therapies rooted in the relationship between physician and patient and solidified by the 
rapport of the “talking cure.” I argue that psychiatrists faced with uncommunicative 
patients and the threat of therapeutic failure did so primarily because they had no choice 
if they wished to pursue an effective course of talk therapy. Yet, these decisions were not 
necessarily unilateral, at least not in the mind of the psychiatrist. It was the patient, 
through his or her lack of responsiveness to conventional forms of psychoanalysis and 
psychotherapy, who generally made all the difference. In effect, unresponsive patients 
were passive agents, rather than outright clinical subjects, whose perceived lack of 
response to psychoanalysis was the primary factor in the decision to introduce stimulants 
into the therapy session. 
 Finally, my examination of the application of stimulant drugs within 
psychotherapy complicates the historiography by suggesting that a biological orientation 
in outpatient psychiatry did not neatly displace analytical and other psychodynamic 
approaches. In line with historians such as Jonathan Metzl and Andrea Tone, my story 
suggests that these clinicians did not immediately change the way they practiced 
psychiatry.4 While a transformation in psychiatry certainly did take place, for a time, 
psychiatrists demonstrated the potential of a hybrid approach within their practices. I 
emphasize the eclectic and pragmatic nature of outpatient psychiatry during the 
                                                





immediate postwar period by suggesting how drug and talk therapies could exist side-by-
side in the minds of some psychiatrists.  
The Rise of Psychoanalysis in the United States 
 A nuanced understanding of the history of psychiatry rests upon comprehending 
the historical division between psychosis and neurosis. For much of its history, modern 
psychiatry was most concerned with addressing the problem of psychosis. As I discussed 
in the previous chapter, many of these patients were confined to institutions during the 
nineteenth and twentieth centuries, and their conditions were most closely linked to the 
profession of psychiatry. During the early twentieth century, however, psychiatry became 
increasingly invested in a second group of individuals, those people who led otherwise 
normal lives but still suffered from anxiety and everyday depression. For much of the 
nineteenth century, these disorders, known collectively as neurasthenia, had been the 
purview of private practice neurologists whose interests in treating the “nerves” of their 
clientele were quite distinct from the psychiatrists who ministered to the mentally ill in 
asylums and other custodial institutions.5  
Much of the credit for psychiatry’s eventual focus on everyday ills belongs to 
Sigmund Freud, indisputably one of the most important figures in modern history.6 
Originally trained as a neurologist, Freud began his eminent career with a concern for the 
                                                
5 F. G. Gosling, Before Freud; and Gijswijt-Hofstra and Porter, Cultures of Neurasthenia.  
 
6 It goes without saying that Freud is one of the most researched and discussed figures in modern 
history. Perhaps the best introduction remains Ernest Jones’s three volume biographical study: Ernest 
Jones, The Life and Work of Sigmund Freud, Vol. 1: The Formative Years and the Great Discoveries, 1856-
1900 (New York: Basic Books, 1953); Ernest Jones, The Life and Work of Sigmund Freud, Vol. 2: Years of 
Maturity, 1901-1919 (New York: Basic Books, 1955); and Ernest Jones, The Life and Work of Sigmund 
Freud, Vol. 3: The Last Phase, 1919-1939 (New York: Basic Books, 1957). Written during the height of 
psychoanalysis in America, Jones’s provides a relatively balanced view of Freud’s life. More recent 
biographies of note include Peter Gay, Freud: A Life for Our Time (1988; reprint, New York: W. W. 






workings of the human brain. This interest manifested itself during the 1890s when he 
sought to reform the diagnosis of neurasthenia. In 1894, he proposed that neurasthenia be 
reduced to two diagnoses, “actual neurasthenia,” which had a somatic basis, and “anxiety 
neurosis,” which was psychogenic in origin. Freud subsequently dedicated the remainder 
of his career to understanding this latter category of neurosis.7 Through the publication of 
such famous works as 1899’s The Interpretation of Dreams, 1914’s On Narcissism, and 
1930’s Civilization and Its Discontents, Freud expounded on his ideas for understanding 
the causes of neurosis, which he ascribed to the repression of certain sexual desires as 
defense mechanisms by the part of the psyche he termed the “ego.” The only way for a 
patient to overcome these neuroses, Freud postulated, was through a set a therapies 
known collectively as psychoanalysis. Relying upon techniques such as dream 
interpretation and transference therapy, the psychoanalyst worked with the patient to 
recover repressed memories, identify the source of the neurosis, and work toward a cure. 
Psychoanalysis relied upon interview sessions that lasted weeks, months, or even years, 
and where the expertise of the therapist was paramount.8 
 During the early decades of the twentieth century, Freud’s ideas were embraced 
most enthusiastically in the United States. While there were a number of reasons to 
explain why psychoanalysis made such headway in America, one motivation was the 
psychiatric profession itself. Originally the province of neurologists, particularly in 
Europe, neurosis and its treatment offered psychiatrists an opportunity to expand their 
professional boundaries. Less charitably, their embrace of psychoanalysis offered them a 
                                                
7 See Tone, Age of Anxiety, 16-19. 
 
8 For more on psychoanalysis as it was practiced, see Quen and Carlson, American 
Psychoanalysis. Also, Freedheim, History of Psychotherapy, provides a number of thoughtful articles on 





chance to move from the back wards of institutions to the respectability of private 
practices. If too simplistic an explanation, there was little doubt that by the mid-twentieth 
century, both psychosis and neurosis had become the domains of American psychiatry.9 
 As historian Gerald Grob has noted, American psychiatry found itself divided by 
the late 1940s. On one side were institutional psychiatrists, many of whom believed that 
the profession should limit itself to the care of the mentally ill and who were committed 
to the idea of organic pathologies and somatic therapies. Opposing this group were those 
psychiatrists who believed that the old institutional model was obsolete and that the 
profession should devote itself to psychodynamic and psychoanalytic ideas.10 In reality, 
each group was a key driver within the profession. Psychiatry was still dedicated to the 
severely mentally ill within institutions where somatic therapies were still the dominant 
forms of treatment. But psychiatry also had been carving out a place for itself in the 
public sphere since the beginning of the century. In this market-driven world of neuroses, 
psychiatrists and patients alike were committed to Freudian psychoanalysis for both 
diagnosis and treatment. Even the publication of the first Diagnostic and Statistical 
Manual (DSM-I) in 1952 validated this binary view of psychiatry’s concerns by 
distinguishing between psychoses and neuroses.11 Yet within much of psychiatry, control 
                                                
9 For a more detailed discussion of Freud’s embrace by American psychiatry during the early 
twentieth century, see Nathan G. Hale Jr., Freud and the Americans: The Beginnings of Psychoanalysis in 
the United States, Freud in America, vol. 1 (New York: Oxford University Press, 1971); and Hale, Rise and 
Crisis of Psychoanalysis in the United States. Other considerations of Freudian ideas in the United States 
may be found in Shorter, History of Psychiatry, chap. 5. Also, John Burnham’s essay “The Influence of 
Psychoanalysis upon American Culture,” in Quen and Carlson, American Psychoanalysis, remains one of 
the best reflections of Freud’s impact on American psychiatry. 
 
10 Grob, Mad among Us, 199-201. 
 
11 Committee on Nomenclature and Statistics, Diagnostic and Statistical Manual: Mental 
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of the professional organizations, journals, and societies fell to analytically oriented 
psychiatry between the late 1940s and late 1960s.12 
Psychopharmacology Redux: Considering Outpatient Psychiatry 
 The dominance of psychoanalysis in the United States, which began to peak 
during the 1950s, was complicated by pharmacotherapies aimed at addressing the 
everyday concerns of anxiety. As I observed in the previous chapter, the first 
beneficiaries of psychopharmacology were institutional psychiatrists. But the 
pharmacological revolution was not lost on private practice psychiatrists, many of whom 
were still using psychotherapeutic methods to address the needs of their patients. The 
anxiolytic drug meprobamate, marketed by Carter as Miltown and by Wyeth as Equanil, 
had a peculiar early history.13 Historian Andrea Tone has observed that when 
meprobamate was introduced in the mid-1950s as the first minor tranquilizer for anxiety, 
its manufacturers were keen to market the drug as an adjunct for psychotherapy, not as a 
replacement for it. In a series of deft advertisements designed to allay possible fears 
within the prevailing psychiatric establishment, Carter and Wyeth promoted the 
medication as a tool to aid psychoanalysis by helping the patient to calm down and 
become more introspective as part of the therapy session. Hence, meprobamate would 
                                                
12 The leadership of brothers Karl and William Menninger in American psychiatry during this time 
provides one example of the professional and public dominance by psychodynamic and psychoanalytic 
proponents. Karl Menninger had been influential in the popularization of psychoanalysis in the United 
States through the publication of a number of bestselling books, the foundation of the Menninger 
Foundation, and the establishment of the Menninger Clinic in Topeka, Kansas. William served as president 
of the American Psychiatric Association (APA) and also played a crucial role in the passage of the 1946 
National Mental Health Act. The Menninger brothers’ belief that the success of battlefield psychiatry 
during World War II could be applied in civilian practice also demonstrated that while there may have been 
distinctions between the treatment of psychosis and neurosis, the two domains were also somewhat porous. 
See Grob, Mad among Us, chaps. 8 and 9.  
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relax the patient into a higher state of suggestibility and openness. Tone has posited that 
few drug companies or psychiatrists in the 1950s and 1960s thought the source of anxiety 
could actually be eliminated by dispensing anxiolytics. But the drugs were believed to 
minimize the social, economic, and political consequences of anxiety, while making the 
job of the therapist easier at the same time by enhancing rapport and communication with 
the patient.14 
Historian Nicolas Rasmussen has also noted how firms positioned stimulant drugs 
to appeal to analytically informed psychiatrists.15 One relevant example was the 
marketing of methamphetamine, manufactured by Burroughs-Wellcome as Methedrine, 
for psychoanalysis (see Figure 3.1). At the same time, however, he has discounted their 
actual use in practice, observing that drug-mediated psychoanalysis “could not have 
represented a very large market” even if “some drug firms did market amphetamines 
explicitly for this purpose, perhaps for prestige value.”16 In this chapter, I argue that there 
is a need to go beyond the marketing of psychostimulants and understand how some 
psychiatrists applied the drugs in their practices. Doing so, I contend, further elucidates 
the history of psychostimulants by parsing the actual relationship that these clinicians had 
with stimulants. 
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Watkins, Medicating Modern America, 163. 
 
15 Rasmussen, On Speed, 122, 134.  
 






Figure 3.1 – 1952 advertisement by Burroughs-Wellcome for Methedrine, 





 The idea that tranquilizers’ properties enabled patients to relax and become more 
introspective during a psychotherapy session seems more intuitive than how 
amphetamines might have been utilized for the same purpose. The difference with 
stimulants was their ability to induce hostility, aggression, and anger as part of the 
abreaction process. For psychiatrists who were adherents of Sigmund Freud, Alfred 
Adler, and other leaders of the psychoanalytic school, such states of tension and the 
resolutions that followed were decisive in achieving therapeutic breakthroughs. The 
psychostimulants produced physical and psychological effects—excitement and lowering 
of inhibitions—congruous with the aims of much of outpatient psychiatry between the 
late 1940s and the late 1960s. Rather than reducing the tension and anxiety of their users, 
these drugs often had the opposite effect. As one proponent of their use in 





It has been found that even an unfavorable side effect of d-amphetamine sulfate, 
such as irritability, may be used in the therapeutic interview….Such an interview 
helps the patient to recognize his own feelings and provides an opportunity for the 
therapist to show his acceptance of the patient’s feelings (anger, in this case) and 
to help him understand and handle them.17 
  
While Miltown and Valium provided outpatient psychiatrists with tools to help manage 
their patient’s symptoms of anxiety, the drugs also threatened to put analytically oriented 
psychiatrists out of business.18 Methedrine and Ritalin, on the other hand, more explicitly 
reinforced psychoanalysis because they were understood not as medications that 
alleviated visible symptoms, but as adjuncts that facilitated talking cures. 
Adjuncts to Psychoanalysis 
Though drug-aided psychotherapy may have reached its apex with 
psychostimulant drugs, there were notable antecedents. The introduction of barbiturates 
led a number of psychiatrists during the 1930s to use these drugs as part of their 
psychotherapeutic interviews, a technique sometimes referred to as narcoanalysis.19 
During World War II, widespread interest in this form of therapy was piqued by the 
reportedly successful use of intravenous barbiturates in battle casualties. Military 
psychiatrists reported that these drugs helped soldiers suffering from “shell shock” to re-
                                                
17 A. Dorothea Pohlman, “The Use of D-Amphetamine Sulfate as an Adjunct to Psychotherapy,” 
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experience the violent emotions of battle and enabled clinicians to relieve their patients’ 
anxiety or hysterical symptoms. As the war progressed, studies published by a number of 
psychiatrists found that more long-standing cases of “conversion hysteria” responded 
better to excitatory agents, particularly methamphetamine. As civilian outpatient 
psychiatric practice came to the fore after the war, psychiatrists began to explore the 
potential of abreaction even more.20 
 A number of abreactive agents were demonstrated with some success in the late 
1940s and early 1950s, including carbon dioxide and barbiturates.21 However, the 
majority of psychiatrists who experimented with chemically induced abreactions showed 
a preference for amphetamine and methamphetamine.22 By the late 1950s, the 
introduction of methylphenidate gave psychiatrists who believed amphetamine to be too 
volatile and dangerous for use in their private practices an alternative deemed “safe and 
effective” by its supporters.23 Despite the introduction of methylphenidate as a less harsh 
drug, amphetamine and methamphetamine would continue to remain popular choices 
among a number of psychiatrists through the early 1960s. 
Abreaction in Practice 
 During the course of their treatment with a patient, psychiatrists did not 
mechanistically resort to the use of drugs in psychoanalysis. Generally, most psychiatrists 
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who used pharmacological aids first attempted psychotherapy without them. 
Nevertheless, psychiatrists found that some patients, for one reason or another, failed to 
respond favorably to psychoanalysis. In one survey of patients, researchers noted that 
failure often resulted from the inability to communicate effectively, impersonal attitudes 
on the part of psychoanalysts toward their patients, difficulties in relating to the 
psychoanalyst, failure to experience meaningful emotional reactions during the 
therapeutic hour, or mounting anxiety as treatment progressed.24 Key to psychoanalysis’ 
success, its practitioners claimed, was good communication and strong rapport between 
the psychiatrist and patient.  
 A potential beneficiary of drug-aided psychotherapy included World War II 
veterans.25 In one case from 1958, a 40-year old advertising executive had seen a 
psychiatrist in New York for anxiety and depression.26 The patient had occasionally 
suffered from these symptoms following his service in the navy during the war. 
According to the psychiatrist’s notes, after three months of “passive, intellectual, detail-
weighted discussions,” the advertising executive began to improve in mood.27 But the 
psychiatrist believed there was still a poor therapeutic relationship. So, he made the 
decision to administer the patient with Methedrine during the session. The patient arrived 
                                                
24 Theodore Rothman and Keith Sward, “Studies in Pharmacological Psychotherapy. I. Treatment 
of Refractory Neuroses and Personality Disorders with Thiopental (Pentothal) Sodium and 
Methamphetamine (Desoxyn),” AMA Archives of Neurology and Psychiatry 75, no. 1 (January 1956): 96 
 
25 For more on postwar rehabilitative psychiatry, see Hans Pols, “The Repression of War Trauma 
in American Psychiatry after World War II,” in Medicine and Modern Warfare, ed. Roger Cooter, Mark 
Harrison, and Steve Sturdy (Amsterdam: Rodopi, 1999), 251-276. A contemporary psychoanalytical 
perspective on the same issue may be found in Edward A. Strecker, Their Mothers’ Sons: The Psychiatrist 
Examines an American Problem (Philadelphia: Lippincott, 1946), 13-22.  
 
26 Gordon Templeton and Vann Spruiell, “Methedrine Interviews: Clinical and Rorschach 
Studies,” Psychiatric Quarterly 32, no. 4 (October 1958): 788. 
 





about an hour or so before his session, a medical work-up was done, and the drugs were 
administered to him intravenously.28 Under the influence of methamphetamine, the 
doctor observed that the patient attempted to maintain the same intellectual control—“but 
in spite of himself, the patient kept returning to his service years,” which he had never 
before discussed. Experiencing mounting tension as he talked, the patient told the 
psychiatrist excitedly about a rescue operation he had directed during the war, in which 
he felt responsible for the death of the group leader. In the words of the psychiatrist—“he 
abreacted strongly, and with relief.”29 
 The abreaction provided the therapist with important leads. Continuing to 
administer methamphetamine, the patient revealed more about his brother, his father, 
sexual identification, and other “dynamic problems.” Thanks to Methedrine, for the first 
time, the patient was able to discuss his “transference feelings, relate fantasies, and tell 
his needs affectively.” After time, the psychiatrist observed how the drug-mediated 
interviews shifted to the patient’s hostility toward his mother, allowing the psychiatrist to 
make a definitive diagnosis and work toward a cure.30 
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Psychiatrists’ Understandings of Drugs as Adjuncts 
 It would be unfair and incorrect to argue that outpatient psychiatrists who elected 
to give their patients stimulants as part of therapy sessions understood the drugs merely in 
terms of their effects during the therapeutic interview. The case of one psychiatrist 
practicing in Philadelphia in the late 1950s illustrates that even as these drugs enhanced 
the nature of the doctor-patient relationship, their benefits extended to alleviating 
symptoms in patients suffering from depression. In 1957, Dr. A. Dorothea Pohlman 
reported her findings on the use of Dexedrine within her private practice. As a 
neuropsychiatrist who had fifteen years of experience with the use of amphetamines, 
Pohlman appreciated the ability of psychostimulant drugs to relieve the symptoms of 
conditions she believed had an organic basis, such as depression. However, the 
psychiatrist had come to believe that drugs such as Dexedrine might have another 
important application: a specific adjuvant, or adjunct, for psychotherapy.  
 In contrast to the use of drugs for the management of depressive symptoms, 
Pohlman believed that psychotherapy’s goal was to aid the patient in the process of 
personality growth, “to gain a better understanding of himself and to develop new or 
modified ideas, attitudes, and patterns of feeling and behavior.”31 In order for such 
psychotherapy to be successful, however, two things were required: the establishment of 
strong rapport between the physician and the patient, and the cultivation of an 
“experimental attitude” by the patient. For psychiatrists such as Pohlman, success or 
failure of psychotherapy was generally in the hands of the patient rather than the 
physician. This point is not insignificant where the decision to resort to drugs as an 
                                                





adjunct to was concerned. As Pohlman considered the role of the patient in 
psychotherapy: 
The psychotherapeutic interview is primarily an emotional experience, a step 
forward in the growth process that should lead to effective action on the part of 
the patient. The prelude to action must be a decision arrived at by the patient. 
Some decisions representing an important change in the patient’s attitudes and 
patterns of reaction can be made only after weeks or months of therapy. 
Implementation of such decisions is often a problem of considerable magnitude 
for the patient. Even for relatively simple decisions, the vital step from decision-
making to action is sometimes long-delayed.32 
 
The psychiatrist’s resolve to introduce drugs into the session may have been a choice 
made actively by the therapist, but it was also a decision made passively by a patient 
unresponsive to the psychotherapeutic interview. 
 What of these patients, then? One case of Pohlman’s is particularly enlightening. 
A 37-year old Miss R. R. sought psychiatric treatment for the relief of “panic attacks, 
depression, insomnia, nausea, gagging, inability to relate to people, and a ‘constant state 
of tension.’” Prior to seeing the psychiatrist, she had been under the care of other 
clinicians who had administered ECT and months of sodium thiopental interviews as 
means to help R. R. with her condition.33 Neither seemed to help. After a hysterectomy at 
the age of 32, the psychiatrist noted that her patient had become more withdrawn and 
discouraged.34 
 Under the care of Pohlman, R. R. undertook a series of interviews, during which, 
“she spoke of herself in a detached, impersonal way and said she wished she could be 
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‘just a walking mind.’” R. R. soon became aware of “some resentment” toward her 
family, whose attitudes had been “critical, cynical, and belittling.” In a second series of 
interviews, R. R. disclosed more about her relationship with her mother. 
During the next six interviews, she discussed her mother’s oft-repeated statement 
to her, “You and I are one,” and her intellectual realization that this was not true. 
She also spoke of a compulsion to stay up late at night talking with her mother. 
After telling herself for years that she wanted to stay up talking, that she was 
comfortable only at home, and that she did not want to have any social life, she 
faced the true situation intellectually and discovered that these things were not so. 
She was dead tired and hated those “dreary, poisonous talks.”35 
 
Seeking to break this debilitating pattern, the psychiatrist decided to introduce 
amphetamines as an adjuvant. In contrast to the practice of some psychiatrists who 
administered amphetamines solely during the psychotherapy sessions, R. R.’s doctor also 
wrote her a prescription for the daily use of the medication. 
 During the first day of taking 2.5 milligrams of Dexedrine, the patient reported 
enthusiastically, “I can think better. It makes me feel good.” Under the influence of 
dextroamphetamine, R. R. “went to bed earlier, arose earlier, arrived at work on time, and 
did her work with greater ease.” According to the psychiatrist’s notes, “Then she slipped 
back to her old pattern, ‘forgot’ her medicine, and felt that she was only a ‘shell, with 
nothing inside.’” After struggling with inner conflicts for several weeks, she announced 
her awareness that other people had different attitudes toward life than those held by her 
family. R. R. then began taking the medication again, “went out several times with girls 
form the office, and reported that she was seeing herself and her mother as separate 
personalities.” At this point, a relative offered to introduce her to “a very nice man.” The 
therapist encouraged her to make a date with him. One tablet, 5 milligrams of Dexedrine, 
at noon on the day of the date “lifted her mood and, with the physiologic stimulus added 
                                                





to her inner motivation and the therapist’s encouragement, she was able to take another 
successful step forward.”36 
 What are we to make of the case of R. R. and the therapeutic relationship between 
her and her psychiatrist? We only have the record of the psychiatrist, but it allows for 
some conclusions. Twelve weeks of psychotherapy involving talk therapy between the 
therapist and patient were sufficient enough to reveal some of the problems faced by the 
patient, as the psychiatrist understood them. In order to break through the perceived 
impasse, the patient’s relationship with her mother, the psychiatrist felt that 
amphetamines would be helpful. At the same time, the use of drugs appears to have been 
as much a choice of the patient’s as much a decision by the therapist, at least according to 
the psychiatrist’s notes. The patient had requested “help in breaking the pattern,” and the 
psychiatrist deemed drugs an appropriate, if not ideal, means of rendering aid.  
 On the part of the psychiatrist, there never seemed to be any fear that drugs would 
impair the doctor-patient relationship. In this case, psychotherapy sessions between R. R. 
and her psychiatrist were key to enabling the patient to understand her own problems and 
make decisions to address them. What psychotherapy apparently could not do, however, 
was enable the patient to act on the plans of action established during her conversations 
with the psychiatrist. Here, Dexedrine helped by lowering the patient’s inhibitions and 
giving her the confidence to act. Psychotherapy established a diagnosis for both the 
benefit of the psychiatrist and patient, as well as a course of treatment. The stimulant 
therapy, however, was identified as the key for realizing that course of action. Note, for 
example, an incident involving a setback experienced by R. R. at work: 
                                                





She had been expecting a salary increase that did not come through, but she had 
never been able to speak to her superior at work. “It gets me violently upset to 
have to stand up to anyone. That’s when I get the panic,” she said. “I’ve always 
been just a semblance of humanity, a frightened rabbit running around.” After a 
discussion of her resentment, anxiety, and panic regarding her disappointment, 
she decided to speak to her employer. The use of medication before she went to 
work enabled her to mobilize her energies to speak on her own behalf.37 
 
In her sessions with the psychiatrist, R. R. was able to determine and work out the basis 
of her neurosis, not to mention develop plans to overcome those obstacles and to achieve 
her specific goals. But it was the use of amphetamines that provided her with the added 
confidence to realize her goals. This scene was enacted frequently, as the medication 
helped R. R. to act on her decision to buy a car, to learn to drive it, and finally, to move 
into an apartment on her own. However, just as empowering as Dexedrine was in terms 
of allowing her to achieve a particular goal, occasional failures without the drugs 
suggested a dependence on it. “Frequently Miss R. R. ‘forgot’ to take her medicine when 
she thought she wanted to succeed in some major undertaking,” her psychiatrist noted. 
“After several attempts failed, accompanied by anxiety, panic, and depression, she 
realized that she had been feeling guilty at wanting to leave her mother. ‘Forgetting’ 
meant failure and self punishment. With this insight, she would take a dose of the drug 
and act on a previously made decision.” Despite occasional setbacks, her psychiatrist 
declared the treatment a success, noting that since she had moved into her own apartment, 
the patient had few occasions to need either psychiatric care or medication and has 
“progressed well in her relations with others and in her attitudes toward herself and 
toward life.”38 
                                                







 Psychiatrists such as Pohlman were able to meld talking cures with drugs to 
provide a comprehensive course of therapy for their patients’ neuroses. As these 
psychiatrists understood them, the two aspects of such treatment worked in tandem and 
did not interfere with the doctor-patient relationship. In fact, drugs such as Dexedrine 
held the potential to strengthen that relationship, as Pohlman noted that the simple 
amelioration of mood provided by amphetamines tended to hasten the development of a 
rapport between patient and physician. The specific action of psychostimulant drugs was 
also notable:  
Because the effect of d-amphetamine sulfate on the subject is almost immediate, 
the patient’s confidence in the physician is increased. He feels the effects of the 
medicine with the first dose, he knows it is not a placebo, and he realizes his 
therapist not only wants to help him but believes he is capable of handling a 
potent medicine.39 
  
The confidence aroused by the effectiveness of amphetamines, Pohlman observed, helped 
the patient cultivate the “experimental attitude” necessary for the success of such drug-
mediated psychotherapy. 
 In its bid to heal patients of neuroses believed to have a psychosocial origin, the 
practice of outpatient psychiatry during the 1950s bore a striking similarity to the “shared 
faith” and “conspiracy to believe” that Charles Rosenberg identified as the hallmarks of 
heroic therapies.40 Patient and physician alike had to hold a common understanding of the 
body, disease, and therapeutics in order for psychoanalysis to possess legitimacy. When a 
patient’s inability to communicate with his or her therapist threatened the expertise of the 
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psychiatrist, stimulants provided a means to maintain the therapeutic relationship and 
ensure the psychiatrist’s authority as a healer.  
Patient Understanding of Drug-Mediated Psychotherapy 
 Psychiatrists reporting on their experiences were often forthright about their 
reasons for utilizing psychostimulants in the therapeutic session. If they privileged 
positive results from their use, they were at least thoughtful about how the drugs affected 
the doctor-patient relationship. What about the patients? Did they have such a 
complimentary view about the use of pharmaceuticals as part of psychoanalysis? 
Historian Roy Porter has called attention to the need for historians of medicine to 
consider “the sufferers’ role in the history of healing.”41 Admittedly, patient perceptions 
of these procedures are more difficult to assess, as their understanding of these practices 
typically filtered through the observations of psychiatrists in their notes. Nevertheless, it 
remains important, where possible, to give voice to the patients who received drug-
mediated psychoanalysis during this period.  
 One study from the mid-1950s conducted by psychiatrist Theodore Rothman and 
psychologist Keith Sward, both of the University of Southern California, considered the 
motivations and reactions of the patient in the introduction and use of psychostimulants 
in psychotherapy. Rothman and Sward surveyed 31 patients they termed 
“psychotherapeutic failures.”42 These patients had terminated their prior therapeutic effort 
out of a feeling of “intense dissatisfaction” and on the grounds that they had “gained 
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nothing” from the therapy. Probing these patients further, Rothman and Sward 
determined that the main cause of the breakdown in the therapeutic relationship related to 
an inability to communicate with the psychotherapist. These so-called therapeutic failures 
fell into two categories. First, there were patients who were characterized as 
underproductive in terms of their communication with the psychotherapist and who were 
labeled as the “silent ones” as a result. Conversely, a second group of patients were 
viewed as overproductive due to the fact that they had “flooded their previous therapists 
with voluminous, repetitious, ritualistic speech that seldom left the plane of 
pseudocommunication or [had] the level of an almost impregnable defense against 
significant and revealing communication.”43  
The study also suggested how patients’ expectations were higher for 
psychoanalysts than other psychotherapists. In the estimation of all the patients surveyed 
by Rothman and Sward, the psychoanalyst was “enshrined originally as a highly 
respected prestige figure and invested with all the aura that surrounds the healer who is 
capable of relieving mental anguish.”44 When these patients began to sense inadequate 
communication or interaction emerging from their sessions, their first inclination was to 
place blame upon themselves and exonerate the experts for the failures. However, 
Rothman and Sward noted that “as time wore on and the psychoanalyst failed to live up 
to expectations—at least in the patient’s eyes—this self-punitive attitude shifted to one of 
growing resentment towards the therapist.”45 The degree of such resentment varied, 
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however, and often depended upon the attitude of the psychiatrist and his or her 
relationship to the patient.  
 However concerned an attitude they had toward their patients, even the most 
active and engaged psychoanalysts were likely to engender hostility because they usually 
reiterated the standard analytic instructions and asked “under-verbalizing” patients to do 
what they could not: “to free-associate, to bring in his dreams, to verbalize.” Of course, 
the situation was no better between a patient and a “psychotherapist who was up against a 
psychotherapeutic stalemate [who] remained inactive or trapped by his own therapeutic 
rituals.” Therapists who clung to predominantly impersonal, nondirective, and permissive 
approaches came to be perceived by their patients as cold, unfeeling, uninterested, or 
threatening spectators. As one patient recalled of such an episode, “My analyst kept 
staring out of the window when I could not say a word.”46 Another patient who could 
only muster a few words over several months of intensive therapy recalled, “I could 
hardly get a word out, yet my analyst acted as if he didn’t care what happened to me. It 
was like talking to a wall. He often sat there, just staring at my face or at his empty 
notebook.”47 
 Up to this point, there has been little distinction made between psychoanalysis, 
those techniques based on the ideas of Sigmund Freud and his disciples, and 
psychotherapy, those talk therapies based on other systems.48 However, the findings of 
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Rothman and Sward are notable because they did actively distinguish between the two. 
Of the 31 “psychotherapeutic failures” surveyed by the two researchers, 19 had received 
psychoanalytic care by a member of the American Psychoanalytic Association, the 
American Society of Adlerian Psychology, or the Society of Analytical Psychology, and 
who was an adherent of the traditions established by Sigmund Freud, Carl Jung, or Albert 
Adler. The remaining 12 patients had received a more generic form of psychotherapy, 
either by psychiatrists or clinical psychologists who were qualified as diplomates by their 
respective professional societies, either the American Board of Psychiatry and Neurology 
or the American Board of Examiners in Professional Psychology of the American 
Psychological Association. The 12 patients who had general psychotherapy seemed to 
retain a more friendly disposition toward their former therapists, generally viewing them 
as “warm,” “friendly,” “earnest,” “understanding,” and “actively interested in [their] 
welfare.” Also, such patients tended to blame themselves rather than the psychotherapist 
for the therapeutic failure. Typical sentiments of such patients included, “I think my 
former therapist understood me,” “he did the right thing,” or “it was I who failed.” Even 
if patients arrived at dead ends in their therapy, they frequently remarked that they had 
“gotten rid of a lot of emotion” and had “understood” or “accepted” many of their 
therapist’s interpretations.  
By contrast, those patients who received psychoanalysis held a more negative 
view of their therapists and blamed them for the failure of psychoanalysis to alleviate 
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their problems.49 The differing perspectives of these two groups of patients had a certain 
reflexivity about them, Rothman and Sward found. Confronted with mounting evidence 
of a therapeutic failure, the clinical psychologist had, as a rule, referred his or her case to 
an “eclectic psychiatrist.” The psychoanalysts, on the other hand, “perhaps more sensitive 
to the consideration of their status in our culture,” seemed less inclined to acknowledge 
defeat or refer their intractable patients elsewhere.50 
 To overcome the communication problems they described in these patients, 
Rothman and Sward reported on their experiments with pharmacological psychotherapy, 
utilizing methamphetamine and a suitable antagonist drug (presumably a barbiturate or 
minor tranquilizer). They noted that a brief period of somnolence, not lasting more than 
few minutes, followed the administration of the drugs. At this point, patients who found 
the drug-mediated psychotherapy to be a new and effective experience often remarked, 
“Why didn’t we use this from the start?” “Why didn’t someone think of this before?” 
“Why did I have to suffer so long?” or “What a relief!” In other instances, the initial 
responses of patients to the drugs included brief sobbing or crying. With the apparent 
breakthroughs induced by pharmacologically mediated psychotherapy, Rothman and 
Sward noted that patients, in succeeding interviews, “show a gradually increasing 
urgency to bring the self back as an object of communication or a greater readiness to 
verbalize about some central areas of conflict.” With expected variations, patients 
reported “feeling better.” And in resolving the impasses of previous therapy, they began 
                                                







to “shed in varying degrees the feelings of frustration and hostility that had been part and 
parcel of [their] previous therapy.”51  
While Rothman and Sward’s findings suggest a bias in favor of stimulant-aided 
therapy, they also reflected a genuine effort to understand patient sentiments toward such 
techniques. Patients were reported as saying, in their own words, “I can talk about things 
without looking the other way,” “It’s as though the walls of self-consciousness were torn 
away,” “Hiding my innermost thoughts from another person’s scrutiny no longer seems 
important,” or “I can let go with whatever I am thinking and feeling, in the presence of 
another human being.”52 When the outcomes of drug-mediated psychotherapy were 
positive, the researchers concluded, patients tended to exhibit warmer and friendlier 
attitudes toward their therapists. With the aid of amphetamines, the communicative 
relationship between doctor and patient was salvaged.53 
 In restoring the doctor-patient relationship by enhancing communication between 
the two sides, however, it is important to probe just how each side benefited. The 
physiological effects of amphetamines in lowering inhibitions and facilitating 
communication on the part of the patient are apparent. Less clear is how the 
administration of drugs in patients improved communication on the part of the physician. 
Perhaps we might suggest that drugs did not benefit only the patients taking them, but 
also the psychoanalysts and psychotherapists whose legitimacy was based on their ability 
to communicate effectively with patients. 
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The Gendered Implications of Drugs and Psychotherapy 
Some historians have contended that modern psychiatry has served as a vehicle 
for reinforcing certain gender norms. In particular, Elizabeth Lunbeck has claimed that 
the “new psychiatry” of psychoanalysis that emerged during the early decades of the 
century became less concerned with addressing problems of insanity and more invested 
with issues of normality, particularly as they related to gender.54 Likewise, scholars such 
as Jonathan Metzl and Ilina Singh have elaborated on the ways in which the rise of 
biological psychiatry reinforced traditional, even sexist, ways of ordering gender.55 One 
cannot say with absolute clarity that clinicians using stimulants to initiate psychoanalytic 
dialogue intended for the drugs to reinforce a particular set of gender roles. Nevertheless, 
ideas of normality deserve consideration where the use of methylphenidate for 
psychiatric interviewing and direct prescribing are concerned. 
Historians relatively sympathetic to the aims of Freudian psychoanalysis, such as 
Nathan Hale and even Gerald Grob, have emphasized psychiatry’s efforts to restore 
neurotic patients’ functionality within society. However, scholars such as Lunbeck have 
countered that normality was the real aim of psychoanalysis. To the extent that the two 
therapeutic goals coexisted and were mutable, gender was always implicated. It is 
difficult and unfair, perhaps, to blame psychiatrists for upholding normative ideas that 
were embedded within the practice of outpatient psychiatry at the time. On the other 
hand, it is necessary to remember that psychoanalysis was built upon a foundation of 
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gendered concepts.56 Individual psychiatrists committed to Freudian principles frequently 
advanced gendered explanations of neurosis and its treatment, not necessarily in a bid to 
change society, but in an attempt to help their patients fit into a society likewise ordered 
according to gender.  
 For example, a 44-year-old housewife sought help from a psychotherapist for a 
“severe obsessional neurosis with hand-washing” and “dirt-phobia.” According to her 
case history, the patient had been raised by an “unstable but house-proud mother” and a 
“short-tempered father.” As a result of her volatile childhood, the patient grew up to be 
“always very tidy and very clean about her person.” The problem only worsened after her 
marriage to her husband, when “her phobia of dirt became increasingly severe so that her 
time became completely occupied with superfluous activity and her house became a 
filthy chaos. This among other factors led to the break up of her marriage.”57  
Attempting to determine the origin of the patient’s neuroses, the doctor noted that 
psychotherapy had been tried to no avail, as the housewife’s “emotional problems were 
intellectualized and she presented considerable resistance and inhibition.”58 Likewise, 
other drugs such as intravenous Methedrine and Pentothal were of no use in helping the 
doctor better understand the patient’s problem. Then, Ritalin was used: “Marked 
relaxation and release of tension, and good rapport was engendered, with recovery of 
forgotten incidents, real and fantasied, accompanied by marked abreaction. The capacity 
to criticize herself was improved resulting in reduction of symptoms and ability to 
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overcome them when they reappeared.”59 The psychotherapist deemed the treatment a 
success, noting that the patient was steadily improving, beginning to cultivate better 
relationships with other people, and considering future plans. In considering the outcome, 
the therapist credited methylphenidate: 
With Ritalin she became able to cut short her own defensive digressions 
(recognizing their true nature!) and spontaneously progressed with the main 
deeper theme….This was a difficult psychiatric problem, almost given up as 
incurable after attempts at psychotherapy and abreaction with [M]ethedrine and 
pentothal. With the aid of Ritalin psychotherapy made considerable progress, 
resulting in alleviation of the patient’s symptoms.60 
 
The patient’s neuroses, stemming from childhood events, carried gendered implications, 
including her inability to keep house and maintain her marriage to her husband.61 Only by 
ascertaining the patient’s “real” problem with the aid of Ritalin was the therapist able to 
place the patient back onto the road to recovery, not to mention better domesticity. 
Similar cases involving Ritalin abound. The use of Ritalin only underscored already 
existing notions held by patients and psychiatrists. When a patient enrolled in a study 
testing the efficacy of methylphenidate in reducing obesity reported to her doctors that 
“after Ritalin she could not find enough housework to occupy her that morning,” the drug 
was merely interacting with established worldviews.62 It is upon the users and not the 
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drug itself where emphasis must be placed in understanding Ritalin’s role in perpetuating 
gendered ideals. 
 At the same time, it is possible that pharmacologically mediated therapy may 
have spared some women from institutionalization and harsher therapeutic interventions 
such as ECT and lobotomy. Consider again the case of R. R., who had already undergone 
ECT before finding success in drug-mediated psychoanalysis. As historian Joel Braslow 
has noted, somatic alternatives also tended to be gendered, and a disproportionately 
higher number of female patients received lobotomies than male patients.63 In a number 
of cases, women receiving lobotomies during the late 1940s and early 1950s were also 
subject to clitoridectomies as part of their therapies.64 
The use of Ritalin could also be implicated in reinforcing the gendered behavior 
of men. In one case, a widower suffering from severe depression and fatigue following 
the death of his wife was prescribed Ritalin twice a day “in an attempt to maintain him at 
his job and dissipate his feelings of fatigue and depression. Improvement was gradual but 
noticeable within 10 days. The patient continued in his job—at first with questionable 
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efficiency. Later, this improved.”65 In another case, Ritalin was credited as a solution for 
a stockbroker suffering from depression and agitation and who “felt guilty about his 
failure at work, was inattentive to his family, and had begun to neglect his own 
appearance.”66 As with women, Ritalin did not create these gendered notions of 
masculinity in postwar America, but its use concurred with and reinforced previously 
held ideals of patients and physicians about the line between normality and disorder. 
Insomuch as men’s ability to continue their breadwinning ways constituted a primary 
concern of psychiatrists, their concomitant understanding of a drug to maintain gendered 
expectations placed upon patients was a logical extension of that interest. 
Conflicts over Drug-Aided Psychotherapy 
 Despite the potential promises that drug-aided psychotherapy held for both patient 
and practitioner, not all psychiatrists advocated their use in the 1950s and 1960s. 
Historian Nathan Hale has observed how some analysts initially resisted the use of 
pharmaceuticals, particularly the anxiolytics, on the grounds that they did not produce the 
permanent personal development that was the cornerstone of psychoanalysis.67 But there 
was also some skepticism about the role of amphetamines and methylphenidate, which 
supposedly reinforced psychoanalytic practice. Some leaders in the field expressed 
concern that the use of drugs often interfered with the doctor-patient relationship.  
Few, if any, of the most ardent supporters of the use of drugs in psychotherapy 
advocated the nondiscriminatory use of pharmaceuticals. Even the most enthusiastic 
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practitioners conceded that the techniques were not for everyone. Nevertheless, 
proponents of such methods stressed that among patients for whom traditional 
psychoanalysis had failed, drugs held the potential to foster productive and efficacious 
sessions. Clinicians resorting to the use of such drugs consistently pointed to the 
difficulties posed by non-communicative or uncooperative patients. Representative of 
such views were those of psychiatrist A. D. Jonas:  
When reaching a plateau or a resistance during the psychodynamic treatment of 
the average psychoneurotic individual, a time-consuming, patient attitude on the 
part of the psychiatrist may or may not eventually bring forth favorable results. 
The very nature of the repressed emotional material with its complicated 
defensive systems makes the conventional methods appear unsatisfactory….An 
ideal situation would result if there were available agents with a selective and 
predictable activity on the central nervous system.68 
 
Sharing Jonas’s insights were other psychiatrists who hailed drugs such as 
methamphetamine and methylphenidate as the “agents” they had long sought. As another 
clinician referring to the use of the anxiolytic Librium proclaimed, “Fortunately, since the 
advent of chemotherapeutic drugs in psychiatric practice, the therapist’s problem in 
obtaining full patient cooperation has to a large extent been overcome.”69 For 
psychiatrists who advocated the combined use of pharmacotherapy and psychotherapy, 
their motives ranged from enhancing communication with their patients to eliciting their 
outright cooperation. What united these disparate views, advocates for the use of 
psychostimulants in outpatient psychotherapy realized that without these drugs, 
successful “talking cures” could be difficult, if not impossible, to obtain. Supporters of 
drug-induced abreactions occasionally invoked psychoanalytical forebears such as 
                                                
68 A. D. Jonas, “The Adjunctive Use of an Intravenous Amphetamine Derivative in 
Psychotherapy,” Journal of Nervous and Mental Disease 119, no. 2 (February 1954): 135. 
 
69 Nina Toll, “Librium as an Adjunct to Psychotherapy in Private Psychiatric Practice,” Diseases 





Sigmund Freud, Josef Breuer, and William S. Sadler to defend their practices. They 
wondered how the use of pharmaceuticals was any different than the hypnosis therapy 
used by psychiatrists to abreact veterans of the First World War. For such proponents, the 
use of methylphenidate and methamphetamine was congruous with these earlier measures 
to facilitate talking cures.70 
 Opposing this group was a more ascetic faction of psychiatrists who argued that 
the use of such drugs tended to impede the doctor-patient relationship rather than 
encourage it, especially among psychoanalysts. For example, one psychiatrist denied the 
value of drugs as adjuncts altogether, opining that they did harm by “stimulating the id 
when what the patient needs is support for the tottering super-ego.”71 As Albert Kerenyi, 
Erwin Koranyi, and Gerald Sarwer-Foner, three leading researchers on the use of drugs in 
psychotherapy suggested, “Psychoanalytically trained workers prefer to use a 
psychotherapeutic technique in which it is left to the patient to spontaneously produce the 
material, as he is able to, without organic adjuvants.”72 Writing in 1959, these three 
researchers at McGill University and Jewish General Hospital in Montreal formulated a 
provocative hypothesis: 
The fact that psychoanalytically trained, or even oriented, psychiatrists tend to 
avoid the use of abreactive or stimulant drugs in interview situations is well 
known….It is nevertheless true that these techniques are often used by 
nonanalytically trained psychiatrists, and it follows that the patient-physician 
relationship is channelled [sic] into the modalities of this relationship. Since many 
patients benefit from treatment in the hands of physicians using these techniques, 
                                                
70 See Frederick Hocking, “Methylphenidate Given Intravenously as an Aid to Psychotherapy,” 
Medical Journal of Australia 49, no. 1 (January 20, 1962): 77-78. 
 
71 Blair, Shafar, and Krawiecki, “Adjunct to Psychotherapy,” 1033. 
 
72 A. B. Kerenyi, E. K. Koranyi, and G. J. Sarwer-Foner, “The Use of Intravenous 
Methylphenidate (Ritalin) in Psychiatric Interviewing,” Canadian Medical Association Journal 80, no. 12 





it can only be assumed that, in their hands, this technique produces symptomatic 
relief in some patients at least.73 
 
Seeking to understand their use in the office setting, these psychiatrists undertook a 
survey of 25 “qualified psychiatrists” in the Montreal area. Of the respondents, 12 stated 
that there was “no need” or “no indication” for such drugs as amobarbital, thiopental, or 
methamphetamine. Another 12 specialists responded that “in select cases they would use 
such drugs in a hospital setting, but not in office practice in view of the dangers and side 
effects, especially the possibility of acting-out and agitated behaviour [sic].”74 Further 
examination of the survey reveals that a majority (61%) of 13 analytically trained 
psychiatrists saw no need for drugs, while only one-third of the 12 non-analytically 
oriented psychiatrists felt they were required. The findings of Kerenyi, Koranyi, and 
Sarwer-Foner, confirm that the use of pharmaceuticals in outpatient psychiatry was far 
from ubiquitous and may have involved only a minority of psychotherapists, particularly 
psychoanalysts. 
Nevertheless, the persistence of the controversy in the psychiatric literature during 
the 1950s and 1960s suggests that a substantial number of psychiatrists did, in fact, 
employ psychostimulants and other drugs in their outpatient practices. A key issue borne 
out in the aforementioned study was the nature of the drugs available for use. The 
rejection of pharmacological abreactions, according to Kerenyi, Koranyi, and Sarwer-
Foner, had less to do with philosophical compunctions than practical concerns. The 
psychostimulants available to most psychiatrists during the late 1950s were of such a 
potent and unforgiving nature that few psychotherapists dared to administer them in their 
                                                







office. As more moderate drugs such as methylphenidate gained wider acceptance, 
resistance to using drug-aided psychotherapy seems to have diminished. 
 Many private practice psychiatrists took a more moderate, pragmatic stance on the 
use of drugs to induce abreactions, by limiting their use to select patients at risk of 
communication failure. In other cases, the decision to resort to pharmaceuticals related to 
the responses, or “material,” the analyst sought from his or her patient. As one 
psychiatrist summarized, 
The kind of material produced by the patient is only partially determined by the 
effect intrinsic to the drug. It is partially determined by the doctor’s predilection 
for one kind of material or another, and consequently the effectiveness of his 
therapeutic response….Therefore indications and contraindications relate to the 
individual doctor plus chosen medication, not of the medication alone; to the 
psychotherapeutic plus the pharmacological technique, not to either alone.”75 
  
Such a statement, often paraphrased by other practitioners of stimulant-aided 
psychotherapy, suggests a certain reality: Psychiatrists who resorted to drugs in private 
practice did so based on their own experiences rather than a strict adherence to dogma. It 
is important to recall that psychotherapeutic and psychoanalytic practices tended to 
revolve around three factors: the specificity of the patient’s case, the qualitative 
observation used by the therapist to make diagnoses and work toward a treatment, and the 
tacit knowledge and experience of the psychiatrist brought to bear in each case. The 
clinical literature reveals that practitioners relied on pragmatism when making the 
decision whether to administer pharmaceuticals to their patients. This fact is an important 
one in reassessing historians’ understandings about the supposed difference between 
practitioners of analytical psychiatry and their biologically oriented followers. 
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 Another factor was the response of the patient to conventional psychotherapy. As 
one proponent of occasional drug-mediated sessions cautioned, “I believe that the 
technique has only a limited place in medical practice….In the treatment of neurosis, 
there is little place for repeated chemical abreaction in the course of ongoing 
psychotherapy; however, one does see a few patients whose symptoms are totally 
disabling and whose verbalization is inhibited.”76 It is for these patients—“mute and 
stuporose psychotics”77 and “‘tension-bound’ neurotics who are unable to verbalize”—
that methylphenidate and amphetamines seemed most appropriate for this and other 
psychiatrists, and only in a select few cases.  
Though analytically oriented psychiatrists may have viewed Ritalin merely as an 
adjunct to a talking cure, they nonetheless played an important role in mainstreaming the 
medication within American psychiatry. The use of Ritalin in private practice meant that 
the drug had the potential for exposure among a greater number of patients than might 
have been the case had it been used exclusively in institutional settings. In fact, use of 
Ritalin in outpatient psychoanalysis legitimized the drug and endowed it with the backing 
of psychiatry and acceptance of the American public-at-large. Pharmaceutical firms, in 
particular, would capitalize on this receptivity and advertise stimulants to non-
psychiatrists for outpatient disorders, as the very moment that historians such as Tone and 
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Metzl have demonstrated that “taking a pill” was viewed as a useful way to treat mental 
illness directly. By the 1960s, Ritalin would be increasingly freed from its attachment to 
psychiatrists and talking cures, facilitating its prescription as a stimulant and 
antidepressant by general practitioners and specialists other than psychiatrists. 
Physician and Industry Receptiveness to Drug-Mediated Psychotherapy 
In spite of reservations held by some psychiatrists about the effectiveness, safety, 
and prudence of drug-mediated psychoanalysis, pharmaceutical firms attempted to 
capitalize on another indication for their stimulant medications. In 1958, Ciba touted 
Ritalin’s potential for psychotherapy by advertising the drug’s ability to make patients 
more cooperative and verbally productive (see Figure 3.2). The following year, the 
company even responded to research that tentatively suggested Ritalin might be effective 
in psychotherapy for the treatment of alcoholism (see Figure 3.3).78 Here again, it is 
possible to discern how Ciba was receptive to the ways in which psychiatrists utilized 
Ritalin during the 1950s and attempted to capture yet another market for its use. 
 
                                                
78 Dietrich Hartert and Albert N. Browne-Mayers, “The Use of Methylphenidate (Ritalin) 
Hydrochloride in Alcoholism: Preliminary Report on its Diagnostic and Therapeutic Use,” Journal of the 
American Medical Association 166, no. 16 (April 19, 1958): 1982-1985. The use of drug-mediated 
psychotherapy for alcoholism has also been noted by historian Erika Dyck, who has studied how LSD was 
similarly utilized at this time. See Erika Dyck, “‘Hitting Highs at Rock Bottom’: LSD Treatment for 
Alcoholism, 1950-1970,” Social History of Medicine 19, no. 2 (August 2006): 313-329. 
 It is also worth noting that in both of these advertisements for parenteral Ritalin for 
psychotherapy, the drug is indicated for intramuscular administration. This form of dosing, in which 
methylphenidate would have been injected once about 10 to 15 minutes before the interview, may have 







Figure 3.2 – 1958 advertisement for Ritalin in psychotherapeutic interviews, “Help 
psychiatric patients talk.” (Source: March 1958 issue of Hospital and Community 










Figure 3.3 – 1959 advertisement for Ritalin in the use of psychotherapy for alcoholism, 
“Break down his resistance to psychotherapy.” (Source: February 1959 issue of Mental 






At the same time, it is virtually impossible to gauge just how many psychiatrists 
relied upon drug-mediated psychotherapy. Psychiatrist Gerald Sarwer-Foner, who had 
published studies on its application with his colleagues at McGill University, reminisced 
on its use in the mid- to late 1950s. As an enthusiast for the technique at the time, he 
conceded that it “was a minority approach….But the people who knew it respected it.”79 
Given the intense influence that psychoanalysis had in American psychiatry during that 
decade, he noted that drug-mediated psychotherapy “was and wasn’t” a fairly standard 
approach. Sarwer-Foner observed that there was always some degree of accommodation 
between psychoanalysis and psychopharmacology: 
Now, interestingly enough, when I was an analytic student, the New York 
Psychoanalytic Institute, the holy of holies, invited me down to lecture to their 
committee on psychotic emergencies, and they knew I was a student in 
analysis....And I came to talk about what these drugs would do, how they could be 
used, and how analysts could analyze…[and do] transference using these drugs, if 
they were very gentle about it and took their time.80 
  
Sarwer-Foner’s experiences remind us of the symbiotic relationship, short-lived as it may 
have been, between these different approaches to psychiatric practice. 
Yet it is impossible to ignore the inroads psychopharmacology was making on all 
facets of psychiatry. While psychiatrists trained in Freudian, Jungian, or Adlerian 
techniques of psychoanalysis may have been content to administer amphetamines and 
other drugs in ways congruous to their practice, pharmacologic psychotherapy was only 
transitory at best. Developments in psychopharmacology during the 1950s and 1960s 
were beginning to alter understandings of mental illness, so that by the 1970s, outpatient 
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psychiatry would barely resemble its psychoanalytic counterpart a couple of decades 
earlier. Illustrative of this crossroads between a psychoanalytic past and a 
pharmacologically oriented future was a conference on “Psychodynamic, Psychoanalytic, 
and Sociologic Aspects of the Neuroleptic Drugs” hosted by the Department of 
Psychiatry at McGill University in 1960 and chaired by Sarwer-Foner and psychiatrist 
Ewen Cameron. Several sessions at the conference were dedicated to a discussion of what 
was increasingly being heralded as one of the most important revolutions in clinical 
practice: how psychopharmacology had transformed private practice.81 
 Sarwer-Foner also noted how pharmacological approaches came to overshadow 
psychodynamic ones. “My approach was that we had to look at each patient individually. 
We had to give enough time to study them individually. We had to give them drugs when 
drugs were needed. And they always got psychotherapy around what their problem was.” 
The rise of psychopharmacology and the concomitant decline of psychotherapy in 
outpatient psychiatry owed more to a “narrowing of a vision” than the superiority of one 
technique over the other. “Now...psychopharmacology, [based on the] DSM III and DSM 
IV, is set up to guarantee a consensus about diagnosis,” he contended. For psychiatrists 
such as Sarwer-Foner, who were rooted in psychoanalysis but also receptive to the 
developments of psychopharmacology, the specificity of the individual patient remained 
paramount. With the increasing use of drugs such as Miltown to treat outpatient 
psychiatric patients and the concomitant reconceptualization of neuroses as anxiety 
disorders, a more generalized form of outpatient psychiatry came to the fore. Put another 
way, one might argue that the major threat to psychodynamic approaches had less to do 
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with a pharmacological orientation toward treatment and more to do with a biological 
orientation toward diagnosis. Psychoanalysis could make a place for the former in its 
practice, but it could not surmount the challenge posed by the latter. 
Psychostimulants and LSD in Psychotherapy 
In 1963, psychiatrist Thomas Ling and psychologist John Buckman exalted the 
role of two recent developments in drugs for treating their patients: “There is reason to 
believe that psychotherapy, combined with regular sessions under LSD and Ritalin can 
greatly shorten psychological treatment and produce the most penetrating experiences 
with great insight.” Anticipating a bright future for these drugs in the treatment of 
neuroses, they concluded, “Patients mature and become really at peace with 
themselves.”82 Little did Ling and Buckman realize that by the end of the decade, the 
backlash against LSD would be so severe that the drug would be outlawed in most 
countries and that Ritalin’s uses in treating neurosis would largely be abandoned for the 
treatment of hyperkinetic children. Nor did they foresee that the psychoanalytic paradigm 
within which they were working would give way to a different model that would 
reconceptualize the causes and treatments for psychiatric disorders. 
 Thus far, this chapter has primarily considered the use of psychostimulant drugs 
such as methamphetamine and methylphenidate in outpatient psychiatry. At the same 
time, however, private practice psychiatrists began to explore the potential of the 
hallucinogen lysergic acid (LSD) for psychotherapy. While the use of LSD for 
psychoanalysis gained some adherents among psychiatrists throughout the 1960s, its use 
would not continue past the decade. The imposition of strict controls by federal and state 
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authorities, beginning in the mid-1960s, suggests one primary reason why the use of 
psychoactive drugs in outpatient psychiatry declined dramatically by the late 1960s.83 
 In charting the uses of LSD in their practices, receptive psychiatrists generally 
reported how the drug could serve as an “aid to the uncovering and acceptance of 
unconscious material and to determine whether the therapeutic process could be 
accelerated.”84 These psychiatrists appreciated LSD for its potential as an adjuvant for 
analytical therapy and for its peculiar properties as an abreactive drug.85 These views 
were articulated in a curious volume published in 1963, Lysergic Acid (LSD 25) & Ritalin 
in the Treatment of Neurosis. Its authors, psychiatrist Thomas M. Ling and psychologist 
John Buckman, both of the Marlborough Day Hospital in London, optimistically 
proclaimed that LSD and methylphenidate could be harnessed as effective tools for the 
treatment of patients’ various psychiatric conditions, ranging from “anxiety” and 
“writer’s block” to “frigidity” and “sexual perversion.” Even bodily conditions with 
ostensibly organic rather than psychosocial origins might benefit from the therapies 
espoused by Ling and Buckman. In one instance, they presented the case of a female 
patient suffering from migraines. Under the care of her psychiatrist and with the use of 
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LSD and Ritalin, the patient relived a traumatic experience in which her father sexually 
abused her at the age of five. Her husband had been in a business partnership with his 
father-in-law, and he became acutely disturbed at this revelation. For two weeks the 
husband seriously contemplated severing relations with his wife’s father and leaving the 
country altogether, and at one point, he became more disturbed than his wife and needed 
psychiatric help. Fortunately, under the pharmacologic psychotherapy, both husband and 
wife made a “satisfactory adjustment.” The wife’s migraine headaches completely 
subsided and “all [was] at peace in the relationship between the generations.”86 While the 
authors were careful to note that this form of treatment, psychotherapy utilizing LSD and 
Ritalin as adjuncts, had great potential for the “right patient in the right surroundings” 
and that proper selection of cases and methods were essential, such selectivity tended to 
be lost in the great sweep of Ling and Buckman’s claims.  
In the treatment of these neuroses, the authors likened their armamentarium of 
psychostimulant and hallucinogenic drugs to the scalpel and techniques employed by a 
surgeon operating on the abdomen. This analogy was quite deliberate. Just as the surgeon 
worked on an unconscious patient in order to repair a problem with the gastrointestinal 
tract, so too, did Ling and Buckman surmise that “LSD provides the means of opening 
the unconscious and exposing primarily to the patient in cooperation with the 
psychiatrist.”87 Not only did such an analogy extend to the nature of the environment in 
which both surgeon and the psychiatrist employing such drugs worked, but it also 
considered the expertise of both making diagnoses, selecting appropriate patients and 
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cases, and making informed decisions in the selection of an appropriate therapeutic 
course. 
 Ling and Buckman’s work helps further historians’ understandings of how 
analytically oriented psychiatrists conceptualized the use of drugs in their practices 
because it suggests an important question: What motivated psychiatrists to introduce 
drugs into outpatient psychotherapy during the postwar era? Why use drugs that could 
impede or, worse, endanger the doctor-patient relationship as much as facilitate it? As we 
have seen, research such as that done by Sward and Rothman during the 1950s strongly 
suggests that adherence to a particular form of psychotherapy—be it Freudian, Jungian, 
Adlerian, or something else—does not provide a definitive answer. Perhaps a better, if 
more provocative, answer is suggested by Ling and Buckman: The patient was 
responsible for the decision, at least in the mind of the psychiatrist, as much as any 
individual psychiatrist’s clinical experience, expertise, or philosophy. The fact that the 
authors thanked their former patients for taking part in the cases and interviews that “will 
be helpful to the progress of scientific knowledge and the alleviation of other patients’ 
suffering” provides one such clue. Despite the enthusiasm of the authors for LSD and 
Ritalin in 1963, the former’s heyday would be short-lived. Increasing regulatory controls 
and the criminalization of LSD in the latter half of the 1960s would effectively curtail its 
potential for use in psychotherapy.  But a greater threat was posed by the rise of direct 
prescribing of stimulants and other drugs for depression. 
“Environmental Depression” and the Decline of Drug-Mediated Psychotherapy 
As the 1950s gave way to the 1960s, a number of psychiatric researchers who had 





psychotherapy began to shift their attention to the role the drugs might play in alleviating 
depression. Among these studies were those of Kerenyi, Koranyi, and Sarwer-Foner in 
Montreal. In 1959, they had published on the potential of methylphenidate in psychiatric 
interviewing. The next year, their attention shifted to the applications of the same drug 
for the treatment of depression, especially that thought to have an organic origin. This 
1960 study further suggests how private practice psychiatry found itself at a crossroads 
between psychoanalysis and psychopharmacology. Consider this description of 
methylphenidate posited by Kerenyi, Koranyi, and Sarwer-Foner: 
Methylphenidate is a stimulating drug. It was most useful with those patients who 
had reached the following clinical level in their depression. They had formed a 
positive transference and therefore considered the physician as a helpful, 
beneficial person, and the showed regression to a level of increased sleep, fatigue, 
lack of “pep,” some apathy, and complained of a dearth of energy. Within this 
context these patients were now beginning to seek (“good”) object relationships. 
Methylphenidate, given at this point, enabled the patients who were ready to form 
new object relationships, as demonstrated in the transference, to perceive an 
increase of necessary “pep.” This offered an impetus to overcome their 
regressions. Such patients felt the physiological effects of the drug as direct 
evidence of the physician’s power to help them have the renewed energy to live 
again and to form new object relationships.88 
 
This depiction of methylphenidate’s effects on the private practice patients studied by the 
three psychiatrists strongly suggests a mingling of the drug’s effects in both 
psychoanalytic and physiological terms. While the authors were capable of noting the 
ability of the drug to aid in transference and the development of healthy object 
relationships as espoused by Freudian tradition, they were unable to overlook the drug’s 
effects in providing patients with increased “pep” and an alleviation of depressive 
symptoms. Even more telling was Kerenyi, Koranyi, and Sarwer-Foner’s 
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acknowledgement that patients were capable of perceiving and appreciating the 
physiological effects of methylphenidate. This disclosure by the three McGill researchers 
implies that patients could appreciate the psychiatrist as a dispenser of effective stimulant 
drugs just as much, if not more so, for their psychotherapeutic and psychoanalytic 
expertise. 
 The antidepressant properties of the psychostimulant drugs were not lost on their 
manufacturers. By 1957, as psychiatrists were reporting on the use of stimulants in 
psychoanalysis, Ciba began to promote Ritalin as an antidepressant for outpatient 
psychiatry (see Figure 3.4). Further revealing of the firm’s attempts to capitalize on as 
many markets as possible, Ciba advertised Ritalin simultaneously as an antidepressant for 








Figure 3.4 – 1957 Ritalin advertisement, “mild stimulant…antidepressant.” (Source: 1957 
issue of the Canadian Medical Directory. The author thanks Christopher Lyons, 








In another advertising campaign about a decade later, Ciba promoted Ritalin for a 
condition its advertisements termed “environmental” depression. Mimicking the covers 
of Time, Newsweek, and other news magazines, the advertisements associated the 
disorder with major problems of urban American life during the late 1960s and early 
1970s (See Figure 3.5). Ads from this particular promotional campaign referenced 
problems of traffic jams and transportation headaches, power outages and brownouts, the 
“new social problem” of noise, ecological pollution, social unrest, and “situations out of 
control” as worthwhile reasons for physicians to prescribe Ritalin to their patients. 
 
 
Figure 3.5 – 1971 Ritalin advertisement for “environmental depression.” (Source: 








While they give no indication of how frequently Ritalin might have been 
prescribed by doctors to their patients for depression, these ads confirm that Ciba 
believed that their drug might be prescribed for such symptoms, which taken together, 
represented a previously unappreciated disorder. A closer examination of the 
advertisements also reveals the ways in which Ritalin’s properties as a stimulant could be 
conflated with its indication as an antidepressant. Environmental depression apparently 
could present with a number of different symptoms, but in all three advertisements, 
“complaints of tiredness” was a consistent theme, one that suggested the appropriateness 
of a stimulant such as Ritalin.89 
 Ciba’s advertising campaigns did not escape the attention of health care officials 
and governmental officials. In 1971, Senator Gaylord Nelson (D-WI) referred to the 
Ritalin ads explicitly as an example of how everyday problems were being recast as 
medical indications in the firm’s advertisements: 
The uses recommended in the Environmental Depression and similar ads are 
clearly not indicated. Those are just normal things that anybody goes through. 
Now, it is done very cleverly, and if you read the material on the other side of the 
page, showing the indications, contraindications, and the side-effects and so forth, 
there will always be a line which can be interpreted to mean, do not use it unless 
medically necessary, but that is not what the commotion is all about. I cannot see 
that the purposes that in the ad are medical purposes.90 
 
Dr. Charles Edwards, the Commissioner of Drugs for the Public Health Service, 
identified Ciba’s correlation between Ritalin for environmental depression and endemic 
                                                
89 It is worth noting, perhaps, that one advertisement for Ritalin in 1966 noted the drug was 
“increasingly prescribed in everyday medical practice,” suggesting, even if anecdotally, that Ritalin was 
being further mainstreamed. See, CIBA Medicare Bulletin 4 (August 1966), Kremers Reference Files, C38 
(a) I – Ciba Pharmaceutical Company, 1966, American Institute for the History of Pharmacy, University of 
Wisconsin, Madison, WI.  
 
90 Statement of David Lewis, Senate Subcommittee on Monopoly of the Select Committee on 
Small Business, Advertising of Proprietary Medicines, 92nd Cong., 1st sess., pt. 2, 1971, 470. Hereafter 





transportation problems: “The inference to be drawn by the viewer is…if you are caught 
in a traffic jam just take a pill.”91 Concurring with Dr. Edwards’s statement, Senator 
Thomas McIntyre (D-NH) suggested that in advertisements such as Ciba’s, “the damage 
has already been done. The idea of prescribing these drugs for everyday frustrations has 
been implanted in the mind of the physician.”92 
 As with the marketing of drugs for geriatric psychiatry during the late 1950s to 
mid-1960s, the mainstreaming of psychiatric drugs for depression was not limited to 
Ritalin. Nelson’s concerns also applied to the anxiolytic Librium, a benzodiazepine 
whose effects on the central nervous system are, in many ways, the opposite of Ritalin’s. 
Advertisements for Librium around the same time also indicated its use in managing 
“environmental depression,” including one involving a female college student trying to 
cope with the stresses placed upon her.93 
As historians Jeremy Greene and Scott Podolsky have demonstrated, 
pharmaceutical promotion was so pervasive in its reach that it influenced postwar 
medical education through the dissemination of industry sources to tout the latest 
therapeutic advances.94 In some instances, medical students demonstrated grave concerns 
about industry influence. During a 1975 symposium convened by students at McGill 
University Medical School to tackle drug related issues, Dr. Norman Eade criticized 
Ciba’s promotion of Ritalin as a prime example of the misuse of advertising for improper 
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94 Jeremy A. Greene and Scott H. Podolsky, “Keeping Modern in Medicine: Pharmaceutical 
Promotion and Physician Education in Postwar America,” Bulletin of the History of Medicine 83, no. 2 





prescriptions. According to Eade, “the drug industry utilizes gross distortions of medical 
terminology to promotion its brand-name products: having developed a drug, it 
‘discovers’ diseases for which it can be used.”95 
Just as germane is the question of which physicians were undertaking the 
prescription of Ritalin for these symptoms. Between the time of its 1955 introduction and 
its indication for environmental depression in the late 1960s, Ritalin seems to have 
become repositioned in two decisive ways: First, advertisements for the drug completely 
discarded references to psychoanalysis in favor of direct prescribing for symptoms. 
Second, and related to the first point, the drug appears to have prescribed by more non-
psychiatrists. During the 1971 Nelson hearings on mood drugs, Dr. David Lewis of the 
Harvard Medical School explicitly suggested that Ritalin was being prescribed less by 
psychiatrists and more by general practitioners. The idea that Ritalin was being 
increasingly prescribed by general practitioners is also indicated in a 1970 editorial, when 
a concerned psychiatrist challenged Ciba’s claims regarding Ritalin. Arguing that many 
doctors were being misled by the advertisements for environmental depression, 
psychiatrist Morton Rapp accused Ciba of simplifying a complex diagnosis such as 
depression, encouraging general clinicians to prescribe a drug for a disorder they barely 
understood.96 While it is unclear what the prescribing rates for Ritalin were by specialty 
during these years, increasing concerns by these medical officials suggest that by the end 
of the 1960s, Ritalin no longer fell under the exclusive purview of psychiatrists. While 
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general practitioners and clinicians in other specialties may have not been prescribing the 
drug as frequently as these alarmed psychiatrists suggest, it is clear that the drug was 
becoming increasingly “mainstreamed” as it entered into the homes and everyday lives of 
non-hospitalized sufferers of depression thanks to prescriptions by increasing numbers of 
physicians who were not psychiatrists. 
Also implicit in the observations of Morton Rapp, David Lewis, and others was 
the fact that these drugs were now taken by patients who had never seen psychiatrists to 
begin with. The mainstreaming of Ritalin reflected more than the weaning of patients 
from psychiatrists’ couches to a “pill-popping” world. The transition also meant that 
therapists now had to confront the reality of Americans taking medications for psychiatric 
conditions and who could not be bothered to consult a psychiatrist in the first place, 
whether out of concerns for the cost of psychoanalysis, the convenience offered by pills, 
or a desire not to submit themselves as psychiatric subjects. Utilizing Ritalin and other 
stimulants to expedite psychoanalysis was one thing, but the shift toward direct 
prescribing by non-psychiatrists, all within the span of a decade, threatened the future of 
outpatient psychiatry by the end of the 1960s. While psychiatry did not disappear, of 
course, the public’s move away from psychoanalysis toward pharmacotherapy meant that 
psychiatry would have to follow along if it wished to remain relevant in the market-
driven world of neuroses. 
Women in particular were prescribed Ritalin far more than men, and they were 





In 1967, Ciba hired comedienne Alice Ghostley to promote Ritalin (See Figure 3.6).97 
Ciba’s decision was influenced by a previous campaign with comedian Louis Nye: 
The decision to add a touch of humor to the Ritalin advertising campaign was 
made last year when Mr. Nye appeared in a variety of amusing poses. All were 
designed to illustrate the difference that Ritalin therapy can make in a patient’s 
mood. So successful was the program that the pharmaceutical advertising staff 
decided to give Mr. Nye a partner in the ’67 campaign. 
 
Ciba’s choice of a female comic was well calculated: “Research reveals that the largest 
number of Ritalin patients are women. It was decided, therefore, that the new character 




                                                
97 Ghostley is best remembered for her roles in the television shows Bewitched (as Esmeralda), 
Mayberry R.F.D. (as Cousin Alice), and Designing Women (as Bernice Clifton).  
 
98 “Comedienne Sparks Campaign,” CIBA News 1, No. 5 (October 1967): 7, Kremers Reference 
Files, C38 (a) I – Ciba Drug Company, 1967, American Institute for the History of Pharmacy, University of 
Wisconsin, Madison, WI. The campaign in question appears to have revolved around the advertisement of 
Ritalin for its ability to “spark energy” in patients. In a 1969 ad, Ghostley appears dressed in colonial garb 







Figure 3.6 – “Let’s go team! Spark Ritalin sales!”: 1967 Ciba promotional photo of 
comedienne Alice Ghostley. (Source: CIBA News, Archives of the American Institute for 




Ciba ads that targeted women suggest another way in which Ritalin was promoted 
for more generalized conditions. In one advertisement dating from the mid-1960s, a 
supposedly tired, mildly depressed housewife contemplates an unbalanced pile of dirty 
dishes poised to tumble over at any minute. In the adjacent panel, the same woman, now 
presumably taking a course of Ritalin, seems attentive and assured as she neatly stacks 
the same pile of washed dishes (see Figure 3.7). Another advertisement for Ritalin 
depicts a lethargic, disinterested housewife sitting on top of a vacuum cleaner (see Figure 






Figure 3.7 – 1965 Ritalin ad for “tired housewife syndrome.” (Source: March 1965 issue 




Figure 3.8 – 1970 Ritalin ad for “tired housewife syndrome.” (Source: February 9, 1970, 





In both advertisements, Ritalin is endowed with the capacity to bestow on these 
housewives the vigor, energy, and disposition they needed to complete their domestic 
duties. While the drug is touted as being able to help women overcome their chronic 
fatigue and mild depression, the juxtaposition of the photographs in the first promotional 
makes very clear the other effects of the drug—the maintenance of a clean, tidy home 
through the medication of housewives. In fact, two things about Ciba’s advertisements 
are striking. First, they seem to be addressed to housewives—“If your diagnosis is 
chronic fatigue”—but the advertisements appear in psychiatric journals where clinicians 
are the intended audience.99 One may infer that the advertisement sent a message to these 
professionals that the housewife’s problem was also the physician’s problem. Second, the 
advertisements reflected the heterogeneous, even paradoxical, nature of psychiatry during 
these years. Just as Ritalin could play a role in reifying notions of proper gender roles 
through psychoanalysis, advertisements such as these relayed a message that the drug 
could do the same directly, without a “talking cure.”100 
 The gendered implications of Ritalin ads did not escape policymakers and health 
officials in the late 1960s and early 1970s. In 1971, Dr. Richard Feinbloom illuminated 
the logic driving advertisements such as Ciba’s: 
We are easily lulled into accepting the status quo. It takes the protest of a group 
which considers itself exploited by psychotropics to jar us to awareness. Such a 
critique is being mounted by what has come to be referred to as the movement of 
women’s liberation. An increasing number of women are seriously questioning 
their assigned role as housekeeper, childbearer, and cook. There is a well known 
clinical syndrome associated with the life style best described as the “tired mother 
syndrome” which when presented to the doctor almost reflexively stimulates a 
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drug being advertised to treat the “tired housewife” syndrome. Serax (oxazepam), a benzodiazepine 





prescription for psychotropics. Concerned women view this kind of response as a 
subconscious maneuver to keep women in their place.101  
 
During the same hearings, Dr. Robert Seidenberg noted how advertisements such as these 
incorporated the rhetoric of the women’s liberation movement by portraying housewives 
as “oppressed, unfulfilled, and imprisoned.”102 Seidenberg lashed out against Ciba: “The 
solution for her is neither liberation, psychological help, [nor] social action but, 
predictably, psychoactive drugs.”103 Whether the feminist rhetoric employed in Ciba’s 
advertisements for Ritalin was deliberate or unintentional, what is certain was the 
hypocrisy behind prescribing a drug to provide women relief from their fatigue and 
depression, only to empower them to finish their household chores. Ritalin prolonged 
rather than cured the burdens of domesticity. 
Conclusion 
 Historians have yet to comprehend the nature of the transition from 
psychoanalysis to psychopharmacology as the dominant paradigm for outpatient 
psychiatry. This chapter has examined an important, but overlooked aspect of this 
transition: how analytically oriented psychiatrists attempted to harness pharmaceuticals. 
The introduction of the minor tranquilizers (beginning with Miltown in 1955 and 
culminating with Valium in 1963) threatened to topple, or at least challenge, the 
dominance of psychotherapy. Now, patients could find direct relief for their anxiety 
symptoms through the aid of drugs. No longer were 50-minute hours of talk therapy 
necessary. But the historical trajectory of psychostimulant drugs was rather different. 
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Rather than posing a threat to old order, they provided a means to preserve it. Drugs such 
as Dexedrine, Benzedrine, and Ritalin were congruous with psychotherapeutic practices 
because they induced in patients a set of effects that enhanced communication between 
therapist and patient, and provided for a pharmacologically induced abreaction that was 
often sought by psychoanalysts. 
 However, the drugs that promised to improve psychoanalysis in the late 1950s 
would hasten its demise by the 1960s. Pharmaceutical firms such as Ciba began to 
capitalize on the potential of stimulants as antidepressants that could be prescribed 
directly to patients without any pretense of a talking cure, and perhaps without any need 
for seeing a psychiatrist. As I explore in subsequent chapters, the mainstreaming of 






“Brother’s Little Helper”: Hyperkinesis and the Rise of Pediatric Stimulant Therapy 
 
The rise of attention-deficit/hyperactivity disorder (ADHD) in children and 
adolescents is a phenomenon associated with the 1990s. Indeed, the diagnostic category 
of attention deficit disorder (ADD) did not exist until its emergence in the third edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), published in 
1980.1 During the 1990s, ADHD and Ritalin converged in the collective consciousness of 
the American public, and contemporary debates surrounding the validity of ADHD as an 
ontologically distinct disorder requiring pharmacological intervention have been coupled 
with the drug of choice implicated in its treatment. Two of the most widely read books on 
the subject during this decade, psychiatrist Laurence Diller’s Running on Ritalin and 
psychologist Richard DeGrandpre’s Ritalin Nation provide good cases in point. In 
questioning Ritalin as the best choice for the management of ADHD, as Diller asks, or 
raising doubts about the legitimacy of the disorder as a genuine condition, as DeGrandpre 
suggests, Ritalin and ADHD have become further entangled.2 
                                                
1 A brief note about the difference between ADD and ADHD might be helpful. In 1987, the DSM-
IIIR revised attention deficit disorder, a diagnostic category most commonly characterized by 
inattentiveness, to attention deficit hyperactive disorder, to acknowledge hyperactive symptoms also 
present in the diagnosis. The principal characteristics of ADHD in children are inattention, hyperactivity, 
and impulsivity. According to the most recent version of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR), there exist three patterns of behavior that indicate ADHD: the predominately 
hyperactive-impulsive type (that does not show significant inattention); the predominately inattentive type 
(that does not show significant hyperactive-impulsive behavior); and the combined type (that displays both 
inattentive and hyperactive-impulsive symptoms). Of these three subtypes, the predominately inattentive 
type is sometimes called ADD, an outdated term for this entire disorder. While ADD currently refers to a 
particular pattern of ADHD, both ADD and ADHD are still used interchangeably in the popular press to 
describe the entire condition. 
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 Despite contemporary concerns over ADHD, the disorder’s antecedents stretch 
back over a century. Scholars observing the rise of this phenomenon have begun to 
consider its historical dimensions. While recent scholarship has furthered our 
appreciation for how the disorder was conceptualized as part of the broad shift from 
psychodynamic to biological psychiatry, it has tended to ignore how clinicians 
themselves understood its pharmacological management. In this chapter, I examine the 
role of psychiatrists in advancing pharmacotherapy for dealing with this set of pediatric 
disorders. For the most part, I accept the assertions of scholars that the development of 
the modern ADHD diagnosis can be attributed partly to broader shifts in psychiatry. 
However, I contend that it was a sense of pragmatism, rather than an embrace of new 
theories and discarding of old ones, that guided the psychiatrists who established the 
efficacy of stimulant therapy during the 1950s and 1960s. Ironically, clinicians and 
researchers who played crucial roles in this development harbored some of the greatest 
doubts about the use of medication. In line with my thesis, my examination of clinicians 
and their views on the disorder and its treatment emphasize the broader contexts in 
accounting for the reception of intellectual ideas in medicine, as well as how clinical 
experience could direct practices more powerfully than theory. 
Introduction 
 In response to contemporary interest in ADHD and Ritalin, scholars have 
examined the broader historical dimensions of the disorder and its management with 
stimulants. Many of these historical inquiries have been driven by an attempt to 
understand how the behavioral problems of children were defined as medical conditions 
                                                                                                                                            






and how pharmacotherapy came to dominate as the preferred treatment. In particular, 
historian Matthew Smith has argued that the establishment of hyperactivity as a 
neurological disorder with an organic basis derived from an internal conflict within 
American psychiatry during the 1960s. Biological psychiatry triumphed over 
psychoanalysis and social psychiatry not because its approach was more scientifically 
valid, he argues, but because the condition’s management with pharmaceuticals was 
deemed more “practical, efficient, inexpensive and, in some ways, more cautious” than 
rival approaches.3 
 Scholars Rick Mayes and Adam Rafolovich take a somewhat less critical view. 
Their analysis minimizes the impact of psychoanalytic and social psychiatric approaches 
to the problem of hyperactivity in children and does not adequately problematize 
competing schools of thought in psychiatry during the postwar era. At the same time, 
however, they provide a coherent narrative for the development of the ADHD diagnosis 
and stimulant therapy. Their interpretation is somewhat positivist, overlooking the 
validity of competing approaches, but they do emphasize that the medication of children 
for behavioral problems was controversial during the immediate postwar era. Moreover, 
Mayes and Rafalovich underscore the role of federal support for research into child 
hyperactivity, especially funding by the National Institute of Mental Health (NIMH) to 
                                                
3 Matthew Smith, “Psychiatry Limited,” 554. Smith’s comment about the “more cautious” 
approach of biological psychiatry deserves some explanation. Pharmacotherapies such as methylphenidate 
were understood by some psychiatrists as only managing symptoms of hyperactivity, not as a treatment for 
the disorder. In addition, these drugs produced untoward effects in some children, including growth 
inhibition, insomnia, irritability, and anorexia. Smith contends that psychopharmacologists accepted 
methylphenidate’s therapeutic limitations and side effects because the drugs did what psychoanalysis could 
not: “they calmed hyperactive children down in a matter of minutes.” Moreover, Smith notes that 
psychopharmacology took a cautiously optimistic tone that emphasized that if the drugs were not perfect at 
the time, then at least their efficacy would improve over time as better products were brought to the market 
by pharmaceutical firms. As an example, Smith points to a 1971 article by psychiatrist Joseph O. Cole that 
was pessimistic on the surface, but concluded that “while there was plenty of work yet to be done, 





establish pharmacotherapy as efficacious for the disorder.4 Although their research is less 
grounded within the history of psychiatry, their perceptive consideration of public policy 
contributes to scholars’ understandings of the broader social and political framework 
within which ADHD emerged. 
 In a somewhat different vein, scholar Ilina Singh calls attention to the ways in 
which the hyperkinesis and ADHD diagnoses have been gendered.5 In particular, she has 
analyzed the ways in which mothers were often located at the center of political, moral, 
and scientific discourses over their sons’ behavioral problems.6 She observes that 
psychoanalytically oriented psychiatry in the immediate postwar period equated 
maladjusted boys with the type of men who suffered psychological trauma during World 
War II.7 In particular, Surgeon General Edward Strecker’s 1946 book Their Mothers’ 
Sons had attributed soldiers’ breakdowns to emotional immaturity stemming from 
improper parenting.8 Against the backdrop of the Cold War, Singh argues that mothers in 
the late 1940s and 1950s endured the burden of expectations to raise mature men 
essential to the future of democracy. Hence, she contends that during the 1960s, women 
who had been “schooled to give their children up to expert treatment, weary of mother-
blame, and anxious to look good in the eyes of society” readily embraced novel 
                                                
4 Mayes and Rafalovich, “Suffer the Restless Children.” 
 
5 Singh, “Bad Boys, Good Mothers.” 
 
6 The identification of ADHD and its antecedents with boys in particular is an important feature of 
the disorder. 
 
7 The best known proponent of this view within psychoanalysis was Frieda Fromm-Reichmann. 
See Frieda Fromm-Reichmann, “Notes on the Development of Treatment of Schizophrenics by 
Psychoanalytic Psychotherapy,” Psychiatry 11, no. 3 (August 1948): 263–273. 
 





biological explanations of hyperactivity in boys and its treatment with stimulant drugs.9 
Through a study of drug advertising, she also demonstrates how drug firms such as Ciba 
marketed Ritalin for problem boys (See Figure 4.1).10 
 
 
Figure 4.1 – 1960s advertisement for Ritalin in the treatment of minimal brain 
dysfunction (MBD), one of the diagnostic antecedents for ADHD. (Source: Journal 
unknown. The author thanks Ben Hansen for this image.) 
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In addition, concern over hyperactive children during this era may also be 
understood in terms of a broader concern with conformity and juvenile delinquency. In 
1960, sociologist and public intellectual Paul Goodman had pointed to the problems of a 
disaffected youth who were “growing up absurd” in an increasing complex society.11  In 
particular, Goodman took aim at America’s “organized society” structured around office-
based occupations that were neither meaningful nor challenging (resulting in a lack of 
what he termed “man’s work”).  He recognized the plight of youth who refused to 
conform to a capitalist and consumerist society’s expectations of them.  Likewise, 
historian James Gilbert has chronicled American society’s reaction to perceived juvenile 
delinquency as part of the 1950s youth culture.12 
In this chapter, I add to scholars’ understandings of the historical dimensions of 
ADHD and stimulants by considering more closely the role of clinicians in establishing 
drugs such as methylphenidate as therapies for children. Noting the aforementioned 
divides within psychiatry at this time, I assert that clinical research and acceptance of its 
findings were driven more by a sense of pragmatism among physicians than by steadfast 
adherence to a theoretical approach to psychiatry. While many of the psychiatrists 
highlighted in this chapter may be identified as biologically oriented, I demonstrate that 
their acceptance of pharmacotherapy was not preordained. Mindful of the philosophical 
divides that existed in psychiatry at this time, I contend that a closer look at the clinicians 
who prescribed the drugs and propelled them into the public mindset provides a more 
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comprehensive interpretation of the disorder and the key historical actors who gave it 
meaning. 
 Although the prescription of stimulants to children included pediatricians, 
neurologists, and family practitioners, I make psychiatrists my focus in this chapter.  An 
important reason for my emphasis on psychiatry derives from its leadership in the 
research advances made during the 1950s and 1960s.  To be sure, there were notable 
exceptions, such as the groundbreaking contributions of pediatrician Charles Bradley. But 
for the most part, pediatric psychiatry led the way. As psychiatrists’ findings translated 
into clinical practice, pediatricians and neurologists came to play important roles as 
prescribers. As I discuss in Chapter 7, pediatricians eventually would displace 
psychiatrists as the primary prescribers.  But given this chapter’s focus on clinical 
research, I have chosen to limit my discussion to the psychiatrists who played a leading 
role. 
 Hand-in-hand with the importance of clinical experience in the rise of 
pharmacotherapy was the advent of new methods, both qualitative and quantitative, for 
gauging children’s reactions to the drugs. Scholars of ADHD have tended to discount the 
importance of these ways of measuring performance and how they helped to solidify 
pharmacotherapy’s place during the 1960s and 1970s. Yet as scholars such as Theodore 
Porter have argued, the ascendency of such tools was vital to the establishment of the 
drugs’ scientific and medical legitimacy.13 
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The Origins of Hyperkinesis: George Still and Alfred Tredgold 
 The first reports of symptoms resembling modern-day ADHD diagnoses appeared 
in 1902, when British physician George Still presented several lectures at the Royal 
College of Medicine. Still described 20 children as possessing a number of common 
traits. He noted that they were “aggressive,” “defiant,” “resistant to discipline,” 
“excessively emotional,” and “passionate,” with an overriding trait of a “major defect in 
moral control.”14 While Still suggested that these children’s shared characteristics might 
be related to their low social class, he more emphatically posited that their behavioral 
problems derived from a biological etiology. Still’s observations were important because 
they anticipated views in medicine that held that an individual’s behavior owed more to 
biology than moral failings. Debates about whether ADHD and its antecedents have 
represented the medicalization of unruly children have continued unceasingly since these 
initial observations. However, Still’s idea that such moral deficits in children represented 
“the manifestation of some morbid physical condition” would guide clinical research on 
what became known as ADHD for the next century.15 
                                                
14 George Still, “The Goulstonian Lectures on Some Abnormal Psychical Conditions in Children,” 
Lancet 1 (April 12, 1902): 1008. 
 
15 George Still, “The Goulstonian Lectures on Some Abnormal Psychical Conditions in Children,” 
Lancet 1 (April 26, 1902): 1165. At the same time, however, Still ideas were informed in part by social 
Darwinism. Note, for example, Still’s argument that the “moral ineptitude” in the children he saw reflected 
“a special inability to loss or failure in development quite in accordance with the phenomenon of 
evolution.” (Ibid.) Although subsequent psychiatric research would be less guided by such a viewpoint, it 
did inherit a belief that the child with behavioral problems was, in the words of Mayes and Rafalovich, an 
“object of science, or the point at which the discourse of medicine began to compete with the conventional 
perspectives that separated morality from any type of medical concern.” Mayes and Rafalovich, “Suffer the 
Restless Children,” 438. 
ADHD’s diagnostic antecedents raise another historical issue. In attempting to understand 
differences between the way the disorder is understood today and how it may have been experienced and 
interpreted in the past, historians would do well to consider the observations of Joan Jacobs Brumberg, 
Allan Young, and Andrea Tone.  In their respective studies of anorexia, post-traumatic stress disorder, and 
anxiety, these historians caution against assuming that psychiatric disorders are fixed in time.  As 
Brumberg notes of anorexia, its epidemiology has been difficult to track over time due to a lack of 





 Still’s approach should be understood within the context of the burgeoning 
eugenics movement taking place in the early twentieth century in Britain and, later, the 
United States. The concept of modern eugenics originated with the British scientist 
Francis Galton, who spent much of his career building upon the ideas put forth by his 
cousin Charles Darwin in On the Origin of Species. Galton coined the term eugenics in 
1883 as a replacement for previous terms such as “viriculture” and “stirpiculture” in 
order to describe the cultivation of good men and women. At the heart of his work was a 
concern for how particular physical and mental characteristics were passed from one 
generation to the next, and how such inherited traits might be controlled to breed “better” 
humans. Galton’s interest in heredity and his development of eugenics were also part of 
the scientific debates regarding man and his place in nature, fueled by Darwin’s ideas, 
which raged throughout Victorian Britain. From Galton’s comments on the subject, 
eugenics quickly gained traction as a science in the United States, Britain, and other 
European nations.16 
                                                                                                                                            
how anxiety had been interpreted in the past as “the manifestation of a troubled spirit, a defective will, a 
lack of courage, or an unhealthy constitution,” partly due to the fact that anxiety had not yet come under the 
purview of psychiatry.  Hence, what is now known as a medical disorder was historically experienced and 
explained in a number of different ways.  See Joan Jacobs Brumberg, Fasting Girls: The History of 
Anorexia Nervosa, rev. ed. (New York: Vintage Books, 2000), chap. 1; Allan Young, The Harmony of 
Illusions: Inventing Post-Traumatic Stress Disorder (Princeton, NJ: Princeton University Press, 1995), 
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Eugenics also influenced biology, psychology, the social sciences, and public 
policy. In his study of eugenics in Britain, historian G. R. Searle has drawn attention to 
the fact that the Eugenics Education Society (EES), the field’s primary society in 
England, included physicians and social workers among its members.17 Even the Medical 
Sociology Section of the British Medical Association was heavily influenced by 
eugenicist ideas.18 In addition to the sway of eugenics on the British medical 
establishment during the early twentieth century, historian Mathew Thomson has 
underscored the movement’s role in the development of concepts such as “mental 
deficiency” and its attempted regulation through policymaking. Britain’s Education Act 
of 1876, which made attendance at a public elementary school mandatory for children, 
was particularly crucial in revealing a group of children who had mental disabilities or 
were otherwise slow learners. The Mental Deficiency Act of 1913 was passed by 
Parliament to provide specialized care, either in institutions or rural “colonies,” for 
individuals newly defined as mentally deficient. Political leaders spearheaded the 
legislation out of a belief that the mentally deficient were unable to serve as responsible 
citizens. Hence, it was necessary for the state to ensure their welfare and control. This 
belief that the mentally deficient required special treatment, as well as their membership 
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as part of a larger “social problem group,” reflected the leading eugenic theories of 
Victorian Britain.19  
 Such a eugenicist orientation informed the research of Britain’s leading expert on 
mental impairment, Alfred F. Tredgold, who first postulated that unruliness in children 
could be attributed to some form of mild brain damage, perhaps suffered during birth, 
that passed undetected until the child reached school age. He credited the passage of the 
Education Act as critical to the discovery of a “group of children who were so far 
mentally defective that they could not be satisfactorily taught in the ordinary public 
schools, but who were not sufficiently defective to be certified as imbeciles or idiots 
under the Idiots Act of 1886.”20 Taking Still’s assertions and elaborating on them further, 
Tredgold argued that the environmental circumstances of these children were not the 
cause, but the product of the condition’s “pronounced morbid inheritance.”21 How then, 
could an interested observer actually see this “inheritance?” For Tredgold, the key was a 
profound inattentiveness in such children: 
Attention.—The most trifling thing serves to distract these children from their 
occupation, so that even where the attention is readily gained, it is with difficulty 
held. Many of them become capable of pursuing a congenial task with a certain 
amount of patience, but the majority have neither sufficient power of 
concentration or will to be capable of sustained mental effort against inclination 
or interposed obstacles….School-teachers often complain of the lack of memory 
of these children…. 
Control is very feebly developed in these children, and action is always 
along the line of least resistance. Volition is by no means absent, but their 
behavior is more often the result of sudden desired and impulses than of 
deliberate purpose.22 
                                                
19 Mathew Thomson, The Problem of Mental Deficiency: Eugenics, Democracy, and Social Policy 
in Britain, c. 1830-1959 (New York: Oxford University Press, 1998).  
 
20 Alfred Tredgold, Mental Deficiency (Amentia), 4th ed. (New York: William Wood & Co., 1922): 
174. 
 







With this description, Tredgold identified what would later become the hallmark of the 
ADHD diagnosis. Still had also described children in similar terms 20 years earlier, but 
what differentiated Tredgold was his belief that the working class did not have a 
monopoly on producing “brain-damaged” children. Rejecting the eugenicist overtones of 
his predecessor, Tredgold postulated that encephalitis lethargica (or, “sleepy sickness”) 
was to blame for children’s behavioral problems. Following a worldwide epidemic of 
encephalitis lethargica, lasting from 1917 to 1928 and killing up to 5 million people, 
physicians noted that some child survivors of the epidemic had symptoms ranging from 
antisocial behavior and irritability to impulsiveness and hyperactivity.23 Though few of 
the child survivors of the encephalitis lethargica epidemic had indications that would 
correspond with the modern ADHD diagnosis, the recognition of “postencephalitic 
behavior disorder” further cemented the idea that behavioral problems in children might 
have a biological explanation.24 
 A conundrum remained: If a child’s behavioral problems could be explained as 
the result of brain damage or disease rather than a product of social development, what 
therapies could medicine offer? The medicalization of these children was a double-edged 
sword. Offering a scientific explanation for the behavior of unruly children brought them 
under the sway of medical authority, but without efficacious therapies, physicians risked 
losing that authority, especially in the face of detractors who claimed that discipline was 
the answer to what were essentially products of poor childrearing and home 
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environment.25 However, an accidental discovery just a couple of decades later would 
provide physicians with a means for treating behavioral problems. As with other 
accidental discoveries in medicine, history has often turned on such details. 
Charles Bradley and the Advent of Benzedrine Therapy 
 In 1934, American researchers Eugene Kahn and Louis Cohen discussed a set of 
children who exhibited many of the symptoms described by Still and Tredgold in Britain. 
Their patients were marked by talkativeness, terseness, and clumsiness. But all of these 
symptoms were secondary to a “primary behavioral abnormality”—hyperactivity.26 For 
Kahn and Cohen, the symptoms, especially hyperactivity, were the result of what they 
termed “organic drivenness,” suggesting how these children’s behavioral problems were 
the result of internal impulses rather than reactions to external stimuli. But what really 
differentiated these children was the fact that Kahn and Cohen could not identify a 
history of neurological trauma among any of them. Earlier explanations that emphasized 
brain damage or disease did not appear to fit. Instead, Kahn and Cohen offered a theory 
that a congenital defect in the part of the brainstem responsible for regulating activity 
levels might be responsible for the “congenital drivenness” they observed.27 At the time 
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of its publication, their work and this thesis received relatively little attention, but it 
would greatly impact an important experiment three years later when their concept of 
“organic drivenness” would guide the diagnostic ideas of physicians at the Bradley 
Home.28 
The Emma Pendleton Bradley Home, in Providence, Rhode Island, opened its 
doors in 1931. The institution was named in memory of George and Helen Bradley’s 
daughter, who was born in 1879 and stricken with encephalitis at the age of seven. Young 
Emma survived her bout with the disease, but it took a horrible toll, leaving her mentally 
disabled and suffering from cerebral palsy and epilepsy. Because of a lack of pediatric 
hospitals and a dearth of pediatric neurologists and psychiatrists, the Bradleys arranged 
for constant home care for their daughter. Despite their wealth, they were forced to 
concede that after 18 years of care, Emma had improved little. After George Bradley’s 
death in 1906, his fortune went to the creation of a medical facility for the treatment of 
children like Emma. Maurice Laufer, a researcher and the eventual director of the 
hospital recalled that children were admitted due to neurological and orthopedic 
disability, but also because they exhibited “difficult or irascible behavior.”29 
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 The activity of the Bradley Home should be understood within the social and 
political contexts of the time, as well as new developments within American psychiatry 
toward children. On the one hand, the clinic could be interpreted as an extension of 
Progressive Era values. From addressing the problems of underage labor to juvenile 
delinquency, child welfare had been a special concern for Progressive reformers.30 The 
Bradley Home was conceived alongside other child clinics of the time that took up 
juvenile delinquency and criminality as main concerns and explained children’s behavior 
along diagnostic lines such as predilenquency or maladjustment.31 As historian Kathleen 
Jones has observed, many social reformers during the day relied upon social or 
environmental explanations to explain and deal with these children. Eugenicist ideas 
imported from Britain also became influential during the late Progressive Era and 
interwar period.32 Historian Ian Robert Dowbiggin has suggested that American 
psychiatrists during this time were influenced by and supported eugenicist ideas, although 
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their support of policies such as sterilization had more to do with their own professional 
interests than notions of “improving the race.”33 
 In addition to the sway of Progressive Era views on child behavior, the Bradley 
Home was also influenced by parallel developments in American child psychiatry. 
Perhaps most influential were the contributions of Swiss psychiatrist Adolf Meyer, who 
emigrated to the United States at the end of the nineteenth century and rose to 
prominence as a professor of psychiatry at Johns Hopkins University and director of the 
Johns Hopkins Hospital’s Henry Phipps Psychiatric Clinic. Arguably one of the most 
influential psychiatrists in the United States during the first half of the twentieth century, 
Meyer is remembered for his theory of psychobiology, which held that in order to 
understand a patient’s particular ailment, it was necessary for the physician to take an 
extensive case study that considered the vast array of biological, psychological, and 
social factors that contributed to the patient’s environment and mindset. The impetus 
behind psychobiology was Meyer’s belief that mental illness was psychogenic rather than 
biological in origin, and that detailed case histories held the key to understanding what 
triggered the mental illness. In reality, however, Meyer’s views were eclectic and 
changed dramatically during the course of his long career.34  
The founders of the Bradley Home modeled their institution after nineteenth 
century asylums, with moral management as the main therapeutic goal for its troubled 
pediatric patients. At the same time, however, the Home’s leaders emphasized the 
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hospital’s commitment to the latest scientific advances. In addition to its clinical 
component, the Bradley Home also contained a rich program of experimental research, 
headed by faculty members at Brown University, in the areas of neurophysiology, 
neurological psychology, and electroencephalography (EEG). With such a broad mission, 
perhaps it comes as little surprise that the Bradley Home was staffed at the time of its 
opening with both pediatricians, headed by Dr. Charles Bradley (no relation to the 
home’s founders), and psychiatrists, under the direction of Dr. Arthur Ruggles. Such a 
cross-disciplinary orientation had its problems. Leading what was then called the first 
neurospsychiatric hospital for children, Charles Bradley was motivated by a belief that 
nervous system abnormalities were the cause of children’s behavioral problems.35  His 
orientation toward neurological approaches contrasted with prevailing theories of the 
child guidance movement.  In particular, Bradley criticized pediatric psychiatry’s focus 
on emotional conflicts as key to understanding the problems of children. Tensions 
between the two groups soon escalated to the point that the psychiatrists left, and the 
hospital was staffed primarily by pediatricians and a few psychologists under Bradley’s 
leadership.36 
 Children admitted to the Home were routinely given a pneumoencephalogram, a 
painful form of spinal tap that resulted in common complaints of headache. In order to 
diminish these unhappy sequelae, the physicians at the Bradley Home theorized that 
agents that would increase the blood pressure could increase the rate of restoration of 
cerebral spinal fluid and help alleviate the headaches. One such agent was the newly 
introduced stimulant Benzedrine, valued here for its qualities as a vasopressor. Bradley 
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began treating children with amphetamine following the procedure, out of a belief that it 
would stimulate the choroid plexus in the ventricular system of the brain to produce more 
spinal fluid, consequently reducing the pressure on the children’s sinuses that caused 
their headaches.37  
One revealing anecdote related by Laufer was that, in “good scientific fashion,” 
this medication was tried not just on children suffering from postpneumo headache but 
also in another group of children who had not undergone this procedure. The children 
themselves noted the appearance of “sudden and unexpected increments” in their ability 
to handle mathematics problems, and they soon began referring to the Benzedrine as their 
“arithmetic pills.”38 Following their initial observations of the drug’s effects on the 
children, the staff began to study more carefully the behavioral results of Benzedrine, and 
such explorations led to its eventual use as a treatment modality.  
Moving to develop these empirical observations into something more 
scientifically rigorous, Bradley had consciously prescribed Benzedrine not only to 
children suffering from headaches, but also to a second group of children who comprised 
a control group. So, although Bradley’s test would not have been a randomized, double-
blind, and controlled experiment (what would be considered the gold standard of 
objective medicine today), it was single-blind and controlled. In 1937, he reported his 
findings. Benzedrine had essentially the same effects on both groups. Children were 
reported to spontaneously remark, “I have joy in my stomach,” “I feel peppy,” “I feel fine 
and can’t seem to do things fast enough today,” and “I start to make my bed and before I 
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know, it is done,” and other similar insights.39 These findings prodded Bradley to 
acknowledge auspiciously that, “It appears paradoxical that a drug known to be a 
stimulant should produce subdued behavior in half of the children.”40 Yet, at the same 
time, he also sought to provide a biological explanation for his findings, concluding that 
“portions of the higher levels of the central nervous system have inhibition as their 
function, and that stimulation of these portions might indeed produce the clinical picture 
of reduced activity through voluntary control.”41 
 Bradley continued his research into the effects of Benzedrine on hyperactive and 
otherwise unruly children until the early 1950s, but his earliest published article on the 
subject probably remains his most judicious and balanced, all while foreshadowing future 
conflicts in the administration of such potent drugs to children. On the one hand, Bradley 
noted that when Benzedrine was discontinued, many of the children’s behavior problems 
reemerged. “To see a single daily dose of Benzedrine produce a greater improvement in 
school performance than the combined efforts of a capable staff working the a most 
favorable setting,” he observed, “would have been all but demoralizing to the teachers, 
had not the improvement been so gratifying from a practical viewpoint.”42 Tempering his 
optimism, however, Bradley concluded that “any indiscriminate use of Benzedrine to 
produce symptomatic relief might well mask reactions of etiological significance[,] 
which in every case should receive adequate attention.”43 Though a pediatrician himself, 
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Bradley went even further to argue that the factors involved in such behavior disorders 
were so many and so varied that only physicians adequately trained in child psychiatry 
could properly evaluate them. 
Psychoanalytic and Social Psychiatric Approaches to Children 
 To varying degrees, Bradley has been remembered for his contributions to the 
development of the modern ADHD diagnosis and its treatment. Among commentators 
today, he has been viewed as something of a historical footnote to current understandings 
of the disorder.44 More recently, scholars have attempted to understand the broader 
contexts and contributions of Bradley’s research.45 However, the influence of Bradley’s 
work on his contemporaries has been less clear, and scholars have yet to comprehend 
why Bradley’s findings would be largely ignored until the late 1950s and 1960s. 
 Historians such as Shorter have emphasized the hegemony exerted by the 
“psychoanalytic hiatus” in American psychiatry during the immediate postwar era. 
Indeed, historian Nathan Hale has identified the 1950s as the peak of psychoanalysis in 
American psychiatry. While it remains necessary to complicate the shift from a 
psychodynamic to a biological orientation, it is also important to bear in mind the 
commanding intellectual heft of psychoanalysis in this era. Of added import, few 
subspecialties were more influenced by analytical ideas than child psychiatry. 
Historian Nathan Hale has called attention to the rise of child guidance clinics 
during the 1920s and 1930s. They were originally designed to rehabilitate juvenile 
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delinquents, but anxious mothers soon began seeking out the clinics in order to provide 
them with advice in rearing their “unhappy, troublesome non-delinquents.” Originally, 
the psychiatrists who staffed such clinics adopted an eclectic approach, but by the 1930s, 
they had become decidedly psychoanalytical in focus. Like much of the guidance 
literature of the day aimed at mothers, the clinics eschewed open references to Freudian 
concepts such as oral, anal, and Oedipal stages of development. But Hale has emphasized 
how the initial emphasis on “habit training” associated with the behaviorist movement 
was replaced after 1930 with one-on-one therapeutic sessions that emphasized “deeper, 
instinctive drives” associated with psychoanalysis and fostered such concepts as 
“maternal overprotection” as the cause of neurosis and delinquency in children.46 
Freudian ideas became increasingly entrenched during the immediate postwar 
period, affecting even hospitals with biological orientations such as the Bradley Home. 
As Charles Bradley’s association with the hospital drew to a close in the early 1950s, his 
research into the effects of amphetamines on children became influenced by two 
competing concerns. On the one hand, the Bradley Home remained committed to organic 
explanations for children’s behavioral problems. Interested in preserving this biological 
orientation, one of Bradley’s trainees, Dr. Eric Denhoff, was given the new responsibility 
of heading neurological research and ensuring that this direction remained prominent 
within the hospital. As the same time, Dr. Maurice Laufer, another associate of Bradley’s 
and the future chief of the hospital, came to believe that the psychodynamic aspects of 
children’s behavior needed more emphasis. Reflecting this increasing influence, Laufer 
took the opportunity to train at the Boston Psychoanalytic Society and Institute. 
Reflecting on this philosophical bifurcation in the way his hospital approached children’s 
                                                





behavior, Laufer conceded that his was a “very uncomfortable situation in which to be. 
Even to hint to fellow candidates that there might be an organic component of 
significance in some of the children under discussion was an invitation to be dealt with in 
a manner remarkably close to ostracism.”47  
While I have accentuated the occasional ambiguities of these two approaches to 
psychiatry, Laufer’s discomfort calls attention to how consideration of biological factors 
in mental illness was perceived as antithetical, if not outright hostile, to psychoanalysis in 
some professional circles. Laufer and Denhoff (and future research partner Gerald 
Solomons) would remain important contributors to hyperkinesis research, but an 
examination of their findings during the 1950s hints at the character of this tension. For 
example, in the late 1950s, as they implicated neurological explanations for a 
“hyperkinetic impulse disorder,” their work also referenced “associated ego disturbances” 
and “ego weaknesses,” as well as “the present permissive era of child management,” in a 
clear nod to the power of Freudian theory.48  
Others have echoed the pervasiveness of a psychodynamic orientation during the 
1950s. Among these was pediatric psychiatrist Leon Eisenberg, who had trained at the 
University of Pennsylvania during the 1940s and spent his early career at Johns Hopkins 
University and Hospital, eventually succeeding the eminent Leo Kanner as the hospital’s 
second chief of child psychiatry.  He observed that child psychiatry was dominated by 
psychoanalysis during these years. While not every practitioner was a psychoanalyst, it 
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was nevertheless “the comprehensive and intriguing psychological theory.”49 Eisenberg’s 
sentiments were shared by psychiatrist Rachel Gittelman Klein, who pioneered the 
treatment of childhood disorders with her husband Donald Klein at Hillside Hospital in 
New York.  She commented that many child psychiatrists had been trained in the analytic 
tradition. Even in the late 1970s, as efforts to reclassify hyperkinesis as ADD in the 
DSM-III were underway, some still defended its value: “Removing these etiological 
concepts from the nomenclature was very threatening. If only we had their wisdom and 
their vast experience, we wouldn’t be doing these terrible things!”50 
So far, I have discussed how the disjuncture between biologically and 
psychodynamically oriented approaches to psychiatry framed a number of conflicts 
within the profession during the postwar era. But as historian Matthew Smith has 
suggested, prevailing psychoanalytic theories were not the only encumbrance to the 
acceptance of pharmacotherapy for children during the late 1950s and early 1960s. Social 
psychiatry suggested a third approach to children’s behavioral problems.51  
Though it tends to be somewhat overlooked by historians who have emphasized 
the struggle between psychodynamic and biological approaches, the American social 
psychiatry movement of the 1960s briefly suggested an alternative path for the 
profession.52 Alternately known as community psychiatry in the United States, social 
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psychiatry was organized broadly around the reintegration of the mentally ill back into 
society through a combination of medication and counselling. But the social psychiatry 
movement had a broader vision that held that mental illness could be traced to 
environmental causes such as poverty, overcrowding, crime, and substance abuse. This 
emphasis on the role of socioeconomic factors was articulated best by President John F. 
Kennedy in his February 1963 Special Message to the United States Congress on Mental 
Illness and Mental Retardation.53 In his address, the President called attention to the role 
of poverty in exacerbating the problem of mental illness, particularly among children, in 
the United States. As part of his broader New Frontier program, Kennedy’s concerns 
provided the impetus for the passage of the Community Mental Health Centers Act of 
1963.54 
 While the major thrust of the Act was the deinstitutionalization of patients from 
mental hospitals, the broader social psychiatry movement showed concern for the role 
that disparities in race and class played in fostering mental illness and delinquency. 
Psychiatric researchers such as Charles Malone and E.A. Grootenboer suggested that 
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poverty and exposure to crime and violence fostered children who were hyperactive, 
distracted, and impulsive.55 The articulation of individual psychiatrists about 
environmental influences on children’s behavior was mirrored by institutional interest. 
The Joint Commission on the Mental Health of Children was created following the 
passage of the Community Mental Health Centers Act, partly to address the 
socioeconomic issues surrounding mental illness in children. In addition, leaders from the 
American Psychiatric Association (APA) and editors from the Journal of the American 
Academy of Child Psychiatry took up social psychiatry’s cause of mitigating 
environmental factors believed to promote psychiatric problems in children.56  
When it came to the issue of how to treat these children, however, solutions were 
less clear. As with psychoanalysis, some adherents of social psychiatry resisted 
pharmacological approaches to managing child hyperactivity. Rachel Klein recalled that 
the issue contained racial and political overtones, as many of the children treated for 
hyperactivity had come from ethnic minorities. Among those critical of the 
medicalization of children, it “was argued that medication was a form of pharmacological 
genocide, by interfering with children’s free will and controlling their behavior.”57 Not all 
proponents of social psychiatry were necessarily opposed to the possibilities of managing 
children’s behavioral problems with pharmaceuticals, however. Leon Eisenberg, 
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responsible for some of the most important contributions in psychostimulant therapy for 
hyperkinesis, was also one of the strongest advocates of social psychiatry.58 There were 
definitely competing views within psychiatry during 1950s and 1960s regarding the 
causes and treatment for children’s behavioral problems. However, the case of Eisenberg 
reminds us of the hazards of reducing them reducing them to a simplistic “clash of the 
perspectives,” as some historians have suggested. 
Prelude to Pharmacotherapy 
Even as psychodynamic concepts were shaping the direction of child psychiatry 
during the 1950s, some psychiatrists began to consider how pharmacotherapy could help 
children. The lauded success of chlorpromazine in the 1950s and its promise of a 
pharmacological solution to mental illness persuaded NIMH to create the Pharmaceutical 
Research Branch (PRB) in 1956. Two years later, the PRB sponsored a conference on the 
promise of drug therapy to treat psychological problems in children.59 Perhaps the best 
summation of the conference was provided by Robert Felix, the first director of NIMH, 
who contended that drug therapy represented “tools of tremendous value but may also 
contain elements of danger.”60 Eisenberg was one of the attendees at the conference and 
served as a leading participant.61 That same year, he received the first federal grant to 
study child psychopharmacology. The major thrust of his proposal, however, was to 
study established tranquilizers such as chlorpromazine, as well as the new class of 
tricyclic antidepressants. 
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 Given that the defining characteristic of these children was hyperactivity, the use 
of tranquilizers such as chlorpromazine and reserpine for the treatment of hyperkinesis 
seemed plausible. In addition, it was difficult to ignore the breakthroughs that these drugs 
had represented for institutional psychiatry. It comes as little surprise, then, that during 
the mid-1950s there were several studies into the efficacy of these drugs for 
hyperkinesis.62 Although such studies would continue over the next couple decades, the 
potency of the tranquilizers, their emerging side effects, and the greater effectiveness 
established by the stimulants in subsequent studies all contributed to the inability of the 
major tranquilizers to take hold as a dominant therapy for childhood hyperkinesis.63 
Nevertheless, the rationale of psychiatrists in 1955 and 1956 to undertake such studies 
into chlorpromazine’s effects on hyperkinesis was compelling. “Why use such a potent 
drug on these children instead of psychotherapy?” asked Herbert Freed and Charles 
Peifer in 1955. “Fundamentally, the chief need was to improve a situation, such as 
individual misbehavior in a school room where the authorities could use only limited 
controls in dealing with the student.”64 Their willingness to prescribe potent medications 
such as chlorpromazine to children suggests how misbehavior was perceived 
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simultaneously as a medical condition and discipline problem. But even more telling was 
the subsequent disclosure by the authors that 80 percent of the children they studied 
“were either illegitimate or from broken homes. Psychotherapy with the remaining parent 
was therefore, for economic or other reasons, impossible.”65 These poor and socially 
disadvantaged children were constructed as patients for whom pharmacological solutions 
were touted as a more viable, if not the only, method for treatment. If psychotherapeutic 
and psychoanalytic methods, as already illustrated in the case of Laufer and Denhoff, had 
gained traction during the immediate postwar period, then the social, economic, and class 
characteristics of hyperkinesis during the 1950s and 1960s were beginning to reshape 
approaches toward the disorder’s management. 
 But why did these new studies concentrate on the major and minor tranquilizers 
and not the stimulants that had been Charles Bradley’s focus? Bradley’s observation that 
Benzedrine had calmed hyperkinetic children faced another hurdle toward immediate 
acceptance. Rachel Klein has observed that because so much time had elapsed since 
Bradley’s findings had been published, and because of the paradoxical nature of using 
stimulants to calm hyperactive children, she and other colleagues in the field simply did 
not find the work “that compelling.”66 
Also at issue were how new pharmaceuticals had come to dominate the field. 
Reflecting upon Bradley’s reported successes in 1962, Johns Hopkins child psychiatrist 
Quentin Rae Grant astutely observed that between the time of these initial findings and 
the early 1960s the face of psychiatry had been transformed by three new discoveries in 
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psychopharmacology. “The surge of papers since 1955 has not been distributed equally 
either in terms of population studied or of drugs under survey,” Grant elaborated. “The 
big three, composed of chlorpromazine, reserpine, and meprobamate, have dominated the 
field and collectively account for about three fourths of the studies. On most other drugs 
there are at most 3 to 4 papers relating...to children.”67 Given the widening scope of 
clinical research taking place at this time, Grant may have overstated the paucity of 
attention paid to children’s psychiatric disorders. However, his assertion that the 
“luxuriance of the growth in the number of agents has not been matched by rigorous 
investigation” apparently resonated with many colleagues.68 For example, Victor Laties 
and Bernard Weiss described a cycle of “panacea, poison, to pedestrian remedy” in a 
thorough study of meprobamate in 1958.69 As the studies on new pharmacotherapies 
evolved from case reports to group studies, and finally to controlled experiments, 
clinicians’ optimism about these medications’ efficacy began to wane.70  
While many psychiatrists were immediate, true believers in the power of 
psychopharmacology to improve their patients’ conditions, such enthusiasm was 
tempered by an increased rigor and even skepticism about the power of drugs to realize 
treatments. This latter view was especially common among clinical researchers (as 
opposed to practitioners) and may provide another explanation for why Bradley’s 
findings had less currency during these years. 
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Reestablishing Stimulant Therapy and the Role of Empiricism 
As psychiatrists embraced psychopharmacology’s potential for children during 
the late 1950s, a few researchers returned to Bradley’s original studies. In one of the first 
studies to study the effects of Ritalin on children’s behavior, two Kansas City child 
psychiatrists, George Lytton and Mauricio Knobel, administered the drug to 20 children 
referred for a variety of behavioral problems, particularly hyperactivity.71 In one case, the 
psychiatrists saw a boy who was “beyond parental control and has caused much 
dissention in the home with brother and sister,” but otherwise had no abnormalities. Yet 
another case suggested sociologist David Riesman’s concerns with conformity in 
schoolchildren during the 1950s.72 Lytton and Knobel described this patient as 
very far below grade level. Plays for attention. He is very negative and irritable at 
times…will ask to talk to the teacher privately, as if upset about something, to 
keep from doing what he doesn’t want to do…is very weak. He attaches himself 
to the moneyed, strong boys and will do anything to be one of them. The principal 
feels he is afraid to be on the side of the teacher. He drifts with the crowd.73 
 
The psychiatrists found it difficult to explain the behaviors exhibited by these children. 
Yet they agreed that in almost all of the cases noted by Lytton and Knobel, Ritalin 
produced marked improvement. “Doesn’t fight as much as before,” “No more tantrums,” 
“The teacher reports he is doing much better in school,” “An entirely different boy,” “Is 
more a part of the family,” “Performs a task,” “Does his homework,” “For the first time 
in ten years I am relaxing,” and “More talkative and friendly,” were all responses that 
medication of these children with Ritalin elicited from parents and teachers. The 
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psychiatrists postulated that perhaps the answer lay in the effect that methylphenidate had 
on “immature nervous systems,” bringing them to a state of greater maturity, both 
psychologically and functionally, through the chemical action of the drug.74 Lytton and 
Knobel’s studies were the first inquiries into the pharmacological management of 
children with Ritalin. 
Elaborating several years later on his experiences with Ritalin therapy, Knobel 
suggested that better diagnostic criteria and testing could help clinicians discern whether 
their patients’ hyperkinesis was psychogenic or organic in origin, or perhaps both. But he 
observed that therapy in all cases was related to the “theoretical approach” of the 
therapist, with psychogenetists postulating psychotherapy or environmental changes as 
efficacious and organicists indicating drug therapy.  However, Knobel articulated his own 
belief that pharmacotherapy did not interfere with psychotherapy; rather, he believed that 
drugs favored it.  At the same time, however, it was difficult to overlook the impact of the 
drugs on his practice.  Ritalin had brought about a marked improvement in 40 percent of 
150 patients when used over an eight-month period, administered in doses of 20 to 40 
milligrams twice daily.  An additional 50 percent demonstrated moderate improvement, 
while 10 percent did not improve.75 
These initial findings soon gave way to a more sophisticated set of studies into the 
role of psychostimulants on children’s behavioral problems. In 1963, NIMH awarded 
psychiatrist Leon Eisenberg and psychologist C. Keith Conners with the first major grant 
to study the effects of methylphenidate on children with behavior disorders. Five years 
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earlier, NIMH had supported Eisenberg’s initial investigation of pharmacological 
therapies for children, but the 1963 grant was unique in its focus on psychostimulants. 
Even more important, however, was the emphasis placed on methodological rigor. While 
Knobel and Lytton had reported the efficacy of methylphenidate several years earlier, 
Eisenberg and Connors’ work into this area marked the first instance of a double-blind, 
placebo controlled study on the drug for children.76 
In the next several years, Eisenberg and Connors discovered further evidence that 
methylphenidate proved significantly more effective than placebo in reducing symptoms 
in institutionalized children who were described as “lead[ing] into trouble,” 
“disobedient,” “lying,” “listless & apathetic,” “childish or immature,” and 
“quarrelsome.”77 In 1966, Eisenberg wrote that his and Conners’s three studies, taken 
together, “serve to establish, both by clinical judgment and by objective test results, the 
efficacy of stimulant drugs in treating hyperkinesis against the negative effects of 
phenobarbital.”78 
It is difficult to overstate the significance of Eisenberg and Connors’ work. Their 
contemporaries identified the findings as seminal to understanding the efficacy of 
stimulant therapy; Eisenberg’s contributions were later lauded in Congressional hearings. 
Yet it is equally important to acknowledge that at the time of their discovery, 
psychiatrists still harbored doubts about the efficacy of psychostimulants within the 
psychiatric community. Historical interpretations have tended to overlook the role of 
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empiricism, and perhaps healthy skepticism, in fueling additional work that cemented 
Conners and Eisenberg’s initial findings.  
Reflecting on how psychostimulants came to be understood as effective, Rachel 
Klein recounted, “Early on, Leon Eisenberg was critical. He was one of the very first to 
conduct psychopharmacological studies in children with behavior disorders.”79 However, 
Klein also conceded that despite the importance of Conners and Eisenberg’s 1963 
findings, she believed that their findings about the efficacy of stimulant therapy for 
hyperactivity did not immediately change clinical practice. Her skepticism that stimulants 
could have a calming effect on children probably explains a great deal of the ambivalence 
that clinicians might have held toward this proposition: 
I thought the findings were extremely curious, and took them with a grain of salt. 
I’m not an easy believer; I don’t join the bandwagon very easily…Don and I 
discussed it and he also found it very interesting and curious. We started treating a 
few children clinically and were impressed. But we didn’t quite buy it, so we 
[decided] to design a controlled study.80 
 
Klein’s reticence to accept these original findings owed much to the paradoxical nature of 
giving children stimulants to calm them down.81 Up to that point, much of the work done 
in child psychopharmacology had been a direct translation from adults to children, as 
evidenced by the initial interest in the major and minor tranquilizers for hyperactive 
children. However, as the Kleins’ follow-up studies confirmed Connors and Eisenberg’s 
discoveries, “we started to work out of that disbelief.”82 
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 In 1966, Eisenberg aptly noted that children failing to respond to one form of 
treatment might respond to some other. Just as combinations of chlorpromazine and 
Ritalin did not work in all patients suffering from schizophrenia or massive depression, 
nor did one particular drug suit the needs of all children suffering from hyperkinesis. 
Perhaps most surprising, at least from the vantage of today’s contemporary viewpoints 
that associate ADHD with Ritalin, is the fact that Eisenberg and Connors initially held a 
preference for dextroamphetamine over methylphenidate in the treatment of hyperkinetic 
children. Why? As Eisenberg noted, “our preference…is more a matter of familiarity 
with the first, of cost, and of greater experience with toxicity than a matter of 
demonstrated superiority.”83 At the same time, however, Eisenberg expressed concern 
about Dexedrine’s anorectic effects on growing bodies.  Despite the fact that the drug 
represented a cheaper alternative and had a longer record of use, Dexedrine’s potential to 
cause weight loss led Eisenberg to return to Ritalin as the more viable of the two drugs. 
Other researchers at the time concurred with Eisenberg’s findings. In 1966, Dr. 
Anthony Sainz of Marcy State Hospital in New York insisted that drug therapy form the 
basis of treatment for hyperkinetic children, as “orthodox psychotherapeutic techniques 
are of value while the child is hyperkinetic.”84 Even among psychoanalytically oriented 
psychiatrists, Sainz argued that only until pharmacotherapy made the child “intellectually 
accessible” by overcoming his “foreshortened attention span” could behavioral therapies 
begin to work.85 Echoing Eisenberg’s recommendations, Sainz insisted that both 
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amphetamines and Ritalin should be used in all cases to treat hyperkinetic children. 
Unlike Eisenberg, however, Sainz asserted that Ritalin should privileged be the drug of 
choice, given its few side effects, but he was acutely aware of its main disadvantage, its 
short duration of action, which generally lasted from one and a half to three hours, which 
posed some major logistical difficulties for giving the drug to children in the school 
setting. Almost prophetically, Sainz proffered a potential solution: “It would be a boon if 
the manufacturers of methylphenidate (Ritalin) would package it in a slow-release tablet 
form, because of the drug’s consistent action, freedom from undesirable side-effects, and 
lack of tolerance production.”86 
Etiology and Evidence-Based Treatment 
 One reason for psychopharmacology’s advance in the treatment of hyperkinesis 
involved the pragmatism of clinical researchers who privileged how stimulant therapies 
worked over why they worked. As Klein recollected of her own research,  
The drug studies we did were atheoretical. We weren’t making any assumptions 
about the nature of the antecedents. We never assumed that medication efficacy 
proved that a disorder had a strictly biological origin. You could treat so-called 
psychological reactions with medication, and you could treat biological 
phenomena with environmental manipulation.87 
 
At the same time, however, psychiatrists were cognizant of the latter and attempted to 
grapple with issues of etiology and their relationship with pharmacotherapy.  The 
attention paid by researchers to the relationship between causation and therapy counters 
historical interpretations that psychopharmacology’s dominance was due solely to the 
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convenience offered by medicating unruly children.  While they may have been more 
attuned to the behavioral effects of drugs as a sign of their efficacy, psychiatrists made 
credible efforts to understand the disorder itself. 
 Returning to Lytton and Knobel’s original 1959 study that put stimulant therapies 
back on the path to acceptance, both researchers attempted to explain why the drugs had 
worked in the first place.  The question of whether brain damage of some sort was 
responsible for children’s misbehavior was still a pertinent question at this time, and 
Lytton and Knobel observed how the “present wide acceptance of mood changing drugs” 
had intervened in the issue of whether hyperkinesis was psychodynamic or organic in 
origin.  If the former, then the use of drugs merely altered behavior without offering true 
insights into what had caused hyperkinetic behavior in the first place; if the latter, then 
the indication of pharmacotherapy appeared no less valid than the use of antibiotics to 
fight bacterial infection.  However, Lytton and Knobel tempered their enthusiasm for the 
effects of Ritalin by expressing their doubts about why the drug worked and its 
applicability for all hyperactive children.  In the absence of a more concrete 
understanding of hyperkinesis, they concluded that a “syndromic approach” might be in 
order to clarify diagnoses, clinical judgments, and therapeutic procedures.  Lytton and 
Knobel acknowledged a common occurrence of signs and symptoms in these children, 
but they also pointed out that a number of unknown factors regarding etiology still 
existed.  The psychiatrists called for clearer definitions of the “hyperkinetic child.”88 
 In spite of these doubts, Knobel and Lytton privileged recent attempts to postulate 
biological explanations for children’s behavioral problems, noting research that 
implicated the cortical system, limbic system, and frontal lobe of the brain as potential 
                                                





culprits, going even further than Tredgold to suggest that such dysfunction would not 
necessarily have any physical evidence, such as a lesion.   Knobel and Lytton were aware 
of the historical dimensions of the disorder and pointed out that organic explanations 
were not novel in understanding behavior.  They contended that a return to neurological 
considerations for child hyperactivity would shift understandings away from a purely 
psychogenic approach toward an “integrated neuropsychologic” point of view.  In doing 
so, they followed the lead of Bellevue psychiatrist Lauretta Bender, who had likewise 
observed in 1949 that, “a dynamic interrelation may describe the psychological problem 
but still doesn’t touch the cause.”89 At the same time, however, Knobel and Lytton 
remained sensitive to the idea that interplay between the social, familial, and biological 
circumstances made it difficult to describe such a syndromic entity.  Cortical damage in 
the brain could vary from child to child, suggesting the need for clinicians to remain 
aware of the individualized onset of hyperkinesis.   
 Accompanying the pragmatism that helped to solidify acceptance of stimulant 
therapies in the 1960s was a turn toward more rigorous methods for establishing the 
drugs’ efficacy. By the early 1960s, much of the literature concerning the diagnosis and 
treatment of hyperkinesis in children was still driven by case studies and qualitative 
methods of assessment. As such, it comes as little surprise that clinical researchers 
oriented toward quantitative measures were conflicted about the findings of their 
colleagues: 
Methodologically, then, the field of such investigations on children is in a parlous 
and unsatisfactory state. This presents a dilemma for the reviewer. On the one 
hand, if one were to apply the most recourse standards of criticism, it would be 
perfectly permissible to discount many positive results and to come up with 
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largely negative conclusions about direct drug efficacy. On the other hand, these 
drugs are being widely used, have been on demonstrable benefit when given in 
various treatment contexts, and do provide for the clinician symptomatic 
improvement in a large number of cases that come to his attention.90 
 
As Eisenberg recalled, about his own experiences with clinical research on hyperkinetic 
children, “The notion of evidence based psychiatry…wasn’t even thinkable then. 
Experienced people who had seen many patients relied upon what they remembered of 
their cases (or, more accurately, on those of their patients that chose to stick with them 
for an idea of longitudinal course).”91 Not only were follow-up studies still uncommon 
during the late 1950s, but the relatively stable demographics of the United States, in 
which doctors and patients were more stationary and informal follow-ups more prevalent, 
made more formal means of tracking unnecessary. 
 Compounding the problem was the fact that clinical research for hyperkinesis 
involved children, who required very different medical, legal, and ethical considerations 
than adults.92 As one psychiatrist inquired during the mid-1960s, 
How can one measure the effects of a drug that acts upon the mind and the 
emotions of a child? Unlike adult patients, children rarely ask for symptomatic 
relief; they are given psychoactive drugs because others complain about their 
behavior. The drugs are given to alter behavior rather than subjective feelings. 
The evaluation of a drug effect, then, depends upon observed changes in behavior. 
In a residential treatment setting, members of the staff can observe the child’s 
behavior; with outpatients the physician must rely on his own observations and 
information from parents and school personnel.93 
 
                                                
90 Grant, “Psychopharmacology in Childhood Emotional and Mental Disorders,” 628. 
 
91 Eisenberg, interview by Healy. 
 
92 As Susan Lederer has noted in her study of human medical experimentation, children 
historically have been among the most vulnerable populations for drug testing.  See, Susan E. Lederer, 
Subjected to Science: Human Experimentation in America before the Second World War (Baltimore: Johns 
Hopkins University Press, 1995), esp. chap. 3. 
 
93 Joel Zrull et al., “An Evaluation of Methodology Used in the Study of Psychoactive Drugs for 





The problems of measuring the effectiveness of stimulants on hyperkinetic children were 
similar in many ways to establishing clearer definitions and diagnostic guidelines for the 
disorder itself. 
 Aside from the research on the effects of stimulants, one of the most important 
advances during the 1960s was the introduction of new methods, primarily observational 
scales and tests, to measure children’s behavior and, more importantly, the effects of the 
drugs administered to the children. Among the most important innovators of these 
methods during the 1960s was Eisenberg’s colleague, Keith Conners. One of Conners’ 
first innovations, a scale to categorize the particular characteristics of children for studies, 
was derived from the textbook of Dr. Leo Kanner, former head of child psychiatry at 
Hopkins whose position Eisenberg had taken. As Conners recounted, “Kanner had a very 
careful observational approach. And, his textbook was very descriptive and he, in effect, 
had chapter headings for different kinds of kids. So, in effect, when we began these 
studies, I essentially took the chapter headings and made a rating scale out of them.”94 
Other important means of testing that would figure prominently in Conners and 
Eisenberg’s studies were continuous performance testing (CPT), psychological tests to 
measure the attention of children, as well as tests such as the Porteus Maze, a pencil and 
paper maze that testing learning ability of children taking the drugs.95  
 These instruments for measuring the symptoms of hyperkinetic children and the 
effects of drug therapy were ostensibly an integral part of developing a more objective 
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approach toward diagnosing the disorder and gauging the effectiveness of drug therapy. 
While they did not completely quell some clinicians’ concerns that children were not a 
part of the self-reporting process, they did contribute to a larger project of moving 
research away from individual observations toward more standardized methods of 
diagnosis and treatment in clinical research. The scales developed by Conners and others 
owed a great debt to the qualitative approaches of psychiatrists who had come before. “It 
was interesting that child psychiatry in those days was basically psychodynamic and there 
was no documentation, so when we did these drug trials we had no tradition to draw from 
on what to measure,” noted Conners. Yet, he agreed that the experiential background of 
psychiatrists committed to individual observations, such as Kanner, who contributed 
greatly to psychopharmacologists’ search for a quantitative approach.  
Increasing Clinical Research and Federal Support 
 The initial progress of Conners, Eisenberg, and others began to intensify by the 
late 1960s when the federal government began to increase support for clinical research 
into the efficacy of stimulants.96 Up to this point, the pharmaceutical industry had not 
financed much research in this area, presumably because the administration of 
psychotropic drugs to children on a large scale was still viewed as unethical.97 Rather, 
many of the individual studies had been undertaken by psychiatrists and pediatricians as 
part of their academic appointments at research universities.98 A key driver in research 
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was NIMH, which awarded another major research grant in 1967 to study the effects of 
stimulants on behaviorally disturbed children to Conners, who had left Johns Hopkins for 
an appointment at Harvard Medical School and Massachusetts General Hospital.  
As Ronald Lipman, then of the Psychopharmacology Research Branch of NIMH 
recounted, NIMH sought studies that could compare the relative efficacy of the 
stimulants, phenothiazines, antidepressants, and minor tranquilizers utilized in pediatric 
psychiatry.99 While noting that some groundbreaking studies on amphetamines and 
methylphenidate had been done up to this point, Lipman also observed that the duration 
of these studies had often been quite short. Hence, the NIMH expressed a particular 
interest in obtaining more long-term efficacy studies, longer than eight weeks and 
perhaps up to several years in duration—studies that could be undertaken more easily 
with the financial support of the federal government. Regarding the differences between 
NIMH’s original 1958 grants and those awarded for stimulant research beginning in 
1967, Lipman noted, “It is fair to say that while the stimulant drugs were mentioned in 
passing by [early researchers]…only a focused reading of the text would have elicited 
this information. In short, in 1958 and 1959 the interest in the stimulant drug treatment of 
hyperactive children was far from overwhelming.”100 
 Between 1967 and 1970, the federal government, through NIMH, awarded nine 
grants totaling nearly $3 million into the study of behavior modification through 
psychopharmacology. Conners’s study, which built on his earlier work with Eisenberg 
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and focused on the further elucidation of the action of the stimulant drugs 
dextroamphetamine and methylphenidate on behavior, cortical processes, and cognitive 
function, had received almost $450,000 in support from NIMH. Other notable recipients 
of federal funding included Donald Klein at Hillside Hospital in New York, Lawrence 
Greenberg at the Children’s Hospital of the District of Columbia, Barbara Fish at the 
Children’s Psychopharmacology Unit of New York University Medical Center, and 
Robert Sprague at the University of Illinois.101 
 The nine projects funded by NIMH between 1967 and 1970 may have been the 
primary beneficiaries of federal largess, but the late 1960s were characterized by a much 
wider research program on hyperkinesis in general. Other leading efforts at this time 
included work led by Gabrielle Weiss, John Werry, and Virginia Douglas, with much of 
the research being done at McGill University in Montreal.102 Leon Eisenberg continued 
to publish in the field, and he occasionally collaborated with Conners through the late 
1960s. In summary, federal funding and the research findings made during the first half 
of the decade were crucial toward building momentum in stimulant therapy research that 
would continue through the rest of the decade and beyond. 
The Decade of Public Discourse 
 If the 1960s can be characterized as a decade predominated by the clinical 
research that would establish stimulant therapy as the best vehicle for the treatment of 
hyperkinesis, then the 1970s were a decade for public debates. By all indications, the 
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treatment of children with powerful stimulants entered American mainstream 
consciousness in June 1970, when a front-page article in the Washington Post 
undoubtedly caught the public’s eye. Revealing that 5 to 10 percent of the 62,000 
children in the Omaha school district were consuming Ritalin, described as a “behavior 
modification drug” for “children identified by their teachers as ‘hyper-active’ and 
unmanageable to the point of disputing regular classroom activity,” the story unleashed a 
flurry of debate that would continue throughout the rest of the 1970s.103  
 Though scholars such as Peter Conrad and Ilina Singh have acknowledged the 
importance of what became known as the “Omaha incident,” they have often regarded it 
as another event in the growing use of Ritalin and amphetamines. However, a more 
detailed look at the case reveals that the use of drugs in Omaha was not some 
discontinuous event, but rather, an indication of the growing networks of medical 
professionals, educators, pharmaceutical firms, and regulators crucial to the increased 
prominence of hyperkinesis during the 1970s. 
 The Washington Post highlighted the case of Dr. Byron B. Oberst, an Omaha 
pediatrician instrumental in the introduction of a “behavior modification” drug program 
in his local school district. In December 1968, Oberst attended a seminar at Syracuse 
University that highlighted the problems of children who fit the description of the typical 
hyperkinetic patient. In addition to a viewing of the film Why Billy Can’t Learn, Oberst 
recounted how a number of physicians at the seminar described the positive results they 
had received with such patients by prescribing Ritalin, Dexedrine, and other similar 
drugs. 
                                                





 Following the conference, Oberst returned home to Omaha “with a new 
mission—to spread among his colleagues and school personnel this new knowledge 
about how to help with a problem” he claimed frustrated “eight to 10 percent” of the 
school population.104 After physicians in the local community were “made aware of the 
new possibilities” by Oberst, they directed their attention toward school officials. 
Seminars were held in the school district, highlighted by viewings of Why Billy Can’t 
Learn. Eventually, a new organization, STAAR (Skills, Technique, Academic 
Accomplishment, and Remediation), was formed. Although teachers took the lead in 
identifying children and parents appropriate for STAAR, the program’s founders 
considered it an extracurricular undertaking not officially sanctioned by the school 
district. “The medical context of the program,” as Oberst explained, “is to keep medical 
problems in the hands of the family doctor. The medicine prescribed has to be in the 
control of the family physician.”105 
 Although STAAR had originated out of the seminars hosted by the Omaha school 
district and had the cooperation of educational leaders, the assistant superintendent of the 
Omaha Public Schools had no firm idea of how many students were taking these drugs. 
Only the family physicians had such records, but experts such as Oberst agreed with 
estimates that 5 to 10 percent, or between 3,000 and 6,000, of Omaha’s public school 
children received stimulant therapy. How did the number become so large by 1970? 
Certainly the STAAR program and its organization by local medical and school 
authorities contributed. But a more precise answer suggests the collaborative nature of 
the program. As assistant superintendent Don Warner observed, “Ten years ago, there 
                                                







were a couple of hundred kids in the Omaha school district on Phenobarbital for 
restlessness associated with some disorder.” But, “after the pediatricians began spreading 
the word in December of 1968, more and more teachers began identifying students they 
felt would benefit.”106  
 Even more telling about the role of increasing interactions between physicians, 
educators, pharmaceutical firms, and regulators are the arguments made by opponents of 
the STAAR program. The Washington Post observed that after the 1969-1970 school 
year began, “some cautions that educators expressed grew to sounds of quiet alarm.”107 
Receiving the most attention were concerns about the addictive potential of the stimulants 
and anecdotal evidence that children who were walking around with potentially 
dangerous drugs were trading the pills on the school grounds at lunch and recess.  
The resistance that opponents to the STAAR program claimed to encounter was 
also revealing. As one concerned school official noted, “Look, if I bucked the medical 
profession in this town, I’d be dead, useless. They are pretty powerful around here.”108 
The fact that Omaha was a relatively small city (less than half a million people) with two 
large medical training institutions, the Nebraska University College of Medicine and 
Creighton University School of Medicine, might account for some of the medical 
hegemony opponents claimed to face. As one young physician interviewed by the 
Washington Post suggested, “This gives the medical profession quite a voice in the 
affairs of Omaha, and they use it.” Another local physician suggested another possibility, 
one hinting of collusion among interested parties: “Which also means that drug 
                                                









companies which subsidize a lot of medical education and research, also have a great deal 
of power.” Regarding the role played by pharmaceutical firms, supporters of the STAAR 
program in Omaha were emphatic in their claims that drug company involvement was 
minimal. “Oh, they come around and address meetings on the subject, but it’s always 
pretty much of a soft sell. They mention the products and the claims, but they don’t push 
too hard in public, or too well, for that matter,” one Omaha school official claimed.109 
Whether or not drug firms were instrumental in the introduction of stimulant drug therapy 
into the school system, and there is little evidence available to suggest they were, their 
very involvement suggests that school districts’ embrace of stimulant therapies were not 
limited solely to concerned physicians. 
  As prominent as the Omaha case may have been, similar controversies could be 
found in other American cities. In November 1970, Isaiah E. Robinson, vice president of 
the New York City Board of Education, charged that pupils in his school district were 
receiving the same drugs as children in Omaha. Vowing to launch an investigation to find 
out, Robinson stated at the morning meeting of New York’s Fall Conference of Drug 
Abuse, “I found out recently that we are also using one of these drugs in the New York 
City schools….It’s a very dangerous precedent to start doping so-called hyperactive 
youngsters.”110 Officials in the New York school district were quick to dismiss 
Robinson’s charges. Board president Murray Bergstraum countered that he knew of no 
such program in New York, while Dr. Simon Silverman, a psychologist and head of the 
school system’s Bureau of Child Guidance, emphasized that medical personnel in the 
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schools could not prescribe drugs to pupils. Despite such bans on prescriptions by school 
doctors, Dr. Albert Hotkins, the Bureau of Child Guidance’s chief psychiatrist, conceded 
that psychiatrists under his supervision had placed children on the medication after 
obtaining parental consent. Though not done indiscriminately, Hotkins insisted, he did 
note that a couple hundred children in New York had been prescribed Ritalin, Dexedrine, 
or other similar drugs in this manner. Of course, his estimate did not account for those 
children who might have received drug therapy for hyperkinesis through direct referrals 
from parents. Nevertheless, despite the insistence of New York officials in late 1970 that 
their school district had no program similar to the one in Omaha, increasing collaboration 
between physicians and the medical establishment, educators and school administrators, 
and parents was evident.  
 One final example also provides insight into how stimulant therapy was making 
inroads into American schools during the first half of the 1970s. In September 1975, the 
Youth Law Center in San Francisco filed a lawsuit on behalf of 17 children in Taft, 
California, alleging that school officials forced them to take Ritalin. The suit contended 
that some of the students prescribed the drug were not personally examined by a 
physician, and in one case, a student purportedly suffered from an epileptic seizure after 
taking the drug. According to the suit, school officials in the San Joaquin Valley oil town 
told parents that they either had to assent to demands that their children take the drug or 
students would be excluded from school entirely or placed in special classes for mentally 
retarded students. In addition to asking for $425,000 in damages for each of the 17 
plaintiffs, the suit asked the court to “order the practice halted on the ground it violates 





schools and to determine medical treatment without the interference of school 
authorities.”111  
As a result of the publicity that the Omaha incident received, Rep. Cornelius 
Gallagher, a New Jersey Democrat heading a study into alleged invasions of privacy for 
the House Government Operations Committee, ordered a preliminary inquiry into the 
matter immediately after the story broke in June 1970. At the same time, Dr. Charles C. 
Edwards, Commissioner of the FDA, also ordered an investigation.112 In that hearing, it 
was revealed that between 100,000 and 200,000 American schoolchildren were taking 
behavior modification drugs for the treatment of hyperkinesis and MBD.113 However, 
despite Rep. Gallagher’s pronouncements about being “very disturbed” about what he 
perceived as the FDA’s “everything is hunky dory” attitude regarding amphetamine 
consumption by children, stimulant use by children in Omaha was not as pervasive as 
first believed.114 Reportage on the Omaha schools program was factually incorrect in 
some fundamental ways. Drugs were not part of any particular school program, but 
rather, were prescribed by some family physicians on an individual doctor-patient basis. 
Moreover, the number of children receiving prescriptions was lower than the 5-10 
percent figure quoted in the Washington Post article; rather, that figure referred to the 
proportion of children believed to be in need of medical help for behavioral problems.115 
While the Congressional hearings on Omaha had been convened in response to this 
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alleged scandal, by their conclusion, they appeared to reinforce the legitimacy of 
hyperkinesis and its treatment with stimulants.  Reflecting on the investigation several 
years later, Ronald Lipman, who had been a participant, remembered that the report  
made it clear that (a) stimulant drugs had an important and legitimate use in the 
treatment of pre-adolescent hyperactive children, (b) stimulant drugs were not a 
chemical strait-jacket but allowed the child the choice of reacting in a more 
situationally appropriate manner vis-à-vis the organization of his motor behavior 
and attentional processes and, (c) no association between the legitimate medical 
use of the stimulants in childhood and drug abuse in adolescence had been 
demonstrated nor would one be anticipated since the ‘set and setting’ factors were 
so different and since hyperactive children were not reported to experience 
euphoria from the stimulants.”116 
 
Cases such as those in Omaha, New York City, and even smaller towns such as 
Taft, California, suggest how drugs such as Ritalin and Dexedrine were beginning to find 
uses in American public schools during the late 1960s and early 1970s and how the 
clinical research of the 1960s was translating into actual patterns of use. While these 
cases may not tell us definitely about the characteristics of such use, they do suggest that 
the prescription of such drugs relied heavily on the interplay between medical, 
educational, and parental authorities, as well as political officials. Well-documented cases 
such as Omaha’s also suggest the active role pharmaceutical firms may have played in 
the introduction of these drugs. Just as important is the fact that by the early 1970s, such 
issues were beginning to elicit greater attention from the American public. The attention 
paid to such issues by media outlets had far-reaching consequences. Throughout the rest 
of the decade, public discourse on the prescription of these drugs for children would only 
continue to escalate. Whether as criticism or support for the pharmacotherapy of 
hyperactive children, these public debates on the matter further suggest how the use of 
                                                





these medical technologies was increasingly framed not solely by the medical 
establishment, but also by its relationship with other parties.  
 One of the most vociferous critics of drug therapies for children during the 1970s 
was journalist Peter Schrag. In an editorial for the New York Times in 1975, Schrag used 
the Taft lawsuit as a platform to launch a broader attack against the use of drug therapies. 
Though his estimates of 500,000 to one million American children who were taking 
Ritalin and Dexedrine seem excessive, perhaps more accurate was his observation that 
this prescription of drugs was driven by a “proliferating establishment of physicians, lay 
organizations, drug companies, and federal agencies.” Yet, Schrag’s claims went much 
further than the acceptance of the hyperkinesis diagnosis and its treatment by these 
groups. Rather, he charged that with the emergence of this cabal,  
A whole industry has been created—drugs, tests, clinics, special schools—and 
millions of children are labeled and segregated into categories that have no clear 
definition and for which there are no remedies. Yet the research that is supposed 
to validate those activities is generally inconclusive, frequently sloppy, and almost 
always misunderstood and misapplied.117 
 
For critics such as Schrag, the movement of drug therapies for hyperkinesis into schools 
during the 1960s and 1970s represented collusion between interests to control children. 
Schrag’s sentiments would reach an even wider audience with the publication later that 
year of his book with Diane Divorky, The Myth of the Hyperactive Child.118 Schrag and 
Divorky popularized the notion that stimulants and other drugs served as “chemical 
straitjackets” to control unruly children. Yet Schrag’s suggestion that the research was 
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lacking failed to appreciate the extent to which clinical researchers had gone to establish 
successfully the efficacy of stimulant therapy.119  
Scholars during the 1970s also began to weigh in on the debates, expressing grave 
concerns of their own. Chief among these critics was the medical sociologist Peter 
Conrad, whose article “The Discovery of Hyperkinesis” extended the medicalization 
thesis to hyperkinetic children. He charged that the hyperkinesis diagnosis was part of a 
longstanding pattern to medicalize otherwise normal behavior.  The “discovery” of 
hyperkinesis involved two major factors, according to Conrad.  First, there was the 
willingness of medical professionals to reconceptualize misbehavior as a disorder in need 
of treatment.  Joining physicians in this effort were parents’ groups whose acceptance of 
such a diagnosis absolved them of charges of bad parenting and alleviated their guilt. In 
short, this interplay involved the rise of expert control to explain and deal with children’s 
behavior, a development viewed by Conrad as nondemocratic and non-participatory. 
Second, there was the involvement of pharmaceutical firms who marketed their drugs, 
particularly Ritalin, for the newly identified problem of hyperkinesis.  Accompanying 
industry efforts was government action that sanctioned the medication of children. The 
result, Conrad contended, was the depoliticization of deviant behavior in favor of its 
medicalization. 
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 The attacks of Schrag and other critics against child pharmacotherapy did not go 
unopposed. One rebuttal to the Times editorial by Jane K. Hochberg, director of special 
education for The Community School in Orange, New Jersey, is illustrative. Calling 
Schrag’s words on the subject “dangerous and destructive,” Hochberg distinguished 
between the abuse of illicit drugs and their medical uses to treat diagnoses such as 
hyperkinesis. She responded to Schrag’s claims that the prescriptions of stimulants by 
physicians unnecessarily opened the doors to drug abuse among children: 
That there is drug abuse in regard to treatment is lamentable as it is true, but to 
suggest that neurologists, pediatricians, psychologists, and learning specialists are 
dedicated to “control” these children with unethical and dangerous practices 
seems to be a reckless generalization. 
There is much being done in this field of medicine and psycho-education 
that is positive and working. Certainly the medical profession must be more 
vigilant in all drug control. Writers, whose intentions may be humanitarian and 
noteworthy, must also be vigilant.120 
 
 Amid the growing controversy, some columnists attempted to mediate the gap 
between polemicists, acknowledging that polarizing debates had “left parents and 
teachers thoroughly confused about how to recognized and deal with a hyperactive 
child.”121 Such confusion was not surprising, given the cacophony of voices seeking to be 
heard. 
The Coming of “Attention Deficit Disorder” 
The 1960s represented the decisive decade for the establishment of stimulant 
drugs as the prevailing therapeutic regime for hyperkinesis. The advent of federal 
regulations for amphetamines and methylphenidate at the end of the decade proved an 
important turning point. In 1969, the federal government announced its intentions to 
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place methylphenidate under stricter controls that would constrain its prescription and 
indications. Following the completion of the Drug Efficacy Study and Implementation 
(DESI) and the passage of the Comprehensive Drug Abuse Prevention and Control Act of 
1970 (Controlled Substances Act), amphetamines and methylphenidate were categorized 
as Schedule II drugs, substances with legitimate medical applications but also a high 
potential of abuse.122 Particularly affected was Ritalin, which, by the early 1970s, had 
emerged as the leading drug in the treatment of hyperkinesis. Under the new federal 
guidelines, Ritalin’s indications were curtailed and limited to the treatment of narcolepsy 
and hyperkinetic children. If federal regulations considerably narrowed the legitimate 
uses for amphetamines and methylphenidate, they simultaneously legitimized its 
approved uses. Hyperkinesis was at the top of the list. 
 As for psychiatrists and pediatricians, the 1970s represented a period of 
consolidation of the diagnostic and therapeutic knowledge developed during the 
preceding decade. One such indication may be found in a large symposium entitled 
“Clinical Use of Stimulant Drugs in Children,” held at Key Biscayne, Florida, in 1972. 
Chaired by Keith Conners, the conference included research luminaries from the 1950s 
and 1960s, including Jonathan Cole, Virginia Douglas, Rachel Klein, Donald Klein, J. 
Gordon Millichap, John Werry, and others.  
With an emphasis on the pharmacotherapy of hyperkinetic children, much of the 
1972 symposium was devoted to studies of individual drugs—methylphenidate, 
dextroamphetamine, levoamphetamine, and imipramine. Receiving the lion’s share of 
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attention was a new drug, pemoline—a stimulant developed by Abbott Laboratories in 
the early 1970s and introduced as Cylert in 1975.123 As Jonathan Cole remarked at the 
opening of the conference, “The area has also been favored by having some old drugs of 
clear effectiveness such as d-amphetamine and methylphenidate and cursed by the fact by 
the fact that both these drugs can be abused….Hopefully, pemoline, one of the drugs to 
be discussed at this conference will alleviate one of the problems facing the drug therapy 
of hyperkinetic children by proving to be free of drug abuse liability.”124 Pemoline’s 
debut was notable for two reasons. First, it demonstrates how, by the early 1970s, child 
psychiatry and pediatrics had come to take seriously the issue of the addiction potential of 
drugs used to treat hyperkinesis. If the backlash against amphetamines and 
methylphenidate triggered charges of “chemical straitjackets” among critics, among 
many psychiatrists, it stimulated a search for new drugs that would be free of these ill 
effects. Second, pemoline did not turn out to be the solution that optimistic psychiatrists 
such as Cole had hoped. Its market life after 1975 was marred by evidence that the drug 
caused hepatoxicity; Cylert had been linked to 21 cases of liver failure, of which 13 
resulted in liver replacement or death. The FDA finally withdrew it from the market in 
2005.125 
If the search for new therapeutic technologies in the early 1970s demonstrated 
how clinical research in child psychiatry had strived to progress, albeit with mixed 
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results, then there was also some continuity with the past. At the symposium, Cole 
referenced the 1958 NIMH conference that had helped set the stage for research efforts in 
the 1960s. Remembering that “at the time of the [1958] conference, there was essentially 
no research on drugs in children except for the relatively informal work done by 
researchers such as Laufer at the Emma Pendleton Bradley Home in Rhode Island,” Cole 
conceded that “a number of the methodological and philosophical problems discussed are 
still with us.”126 However, he also observed the progress made in the years since, 
particularly the work of Leon Eisenberg and Keith Conners, whose drug studies in 
children he declared “the oldest and most productive one NIMH has supported.” More 
important, Cole concluded that the methodology in establishing the effects of stimulant 
therapy had improved immensely since that time.127 If some methodological problems 
had remained after 14 years of research, progress had been sufficient enough for Cole and 
others to see how far child psychiatry had come. Implicit in his observation was the 
important role the federal government in the quest to diagnose and treat the psychiatric 
disorders of children.128 
Conclusion  
 The 1972 symposium on the clinical use of stimulant drugs in children was a 
harbinger of subsequent research efforts. On the one hand, psychiatric research continued 
to make strides in understanding the physiology of hyperkinetic disorder, the intricacies 
of drug action, and better modes of treatment. On the other, each new finding tended to 
complicate the situation further. While progress was certainly made, discoveries tended 
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to reinforce the adage that “the more one learns, the less he or she knows.” One superb 
case in point was the work of Judith Rapoport, a researcher with the NIMH’s Biological 
Psychiatry Branch, during the late 1970s. In 1978, Rapoport published a highly visible 
article in Science on her findings that stimulants, namely Dexedrine, had the same 
calming effect when administered to normal children as they did to hyperactive 
children.129 If Rapoport’s research suggested the existence of a drug interaction unique to 
children resulted in physiological and behavioral changes, regardless of hyperkinetic 
symptoms, it raised more questions than it probably answered. Her research underscored 
the need for better measures of diagnosing children with hyperkinesis, lest all children be 
considered hyperkinetic mainly because they reacted positively to amphetamines. 
 While physicians, journalists, and activists contended with Rapoport’s finding, 
efforts were underway to revise the diagnostic category of hyperkinesis for the revision 
of the DSM-II, published in 1968. With the publication of the DSM-III in 1980, the new 
moniker of attention deficit disorder (ADD) officially replaced hyperkinetic syndrome as 
the new disorder.
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 As physicians explored the applications of psychostimulants to combat the 
untoward effects of antipsychotics, relieve minor depression, and manage hyperkinesis in 
schoolchildren, extramedical consumption of the same drugs escalated dramatically.1 In 
this chapter, I focus on this other side of psychostimulant drug use during the postwar 
era. While recreational consumption of amphetamines had existed from the very 
beginning, the years after World War II were marked by an unprecedented boom in their 
nonmedical use, culminating during the 1960s with the discernable formation of what 
Lester Grinspoon and Peter Hedblom termed “the speed culture.”2 I contend that the 
consumption of stimulants is best understood in terms of multiple cultures, each with its 
own constituents, modes of use, and relationships with medical professionals, regulatory 
authorities, and cultural brokers. In this chapter, I consider four “amphetamine cultures” 
in particular: the “speed freaks” of the 1960s counterculture, diet pill consumers, truck 
drivers, and athletes.3  
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While these cultures may have had similarities, such as an emphasis on 
performance enhancement through stimulant use, they were quite distinct. I argue that the 
specificity of each form of consumption determined how medical and political authorities 
responded to it. As controls on the extramedical use of these drugs were tightened in the 
1960s and 1970s, these drug cultures diverged, following different paths. Of particular 
concern to medical and political authorities was the consumption of stimulants by 
adolescents and young adults. In such cases, authorities focused their efforts on linking 
amphetamine abuse to high rates of crime and juvenile delinquency. In stamping out uses 
defined as patently non-medical and illicit, political leaders and medical authorities 
upheld a common understanding of the problem and worked together to address it. 
However, the quasi-medical consumption that flowed from legitimate medical 
applications, such as overuse of amphetamines prescribed to women as diet drugs, 
created a number of tensions between the various sides. Policymakers would call into 
question the prescribing patterns of physicians and marketing practices of pharmaceutical 
firms.  In contrast to the agenda of political authorities, many patient-consumers would 
demand stimulants’ continued availability on the medical market. 
 At the same time, I argue that it was necessary for physicians, particularly 
psychiatrists, to cultivate a new understanding of the dangers of stimulants. Historian 
Nicolas Rasmussen has documented how amphetamine consumption reached 
unprecedented levels by the 1960s, while also explaining some of the key scientific 
developments that suggested the drugs’ potential for dependency.4 Less understood, 
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however, is how clinician thinking and practices evolved to meet these concerns. After 
World War II, many medical professionals still held fast to the idea that psychostimulant 
drugs posed few hazards. Only during the 1960s did the profession openly reassess this 
position and, by the end of the decade, take a more cautious stance. This changing 
orientation would be an important driver in policymakers’ efforts to impose tighter drug 
controls, an issue that I take up in the next chapter.  
The Many Cultures of Speed 
 In their 1975 study of amphetamine consumption, Grinspoon and Hedblom 
articulated the many facets of the speed culture, especially the use of amphetamines by 
adolescents and young adults who sought the drugs for productivity, pleasure, or, often, 
both. The authors demarcated the boundaries of consumption in a comprehensive 
manner, and took pains to contextualize extramedical consumption within the broader 
drug culture, youth culture, and general countercultural movements of the 1960s and 
early 1970s. However, Grinspoon and Hedblom often failed to distinguish between users 
of stimulants and other popular drugs. One particular example of this gap was their 
conflation of the amphetamine and the LSD cultures. Another was their association of 
amphetamines with artistic and cultural leaders of the 1960s, unaware that many of them 
were stridently opposed to amphetamine consumption.5 
“Speed Freaks vs. Acid Heads”: Amphetamine Youth Culture 
 In their consideration of amphetamine use by adolescents and young adults, 
Grinspoon and Hedblom located the most visible part of the speed culture in the Haight-
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Ashbury district of San Francisco.6 Given the visibility of Haight-Ashbury during the 
1960s, this focus comes as little surprise. Indeed, a study on the social characteristics of 
speed users published in 1970 observed that of the few systematic studies done, all were 
from the San Francisco area and none contained a sample larger than 36 individuals.7 
Nevertheless, a few generalizations could be, and often were, made about speed users. 
Speed was attractive mainly to young people in their teens and early twenties. One 
sample of amphetamine abusers admitted to Bellevue Psychiatric Hospital had a mean 
age of 24.8 years.8 Other studies referred to the drug’s popularity with the “baby boom” 
generation.9 
 However, the use of amphetamines by young people was hardly a phenomenon 
born of the 1960s. In the late 1940s, amphetamines became an integral part of the final 
exam ritual, as college students turned to the drug to help them cram during all-night 
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study sessions.10 Two researchers corroborated these observations in a study of 
amphetamine abuse among medical students at the University of Oregon, where they 
found that just under half of the students surveyed had consumed amphetamines, with the 
majority of users taking them more than once. Even more striking was their finding that 
seven percent of these users had taken doses of 30 to 100 milligrams, exceeding the 
normal therapeutic dose of 5 to 12 milligrams of amphetamine per day.11 By the 1960s, 
high school students began to rival college students in their consumption habits. A survey 
from 1968 found that 22 percent of juniors and seniors at a San Francisco high school had 
taken amphetamines orally once or twice, and that 75 percent of users had consumed the 
drugs three or more times.12 These statistics suggest that the illicit consumption of 
amphetamines and other stimulants was growing on the West Coast in the 1960s. What 
they cannot reveal is how people experienced the drug culture. Historians have discussed 
the use of these drugs by thrill-seeking American youth, noting in particular that speed 
was often viewed antagonistically by many leaders and spokespersons of the hippie 
movement.13 The consumption of cannabis and LSD was congruous with hippie ideals of 
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creativity and communalism, while the use of amphetamines by “speed freaks” 
threatened to upend them.14 As the famed poet Allan Ginsberg articulated in a 1965 
interview with the Los Angeles Free Press, “Let’s issue a general declaration to all the 
underground community, contra speedamos ex cathedra. Speed is anti-social, paranoid 
making[;] it’s a drag, bad for your body, bad for your mind, generally speaking, in the 
long run uncreative.”15 In that interview, Ginsberg set LSD in sharp relief against 
amphetamines by highlighting the antisocial tendencies of the latter’s consumers. Similar 
views about the dangers of speed to the youth and counterculture of the 1960s were also 
expressed by Timothy Leary, the Beatles, Frank Zappa and the Mothers of Invention, and 
Donovan.16 As Canada’s Le Dain Commission, convened to investigate the legal status of 
cannabis, noted of amphetamines, 
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considerable opposition to such use of amphetamines has developed within the 
‘hip’ community. The “speed trip” is in many respects the antithesis of the 
experience sought with the psychedelic drugs. Instead of the orientation towards 
the “consciousness expansion,” personal insight, and aesthetic and religious 
awareness often attributed to the psychedelic drug experience by users, the speed 
phenomenon is usually characterized by action, power, arrogance and physical 
pleasure (“kicks”), and regularly leads to suspicion, paranoia, hostility and often 
aggression. In addition to these undesirable personality changes, which render 
“speed freaks” highly unpopular in the community, such individuals generally 
present a picture of chronic ill-health unparalleled among youthful drug users.17 
 
The pharmacological properties of amphetamines, not to mention the visceral image of an 
addict injecting the drug, contrasted with the more tranquil, colorful experiences of 
marijuana that was smoked or acid that was ingested. 
 Less appreciated by historians are the ways that the amphetamine youth culture 
defined itself and was interpreted by opposing cultures. A September 1967 study revealed 
that one-third of 413 residents of the Haight-Ashbury district surveyed had, in fact, 
injected amphetamines at least once.18 If there was rancor over the use of speed by the 
leaders of the Haight-Ashbury scene and their counterparts elsewhere, how did the drug 
manage to become popular in the first place? One explanation was that the mainstream 
press had made the dangers of LSD and cannabis its primary targets, while ignoring the 
hazards associated with amphetamines. Police and narcotics officials were so concerned 
with seizing marijuana and acid that they tended to overlook the potential problems of 
amphetamine use. As one 17-year-old girl whose friends used speed observed, “Some 
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police officers we interviewed said pot was deadly and addictive! When kids try it and 
see it’s all a lie they figure the stuff about speed is false, too.”19 This undue emphasis 
elicited some concern in the medical press. In a study of adolescents who ran away to 
Haight-Ashbury during the “Summer of Love” in 1967, three researchers also suggested 
the misguided priorities of law enforcement when they observed that the “horrible 
reactions to marijuana predicted by various authorities were virtually never seen. The 
runaways generally took this to mean that all the widely advertised dangers of drugs were 
establishment lies. This further alienated them from the social structure and made them 
more willing to experiment with all sorts of chemicals.”20 Chief among these substances 
were amphetamines. One of the ironies of the policymaking and enforcement surrounding 
illicit drugs during the 1960s is how laws, policies, and educational campaigns could 
work to encourage a shift away from the use of some drugs—cannabis and LSD—and 
toward others, such as speed, all by a matter of emphasis by authorities.21  
 Despite exhortations against the use of amphetamines by leaders of the 
counterculture, young people were, in fact, using speed. Within this broader culture of 
drug experimentation, there were opposing subcultures at play, particularly the “heads,” 
proponents of LSD and other hallucinogens, and the “freaks,” users of amphetamines. 
Caught amid the maelstrom of these conflicting drug subcultures were physicians such as 
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David E. Smith, the founder and director of the Haight-Ashbury Free Clinic.22 In a 1969 
commentary for Clinical Pediatrics, Smith emphasized these distinctions by drawing 
upon observations of his own clinic population. Of particular significance, the speed 
freak exhibited a personal philosophy that was the direct antithesis of the acid head’s. 
Whereas the former sought a “flash” or thrill as part of the drug experience, the latter 
typically developed a complex set of motivations for his or her drug use, including 
introspective, pseudoreligious, and creative aspirations.23 Based on a previous study that 
identified four sub-groups in the Haight-Ashbury community, the use of LSD and 
cannabis was associated with the group known as “the core”: committed hippies with 
consistent philosophical systems identifiable by their consumption of drugs on social 
grounds (marijuana) and for mystical, creative reasons (LSD). Conversely, amphetamine 
was associated with “the sociopathic element,” such as members of the Hell’s Angels and 
Gypsy Jokers motorcycle gangs, “Negro militants,” methamphetamine dealers, and 
criminals, as well as a “prepsychotic element” that included individuals “who could not 
make it” in mainstream society.24 Particularly alarming to these researchers was the 
increasing association of amphetamine use with “the teenyboppers”: the influx of 
teenagers into the Haight-Ashbury area that made up the fourth subgroup in question. 
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High school students described as going to Fort Lauderdale during their vacations to 
drink beer were now perceived by Haight-Ashbury medical authorities as coming to their 
neighborhood to “shoot speed.” Apparently, it was the new “in” thing to do.25 
Leadership of the Haight-Ashbury Free Clinic and its prominence within the 
hippie movement provided Smith with an exceptional vantage for discerning competing 
modes of recreational drug use. In a June 1967 article for Look highlighting the recent 
opening of the clinic, Smith emphasized the need to break through misconceptions and 
misinformation about drug use by hippies. “We can earn their respect only by telling 
them the truth and treating drugs as medical, more than police, problems,” he observed.26 
Toward these ends, Smith’s endeavors as a healer for the hippie community were 
accompanied by efforts to understand the pharmacological properties of the drugs. One 
such substance that took Haight-Ashbury by storm during the summer of 1967 was a 
combination hallucinogen-stimulant called Serenity, Tranquility, and Peace, or STP.27 
Distributed widely within the district, the drug proved disastrous for some users and 
vexing for medical professionals who treated them. The 20-milligram dose was unusually 
high, and its slow onset and long duration caused experimenters unfamiliar with its 
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effects to re-dose, frequently leading to overdoses. Commenting on the drug’s 
introduction to the Haight-Ashbury community that summer, Smith pointed to the 
importance of pharmacological knowledge in his practice, while complaining about the 
legal barriers he faced: “We found STP before it could spread, and could warn kids and 
doctors. But we are still far from an antidote.”28 In particular, Smith vented frustration 
with federal and state laws that inhibited testing of drugs to understand their effects, as he 
explained the “value of acting, rather than reacting to a problem.”29 
 
 
Figure 5.1 – Dr. David E. Smith of the Berkley Free Clinic (center) with two hippies in a 




While Smith appeared to exhibit guarded tolerance for LSD (or at least 
demonstrated more sensitivity to users’ rationales for “dropping acid”), he was less 
sympathetic toward speed. In 1969, he lent his talents and concern to a 17-minute 
                                                







documentary entitled Speedscene: Problems of Amphetamine Abuse.30 The educational 
film included interviews with young hippies who described their initial experiences with 
speed as “groovy.” Their stories soon turned sinister with discussions of lost friends, 
resorting to prostitution, and stealing or forging scripts to obtain amphetamines. 
Accompanying firsthand accounts that luridly related speed’s horrors were discussions by 
physicians who brought a sense of medical urgency to the speed epidemic that afflicted 
Haight-Ashbury and other countercultural communities in the late 1960s. 
 
 
Figure 5.2 – Dr. Smith stands outside Examination Room 2 of the Berkeley Free Clinic in 




 References to drugs in the “underground” or “alternative” press of the 1960s, 
particularly newspapers published in countercultural cities—New York, Berkeley, San 
Francisco, and the like—provide another dimension for understanding the peculiarities of 
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this culture of amphetamine consumption. In her contemporaneous study of drug-related 
material in the underground press of the late 1960s, Anne Jessica Siegal noted how 
leading newspapers, such as the East Village Other, Berkeley Barb, and San Francisco 
Oracle, differentiated between the various drugs used by youth and other participants of 
the counterculture. Many of these publications viewed cannabis as harmless and often 
lobbied for its decriminalization, if not outright legalization. Likewise, countercultural 
newspapers and magazines opined that psychedelic drugs such as LSD did not appear to 
have any truly adverse effects and the decision to engage in their use was a personal one. 
But permissive outlooks on these substances contrasted sharply with the positions taken 
on amphetamines, as well as other “hard” drugs such as barbiturates and heroin. These 
drugs were viewed by the underground press as dangerous and to be avoided.31 One such 
example was the case of “Dr. Hip Pocrates,” a column written by physician Eugene 
Schoenfeld, published by the Los Angeles Free Press and Berkeley Barb, and syndicated 
in fifteen other publications. Over the course of several years, Schoenfeld repeatedly 
warned of the ill effects of amphetamines for both users and their unborn children. Such 
advice contrasted with the moderate stance he took on other drugs, particularly cannabis. 
 Despite the emphasis placed upon the “speed culture” developing on the West 
Coast during the 1960s, the youth drug culture was not confined to a single geographic 
area, nor was amphetamine the only drug of concern. By the late 1960s, Ritalin was 
implicated in a much broader problem of drug abuse in Sweden, which arguably had the 
highest incidence of stimulant abuse in the world, prompted partly by its 
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overprescription. Commenting on the fact that Sweden had between 10,000 and 12,000 
stimulant addicts, more than any other country in Europe, a 1970 article in the New York 
Times drew comparisons between Sweden’s drug problem and those afflicting New York 
City. The two most widely abused drugs were Preludin (phenmetrazine), legally sold in 
the United States as a diet drug, and Ritalin, then gaining currency as the front-line 
treatment for hyperkinesis in children.32 While the problems of stimulant abuse in 
Sweden might seem somewhat remote from the issue in the United States, I discuss later 
how the Swedish experience would inform both medical experts’ opinions, as well as the 
positions that policymakers would take on drug regulation.  
The Diet Pill Culture 
 One of the earliest uses for amphetamines discerned by medical professionals was 
their application for the treatment of obesity.33 In 1938, two years after the introduction 
of oral Benzedrine to the market, Poul Bahnsen and his associates undertook a 
comparative study of 100 subjects receiving amphetamine versus an equal number of 
individuals who did not. They found that 19 people in the active drug group and one 
person in the control group reported a reduction in appetite.34 The application of these 
initial findings began in earnest when the first study detailing the use of amphetamines in 
                                                
32 Richard Severo, “Mainlining Amphetamines Rising Problem in Sweden,” New York Times, 10 
April 1970. 
 
33 For more on the history of obesity in the United States, see Deborah Levine, “Managing 
American Bodies: Diet, Nutrition, and Obesity in America, 1840-1920,” (Ph.D. diss., Harvard University, 
2008). For more on the history of diet pills, see Eric Colman, “Anorectics on Trial: A Half Century of 
Federal Regulation of Prescription Appetite Suppressants,” Annals of Internal Medicine 143, no. 5 
(September 6, 2005): 380-385. FDA historian John P. Swann has also explored the history of diet drugs in a 
recent series of presentations entitled “Rainbow Diet Pills in Medical Practice, Industry, and Regulation.”  
 





the clinical management of obesity was published the following year.35 Within a decade, 
the use of amphetamines for weight management was studied under carefully controlled 
conditions when S. C. Harris, A. C. Ivy, and L. M. Searle found that seven obese patients 
lost more weight when administered amphetamine than when given placebo; however, 
the main cause of weight loss was attributed to the suppression of appetite rather than a 
higher activity level. This and other studies published during the late 1940s suggested 
that by reducing appetite, amphetamines might make it easier to adhere to a dietary 
regimen requiring less food consumption. Interest in the potential of amphetamines as 
weight loss drugs persisted among researchers. In the 1950s, a second series of 
publications indicated the potential of combination drug therapy, usually amphetamine 
and barbiturate, to manage the emotional extremes found in obese patients trying to lose 
weight. 
 Beginning in the early 1940s, physicians began to prescribe amphetamines on an 
off-label basis for patients seeking to lose weight. However, this particular application 
did not have the approval of the American Medical Association (AMA), and Smith, Kline 
& French (SKF) did not advertise this particular indication. Competitors soon stepped in 
with their own products, and the firm found itself defending its patents in court. In one 
such case, SKF sued the New Jersey firm Clark & Clark for its combination of 
amphetamine and thyroid hormone, which claimed to boost metabolism as it suppressed 
appetite.36 According to Rasmussen’s calculations, based on an examination of the 
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relevant court records, production of amphetamine for civilian consumption was around 
30 million tablets per month in 1945. Put another way, enough amphetamine was 
produced to provide half-a-million Americans with two tablets daily of the standard 
amphetamine dose for depression or weight loss.37 
 While the courts upheld SKF’s patents on oral amphetamine, the firm maintained 
its monopoly only until 1949. In the meantime, the AMA approved amphetamine for 
weight loss indications in 1947. Taking advantage of a growing market for this 
application and responding to research on the efficacy of amphetamine-barbiturate 
combinations, SKF debuted Dexamyl in 1950. With SKF’s exclusivity over amphetamine 
lost by then, however, numerous other companies responded in kind with their own 
products to capture the weight loss market, initiating fierce competition in the 1950s. By 
1962, the FDA suggested that enough amphetamine was being produced annually to 
manufacture 8 billion 10-milligram tablets, enough to supply every American with 43 
doses per year.38 There was little question that much of this supply was prescribed for 
weight loss. Historian John Swann has even suggested that weight loss clinics at this time 
were frequently subsidiaries of off-brand drug companies.39  
 In April 1971, the New York State Commission on Revision of the Drug Laws 
held hearings to address the issue of amphetamines and, in particular, their prescription 
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for weight loss. Based on the findings of the New York State Narcotic Addict Control 
Commission, the commission’s interest in amphetamines and their use in controlling 
obesity come as little surprise. “Pep pills,” amphetamines, and amphetamine-like 
compounds were discovered to be the most abused drugs in the state, and more than half 
of the users in New York obtained these drugs without prescriptions. According to the 
Committee’s findings, some 222,000 people within New York State regularly used diet 
pills, 19 percent of which were obtained illicitly. Even more revelatory were the findings 
of a survey of 4,000 women, published in the November 1971 issue of the Ladies Home 
Journal. The survey found that 17 percent of women reported having used diet pills, most 
containing amphetamines. Only relaxants (presumably minor tranquilizers), 
noncontrolled narcotics, and barbiturates were more widely used by American women.40 
The association of a diet pill culture with women can be confirmed with other findings 
from the survey, which noted that while women comprised 53 percent of the overall 
population in the United States in 1971, 80 percent diet pill consumers were women.41 
 Among experts concerned about the culture of diet pill use in the United States, 
many were quick to point out that the conceptions of female drug users rooted in images 
of singer Janis Joplin, dead of a heroin overdose at age 27, or other such stereotypes, 
needed a sharp reality check.42 For Carl Chambers and Dodi Schultz, the authors of the 
Ladies Home Journal study: 
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The typical woman who uses drugs to cope with life is not a fast-living rock star, 
nor a Times Square prostitute, nor a devotee of the drop-out-and-turn-on 
philosophy of Dr. Timothy Leary. She is an adolescent, confused by the stresses 
of impending adulthood. She is a newlywed, by turns anxious and depressed by 
the strains of adjustment to a new relationship and new responsibilities. She is a 
once-busy housewife, her youngsters grown, who finds her days increasingly 
empty and her thoughts obsessed with the inexorable passing of the years. She is, 
in short, an average, middle-class American—one of the folks next door. She 
could even be you.43 
 
While observing that women were underrepresented among users of illicit drugs, 
smoking substantially less cannabis and injecting less heroin than men, their 
overrepresentation among users of prescription drugs caught the attention of the authors. 
Conceptualizing a culture of diet pill consumption means understanding the ways in 
which it was unique from the “speed culture” at the heart of Grinspoon and Hedblom’s 
inquiry. Most prominently, the use of diet pills was predicated on a system whose 
components included large pharmaceutical firms that manufactured and promoted the 
drugs, physicians willing to diagnose weight problems as a medical disorder in need of 
therapeutic intervention, and women who exercised economic agency as consumers of 
medical services. 
 In a follow-up article for Ladies Home Journal in December 1971, the authors 
told the story of Betty Ann, a housewife in a middle-class suburb of a major Southwest 
city. So Betty Ann and her husband Don could buy their first home, the couple agreed 
that she would return to work for a year or so in order to afford their mortgage payment 
without relying upon their hard earned savings. Betty Ann answered an ad seeking 
women to sell cosmetics door-to-door. The problem, the authors related, was that she had 
gained a little weight in the intervening years—“not much, but enough”—to make it 
difficult for Betty Ann to maximize her effectiveness in an appearance-conscious 
                                                





profession.44 Recalling “glowing tales of a wonder-working specialist in fast weight 
loss,” she consulted a local physician who offered a system with no difficult diets, 
strenuous exercises, or complicated calorie counting; “his special medications did all the 
work.”45 The medication in question turned out to be Dexedrine. After a few weeks, 
Betty Ann was able to lose the excess weight, obtain the job she sought, and delighted in 
impressing her husband and enjoying a newfound vitality. 
 In relating this story and others like them, many journalists outlined some 
prominent features of this mode of amphetamine consumption. An innocent housewife, a 
doctor promising miracle cures, and a wonder drug that facilitated a patient’s goals: all 
are common components of these stories. Sometimes other factors might be present, such 
as a husband who encouraged, either explicitly with a suggestion or indirectly with 
compliments or other reactions, his spouse to seek out “fat doctors.” Occasionally, such 
medical professionals might be juxtaposed with the woman’s family physician who either 
told her that the excess weight should not be a cause for concern or that diet modification 
and exercise would be optimal for losing weight. In some cases, these various elements 
produced stories of initial happiness that gave way to incredible pain and suffering for the 
unwitting patient, with the drugs and the doctor who prescribed them as the culprits. 
 However, the story of Betty Ann also suggests how diverse and irresolute the tales 
of women diet pill users could be. After achieving her weight reduction goal and 
successfully obtaining the temporary employment needed to help her and her husband 
afford their new home, Betty Ann still found herself using Dexedrine. But her daily dose 
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had increased to a total of 350 milligrams per day, consumed as twenty 15-milligram 
capsules and ten 5-milligram tablets (roughly equivalent to the caffeine in 70 cups of 
black coffee per day). While other narratives related ruined lives stemming from 
addiction and other untoward effects of amphetamine consumption, Betty Ann’s had an 
uncertain resolution that realistically demonstrated how the benefits and problems of drug 
consumption could not be so easily disaggregated. In her case, Betty Ann had to contend 
with the dent that increasing doses of Dexedrine were putting in the household budget, 
but as she observed, “Don doesn’t say much about the cost; we never really discuss it. He 
likes me thin. And I like me better this way, too. I feel pretty, and I’m not afraid of 
people the way I used to be.”46 Such a case demonstrates how, within a culture of diet pill 
use, it could be difficult to parse a choice to consume drugs freely with the possibility 
that dependence was driving such use. 
The nature of such a complex culture can be explained further by the 
correspondence received by Senator Birch Bayh’s (D-Indiana) office as a result of his 
Subcommittee’s 1972 investigation into amphetamines and other diet pills for the 
treatment of obesity. In one letter to the senator, a Charleston man detailed his wife’s 
experiences with a local “fat-doctor” over a 10-year period. In any given month, the man 
claimed, his wife took up to 460 pills, most of them amphetamines, plus injections of 
drugs that the doctor sold to her at his office, also amphetamines. In exchange for a loss 
of 30 pounds, the concerned husband claimed that his wife suffered from insomnia, 
hypertension, nose bleeds, and that, in general, “our life together is a wreck.”47  
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In another case, a woman from Chicago recounted to Senator Bayh her own 
experiences using diet pills as a teenager. At the suggestion of her high school physical 
education teacher, the woman had gone to a “diet doctor” who gave her an “unlimited, 
easily refillable, and not too closely supervised” supply of amphetamines.48 Told by her 
doctor to report any difficulties she might have had with the pills, the young lady 
confessed that she didn’t interpret the “great feeling” the drugs gave her as a “difficulty.” 
Conversely, the medication gave her such euphoria that she began taking double and then 
triple the recommended dosage. Only after running out of pills one day and having to 
experience withdrawal symptoms did the woman claim to understand what they had done 
to her: “My craving for a ‘diet’ pill was so strong I would have cut off my arm to get one, 
yet, because of this very craving, I was so terrified of what had happened to me that I 
never touched them again. This wasn’t easy, mind you: I wanted those pills. But 
fortunately I was simply too frightened to buy more.”49 The threat of addiction was not 
the amphetamines’ only drawback. While the woman lost weight taking them, she gained 
it back, plus about 100 pounds more, after stopping. For her, only enrollment in a Weight 
Watchers program proved to be permanently effective. 
Aside from stories of individual grief, pain, and suffering, even amidst the weight 
loss sought by consumers of amphetamine-containing diet drugs, individuals enmeshed 
within this culture identified other bothersome aspects of the system. One Minnesota 
woman claimed that doctors who failed to give patients adequate check-ups were to 
blame for the problems associated with diet drugs. She noted the case of a doctor in St. 
                                                








Paul who overcharged patients for unnecessary weekly visits and simply dispensed the 
pills sought.50 In another case, a pharmacist charged that physicians dispensed pills in 
unnecessarily large quantities as a result of patient cajoling. He also alleged that such 
large prescriptions undermined pharmacies’ profits by allowing patients to shop around 
for the best deals.51 Whether the blame rested with unscrupulous doctors, overzealous 
patients, or even profit-hungry pharmaceutical firms, it was clear to these complainants 
that diet drug abuse was fast becoming a medical and political problem.  
Yet, not every person viewed the issue with such disdain. For some consumers, 
the possibility of increased regulation and controls threatened a viable means of 
achieving otherwise unobtainable goals. One woman recounted how, after a number of 
gimmicks and “crash” diets, she visited a “very reputable” physician in San Francisco. 
After a thorough examination and a determination that her overweight situation was not 
injurious to her health, the doctor prescribed some appetite suppressants. “I am both 
happier and healthier now,” she remembered, “and I don’t feel the medication has been at 
all dangerous to me. I can eat properly now, without the fear of seriously endangering my 
health with the crash diets I had tried in desperation.”52 This patient, who continued to 
see her physician twice a month and received instructions on the proper use of her 
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medication, could “see no reason for these drugs to be restricted from the vast majority of 
responsible patients, in order to pay for the mistakes of a few.”53  
Others protested to Bayh on the grounds that control of amphetamine-containing 
diet drugs would constrain their options for weight loss. Where problems did exist, as the 
letter from Melissa Tidd of San Francisco suggests, these were often the mistakes of a 
few unscrupulous physicians or inattentive patients who jeopardized the interests of a 
responsible majority. Shirley Deator of Modoc, Indiana, typified such thinking when she 
related that it had been months since she had sought a prescription for amphetamines 
from her doctor: “Do you call that being hooked? They aren’t habit forming and I 
certainly want you making a lot of notice about their continuance, please!”54 
 Such uncompromising testimonials about the safety of amphetamines should not 
obscure the fact that for many patients who appealed for their continued availability, 
these drugs were, in fact, a support. Though not necessarily proud of their reliance on 
them, some women were receptive to a little pharmacological help now and then to help 
them manage their weight. Deator explained that amphetamines were the “lesser of 
several evils that are a direct cause of overweight [sic]. A crutch, perhaps for a lot of 
people but if it helps some poor unhappy fat person to loose [sic] weight, why knock 
it?”55 Pauline Miller, of Chicago, couched her reliance on the drug in terms of other 
habits. “I’m afraid I’m a person who needs a ‘crutch’ when I diet,” she confessed. “I have 
no other vices like a couple of martinis before dinner or smoking a pack or two a 
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day….There are many elements on this earth that aren’t very good for us but it is up to 
the individual to think for himself. I would hate to fill my diet requirements (dosage 
under 15 milligrams or whatever) at the friendly corner junk peddler who will definitely 
continue to flourish…for a lot of money and risk.”56 If confessing that their reliance on 
diet drugs containing Dexedrine, among other psychostimulants, was a sign of weakness 
in terms of weight maintenance, was it really any worse than regular consumption of 
alcohol or tobacco? For Miller, who argued that “I figure I’m ahead, a little bit of 
drinking, no smoking, no birth control pills, no saccharin, a moderate amount of sex,” 
and others like her, the answer was “no.”57 Moreover, some of those opposed to more 
stringent regulations noted that the choice should be theirs to make, not the 
government’s. Common to these letters is an assertion that authorities would do better to 
crack down on illegal drugs and their dealers, and leave these ordinary citizens (most of 
them women) and their trusted, respectable physicians alone. 
 These and other narratives suggest the panoply of experiences of women (and 
occasionally, men) who relied upon amphetamine-containing compounds. If the myth of 
the unwittingly addicted housewife who fell prey to dishonest doctors and drug firms 
failed to capture the reality of all women, neither can one say that users were completely 
free of physical, mental, and emotional side effects. Many patients confessed that the 
drugs had untoward effects on them or their loved ones, ranging from psychological 
dependence to a number of very real physical ailments. At the same time, some believed 
that physicians had taken advantage of them and their desire to lose weight and, as such, 
                                                








called on authorities to control the problem. Yet, their views were by no means 
unanimous. Many women reported how these drugs had helped them realize their goals, 
especially when other means of reducing weight had failed. Often they recounted that the 
physicians who had prescribed these drugs were reputable and ethical—far from the 
charlatan “fat doctors” portrayed in some publications. Another contingent noted that 
even if their reliance on drugs suggested weakness or a lack of willpower then they 
should be permitted the freedom of choice to seek their support. Finally, the story of 
Betty Ann also suggests that for some women, neither of these two positions—for and 
against stronger controls of drugs—seemed wholly satisfactory. 
 Diet pill users’ simultaneous identities as consumers and patients within the 
medical marketplace also characterized their culture of amphetamine consumption.58 
Historians have suggested that patients, particularly those seeking outpatient care, should 
also be interpreted as economic agents who consume products within a medical 
marketplace.59 In contrast to the psychiatric applications of stimulants, the consumption 
of diet pills afforded patients an exceptional level of agency as consumers.60 
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 How did the pharmaceutical firms manufacturing these drugs understand their 
utility and contribute to the diet pill culture? One indication may be gleamed from their 
advertisements. Until the 1970s, a steady stream of ads touting the benefits of 
amphetamines and other stimulants for weight reduction proliferated in medical journals. 
Moreover, a number of pharmaceutical firms introduced products with names suggesting 
their intended use. SKF introduced Eskatrol, a weight loss drug containing 
dextroamphetamine (precisely the same drug as firm’s bestselling Dexedrine). Wallace 
Pharmaceuticals marketed Appetrol, a dextroamphetamine-meprobamate combination, 
while Massengil promoted Obedrin, a methamphetamine-phenobarbital combination. In 
addition, a number of other amphetamine drugs were commonly advertised for weight 
management, including SKF’s Dexedrine and Dexamyl, Robins’s Ambar 
(methamphetamine-phenobarbital), and Strasenburgh’s Biphetamine (amphetamine-
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dextroamphetamine). Also notable was the marketing of methamphetamine products for 
dietary purposes by Abbott as Desoxyn, Endo Products as Norodin, and McNeil as 
Syndrox. The amphetamine-like drug phenmetrazine, marketed by Geigy as Preludin, 
was another bestseller. 
 An analysis of ads confirms that the intended patients were women. For instance, 
SKF advertisements from 1967 for Dexamyl employed an art deco style, evocative of 
1920s fashion, to tout the ability of women to “say ‘no thank you’ to the praline sundae” 
and a host of other tempting desserts and sweet concoctions (see Figure 5.3). Users of 
Dexamyl were depicted as beautiful and glamorous, enjoying active social lives. For 
these women, amphetamines provided or helped to maintain a sexually appealing 
appearance and a secure place in fashionable society. Conversely, advertisements such as 
that for Wallace’s Appetrol in 1967 occasionally depicted the targeted patient as an 
unhappy, morbidly obese woman who was either socially inept or unhappy (see Figure 
5.4). The Appetrol ad paralleled the Volkswagen ads of the day by showing a dissatisfied, 
almost resigned housewife named Peg stuck in the sunroof of a Volkswagen Beetle. As 
further proof of her problems, she is described as a “round Peg in a square hole.” Other 
marketing tools took a similar approach, such as a 1956 ad for Ambar, which portrayed 
an overweight couple struggling to sit next to one another in a Victorian loveseat too 







Figure 5.3 – 1967 SKF advertisement for Dexamyl for weight loss. (Source: Journal 






Figure 5.4 – 1967 Wallace advertisement for Appetrol. (Source: Journal unknown. The 






Advertisements such as these took aim at a common problem to be solved and a 
solution to be obtained. Women who successfully controlled their weight through the use 
of amphetamines were viewed as young, beautiful, and socially active, whereas women 
in need of treatment were old, unattractive, unhappy housewives whose weight was 
perilously out of control. While the suggestion that women who relied upon these 
medications for successful treatment would become miraculously younger, richer, 
popular, and carefree may have been wishful thinking, the idea that such qualities were 
related to, if not predicated on, a woman’s control of her weight is unmistakably apparent 
in these ads. 
 While women predominated in journal marketing, men were not altogether 
absent. Most advertisements featuring men attempted, in some form, to counter the idea 
of the “happy fat man,” which a 1950 Benzedrine ad featured in JAMA explicitly called 
“a popular misconception.” Echoing promotional efforts aimed at doctors who bought 
into popular perceptions of women, several ads addressed the issue of male sociability 
and the problem of the isolated, obese man. A series of for Preludin illustrates this point. 







Figure 5.5 – 1958 Geigy advertisement for Preludin. (Source: Journal unknown. The 






Willpower is another theme common to advertisements featuring men. A 1957 ad 
for Ambar observed that the drug makes “him want to stop overeating,” a sentiment 
echoed in marketing by other companies. These ads illustrate, through attention to such 
issues as male sociability and failing willpower, that marketing aimed at men as 
consumers could be as gendered as those directed toward women.  
Truck Drivers and Amphetamines 
 One often-overlooked culture of amphetamine consumption involved their use by 
long-haul truck drivers in the 1960s and early 1970s.61 Yet an abundance of evidence 
suggests how large a constituency they were. As Senator Harold E. Hughes (D-Iowa), 
Chairman of the Senate Subcommittee on Alcoholism and Narcotics and himself a former 
trucker, so eloquently observed: 
The American public does not hear much from the truckdriver [sic]. They have 
heard about the high salaries, but they have not heard about the terrible human 
costs of those salaries. For to be a truckdriver in America today is, in some cases, 
to be a human self-destruct machine, albeit a well-paid one…. 
 I have lived problems of both the trucker and the driver. I know what it is 
to be on the road for 15 hours straight without any rest. I know what it feels like 
to come home to your family after having been on the road for 2 or 3 days, and be 
too exhausted to sit down and talk. And I know what it feels like to operate on the 
thin edge between fatigue and anxiety.62 
 
Bridging this “thin edge” described by Hughes was the use of amphetamines by a 
growing number of truck drivers since the early 1950s. A study of 200 drivers, conducted 
in the late 1960s by a team of physicians led by Donald Dawson, revealed that 20 percent 
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of truck drivers admitted to taking amphetamines to stay alert on the job.63 Even more 
drivers, the authors speculated, might be consuming stimulants and not admitting it. To 
better understand drug use among truckers, the Center for Responsive Law undertook a 
study of how the Interstate Commerce Commission was addressing the problem. 
Approximately 1,300 truckers responded to a survey as part of the center’s research, and 
61 percent of respondents stated that the use of pep pills was widespread in their 
industry.64 
 What led these drivers to rely so heavily upon stimulants? Famed consumer rights 
advocate Ralph Nader offered one explanation during the 1971 Senate hearings on the 
topic.65 Quoting from the Interstate Commerce Commission Study, he observed: 
A sense of necessity, certainly not a desire for “kicks,” leads most drivers to 
reliance on drugs. A driver who reluctantly admits to having resorted to pills says, 
“With a family, and kids approaching college age, what else can you do?” To the 
drivers who must stay awake or lose their jobs, the pills are not only an economic 
necessity but a safety precaution as well…. 
Drugs substitute for sleep for the man caught in this ordeal. One driver 
reports that all kinds of people approach him for drugs, thinking that he, as a truck 
driver, must have a source of supply.66 
 
Compounding the problem of amphetamine consumption was the fact that cross-country 
truck driving was already a dangerous profession. In 1970, the National Safety Council 
reported 5,350 truck occupant fatalities and 12,000 fatal accidents involving trucks. 
                                                
63 Statement of Donald Dawson, Use among Truckdrivers, 69. 
 
64 Statement of Ralph Nader, Use among Truckdrivers, 2.  
 
65 Ralph Nader’s concern for highway safety and consumer advocacy is best encapsulated in his 
1965 book Unsafe at Any Speed: The Designed-In Dangers of the American Automobile (New York: 
Grossman, 1965), which criticized the automobile industry for its resistance to including safety features in 
the vehicles it produced. Also important in the context of highway safety was the passage of the 1966 
Highway Safety Act, which created the National Highway Safety Bureau (later known as the National 
Highway Traffic Safety Administration), as well as the 1966 National Traffic and Motor Vehicle Safety 
Act, which mandated new standards for vehicles and roadways in order to make them safer. 
 





Likewise, the U.S. Department of Transportation’s Bureau of Motor Carrier Safety 
revealed that 59.4 percent of truck driver fatalities in 1969 were among carriers involved 
in single-vehicle accidents.67 In addition to the relative dangers of such driving were the 
conditions under which truckers tended to labor: inadequate safety features on their 
vehicles, the problem of incessant noise, and the intense scheduling of routes by their 
employers.  
If the 1971 Senate hearings on amphetamine use by truck drivers provided 
invaluable insights into the important role played by these drugs, just as revealing were 
the labor conditions that accompanied and often facilitated amphetamine consumption. 
Lincoln Merrill, a driver from Winston-Salem, North Carolina, recounted that many 
truckers did not drive regular routes or schedules. In his case, he might get home from 
work at 8:00 in the evening, only to leave again by 6:00 the next morning. A ten-hour 
route might take him 12 to 14 hours to complete, only to have eight hours to rest. In many 
cases, he had as little as five to six hours off before returning to duty. To cope with such 
stresses, Merrill admitted that he regularly used amphetamines. Commenting more 
broadly on the situation, he observed that, “I think you can determine that possibly 90 
percent of the drivers on long-line operations take pills. They don’t take them just to get 
hopped up. They take them so they can drive without running over people on the road.”68 
Another driver, Robert Lyons of Cincinnati, Ohio, elaborated on the dangers of 
such work and the labor conditions that compelled him and other drivers to resort to drug 
use. Ralph Nader recounted how Lyons had confessed to passing other vehicles regularly 
on double yellow lines and that “under no conditions” could he have made his routes 
                                                
67 Statement of Ralph Nader, 3. 
 





from Cincinnati to Atlanta in the scheduled ten hours if he had been following the law.69 
Lyons elaborated that when driving in the State of Georgia, over 100 miles of road on a 
481 mile route had a posted speed limit of 45 miles. “They give us 12 hours to make the 
run,” he explained. “Now, I can make the run. I have driven it in 8 hours and 36 minutes. 
We have drivers who do this all the time, not because, I don’t think, that they really want 
to.”70 Rather, he charged that employers were responsible for imposing such strenuous 
schedules on their employees, as well as the accompanying consumption of stimulants to 
help them work. Lyons noted that he had been using amphetamines since 1954, and that 
they had damaged his life in many ways. 
Mrs. James Root of Toledo, Ohio, and Mrs. Edward Hensley, of Roanoke, 
Virginia, both wives of truck drivers, provided their own perspective on their husband’s 
experiences. Both women observed how the transition from an ABA dispatch, where 
truckers went to one destination and then returned home, to an ABCD system, where 
drivers might go for up to three routes before returning home, had adversely impacted 
their husband’s lives and relationships. In addition to seeing their husbands less often and 
being unable to contact them easily, Root and Hensley also detailed that such a mode of 
work often meant an increased reliance upon drugs. As Hensley recounted: 
I have followed behind my husband on many occasions in my car. If something 
happens[,] they cannot make the schedule[;] they are subject to a warning letter 
for delaying freight. According to the freight master agreement, with one warning 
letter they can be subject to discharge. So, what do they do? They take a pill and 
proceed on to their destination. Upon arriving they are given a hotel ticket and 
wait sometimes an hour or hour and twenty minutes for a hotel car. They have to 
eat and this leaves them 6 or 7 hours to sleep. 
So, they take another pill to sleep or in most cases turn to alcohol. In a few 
hours they are back on the road again, and still many drivers complain they doze 
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at the wheel. This goes on day after day, until soon they feel they cannot climb 
into the cab or truck without first taking their pill.71 
 
Of particular concern for the wives of these truckers was how amphetamine use to stay 
awake while on the road was often compounded by the consumption of alcohol or other 
drugs to help their husbands relax or simply sleep when not on the job. The fear of 
alcoholism was a particular concern elicited by Root and Hensley. Amphetamines posed 
a grim conundrum for many truck drivers, forcing them to decide between falling asleep 
at the wheel or the prospect of substance abuse. 
Amphetamine Use in Athletics 
 While many athletes have been content to perfect their bodies and abilities 
through healthy diets and extensive training, some have relied upon drugs to enhance 
their performance.72 “For 50 years, bike racers have been taking stimulants,” the French 
cyclist and five-time winner of the Tour de France, Jacques Anquetil, proclaimed in 
1967. Uttered with remarkable candor at a time when his sport had been wracked by drug 
scandals, the French superstar elaborated, “Obviously, we can do without them in a race, 
but then we will pedal 15 miles an hour instead of 25. Since we are constantly asked to 
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go faster and to make even greater efforts, we are obliged to take stimulants.”73 Whether 
his assertions that the decision to take stimulants rested with an unsatisfied public rather 
than the athletes who consumed them were accurate, there can be little doubt that 
Anquetil’s claims that athletes routinely used amphetamines as a means of improving 
their athletic performance were true.74 
 Although their use was not as widespread as the anabolic steroids used by many 
athletes to increase muscle mass, the amphetamines had an appeal in certain sports. They 
were once described as a “triple threat.” Their qualities as appetite suppressants made 
them attractive to wrestlers, jockeys, boxers, and other athletes who would go on crash 
diets to “make weight.”75 In addition, the drugs sped up the circulatory and respiratory 
systems, inducing a hyperactivity that can mask fatigue. Finally, they facilitated 
aggression. In high doses, amphetamines can help make individuals oblivious to pain and 
give them a sense of reckless abandon, invincibility, and anger—all psychological 
manifestations that some football players and other athletes in contact sports have 
considered desirable.  
Amphetamines have been used on occasion throughout athletics, ranging from 
auto racing to yachting, but by the late 1970s, their widespread use had coalesced around 
several key sports. One such example, identified by Irving Dardik, chairman of the U.S. 
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Olympic Committee’s Sports Medicine Committee, was professional football. Similar 
sports requiring an “explosive effort” or “high-tension” types of athletics where 
endurance was a big factor, such as soccer, were also identified by Dardik as prone to 
amphetamine abuse.76 
Such experiences were corroborated by an anonymous member of the Washington 
Redskins who recounted,  
Half an hour before we go onto the field...you see the guys who use 
amphetamines start to go to the water faucet….You definitely see personality 
changes. Some guys become very hard to talk to. I’m sure a lot depends on the 
different dosages, but some players are just impossible to communicate with. You 
see a glazed look in their eyes. You’ll be talking to them, and they’ll just walk 
away and start pounding on a locker or something.77 
 
If such a quote suggests that the main ends sought by amphetamine-using athletes was the 
inducement of aggression, or that its applications were limited to football, then consider 
the perspective of Johnny Bench, the Hall of Fame catcher for the Cincinnati Reds. In his 
autobiography, Bench recounted that when he and pitcher Gary Nolan were newcomers 
to major league baseball during the late 1960s, the use of Dexamyl and Darprisal (a 
proprietary form of amobarbital) were common. “The trainers had them and nobody 
thought twice about passing them out,” Bench recalled. “A lot of pitchers popped. Gary 
would get a couple of daps in him and he’d start chirping away, just sitting in the dugout 
and talking a blue streak. He would get all googly and he wouldn’t answer a question, 
just stay as high as he could and pitch his head off.”78 Such practices, Bench later noted 
in his autobiography, had changed within a decade, partly because of government 
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regulations on amphetamines during the early 1970s, but also because players’ attitudes 
about drugs and their effects had come a long way. In the end, he contended, “Pills were 
misused, and not just by pitchers, and for that I blame the trainers who dispensed them as 
much as the players who took them. In the pros, you look for any leg up, and a lot of 
guys, especially pitchers facing a tough start, thought daps and dexys were that edge.”79 
 In addition to their popularity in team sports, amphetamines also found a large 
following among track and field athletes during the 1960s and 1970s. A classic case was 
that of Jim Neidart, a Long Beach, California, athlete who was the leading high school 
shot-putter in the country in 1973. While in high school, he began using amphetamines to 
increase his performances, only to continue increasing his intake throughout an ill-fated 
college career. One notorious drug-induced rampage occurred following the 1976 
Pacific-Eight Conference Championships at Berkeley. Neidart, representing UCLA at the 
meet, was favored to win the shot put competition, but he came in a disappointing second 
place. After the match, already fortified by a massive dose of amphetamines, he began 
consuming a large number of tranquilizers and alcohol to “unwind.” And then, in the 
words of a witness, Neidart “just went berserk,” as he dismantled his motel room and 
crashed through a plate glass window.80  
Making Sense of the Stimulant Cultures 
In 1970, two surveys provided a snapshot of amphetamine consumption in the 
United States. The first of these, a national study conducted by the Social Research 
Group of George Washington University and the Institute for Research in Social 
Behavior in Berkeley, considered the use of psychotherapeutic drugs by Americans aged 
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18-74. The survey found that a total of 11.6 percent of the population had used 
amphetamines at some point in their lives. Furthermore, 3.7 percent of the population had 
used them for medical purposes at some point in the previous year, while 0.6 percent had 
taken them for non-medical reasons. The majority of medical users had consumed the 
drugs 30 times or less over a two month period. A survey of users in New York State, 
aged 14 and older, corroborated the findings of the national survey. It revealed that 13.6 
percent of New Yorkers had used amphetamines at some time in the past. Within the past 
six months of the survey period, 3 percent of respondents acknowledged that they had 
used amphetamines for medical reasons, and 2.2 percent had used them for non-medical 
indications.81 
 That a considerable portion of the American population had experience with 
amphetamines is notable, but how might historians make sense of the disparate cultures 
of drug use presented here? While amphetamines were consumed by people for a variety 
of reasons, the idea of taking drugs to enhance performance provides common ground for 
understanding their extramedical use. Whether to permit college students to be more 
productive in studies, aid a housewife in losing a extra weight, keep a truck driver awake 
on a long and potentially perilous route, or to give an athlete a competitive advantage, 
stimulants often delivered on elusive promises of performance enhancement. 
 However, some of these applications were viewed as more legitimate than others. 
The potential for drugs to improve the performance of users’ minds and bodies may have 
provided a universal experience for comprehending the overall raison d’être for the 
existence of the speed culture, but for medical experts, regulators, and enforcement 
officials, distinctions could, and needed to be, made between these various modes of use. 
                                                





Why, for example, would authorities be more likely to penalize the recreational use of the 
drug by teenagers living in Haight-Ashbury than they were to arrest an Indiana housewife 
who may have relied on diet drugs to give her more “pep” while performing household 
tasks? The key to that issue, I contend, is the relationship between medical and 
extramedical use. Historian David Courtwright has illuminated how medical 
overprescription of a drug can inform its extramedical consumption through what he 
terms “parallel chain reactions.”82 Physicians prescribe allegedly safe drugs for vague 
symptoms, and a minority of patients continues taking them for a host of nontherapeutic 
reasons.  Such patterns of use spread and eventually the drug becomes “democratized,” 
especially as pharmaceutical firms intensify their marketing and clinicians continue 
prescribing it.  
This very issue came to the fore when the Select Committee on Crime in the 
House of Representatives held hearings on the matter in November 1969. These hearings 
were notable because they represented the first time legislators posed the question of 
whether the hazards of amphetamine misuse outweighed their medical benefits and if so, 
what measures were necessary to fix the problem. The Committee heard a wide array of 
testimony on the subject of stimulant abuse. Among the most outspoken experts seeking 
more stringent controls was physician Sidney Cohen, director of the Division of Narcotic 
Addiction and Drug Abuse for the National Institute of Mental Health (NIMH). Cohen 
differentiated among three types of misuse. Of least concern was the person who 
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infrequently took amphetamines to exceed his psychological limits, whether to stay 
awake, study for an exam, or to drive through the night. Somewhat more problematic was 
the person who took amphetamines without supervision, especially the person who self-
medicated or increased his or her intake to exceed prescribed amounts, such as an obese 
patient who continued to take drugs after attempts to lose weight had been abandoned. 
But both of these types of extramedical use paled in comparison, Cohen reasoned, to the 
problem of the “speed freak” who swallowed handfuls of amphetamine tablets at a time, 
snorted amphetamine powder, or injected mass quantities of the drug directly. The 
amphetamine abuser seeking a euphoric high from the drugs, and often finding instead 
panic and paranoid states, malnutrition, nervous breakdowns, and unexpected infections, 
were of greatest concern to experts such as Cohen.83 However, in differentiating between 
these forms of extramedical consuming and the degree of danger associated with each, 
physicians first had to establish the psychostimulants were, in fact, hazardous.    
Pondering Psychostimulant Addiction 
 Previous chapters have documented the enthusiasm of clinicians over 
psychostimulants. But in parallel with such interest in the therapeutic potential of these 
drugs was a growing concern about their potential for addiction.84 The late 1940s and 
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1950s may be characterized as a time when physicians were excited about the potential 
for amphetamines in medical practice. Nascent concerns voiced during these years about 
amphetamines’ potential dangers existed in the shadows of this more dominant narrative 
of therapeutic receptivity. During the 1960s, a reversal began as doctors reassessed the 
impact psychostimulants were having on American society.  
 Nicolas Rasmussen has implicated both the pharmaceutical industry and the 
medical profession for escalating patterns of consumption since the Benzedrine inhaler 
was brought to market in 1933. During the drug’s first decade on the market, SKF sought 
new indications for its amphetamine products, facilitating their prescription for 
narcolepsy, postencephalitic Parkinsonism, and especially mild depression. Off-label uses 
of the drug for dietary purposes also began to surface in the early 1940s. Also important 
had been the military’s use of the drug during World War II. The sum effect was that by 
1945, a million civilians were consuming the drug either for psychiatric or weight loss 
purposes, and an additional 16 million American military personnel had been exposed to 
the drug during the war. This scale of use was accompanied by a medical and legal 
environment that held the drugs to be relatively safe, thus encouraging their extramedical 
consumption. 
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 Between 1945 and 1960, Rasmussen contends that rivalries between SKF and its 
competitors created an innovative and aggressive market to expand amphetamine 
consumption. One case in point was the introduction of Dexamyl, marketed for a wide 
array of applications, but especially as a diet drug and mood energizer. Competitors’ “me, 
too” drugs also played an important role in this trend.85 As I have already noted, 
amphetamine consumption in the United States numbered in the millions of users 
consuming billions of tablets by the early 1960s.86  
 Rasmussen’s case for the escalating consumption of amphetamines by Americans 
is strong, as are his arguments regarding the role played by the pharmaceutical industry 
and medical establishment. But what of stimulant addiction? Here, the matter comes 
down to the physical and psychological effects that the substances had on users’ bodies 
and minds. Prior to the mid-twentieth century, drug addiction had largely been 
understood in terms of an opiate model that privileged physical dependency and acute 
physiological effects that accompanied withdrawal from the drug. A shift was made 
toward a new psychosocial model during the 1950s, led particularly by the World Health 
Organization (WHO). This new model of “drug dependency” considered both physical 
and psychological compulsions toward use of a drug and an erosion of everyday life 
functions that ensued as a result. The broader interpretation of drug addiction resulted in 
the reconceptualization of drugs that had been formerly considered “habituating” but not 
“addicting.” Caffeine provides an excellent case in point. For much of its history, the 
                                                
85 “Me, too” drugs are those pharmaceuticals that have essentially the same chemical formulation 
and identical physiological action on the user. Frequently, they are understood as products that imitate and 
compete against the original proprietary drug (i.e. SKF’s Benzedrine or Ciba’s Ritalin). 
 
86 Rasmussen, “America’s First Amphetamine Epidemic.” See also, Rasmussen, On Speed, chs. 4-
7. Rasmussen’s periodization of amphetamine consumption is instructive: the years 1929 to 1945 are 
termed “origins of the epidemic”; 1945-1960 are considered “growth of the epidemic”; the 1960s are 





drug had been considered habituating, but not necessarily addicting. When amphetamines 
arrived on the scene, they were compared to caffeine as habit-forming, but not 
necessarily addicting. So, too, was Ritalin after its introduction in 1955.87 
 Rasmussen observes that scientific research conducted by British medical 
researchers during the early 1960s began to establish the potential of amphetamines, 
particularly Dexamyl, to induce dependency in users.88 He has contended that on the 
basis of these studies, between 2.2 to 3.3 percent of all patients receiving amphetamines 
were addicted to them. In a review of the historical scholarship on addiction, Howard 
Kushner has called attention to the importance of certain biological realities in 
comprehending the history of addiction. Kushner does not necessarily condemn history 
that has considered social, political, and cultural factors in explaining addiction, but he 
does suggest a need for historians to consider the contemporary scientific findings in their 
attempts to understand the past.89 Where psychostimulants are concerned, Iverson’s 
synthesis of the current biological research suggests that the drugs’ potential for addiction 
has been a very complex issue, and while some users may become dependent, not all 
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necessarily do. Basing his conclusions on the scientific research, he has cautioned against 
conflating the potential for dependency with the overall danger of the drugs.90 
Growing Concern by Physicians 
The recreational abuse of amphetamines between the 1930s and 1950s has been 
well documented by historians. Less understood, however, is how clinicians reacted to 
recreational practices. I argue that during the immediate postwar period, while physicians 
occasionally commented on problems of addiction, they had yet to form a consensus on 
the extent of the problem. Many physicians, in fact, downplayed amphetamines’ potential 
for abuse. Indicative of such views were the observations of psychiatrist Peter Hobart 
Knapp, who published a detailed study on amphetamine and addiction in 1952. 
 Knapp acknowledged the euphoric sensations that Benzedrine induced in its 
users, ranging from a feeling of increased confidence and decisiveness to a “warm glow” 
interpreted as elation in many users. The euphoria experienced when taking the drug 
often had consequences, though. “Regardless of its exact effect, amphetamine is, for most 
people, pleasant,” Knapp observed. “Logically, habit-forming qualities appeared as a 
danger to early workers. [But a] mass peril has never materialized.”91 The 
pharmacological properties of Benzedrine were of interest to psychiatrists, such as the 
drug’s ability to produce energetic wakefulness accompanied by increased verbal and 
motor activity, elevation of mood, and specific applications for the treatment of 
narcolepsy. But Knapp could not overlook another use for amphetamines—the “vague 
yearnings of unregimented and uncounted individuals in search of more ‘pep’” that led 
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some users to go so far as to eat the paper inserts of Benzedrine inhalers in order to obtain 
a high. These peculiar uses led him and other physicians to question whether addiction to 
amphetamines was possible and, if so, whether the potential for abuse could help 
physicians understand better the stimulation that the drug produces. 
 During the late 1940s and 1950s, physicians became increasingly interested in this 
question. Knapp’s query was of particular note because he was cognizant that then-
current definitions of addiction were not sufficient to explain amphetamine’s effects. 
Writing in 1940, physician Wilfred Bloomberg concluded that, after following a small 
number of narcoleptic patients for up to two years, he found no instances of “craving” for 
the drug.92 Even more notable were the observations of Louis S. Goodman and Alfred 
Gilman, co-authors of The Pharmacological Basis of Therapeutics, a text widely 
considered the “bible of pharmacology.” In 1941, they echoed Bloomberg’s sentiments 
about Benzedrine by stating that while habituation similar to tobacco or caffeine to 
amphetamine occurred, addiction to amphetamine was unknown.93 The contribution of 
Knapp to this dialogue was to ask precisely what is meant by addiction. If the concept’s 
definition depended solely on physical dependence and characteristic withdrawal 
symptoms, then suggestions that amphetamine did not cause addiction could have been 
viewed as correct at this time. However, one could apply the formulation proposed by the 
National Research Council in 1950 that 
Addiction is a state of periodic or chronic intoxication, detrimental to the 
individual and to society, produced by repeated administration of the drug. Its 
characteristics are a compulsion to continue taking the drug and to increase the 
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dose, with the development of psychic, and sometimes physical, dependence on 
the drug’s effects. Finally, the development of means to continue the 
administration of the drug becomes an important motive in the addict’s 
experience.94 
 
When so viewed, the problem of amphetamine’s potential for addiction became 
considerably more complex. In their study of alcoholism and the use of Benzedrine 
therapy for its treatment, Edward C. Reifenstein and Eugene Davidoff contended that 
“alcoholics, other addicts, and neurotics with a morbid craving for medication” tended to 
procure Benzedrine on their own and use it excessively. “Convinced that in certain 
persons…[B]enzedrine is habit forming,” they recommended the use of amphetamines 
for the treatment of alcoholism only within institutional settings where patients could be 
medically monitored.95 In another case from 1947, Russell Monroe and Hyman Drell 
emphasized prisoners’ use amphetamines despite warnings from authorities. In one 
military prison, they found that a quarter of inmates had consumed amphetamine for its 
stimulating effects. Half of the prisoners had stated that they had started taking the drug 
while civilians, often by swallowing the paper found in Benzedrine inhalers.96  
 Do such observations of physicians mean that, in contrast with their colleagues 
only a few years earlier, clinicians suddenly viewed amphetamines as dangerous drugs? 
Not necessarily. While concerned about the excessive use of amphetamines, it would be 
unfair to say that medical authorities were convinced that amphetamine abuse was a 
problem. Despite his own efforts to conceptualize addiction in broader terms, Knapp 
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concluded that amphetamine was “not accompanied by marked physical dependence, or 
disabling physical consequences. Various addicts have used it in combination with other 
drugs. While taking it some unstable personalities have broken down, but others stayed at 
least as well as they were before its use. Addiction to it alone is infrequent, and in 
comparison to other addictive states, may be relatively benign.”97 While addiction to 
amphetamines was possible, it seemed so infrequent to be a major problem for many 
clinicians. Moreover, addiction to these drugs was often viewed as ancillary to the abuse 
of other drugs, such as barbiturates and alcohol. Recognition of how widespread the 
problem might be was still years away. Consider the observation of Marie Nyswander, 
who wrote in 1959 that “addiction to Benzedrine and Dexedrine seems to have lessened 
in the past 5 years.”98 
 The finely gradated views of psychiatrists and other physicians about the 
implications of extramedical amphetamine use during the late 1940s and 1950s meant 
that medical authorities could address the problems of amphetamine abuse only 
tenuously. A decision to distinguish between addiction, predicated on physical 
dependence and withdrawal symptoms, and habituation, based on the psychological 
effects of the drug on its user, meant that many clinicians adopted a nuanced approach. 
Ironically, this particular understanding meant that physicians downplayed the potential 
problems posed by the extramedical consumption of these drugs. Only after considering 
psychological dependency as deleterious as physical dependency could clinicians begin 
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to forge a consensus on the hazards of amphetamines.99 Their engagement of this issue—
one of careful, if inconsistent, consideration—was a necessary step in the transition from 
a tolerant, permissive attitude toward a more cautious stance regarding their dangers. 
One case in point involves methylphenidate, long considered a safer alternative to 
amphetamines. In their enthusiasm for Ritalin, physicians had downplayed the drug’s 
potential for causing dependence. As psychiatrist Berchmans Rioux of the North Dakota 
State Hospital suggested in 1960, “Unlike the more powerful stimulants, Ritalin does not 
reportedly produce the untoward effect of addiction. Lacking proof, this possibility has 
only been mentioned without actual reference to the case involved.”100 This oversight, 
Rioux explained, was not entirely the fault of clinicians. Part of the problem was that 
most definitions for addiction, even those compiled by the World Health Organization, 
presumed that a depressant or narcotic was the culprit. Nevertheless, Rioux noted the 
potential for amphetamines to cause addiction or habituation if the necessary interplay 
between the pharmacological action of the drug and the psychological make-up of the 
user were present. Just as amphetamines had the potential for addiction, so, too, did 
Ritalin. To make his case, Rioux noted the case of a 37-year-old female stenographer 
who was hospitalized for excessive use of Ritalin during a year-and-a-half period in 
which she “had taken the drug in order to counterbalance…feelings [of inferiority].”101 
Moreover, her mother had recently passed away and had a problem with the drug. Of his 
patient, Rioux noted, 
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With ingenious variations she appealed repeatedly for the medicine….She 
downplayed the seriousness of her consumption of Ritalin in the face of her own 
belief that it had killed her mother. This belief was a contraindication of her 
opinion that Ritalin was “good.” For a long time, the patient maintained that…the 
drug…was the sole treatment for her condition.102 
 
Rioux provided another example of a patient hospitalized for schizophrenia and 
prescribed Ritalin. She had escalated to a point where she was taking up to 125 tablets of 
Ritalin a day. “Given another person, it might have brought on a simple state of 
habituation,” her doctor concluded, but “this kind of Ritalin abuse demonstrated by this 
patient pertains to addiction.”103 Unfortunately, views such as Rioux’s tended to be 
isolated and would not be taken very seriously for a number of years.  
  By the mid-1960s, the views of psychiatrists about the potential of amphetamine 
abuse were beginning to change. Indicative of this shifting ground were the observations 
of the Cedar Grove, New Jersey, physician Henry A. Davidson, who told the story of a 
37-year old woman in a 1964 article evocatively titled, “Confessions of a Goof Ball 
Addict.”104 Among the cognoscenti who consumed them, a goof ball was generally 
understood as the combination of a “green heart” and a “red bullet”—the green heart is a 
triangular tablet containing dextroamphetamine and amobarbital (Dexamyl), and the red 
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bullet is a capsule of secobarbital. Davidson related his own belief that when mixing a 
sedative and a stimulant, the user would get either a mildly stimulating or mild 
depressing experience depending on which drug was pharmacologically dominant. 
Buttressing Davidson’s own view was a clinical literature that, by the mid-1960s, still 
provided only a cursory look at such extramedical uses.105 
 The titular “goof ball addict,” whom Davidson called simply “O”, related that it 
was sheer boredom of life and the excitement induced by drugs that fed her addiction. 
Davidson probed further to understand what these extramedical uses actually did for the 
addict. He deduced that the drugs alleviated O’s boredom and provided her with a sense 
of intellectual, emotional, and even sexual fulfillment. As she elaborated, “With goof 
balls, everything seems so wonderful that you want to get deeply embroiled in things, 
instead of sitting back as an onlooker….Goof balls make the world seem endlessly 
interesting and potentially wonderful—in fact, about to be wonderful the next 
moment.”106 While marveling at such responses, Davidson attempted to contextualize 
those answers within the patient’s state of addiction. While acknowledging the pleasure 
that drug use brought patients, he also expressed deep concern about the detrimental 
effects it was having on intelligent people. Also of note was Davidson’s worry that 
physicians abetted such uses through careless prescribing and a permissive attitude 
toward stimulant consumption.  
 The concerns of physicians over the extramedical use of amphetamines rarely 
matched those expressed by psychiatrist John Griffith. In 1966, he published a study of 
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the illicit amphetamine drug traffic in Oklahoma City.107 Griffith’s findings suggested 
how the different experiences of medical caregivers and law enforcement impeded a 
common understanding of the problem.  On the one hand, he discovered that users of 
illicit drugs rarely sought care through conventional medical channels; so a review of 
hospital records yielded only incomplete results about amphetamine abuse. Equally 
problematic was the fact that police records could identify the names and faces of drug 
users, but they lacked a proper medical or sociological context for understanding this 
illicit use. Griffith and his staff undertook interviews with drug peddlers and drug users, 
gaining information from three dealers and 43 users after over 100 attempts. While he 
chronicled the use of drugs by dependent individuals, his study’s major focus was the 
role played by physicians and pharmacists in fostering their illicit distribution. Griffith’s 
research further demonstrates the growing concern beginning to take hold among 
physicians regarding the problems of amphetamine abuse during the late 1960s, 
especially the role that the medical profession might have played in unwittingly fostering 
the problem. 
 In 1966, the issue of amphetamine abuse appeared to be reaching a climax among 
concerned medical leaders when the American Medical Association’s (AMA) Committee 
on Alcoholism and Addiction and Council on Mental Health issued a formal statement on 
amphetamine and stimulant dependence. While beginning with a concession that 
amphetamines and other psychostimulant did not cause physical dependence along the 
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same lines as narcotics and barbiturates, the report went on to argue that the 
“dependence-producing characteristics” that were “perpetuated solely by psychic needs 
to overcome depression or fatigue or to attain the euphoric and excitatory” effects of the 
drug were a pressing concern for the committee.108 While outlining nonmedical uses by 
truck drivers and thrill-seeking teenagers and young adults as particular concerns, the 
report went on to state that overprescription by physicians was “serious enough to 
warrant the concern of the medical profession.”109 To underscore its point, the committee 
distinguished between “use” as the “proper place of stimulants in medical practice,” 
“misuse” as “the physician’s role in initiating a potentially dangerous course of therapy,” 
and “abuse” as the “self-administration of these drugs, without medical supervision and 
particularly in large doses, that may lead to psychological dependence, tolerance, and 
abnormal behavior.”110 In making its position, the AMA suggested that the medical 
profession had officially begun to consider the seriousness of amphetamine abuse, as well 
as the profession’s possible complicity in the problem. 
Physicians Debate among Themselves 
 In 1970, the Australian physician Allen Bartholomew perceptively observed that, 
“The position has now been reached where many clinicians are all but prepared to jettison 
the amphetamines from the therapeutic armamentarium.”111 Within the span of two 
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decades, the medical profession had, as a whole, moved away from a consensus that 
regarded amphetamines as safe and non-addicting to a new view tinged with suspicion. 
Yet if doctors were beginning to agree about the dangers of recreational use, they still had 
to contend with psychostimulants’ place in medical practice. 
In addition to debating the clinical efficacy of the drug, physicians also 
considered the social contexts within which stimulants were prescribed. In a letter to the 
editor of the Canadian Medical Association Journal in 1970, psychiatrist Morton S. Rapp 
underscored he viewed as “particularly misleading” advertisements by Ciba promoting 
the use of Ritalin for states of apathy, chronic fatigue, and mild depression. In addressing 
the marketing of methylphenidate for such applications, Rapp implied that Ciba’s own 
advertisements ignored the pharmacological properties of a central nervous stimulant he 
believed was indistinguishable from amphetamine. “It is generally accepted that 
amphetamines have few genuine medical uses, that they are over-prescribed, and that 
they have a high potential for habituation. The same thinking should apply to 
methylphenidate.”112 In true depressive states, he argued, stimulants were not necessarily 
curative, and, in extreme cases, could be deadly for patients with suicidal ideation. If such 
risks remained unsubstantiated and perhaps unlikely for many patients, Rapp at least 
discerned that the physiopathology and psychopathology of chronic fatigue and apathy 
were being increasingly understood as complex. Implicit in Rapp’s criticism was a charge 
that Ciba’s marketing of Ritalin for a variety of conditions ignored the etiological factors 
physicians had to consider. Put another way, the firm sold the drug on the pretense of its 
effects rather than addressing a condition’s cause. But even more grievous for physicians 
like Rapp was the drug’s potential for habituation and the clinician’s role in causing the 
                                                





problem: “Finally, if methylphenidate is prescribed for a young person whose fatigue or 
apathy stems from unalterable psychosocial conditions, the patient will require the drug 
for as long as these conditions prevail; this renders meaningless the claim that psychic 
dependency is rare.”113 
 An even more explicit indicator of physicians’ reflexivity about their prescribing 
practices can be discerned from the medical debates on stimulant abuse in Sweden during 
the late 1960s that preceded the tighter regulation of amphetamines in the United States 
by 1970. In a letter to the New England Journal of Medicine published in October 1970, 
physician Einar S. Perlman attempted to contextualize Sweden’s problems with stimulant 
abuse and their relevance for medical professionals in America. Amphetamines had been 
introduced in Sweden in 1938, but because of increasing oral abuse, they had been 
classified as narcotics in 1944.114 As Perlman observed, since that time, Swedish doctors 
generally had been aware of amphetamines’ abuse potential and cautious about their 
prescription. As a result, relatively little medical amphetamine had made its way to the 
illegal market. However, when newer central nervous system stimulants, particularly 
methylphenidate (Ritalin) and phenmetrazine (Preludin), appeared in Sweden during the 
1950s, they were not classified as narcotics because their abuse potential was still 
unknown. As a result, they were prescribed for myriad ailments, from obesity to 
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depression. Recreational users who encountered difficulties obtaining supplies of 
amphetamines on the illegal market soon learned of Ritalin and Preludin through its 
increasing medical prescription, and they turned to these readily available stimulants as a 
substitute for amphetamines.115 
 Consumption of these drugs by addicts intersected directly with the prescribing 
practices of physicians. The illicit market for newer stimulants initially obtained much of 
its supply, Perlman reasoned, “from ‘patients’ (often fat girls) who obtained prescriptions 
without much difficulty.”116 An expanding illegal market, one that resulted in an 
estimated 10,000 stimulant abusers in Sweden by 1970, had initially attained its drugs 
through duplicitously obtained prescriptions.117 Although Preludin and Ritalin were 
withdrawn from the Swedish market in 1965 and 1968, respectively, the damage had 
already been done. Although there had been some indications in the early 1960s that 
abuse of these two stimulants had reached serious proportions, Swedish authorities were 
slow to react. Beginning in 1967, physicians could prescribe stimulants only with a 
personal license from the National Board of Health—one granted for each patient—in the 
case of specific indications such as narcolepsy and hyperkinesis. For Perlman, the hard- 
lesson learned in Sweden had implications for the American doctors who were the core 
audience of the publication: 
In view of what has happened, Swedish doctors and medical students have been 
so sensitized that advertisements of the responsible agents in such journals as the 
New England Journal of Medicine have caused considerable resentment (although 
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the drugs in question are not marketed in Sweden). Swedish doctors see no reason 
why similar abuse of central stimulants could not appear in other countries if their 
serious abuse potential is not carefully weighed against their rather limited 
therapeutic application.118 
 
 Why was psychostimulant abuse, not to mention physicians’ role in accidentally 
supporting it, becoming rampant in the United States? In a response to Perlman’s letter, 
the editor of the New England Journal of Medicine contemplated recent controls placed 
on amphetamines and other stimulants such as methylphenidate by the federal 
government in August 1970. The decision of FDA Commissioner Charles C. Edwards to 
limit the legitimate applications of these drugs “must have jolted countless patients who 
use amphetamines, many doctors who believe in them, and the firms that make and 
market them, [as] the FDA action cannot be seriously challenged.” But, the editor 
queried, “did it have to be so precipitate—or for that matter, did have to be so late in 
coming? If more attention had been paid by the FDA, by the medical profession, and by 
the profession’s journals (including this one) to the Swedish warning flags that have been 
flying so grimly…the sheep-to-wolf act might have been more gradual and hence more 
readily acceptable to patient, doctor, and pharmacist.”119 
 The editor’s response reposed the question of how amphetamines, their 
derivatives, and related drugs such as Ritalin and Preludin were recast from valued 
therapeutic agents to pernicious drugs of abuse. One answer is that such a framework is 
partially artificial, and that such an understanding obfuscates how legitimate medical uses 
stood side-by-side with patterns of abuse. In the editor’s opinion, policymakers espoused 
a more simplistic view of the problem, which stood in contrast to the more scientific 
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debates of medical leaders and their attempts to reconcile amphetamines’ clinical utility 
with their threat of abuse. To make his point, he asserted that a major role in the “about 
face” on amphetamines had been played by Representative Paul G. Rogers (D-FL), who 
argued that control of the psychostimulants would reduce overall drug abuse in the 
United States by 20 percent. Rogers requested Commissioner Edwards to “lay a 
foundation for eliminating amphetamines by conducting studies to show that they are 
necessary and effective in only very limited medical situations.”120 Taking care not to 
misquote the senator, the editor for the New England Journal of Medicine retorted that, 
“the Congressman’s words suggest more of an inquisitional rather than a double-blind 
approach, but an unbiased re-examination of amphetamines is in order.”121 If concerned 
by the approach that some legislators and policymakers were taking to address the issue 
of amphetamine abuse, the editor still empathized that an unknown proportion of these 
drugs were being diverted for illicit extramedical uses. “In spite of the fact that medical 
use of central-nervous-system stimulants is now under strict control, and in spite of 
widespread public concern, it is proving difficult to check the momentum of speed in 
Sweden.” The editor continued, “Illicit channels sustain the market. Yet Dr. Perlman’s 
account also makes clear than an approved use of pep pills for mood or weight reduction 
may have conditioned the situation and may have facilitated the sprouting and grown of 
Sweden’s most serous drug-abuse problem.”122 As for the United States, the editor found 
Rogers’s claim that more controls of amphetamines would reduce drug abuse by 20 
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percent unduly optimistic. But he could support policymakers’ motivations by observing 
that “drug abuse is an epidemic that to date has found the forces of public health helpless 
and unprepared. Epidemics call for drastic measures, and in this context any measure that 
may help, even if to an unknown degree, deserves support.”123 
Conclusion 
 The characterization of extramedical stimulant consumption as an epidemic by the 
editor of the New England Journal of Medicine provides further evidence that by the end 
of the 1960s, the freewheeling speed culture was out of control.  No longer could doctors 
continue to prescribe amphetamines without regard for their safety.  Going forward, 
physicians would have to balance their medical usefulness with their potential for danger.  
Clinicians would also have to come to terms with how lax prescribing practices 
contributed, in part, to the problem of stimulant abuse.  
 
                                                












 On June 22, 1971, President Richard Nixon addressed the American Medical 
Association’s (AMA) House of Delegates. He condemned the rising use of drugs in the 
United States. Especially troubling, Nixon opined, was the idea that “we have created in 
America a culture of drugs. We have produced an environment in which people come 
naturally to expect that they can take a pill for every problem—that they can find 
satisfaction and health and happiness in a handful of tablets or a few grains of powder.”1 
Passage of the Controlled Substances Act the previous year suggested that policymakers 
had become serious enough about the “culture of drugs” to do something about it. 
However, the legislation marked a beginning, not an end, of federal efforts to address the 
speed culture. The 1970s would be a pivotal decade for the history of psychostimulants in 
America. On the one hand, legislative, regulatory, and judicial attempts to control the 
illegal production, illicit consumption, and overprescription of amphetamines would 
reach a fevered pitch. But their impact on the ground was mixed, as aspects of the speed 
culture would become so entrenched that by decade’s end, they threatened to remain 
permanent fixtures of American society.  
 In this chapter, I explore efforts by lawmakers during the 1970s to impose and 
strengthen controls on amphetamines and other psychostimulants. At the same time, I 
consider the opposition of physicians who equated more stringent regulations with 
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attempts to limit their professional power. The forces of drug control would prevail, at 
least on paper. But passing a law is one thing; putting it into action is a different matter. 
Despite attempts at regulation and enforcement throughout the 1970s, some elements of 
the speed culture would prove difficult to curtail. Doctors, some motivated by profit, still 
prescribed amphetamines to their patients by the millions. Housewives seeking more pep 
and hoping to lose weight still turned to the drugs, as did athletes. If efforts to stem the 
tide of amphetamine overconsumption could not work by addressing matters of 
production and distribution, then perhaps it would be necessary to modify physician 
practices through education and the imposition of penalties for overprescribing. 
Prelude to Controls and Issues of Illicit Use 
 The regulatory control of drugs of abuse in the period between World War II and 
the early 1970s was first marked by the enactment of strong legal sanctions directed 
against abusers themselves, and then, in the early 1960s, a reactionary shift that 
reassigned responsibility for these drugs to physicians.2 This trajectory delineated by 
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historian David Musto, which describes the control of narcotics, did not apply so neatly 
to amphetamines. They took a largely exceptional course for three reasons. First, 
although patterns of abuse were evidenced as early as the 1940s, the amphetamines 
retained their therapeutic utility during the postwar period. Their medical legitimacy 
never disappeared, despite new regulations and sustained attacks from within the medical 
establishment. Second, the concept of addiction, taken to mean physical rather than 
psychological dependence, did not apply to the amphetamines the way it did to narcotics. 
Only with the changing concept of addiction proffered by medical professionals 
concerned about amphetamine abuse during the late 1950s and 1960s did stimulants 
come under greater scrutiny. Finally, there was the fact that amphetamines were produced 
and marketed by reputable pharmaceutical firms and whose distribution and consumption 
were embedded within a medical-pharmaceutical establishment that stood in stark 
contrast to the cannabis and heroin that were the concern of policymakers and authorities.  
 As noted before, Benzedrine inhalers served as the first major source of 
amphetamine abuse. Monroe and Drell’s research revealed that of a sample of 1,000 
military prisoners, a quarter of them abused amphetamines in this manner. The misuse of 
amphetamine inhalers had become such a widespread problem that many companies, 
most notably Smith, Kline & French (SKF), withdrew them from the market before the 
Food & Drug Administration (FDA) banned their sale outright in 1959.3 That same year, 
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the FDA undertook an extensive investigation into the sale of amphetamines at truck 
stops and obtained positive evidence in more than 200 cases.4  
 Following these initial investigations, several bills were introduced to control the 
illicit trade in amphetamines, but no substantive legislation was passed until the Drug 
Abuse Control Amendments of 1965. Intended to redress the diversion of legal supplies 
for illicit purposes, the law required the registration of manufacturers, formulators, and 
wholesalers of amphetamines. Retail pharmacies and physicians were exempt. Penalties 
were enacted against illicit distribution, but they did not cover the possession of 
amphetamines for personal use.5 
 It was only with the passage of the Comprehensive Drug Abuse Prevention and 
Control Act of 1970, commonly known as the Controlled Substances Act, that all federal 
laws dealing with the abuse of drugs were unified into a single piece of legislation. The 
cornerstone of this law was the creation of five Schedules, or classifications, for all drugs, 
based on their potential for abuse.6 Schedule I drugs are those with a high potential for 
dependency, no currently accepted medical use in the United States, and a lack of 
accepted safety.  At the other end, Schedule V drugs are those with a low potential for 
abuse and legitimate medical applications. With the exception of injectable 
methamphetamine, which was more tightly controlled, the amphetamines were placed 
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initially in Schedule III. The regulations pertaining to the class of drugs added only a few 
minor controls beyond those imposed by the 1965 Amendments. Pharmacies, physicians, 
and laboratories, as well as manufacturers and distributors of the drugs were required to 
register with the Bureau of Narcotics and Dangerous Drugs (BNDD).  
 The following year, in 1971, amphetamines were moved from Schedule III to 
Schedule II, which entailed a more rigorous set of controls. Manufacturers were required 
to produce such drugs in facilities with heightened security in order to prevent their 
diversion. Preprinted BNDD order forms containing the name and registration number of 
the purchaser were necessary for each transaction, and all import and export shipments 
required the permission of the BNDD. Telephone and refill prescriptions of these drugs 
were prohibited. But perhaps the most notable control imposed by the Schedule II 
regulations was a provision setting limits on the amount of the bulk drug that could be 
manufactured and sold to dosage formulators. Such quotas were based on estimated 
medical needs, and the 1972 quota for amphetamines was set at only 20 percent of the 
amount produced in 1971.7 
 What brought about the rapid transition of the psychostimulants from Schedule III 
to Schedule II, along with the imposition of more stringent controls? A main reason for 
the shift in classification stemmed from concerns of lawmakers about the overproduction 
of amphetamines and their supposed diversion from licit to illicit uses. Of particular 
interest were the hearings and subsequent campaigns by the Select Committee on Crime 
in the House of Representatives and the Subcommittee to Investigate Juvenile 
Delinquency in the Senate. These hearings were dominated by issues of amphetamine 
overproduction and the failure of manufacturers and wholesalers to maintain control at 
                                                





critical points in the distribution chain. As early as 1962, the FDA estimated production 
of 10-milligram amphetamine tablets to be around 8 billion per year, or roughly 40 
tablets per capita!8  
Firming the Controls on Psychostimulants 
 Passage of the Controlled Substances Act brought a wide array of drugs under a 
comprehensive set of regulations to govern their manufacture, prescription, and use. In 
1971, Senators Birch Bayh of Indiana and Thomas Eagleton of Missouri introduced 
Senate bill 674 during the 92nd Congress. The bill proposed a tightening of controls on 
the manufacture and distribution of psychostimulants by relocating them to Schedule II.9 
Since July of that year, the Bureau of Narcotics and Dangerous Drugs (BNDD) had 
already acted administratively to reschedule amphetamines and methamphetamines, but 
the senators sponsoring the legislation believed the order did not go far enough to protect 
the public. Their bill sought to formalize the move, while also adding methylphenidate 
and phenmetrazine to Schedule II.  
 In his opening remarks for the hearing on the proposed legislation, Senator Bayh 
pointed out that 5 million Americans took pep pills without prescriptions or medical 
supervision, while almost 100,000 “speed freaks” used the drugs intravenously. For him, 
the issue was primarily one of abusers who “come from every strata of society,” be they 
college students, truck drivers, or housewives.10 His colleague, Senator Eagleton, 
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couched his concerns differently. While he commended the work of the Justice 
Department to address the issue of amphetamine controls, Eagleton was deeply bothered 
by the Nixon administration’s supposed opposition to the legislation. He contended that 
Congress was responsible for “closing the gaps” left by the Justice Department’s order.11 
Another point of departure with Bayh was Eagleton’s emphasis on the issue of 
overproduction rather than the misuse or abuse of the drugs. In his opinion, responsibility 
for the mounting amphetamine problem lay at the feet of the manufacturers as much as, if 
not more than, physicians and consumers. Put another way, it was the problem of billions 
of pills rather than millions of users that needed to be addressed.12 
The senators sponsoring the proposed legislation articulated two different, though 
not mutually exclusive, positions embraced by policymakers seeking tighter controls. 
Bayh feared that the public was imperiled by physicians who prescribed in excessive 
quantities and without consideration for their potential danger. That Americans from all 
walks of life, even schoolchildren, were taking these drugs for a wide variety of 
conditions made their consumption a pressing public health issue. For Eagleton, however, 
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the salient concern involved drug companies that produced and profited from 
amphetamines. He expressed legitimate fears about pharmaceutical firms’ exploitation of 
legislative loopholes in order to keep their drugs in the marketplace. Under the Controlled 
Substances Act, authority for changing the scheduling classification of specific drugs 
originally established by Congress was vested with the Attorney General. Parties 
objecting to such changes had the right to file their objections by requesting hearings on 
the matter. Eagleton was extremely concerned about how drug companies availed 
themselves of this option. SKF had sought an exception for its dextroamphetamine diet 
drug Eskatrol, the largest selling diet pill in the United States with about $11-12 million 
in annual sales. Following SKF’s lead in protesting the rescheduling by the Justice 
Department were smaller companies such as the Mission Pharmacal Company whose 
drug Fetamin, made the company about $100,000 in sales. Eagleton was bothered by 
what he viewed as the Justice Department’s decision to permit exceptions to the Schedule 
III regulations, essentially undermining the law’s intent. He also contended that the new 
law was necessary to impose tighter controls on two drugs, Ritalin and Preludin, whose 
association with hyperkinetic children and addicts in Sweden during 1970 and 1971 had 
caused them to escalate in notoriety.13  
 What of the experts called upon to help inform the policymaking decisions of 
Bayh and Eagleton? They favored tighter controls. Among the most prominent voices at 
the hearings was physician David E. Smith, still the director of the Haight-Ashbury 
Clinic in San Francisco. Smith’s experiences with amphetamines during the late 1960s 
had only hardened his stance against them. He emphasized a need to redefine drug abuse 
to consider more broadly the “use of a drug in a way that interferes with the individual’s 
                                                





health, economic, or social functioning.”14 In doing so, Smith advanced the idea that 
addiction encompassed substances that did not cause physical dependency. In lurid 
details he related how users of speed were, in many cases, worse off than abusers of 
drugs such as heroin and barbiturates, whose addictive qualities were better understood 
by the public. Smith related the crime, violence, and deleterious health effects associated 
with speed. Having dealt with the treatment of “freaks” in San Francisco, he warned that 
places such as Haight-Ashbury and Greenwich Village in New York were epicenters for 
a “ripple effect” that would occur in other American cities and small towns were the 
problem of amphetamine abuse not checked by legislators. 
 Psychiatrist John Griffith was another expert who had the ear of the senators 
sponsoring S. 674. Among those inclined toward increasing controls, he probably exerted 
the greatest influence. Since publishing his findings on the diversion of amphetamines in 
Oklahoma City in the mid-1960s, Griffith had become a professor of psychiatry and 
pharmacology at the Vanderbilt University School of Medicine in Nashville. He tirelessly 
testified before a number of Congressional committees investigating the problem of 
amphetamines during the early 1970s, expressing his strong belief after the passage of the 
Controlled Substances Act that the amphetamines and other psychostimulant drugs were 
not regulated tightly enough. As for their medical uses, Griffith argued that the drugs 
were poor treatments for mild emotional depression, that their effects in the treatment of 
narcolepsy were inconclusive, and that the use of amphetamines for the treatment of 
alcoholism was especially ill-advised. Recounting the servicemen who consumed 
amphetamines during the Second World War, and Air Force pilots who continued to be 
administered the drug, Griffith pointed to his own Veterans Administration Hospital case 
                                                





files to provide evidence that many such soldiers had become addicted. The only 
exception he could condone was the prescription of stimulants for the treatment of 
hyperkinesis, predicated on the belief that the disorder would eventually subside in those 
few children who suffered from it and they would no longer need the medication once 
their behavior had normalized. In the end, Griffith concluded to the subcommittee: 
Physicians by and large agree that if amphetamines were to disappear from the 
market tomorrow, almost all patients would benefit except these children. A 
problem now being considered in most of the capitals of the free world is whether 
the benefits derived from amphetamines outweigh their toxicity. It is the 
consensus of the world scientific literature that the amphetamines are of very little 
benefit to mankind. They are, however, quite toxic.15 
 
On the one hand, Griffith was not disingenuous in his remarks. As I noted in the previous 
chapter, the 1960s saw the increased publication of findings casting doubts on the safety 
and, in some cases, the efficacy of amphetamines in medicine. All the same, the views of 
physicians were not universal. Griffith’s viewpoint on the dangers of stimulants was 
supported by a rather selective review of the clinical research literature.  
 Of the handful of physicians who testified before the Senate subcommittee on 
July 15 and 16, 1971, the overwhelming majority expressed views that controls on 
amphetamines were too lax and needed to be increased. Whether couching their 
arguments in terms of clinical experience, as David Smith had done, or making a case 
based on pharmacological and clinical research, as John Griffith had done, a clear 
majority of the testifying physicians asserted a need for tighter controls. Their arguments 
had resonance, too. In their statements, co-sponsoring senators such as Lawton Chiles of 
Florida and Thomas J. McIntyre of New Hampshire cited these medical experts to 
buttress their positions on the need to regulate psychostimulants more tightly. 
                                                





 Joining medical experts in their support of assigning amphetamines, 
methylphenidate, and phenmetrazine to Schedule II were representatives from various 
drug enforcement agencies. Of particular importance were the testimonies of John 
Finlator, deputy director of the BNDD, and Henry Simmons, director of the Bureau of 
Drugs within the FDA. For his part, Finlator explained to the Subcommittee that the 
BNDD and Congress were not as far apart on the issue of tighter controls as some 
senators believed. After all, it was his Bureau that took the preemptive measures to 
classify the amphetamines as Schedule II drugs. Regarding assertions made by Senator 
Eagleton that the BNDD was soft-pedaling regulation on methylphenidate and 
phenmetrazine, Finlator responded that his Bureau believed that the drugs had a 
“potential for abuse.” Nevertheless, more data was necessary before the BNDD could 
make a final determination on the matter. While still favoring an administrative approach 
toward regulation, Finlator diplomatically added that “if, in the wisdom of Congress, this 
bill should be enacted, we are law enforcement people and we will enforce it to the ‘nth’ 
degree.”16 
 By contrast, Bureau of Drugs director Henry Simmons asserted that the drugs in 
question had legitimate uses and openly questioned the wisdom of the proposed move. 
For Simmons and the FDA, the issue was not as clear-cut as others averred. There was a 
need to differentiate between “addiction as compared to simple habituation” where the 
amphetamines were concerned. While acknowledging that psychostimulants had 
powerful effects on the central nervous system, Simmons contended that it was unclear 
that potential drawbacks associated with the drugs outweighed their medical benefits. 
While the FDA did express reservations about the potential misuse of the drugs, it took a 
                                                





formal position via a policy statement published in the Federal Register that placing 
stricter labeling limits on the amphetamines was a more appropriate measure than 
outright controls. Simmons was grilled by Senator Bayh about why the FDA had not 
done more to promote greater controls on amphetamines. The position of Simmons’s 
superiors in the FDA and at the Department of Health, Welfare, and Education was that 
the Controlled Substances Act had been passed less than a year earlier and that time was 
still needed to determine whether the law and the administrative procedures for executing 
it were effective.17 By moving so hastily to reschedule the psychostimulants, Simmons 
intimated that Congress would undermine the intent of the original legislation. Bayh 
responded sharply to this charge: 
I think the unspoken question perhaps speaks for itself. I still feel there is little 
excuse for our Government not to profit from the experience of the Swedes and 
we are suggesting exactly the same thing that happened to Sweden can happen 
here. Yet our Government is not willing to accept your recommendations…based 
on a rather dramatic explanation of what happened in Sweden….We aren’t 
willing to go forth with a comprehensive, total program to keep from shifting 
from one series of drugs to another.18 
 
Such a reaction suggests that despite the outward friction between the senators and the 
Justice Department over a need to reschedule the amphetamines, methylphenidate, and 
phenmetrazine formally, Bayh and his colleagues at least appreciated the willingness of 
the BNDD to enforce the law if Congress saw fit to pass it. In contrast, lawmakers 
appeared less tolerant of the FDA’s nuanced and contextualized explanations of the issue. 
Perhaps the divergence is best explained by considering the distinct domains of the 
BNDD and the FDA. Whereas the BNDD was primarily an enforcement agency charged 
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with overseeing pharmaceutical manufacturing and stemming the tide of illicit production 
and distribution, the FDA’s main concern was the drugs’ uses, as well as their safety and 
efficacy. Hence, the FDA’s original proclivity to address the problem of amphetamine 
misuse through stricter labeling underscored a belief that the medical profession and its 
individual physicians could exercise the restraint necessary to prevent misuse. Such a 
position, however, did not seem to court as much favor with Bayh and his colleagues. 
Perhaps no group was as greatly affected by the federal government’s decision to 
place controls on stimulants than the pharmaceutical firms who produced, marketed, and 
profited from these drugs. However, the response of the industry to increasing regulation 
was not uniform, as illustrated by the different positions of SKF and Abbott Laboratories. 
SKF was still the leading producer of amphetamine drugs, and it probably comes as little 
surprise that the company’s leadership opposed tightened controls on the drug.  But not 
every amphetamine manufacturer took such a stance.  Abbott produced 
methamphetamine as Desoxyn and a combination of methamphetamine and the 
barbiturate pentobarbital as Desbutal. The firm had officially supported the enactment of 
the Drug Abuse Control Amendments of 1965 and the Controlled Substances Act of 
1970, as well as accompanying manufacturing limits on the drugs. In fact, Abbott vice 
president Glenn Utt, Jr. observed that his firm supported the proposed move of 
amphetamines from Schedule III to Schedule II status. His company had made the 
decision in 1969 to cease the production of injectable methamphetamine, partly because 
it was not a high volume product for the company, with sales of less than $50,000 per 





readily diverted for illicit uses.19 Such support was tempered by a continued belief among 
executives that Abbott’s amphetamines had valid medical use, particularly for obesity. 
Even though it acknowledged the wide array of opinions held by physicians about 
amphetamines’ clinical applications, the company maintained that many doctors believed 
the drugs were appropriate for their patients. But in light of what Utt called a “record of 
diversion and abuse of amphetamines in this country that is beyond dispute,” the 
company supported the proposed Schedule II controls, hoping that they would satisfy 
lawmakers’ concerns over diversion without interfering with the legitimate prescription 
of amphetamines.20 
 How does one account for such open support of regulatory controls by a company 
that, on the surface, stood to suffer from such laws? One answer might have been that the 
drugs in question were not generating sufficient revenue in the first place, or that such 
limited profits did not outweigh an amicable relationship between the firm and 
policymakers. The removal of injectable methamphetamine from the market because of 
its low volume of sales is one such indication. Another possibility is that the leadership of 
firms such as Abbott were genuinely concerned about the problems associated with 
diversion and abuse, particularly the association of the patent drug industry with such 
practices. Abbott’s support of the legislation contrasted with SKF’s opposition. During 
the early 1970s, SKF’s Eskatrol was the leading amphetamine medication in the United 
States, accounting for one-fifth of all drugstore purchases of amphetamine drugs.21 While 
SKF’s opposition may be understood as the rational response of a company concerned 
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about the declining sales of one of its best products, Abbott’s approach was measured and 
balanced, pitched between ensuring the continued medical applications of amphetamines 
and controlling illicit uses that might undermine the drugs’ legitimacy entirely. In 
hearings to consider the 1971 Senate bill (S. 674) to move the amphetamines and other 
psychostimulants from Schedule III to Schedule II, Utt explained to Chairman Birch 
Bayh that placing the drugs in Schedule II would likely have a detrimental effect on sales 
of the drugs, but the continued ability of physicians to prescribe them, even if more 
conservatively, was more important to the firm. 
Outright opposition to the proposed tightening of controls was not necessarily 
absent from the proceedings. Bariatricians, whose profession stood to be most affected by 
the new regulations, voiced the loudest cries of dissent. W. L. Asher, the executive 
director for the American Society of Bariatrics, expressed his specialty’s dilemma in a 
letter to Eagleton. While complementing the senator on his zeal for doing something 
“tangible” about the growing drug abuse problem, he warned that physicians might suffer 
unfairly. Asher noted that most bariatricians affiliated with his society dispensed only 
enough amphetamine to last 28 days and would only write another prescription after an 
in-person visit by the patient. Despite their potential for abuse, “amphetamines, in spite of 
all of their shortcomings, are the only classes of pharmacologic agents which may be of 
use in restraining the eating habits of the obese millions” in the United States, Asher 
contended.22 
While Eagleton and Asher disagreed on the specifics of how to address the 
problem of illicit amphetamine use, both men agreed on a need to ensure that legitimate 
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medical uses by doctors were not undermined by issues of illicit production, smuggling, 
and street-level abuse.23 The two sides were amenable to each other as long as the right of 
physicians to continue their practices was not imperiled. Such cordiality was pierced, 
however, when Asher wrote to Eagleton several months later to express renewed concern 
that the “lawmaking prerogatives of Congress are being usurped by various Government 
agencies, namely the BNDD.”24 At issue were the plans revealed by the BNDD to assign 
amphetamines to Schedule II status. Such a move flew in the face of what Asher 
understood to be the Congress’s original mandate in the passage of the Controlled 
Substances Act, not to mention the position statements of AMA and other medical 
leaders. Expecting sympathy from Senator Eagleton on this matter, Asher was shocked 
and angered when he received a reply that Eagleton intended to tighten the controls 
through legislative means, as well.25 Perhaps it comes as little surprise that, in the face of 
an apparent betrayal of trust, representatives from the American Society of Bariatrics 
declined to testify at the hearings. 
Considering Dissent to Controls 
 In the previous chapter, I suggested that the medical establishment’s growing 
awareness of the potential for psychostimulant dependency helped alter physicians’ views 
on their safety and utility. Yet, if many practitioners were convinced of the potential 
dangers of amphetamines and other psychostimulant drugs by the end of the 1960s, they 
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did not necessarily concur on their fate. While few doctors would pronounce the 
psychostimulants as completely safe, many argued that the drugs’ therapeutic benefits 
outweighed their risks. This disagreement with the views of Smith, Griffith, and others 
can be interpreted in two ways. First, the positions of medical leaders were symbolic of 
how particular medical specialties differed over the utility of psychostimulants and their 
fate. Second, and more important, individual physicians vied to gain the ear of 
policymakers and influence the crafting of regulations in the early 1970s that would 
shape the future for Benzedrine, Dexedrine, Ritalin, and other similar drugs throughout 
the English-speaking world. If physicians such as Griffith managed to court favor with 
regulators, rival physicians who continued to believe that the drugs were still an 
important part of the therapeutic armamentarium refused to remain silent. Among the 
most outspoken opponents of amphetamine controls was Heinz Lehmann, chair of the 
Department of Psychiatry at McGill University in Montreal. Among his many 
accomplishments, Lehmann was best known for his discovery of chlorpromazine’s 
effects on psychosis.26 Hence, he may be understood as an elite within the field whose 
disagreement with authorities over amphetamine controls carried particular significance.  
 In the previous chapter, I noted some similarities between the United States and 
Canada regarding the regulation of drugs during the late 1960s and early 1970s. Despite 
the work of such investigatory panels such as the Le Dain Commission of Inquiry into the 
Non-Medical Use of Drugs, which recommended a loosening of restrictions on cannabis 
and other drugs, the Canadian federal government followed the United States’ move 
                                                
26 For more background on Lehmann, see Andrea Tone, “Heinz Lehmann: There at the 
Revolution.” Collegium International Neuropsychopharmacologicum Newsletter (March 2004):16–17; 
Heinz Lehmann, “Psychopharmacotherapy,” interview with David Healy, in David Healy, The 





toward stricter controls during the early 1970s. As a sign of such a direction, A. B. 
Morrison, assistant deputy minister for the Ministry of National Health and Welfare, 
recommended in August 1972 that restrictions be placed upon the medical applications of 
amphetamines and a number of related classes. Effective January 1, 1973, physicians 
would be allowed to prescribe amphetamines for narcolepsy, hyperkinetic disorders in 
children, mental retardation (specifically, minimal brain dysfunction), epilepsy, 
Parkinsonism, and hypotension in patents under anesthetic sedation.27 While a relatively 
wide array of indications for amphetamines were still to be permitted under the new 
regulations, a number of notable uses for the drugs, such as the treatment of depression 
and management of obesity, were excluded. But even more onerous was a requirement 
that practitioners could not provide prescriptions for more than 30 days, and they had to 
notify the Ministry of National Health and Welfare regarding the name and address of the 
patient, the drug prescribed and its form and dosage, and the name and date of the 
practitioner. Physicians who wished to administer the drug for longer than 30 days were 
required to obtain a second opinion from a colleague to confirm the initial diagnosis. In 
such cases, more detailed information was required by the Ministry.28 
As I noted in Chapter 2, Lehmann had undertaken a series of studies during the 
1960s to explore psychopharmacology’s promise for the treatment of mental illness.  His 
expertise had prompted the Ministry of National Health and Welfare to approach 
Lehmann about serving as the Chairman for the Special Advisory Committee on the uses 
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of amphetamines for behavioral disorders. However, Lehmann demurred and his 
colleague and friend, psychiatrist Thomas A. Ban, was chosen to lead the panel.  
 In December 1972, less than a month before the new controls on amphetamines 
were to take effect, Lehmann sent a scintillating letter to Marc Lalonde, the Minister of 
National Health and Welfare for Canada. Lehmann responded vociferously to the 
pending regulations. Writing as a “concerned physician,” he explained his reasons for 
turning down the chairmanship of the Advisory Committee. Having served as a member 
of the La Dain Committee, Lehmann expressed his fears that such committees were 
designed less as a “worthy guide to Government” and more as an “endorsement of 
courses of action already predetermined within [Lalonde’s] department.”29 While the 
report of the La Dain Commission, published earlier in 1972, had been largely praised as 
a thorough study into the issues of drug use, the recommendations were largely ignored 
by federal authorities. Lehmann feared that the committee convened to study 
amphetamines would suffer a similar fate. Referring to a recent article in the Globe and 
Mail, Lehmann suggested that his concerns were justified when it was revealed that, 
This committee, headed by Dr. T. A. Ban, director of the psychiatry department at 
Montreal’s Douglas Hospital, initially also recommended amphetamines be used 
for treating certain forms of depression (called reactive depression) for short 
periods of time (less than 14 days). But this recommendation was dropped after 
conversations with Health Department officials.30 
 
Referring to this particular quote, Lehmann observed,  
I cannot understand what type of ‘conversations with Health Department officials’ 
could negate the considered opinion of a group of medical experts convened by 
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your Department as a committee for the defined purpose of assisting the Health 
Department to arrive at medically sound decisions.31 
 
While bothered that, among other things, a suggestion to allow the temporary use of 
amphetamine-like stimulants such as fenfluramine as a maintenance drug to help wean 
addicts from their dependency on amphetamines was ignored, Lehmann maintained that 
his intention was not to defend or attack the drugs in question. Rather, he viewed the 
haste with which the proposed 1973 controls were being implemented as a possible 
“attack on the medical profession and its capability to serve and safeguard the health of 
our citizens.”32 
 In a diplomatic reply to Lehmann’s letter, Minister Lalonde expressed his 
condolences that Lehmann had been unable to serve as the chairman of the committee. 
Nevertheless, he contended that regulations on amphetamines resulted from months of 
negotiations with representatives from the various medical associations in Canada and 
that such decisions were based on scientific and medical advice. In response to 
Lehmann’s accusations, Lalonde asserted that while such sentiments were 
understandable, the recommendations made by the various committees were not identical 
and that discussions with the various chairmen were required to arrive at a final 
decision.33 In addition to deflecting Lehmann’s charge of politicization, Lalonde went 
further to assert that “the amphetamine regulations aim only at contributing towards the 
solution of a problem that has been of serious concern to the profession.”34 
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 The issue between the two men was a matter more profound than the legal status 
of a class of drugs. At stake was the role that the medical profession and its individual 
practitioners would play in determining what was best for their patients. In an article 
published in the Medical Post, Lehmann conceded that 70 to 80 percent of amphetamine 
prescriptions were for the effects as anorectics in the management of obesity. But 
whereas many colleagues in both the United States and Canada viewed the potential 
overprescription of stimulants to patients for weight loss as a problem to be addressed, 
Lehmann considered the other side of the issue, that “removing the physician’s freedom 
to prescribe amphetamine or one of its derivatives (phenmetrazine or phendimetrazine) is 
essentially questioning the judgment and medical ability of the doctor.”35 Lehmann 
applied this same logic to other issues such as hyperkinesis in children and depression in 
adults. While recognizing that the administration of psychostimulants for such disorders 
was contentious, Lehmann nevertheless argued that such decisions were best left in the 
hands of individual physicians. Certainly, he acknowledged that amphetamines were not 
suitable for all types of depression and should only be used sparingly after consultation 
with a psychiatrist, but for Lehmann the issue was whether the calculated risks associated 
with their prescription should remain one of medical choice: “To me, it is a very peculiar 
kind of mixture when the law and the government begin to tell you for what pathological 
conditions a drug may be prescribed.”36 Such ire over government intervention could also 
be found in Lehmann’s rejoinder to Lalonde in January 1973. Noting with “regret” the 
                                                                                                                                            
34 Marc Lalonde, Ottawa, ON, to Heinz E. Lehmann, Montreal, QC, January 22, 1973, Heinz E. 
Lehmann papers, International Neuropsychopharmacology Archives, American College of 
Neuropsychopharmacology, Vanderbilt University, Nashville, TN. 
 
35 Heather Carswell, “Ottawa Said ‘Just Meddling’ in Amphetamine Issue,” Medical Post,  







new regulations, he remained convinced that the new controls were “unnecessary and 
unneeded.” Furthermore, Lehmann responded that one chairman he personally knew was 
not approached by the Ministry for further discussion after the committee had submitted 
its findings, “which were then to a considerable extent simply disregarded by the 
Government.”37 
 The Medical Post, a leading newspaper for physicians in Canada, covered the 
issue extensively during late 1972 and early 1973. While interested in advancing the facts 
about the upcoming regulations and clarifying potential misunderstandings, a number of 
articles subtly suggested the loss of physician power to determine the best course of 
treatment for some patients, as well as the potential punishments for practitioners who 
failed to comply with the new law. In one case, the Medical Post’s editor openly lashed 
out against the law, and curiously siding with SKF’s position that the proposed controls 
were unwarranted. On December 20, 1972, William M. Robson, the president of SKF 
Canada, sent a telegram to Lalonde to ask that he reconsider the legislation. While it 
might be easy dismiss Robson’s telegram as a last-ditch effort on the part of one of the 
world’s largest manufacturers of amphetamines to rescind or postpone a measure that 
threatened the company’s very livelihood, the editors of the Post determined that 
Robson’s communication made some good points and merited serious attention. Echoing 
arguments made repeatedly by Lehmann in his correspondence with Minister Lalonde, 
Robson pointed out that amphetamine prescriptions in Canada had been on the decline 
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since 1966, suggesting that physicians had made their own re-evaluation of the safety of 
amphetamines without any need for prodding by the government. 
 But what bothered Robson and the editors the most was the perceived philosophy 
behind the amphetamine restrictions: Even in light of the reported reduction in physician 
prescriptions of amphetamines (up to 77 percent according to some claims), the Ministry 
had decided to take it upon themselves to limit physicians’ application of the drug to only 
six disorders and to place strictures on even those uses. “Why then is the government 
restricting the physicians’ use of amphetamines and thereby infringing on the 
profession’s traditional right to select medication and procedures in the best interest of 
the patient?” the editors queried. Were such a philosophy espoused by authorities carried 
to its logical end, “the time may come when a physician must carry around a little 
government handbook telling him what he can or cannot prescribe,” they warned. At the 
heart of such probing questions posed by both representatives from the pharmaceutical 
industry and the medical press were fears that practitioners would be reduced to 
“handbook robots” unable to think for themselves and lacking the trust to act on their 
own intelligence and training.38  
 While some quarters of the medical establishment took an opposition stance 
regarding amphetamine restrictions, not everyone did. In particular, the Canadian 
Medical Association (CMA) and the Association des Medecins de Langue Francaise du 
Canada (Canadian Association of French Speaking Physicians, or AMLFC) seemed more 
ambivalent regarding the impact of the legislation. In a letter to the editor of the 
Canadian Medical Association Journal (CMAJ), Laurent Constantin, vice president and 
medical director for SKF Canada, suggested that both associations were taking 
                                                





paradoxical positions on the matter. Referring to a report in the January 6, 1973, issue of 
the CMAJ expressing regret that such legislation was necessary while simultaneously 
acknowledging the role of the pharmacy profession and pharmaceutical industry in 
eliminating misuse, Constantin hinted at the CMA’s inconsistencies. He was particularly 
troubled by the CMA’s earlier insistence to the Le Dain Commission that education and 
“voluntary restraint” should form the core of the approach to correcting physician misuse 
of such drugs.  The association’s decision to reverse course and support the proposed 
controls struck Constantin as hypocritical and even dangerous. By backing away from 
this earlier stance to accept, however grudgingly, a need for actual regulations, 
Constantin argued that “the only conclusion…that can be drawn from the acceptance of 
the C.M.A. [sic] of the new regulations is a willingness to accept government 
intervention…[that] sets a dangerous precedent for even more government control and 
decision making by government as to how doctors should practise [sic].”39 
 The leadership of the CMA did not take such accusations lightly. In his reply to 
Constantin, CMA Secretary General J. D. Wallace responded that he could not agree with 
the assertion that acceptance of the new regulations by the Association indicated a patent 
willingness to accept government intervention. In fact, the situation might have been 
more dire had the CMA and AMLFC not become involved in the first place, as Wallace 
retorted: 
I can assure you that the controls established…would have been more rigid than 
those that went into effect….In other words, had the only action of the 
Associations been to sit back and do nothing but express a negativistic viewpoint, 
we would likely have accomplished far less for the Profession than the result that 
was eventually achieved. On the basis of publicly expressed government policy it 
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was evident that controls on amphetamines would be established, with or without 
our participation in the preparatory phase of regulations…I can assure you that a 
great deal was accomplished by such participation.40 
 
 The social and political environments of the United States and Canada were not 
identical, but there were enough similarities between them regarding the increased 
controls on amphetamines and other drugs during the late 1960s and early 1970s to 
permit an analysis germane to both nations. Particularly true in this regard is the issue of 
the various players in the controversy and understanding their positions on the matter of 
amphetamine regulation. While a number of medical authorities in both the United States 
and Canada lent their expertise to those policymakers interested in better controlling a 
medical profession that was too freely prescribing psychostimulant drugs, the position of 
Heinz Lehmann suggests that such views were not uniform. Having already served on 
one commission whose findings he believed were largely ignored by the government, 
Lehmann railed against controls he believed were motivated by political expediency 
rather than sound research. Lehmann’s opposition position was buttressed by support 
from within the medical press. 
 Pharmaceutical firms such as SKF, which clearly stood to lose profits if 
legislation passed that limited the prescription of lucrative drugs, joined in a peculiar 
alliance with some medical leaders. For their part, the editors of the Medical Post 
acknowledged the self-serving motivations of the company, and the exchange between 
Constantin and Wallace on the matter suggests that SKF was cloaking itself in a veil of 
objectivity to assail those groups whose views were not congruous with their own. 
Nevertheless, the company’s argument that physician decision making was imperiled by 
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the pending legislation found favor with at least some voices within the medical 
establishment. 
 On the one hand, there were those in favor of enacting stronger controls on 
amphetamines, particularly Lalonde and the selected medical experts whose conclusions 
supported the legislation. Conversely, there were those who spoke out against the 
policymaking and argued that such decisions were more political than scientific. Yet, the 
position of the CMA and other like-minded associations suggests that there was also a 
middle ground. By negotiating the space between these two extremes and attempting to 
mediate both positions, the leadership of the CMA asserted that its role was not as 
irresolute as Constantin suggested. It functioned pragmatically as the key broker between 
the two sides.  
 What are we to make of these various positions? First of all, Wallace’s use of 
“Profession” with a capital “P” in his correspondence with Constantin is revealing. Each 
of these groups claimed to speak for the medical profession with great verve. Perhaps the 
shrillest cries came from Lehmann and his colleagues at the Medical Post, whose fears 
that physicians would be reduced to automatons unable to think and act freely as healers. 
Federal assertions that misuse of amphetamines remained intractable problems were 
almost as strident. If not as loud in the dialogue, the position of the CMA as expressed in 
its journal suggested that, in fact, speaking for the “Profession” meant acknowledging 
that both sides had merit.  
Putting Controls into Practice 
 At the end of the previous chapter, I considered briefly how American 





the late 1960s and early 1970s. As I noted, the most important development was passage 
of the 1970 Controlled Substances Act. While the law represented a watershed in 
American drug regulation, it is important to bear in mind two key points. First, while the 
law remains in effect today and is the cornerstone of federal enforcement efforts via the 
Drug Enforcement Administration (DEA), the Act’s finer points have changed during the 
past four decades. Second, the passage of legislation was a necessary but not sufficient 
action on the part of lawmakers to effect the controls they sought for drugs such as 
amphetamines. Efforts to enforce the regulations were required, and this endeavor was 
carried out by agencies and individuals with their own goals and interpretations of the 
legislation. Like the Controlled Substances Act itself, enforcement efforts also changed 
over time and frequently involved a process of negotiation, and re-negotiation, with the 
historical actors involved, including pharmaceutical manufacturers, physicians, 
policymakers, and drug consumers.   
 Before the BNDD could begin its efforts to enforce the Controlled Substances 
Act, a major obstacle faced by the Bureau was establishing knowledge regarding the 
production, importation, and exportation of amphetamines.41 Since one of the 
cornerstones of the new regulations was the establishment of production quotas, such 
information was crucial to authorities. In 1962, the FDA conducted the first major survey 
of amphetamine and barbiturate production in the United States. The testimony of then 
Commissioner George Larrick to the Senate during consideration of what would become 
the Drug Abuse Control Amendments of 1965 suggests the problem faced by the FDA at 
the outset of controls. Larrick revealed to the Senate that the FDA’s survey of production 
was inaccurate because records maintained by several basic manufacturers were 
                                                





incomplete and because two of the nation’s largest pharmaceutical firms declined to 
provide requested information.42 Despite this gap, Larrick surmised that there was 
enough basic material produced in 1962 to make “over 9 billion doses of barbiturates and 
amphetamines.”43 The fact that the FDA, at another point, described the same 1962 
survey as recording amphetamine production as sufficient to manufacture 4.5 billion 10 
milligram tablets of amphetamine, only to then estimate production at 8 billion tablets or 
more, suggests the disarray of knowledge surrounding amphetamine production during 
the early 1960s.44  
The situation began to improve somewhat in 1966, when the Bureau of Drug 
Abuse Control (BDAC) began an independent survey of amphetamine production 
following the passage of the 1965 Amendments.45 At the time the first quotas were 
established in 1971, the BNDD had obtained detailed information on bulk amphetamine 
production, either for intra-firm formulation or for sale to other companies, from the three 
main producers in the United States. In his analysis of these figures, UCLA researcher 
William McGlothlin suggested that questions needed to be raised about the accuracy of 
production data prior to the anticipation of the 1971 controls.46 While Congressional 
hearings bearing such evocative titles as “Crime in America – Why 8 Billion 
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Amphetamines?” hinted at the magnitude of the problem, their credibility was 
undermined by figures that apparently overestimated amphetamine production by 25 to 
40 percent for the years preceding 1969. Even academic studies such as Grinspoon and 
Hedblom’s The Speed Culture, which estimated production in 1971 at 12 billion dosage 
units, were considered by subsequent researchers as “simply gross exaggerations without 
any basis.”47 
The imposition of stricter controls on amphetamine production and distribution 
certainly deprived some companies of profits, and regulations on their prescription and 
possession placed limits on physician and patient alike. But an unambiguously positive 
outcome of the 1971 legislation moving the psychostimulants to Schedule II status and its 
subsequent enforcement was a reliable census of drug production. While policymaking in 
the years prior may have been somewhat more permissive regarding stimulant drugs, it 
was nevertheless informed by inaccurate information. If subsequent legislation and 
enforcement efforts were more rigorous, at least they could be driven by more reliable 
data. 
For an indication of how problematic the estimates that drove amphetamine 
policymaking were, one need look no further than Raymond Gosselin’s National 
Prescription Audit (NPA). Based on his research while a master’s student at the 
Massachusetts College of Pharmacy in 1950, the audit relied on population-stratified 
random sample of Massachusetts pharmacies for its findings. It grew larger in scope to 
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the point that, within a decade, pharmaceutical industry executives conceded that the 
NPA of R. A. Gosselin & Co. was more accurate than their own information.48 
Regarding amphetamines and methamphetamine consumption, the Gosselin NPA 
revealed that between 1968 and 1971, the total number of prescriptions dropped from 
around 23 million to 16 million.  If the figures for the first half of 1972 are extrapolated, 
then the number of prescriptions for that year totaled around 8 million, dropping by 
almost in just a year’s time.  The dramatic decline in amphetamine prescriptions is also 
revealed when considering both the drop in dosage units and total weight.  The decline in 
both amphetamine and methamphetamine prescriptions was especially marked between 
1971 and 1972 (extrapolating the first six months of data for the entire year), as both 
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Table 6.1 - Number of Prescriptions for Amphetamine and Methamphetamine, 1968-
1972 (first six months) (Source: Gosselin National Prescription Audit, cited in 
McGlothlin, Amphetamines, Barbiturates, and Hallucinogens) 
 
Year     Amphetamine and Methamphetamine 
1968      23,004,000 
1969      22,026,000 
1970      20,782,000 
1971      16,230,000 




Breaking down these statistics further, it is possible to ascertain both the number of 
dosage units and amount of drugs prescribed, in kilograms: 
 
Table 6.2 – Dosage Units and Amount Prescribed, in Kilograms, of Amphetamine and 
Methamphetamine, 1970-1972 (first six months) (Source: Gosselin National Prescription 
Audit, cited in McGlothlin, Amphetamines, Barbiturates and Hallucinogens) 
 
     1970  1971  1972 (1st 6 months) 
Dosage units (in millions) 
Amphetamine    533  486  135 
Methamphetamine   208  208   45 
   Total  741  694  180 
 
Number of kilograms 
 
Amphetamine    6,522  5,823  1,583 
Methamphetamine   2,453  2,420    540 
   Total  8,975  8,243  2,123 
 
Mean dosage units per prescription 35.7  42.8  43.949 
 
                                                






These figures convey a great deal of insight about the prescription and supposed 
consumption of amphetamines in the years immediately preceding and following the 
passage of the Controlled Substances Act. Most obviously, they suggest how drastically 
the prescription of amphetamines dropped following their reclassification as Schedule II 
substances in July 1971. Were the figures for the first 6 months doubled to provide an 
estimation for the entire year, it would be evident that dosage units for amphetamines 
were half those prescribed the previous year. At the same time, however, it may be 
suggested that amphetamine consumption had been steadily declining in the years 
immediately preceding the passage of the Controlled Substances Act. 
 Another insight gleamed from these figures is a scope of how supposed 
production figures were incongruous with actual prescription and consumption of the 
drugs. If eight billion amphetamine tablets were really being manufactured annually 
during these years, then prescriptions for only 741 million tablets were being filled by 
pharmacies. Even if one were to take into account direct dispensing by physicians at this 
time, that figure would increase only by about 4 million tablets.50 
Dealing with Diversion 
 Despite coming to grips with overestimates of amphetamine production, there 
remained discrepancies between total production and the legitimate distribution of 
amphetamines. Of particular concern to the BNDD during the early 1970s were four 
illicit sources of drug diversion: prescription forgeries, drug thefts from institutions such 
as hospitals, domestic clandestine manufacture, and smuggling. Each of these means had 
their own complicating factors. Forgeries and prescriptions acquired by other fraudulent 
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methods were generally counted along with legitimate prescriptions, making them 
difficult to track. Likewise, consumer level thefts, from hospitals, the military, or 
household supplies (but not pharmacies), were rarely disaggregated from tallies of 
legitimate retail sales, also making their scope difficult to assess. 
 Nevertheless, diversion of licitly manufactured amphetamines was an issue of 
great importance to the BNDD during the early 1970s. Such activities took place at all 
levels, from thefts of bulk manufacturer supplies down to adolescents stealing drugs from 
the household medicine cabinet. While there were a few documented instances of 
intentional diversion involving the management of large manufacturing and wholesaler 
firms, the BNDD reported that such actions were relatively rare. More often, diversions at 
the firm level were the result of thefts, employee collusion, or fraudulent representation 
on the part of the buyer, with the largest thefts involving bulk material at the 
manufacturing level. One documented case from 1968 resulted in the loss of almost 500 
pounds of methamphetamine, which would have accounted for seven percent of the 
estimated retail sales of that drug.51 In order to combat such issues, the BNDD began 
keeping track of manufacturer and wholesaler violations of security and record-keeping 
regulations in 1971. A General Accounting Office review of these activities found that 
550 follow-up investigations by BNDD resulted in 151 seizures of drugs, including 48 
million dosage units of amphetamine, representing about 4 percent of the estimated retail 
sales for the previous year.52 Findings such as these suggest both the scope of diversion at 
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the manufacturer level, as well as the BNDD’s response to the implementation of more 
rigorous controls. 
 Another issue faced by federal authorities regarding the diversion of 
amphetamines was the export of American manufactured drugs, including amphetamines 
and barbiturates, to Mexico and their suspected illicit return to the United States.  By the 
early 1960s, Mexican pharmacies became a convenient source of non-prescription 
stimulants. In some instances, single purchases from pharmacies were reported in the 
hundreds of thousands of dosage units.53 Following the passage of the Drug Abuse 
Control Amendments of 1965 in an attempt to address illegal amphetamine trafficking, 
the BNDD began to collect and provide more information on this issue. In one instance, 
an unnamed American firm shipped 950 kilograms of bulk amphetamine to a Mexican 
subsidiary during a 17-month period. The raw drug was formulated into tablet form and 
then illegally smuggled back into the United States for distribution.54 A more celebrated 
case involved the diversion of amphetamines, some 15 million dosage units over a 10 
year period, to a fictitious address corresponding to the 11th hole of the Tijuana Golf 
Course.55 
 What of other means of diversion too difficult to track? The large number of retail 
and hospital pharmacies made the monitoring of distribution at this level virtually 
impossible, while the regulation of routine sales was generally the legal purview of the 
states. Such efforts to stem illicit activity usually involved annual routine checks of a 
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fairly large sample of pharmacies, coupled with a small number of in-depth 
investigations. Pharmacy investigators for the state typically examined a sample of 
prescriptions for gross evidence of forgery, along with depending on their skill for 
detecting irregularities on the prescription form rather than a systematic check of the 
prescribing physician’s records. 
 When considering the issue of amphetamine diversion during the 1970s, it is 
important to bear in mind that the phenomenon differed across different parts of the 
country. For example, diversion of domestic sources of amphetamines tended to be more 
common on the East Coast of the United States. But stricter controls over physician 
prescribing, an increasing awareness of illicit drug use by pharmacists and 
pharmaceutical wholesalers, and the growing sophistication of local and state narcotics 
enforcement officers in California meant that the amphetamines from the West Coast 
were less frequently diverted. Rather, illicit amphetamines in this region came from 
illegally manufactured and imported sources.  
The Intersection between Illicit Activities and Enforcement  
 Of particular concern to lawmakers during the late 1960s was the implication of 
stimulant drugs in violent crime. However, a search of state court cases for the years 
before 1970 reveal that only eight homicide cases involved amphetamines in some way.56 
In the next, the implication of the drug in the most violent of crimes increased to 53 
cases.57 Such a finding suggests that while violent crime may have been a concern and its 
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perpetration by people under the influence of amphetamines was not unheard of during 
the so-called “speed years” of the 1960s and before, the imposition of controls to keep 
such substances out of the hands of non-medical users did not result in an abatement of 
crime associated with these drugs. 
 As I have suggested, the conceptualization of extramedical stimulant use as a set 
of distinct cultures provides one vehicle for understanding the motivations of 
amphetamine consumption among certain groups of people. Many of these users had 
rational, if not completely licit, reasons for their drug use, ranging from weight loss to 
staying awake on long drives. However, the idea that such cultures were generally 
innocuous and sustainable collides with the more horrific outcomes of amphetamine 
consumption—crimes as the result of amphetamine abuse and the phenomenon of 
amphetamine psychosis. Such problems punctured holes in the notion that amphetamine 
consumption was inherently safe, while buttressing medical and regulatory opinion that 
greater controls were needed. 
 At the 1970 annual meeting of the American Psychiatric Association in San 
Francisco, psychiatrist Everett Ellinwood, Jr. presented the case histories of 13 
individuals who had committed homicides while high on amphetamines. Notable about 
Ellinwood’s presentation was his articulation of the distinct pharmacological properties 
of amphetamines that, when consumed in excess, could lead abusers to commit such 
heinous crimes. While crime has been linked to alcohol and narcotics, the association of 
amphetamines and other stimulants with aggression and violence were of specific 
concern to medical authorities. The consensus among those professionals who worked 
with drug abuse, Ellinwood claimed, was that opiates did not tend to induce unwarranted 
                                                                                                                                            





violence, while alcohol and other sedatives were generally associated with an incidence 
of violence secondary to a lowering of impulse control. Contra these drugs, 
amphetamines were linked in reports from law enforcement personnel and psychiatrists 
with aggressive behavior as a primary effect of overconsumption.58 To prove his point, 
Ellinwood presented the case of 27-year-old truck driver who shot his boss in the back of 
the head because he believed his employer was trying to release poison gas into the back 
seat of the car in which he was riding. Prior to the incident, the truck driver had spent the 
previous 20 hours making a nonstop 1,600 mile trip in which he had ingested 180 
milligrams of amphetamine and had not slept for 48 hours. The driver’s normal dose was 
generally no more than 40 milligrams.59 
Crimes stemming from the overconsumption and abuse of drugs were not limited 
merely to their extramedical use, as a bizarre murder case from Georgia attests. Dr. 
William Henry Johnson was forced to retire from medicine in 1970, following an 
automobile accident in which his narcolepsy had been the cause. Johnson sought the help 
of a local doctor, who prescribed him Ritalin to help him control his sleeping disorder. 
However, the doctor seen by Johnson took little initiative in treating his patient, but left 
him to dictate his own treatment.60 Johnson had tried several other medications, but he 
found that the injectable form of Ritalin worked best for his disorder. While Ritalin did 
provide a measure of relief for Johnson’s narcolepsy, Ciba ceased production of the 
intravenous form of Ritalin in February 1974. According to the court documents, Dr. 
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Johnson was no longer able to function and became bed-ridden. He and his wife, with the 
local doctor's knowledge, thus began to experiment with grinding up Ritalin tablets in a 
blender and administering the resulting suspension rectally by enema. This avoided the 
undesirable side effects of taking so many tablets orally, but by Johnson’s own testimony, 
he was uncertain as to the dosage he was consuming. One day, Johnson’s son came home 
to find his stepmother dead from shotgun wounds and his father “in shock or near 
hysteria and incomprehensible.”61 
The authorities involved in Johnson’s arrest later testified to his “strange and 
confused behavior.”62 In fact, Johnson’s cellmate in the county jail even reported that 
Johnson proclaimed that he was Jesus Christ and later tried to commit suicide by 
drowning himself in the cell toilet. Johnson was later sent to the state mental hospital in 
Milledgeville, Georgia, where a staff psychiatrist diagnosed him with toxic psychosis, 
resulting from “either an overdose or withdrawal from Ritalin, or a combination of 
excessive use of Ritalin and excessive use of Darvon and alcohol.”63 Johnson would later 
testify at his trial for murder that during the week he killed his wife, he told her that he 
had decided to stop taking Ritalin, and he ordered her not to give him any more. 
However, he did not remember the murder taking place. 
These cases demonstrate that cultures of amphetamine use could be tainted by 
crimes that defined the limits of a drug-consuming culture and also hinted at its possible 
dissolution. Another issue was that of amphetamine psychosis, first described in 1938 by 
D. Young and W. B. Scoville but given its first detailed description by British 
                                                









psychiatrist Philip Henry Connell some two decades later.64 In his study, Connell 
demonstrated that an overconsumption of amphetamines could lead to a condition similar 
to, but distinct from, schizophrenia. Extremely high doses of amphetamines can produce 
a psychosis that results in paranoia, delusions of persecution, and auditory and visual 
hallucinations while fully conscious. While most closely associated with the use of 
amphetamines by “speed freaks,” more conservative extramedical and even medical uses 
of amphetamines could result in similar ends for some users. 
In one case, a 24-year-old mother of two was admitted to a Michigan hospital 
with the chief complaint, “It started when I took diet pills; things went crazy.” Since the 
age of fourteen, the woman had been treated with amphetamines by a diet doctor, 
continuing to use the drugs over the years without any ill effect. Then one month prior to 
being admitted to the hospital, the woman began increasing her intake of 
methamphetamine, against her physician’s advice, from 30 milligrams to 72 milligrams 
per day, in order to “maintain her feeling of pep.” Such overconsumption continued and 
the woman began to experience perceptual problems and hallucinations and act 
suspicious toward her coworkers, only to become uncontrollably agitated by the time she 
was admitted to the hospital.65 
  Several cases from these years demonstrate the extent to which the illicit use of 
amphetamines could be implicated in heinous crimes. For example, amphetamine use 
was implicated in a triple homicide case from Alabama in 1976, in which a man was 
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convicted of killing his ex-wife, former mother-in-law, and another man while his young 
son watched.66 For his crimes the man was sentenced to death in the electric chair. In 
another case from Colorado, a man under the influence of amphetamines was convicted 
in 1976 of vehicular homicide and sentenced to five years probation after the passenger in 
his automobile was killed in a one-vehicle accident.67  
In another homicide case from Alabama in 1973, Wilton O’Neill Trott was 
sentenced to life in prison after a conviction of murder in the first degree. Following the 
conviction, he appealed the case on the argument that he had been improperly questioned 
by authorities and unwittingly given a confession while under the influence of 
amphetamines. On the day of his arrest, Trott testified that he had purchased about 100 
“bennies” (i.e. Benzedrine tablets) at a nearby truck stop, only to drive to Mobile and 
purchase fifty more. He had consumed all these pills prior to his arrest, and he had taken 
about twenty-five the day of his arrest, the last one two hours before his arrest.  Trott’s 
admission of guilt during questioning would be complicated by the fact that authorities 
pursued the confession while he was still under the influence of amphetamines.  During 
an appeal after Trott’s conviction, C. B. Relfe, a licensed physician in the State of 
Alabama, testified as an expert witness that a person under the influence of these pills 
would have less will to resist interrogation due to fatigue. In light of such strong 
testimony that authorities ignored Trott’s state of mind while on drugs, the judges in the 
case overturned the original conviction.68 
                                                
66 Dudley Wayne Kyzer v. State of Alabama, 399 So. 2d 317 (Ala. Ct. App., 1979). 
 
67 People of the State of Colorado v. Robert Clayton McCollum, 38 Colo. App. 283 (1976). 
 






“The Speed Years” Revisited 
 What did the increased efforts by the federal government at increased reform and 
regulation mean for the various amphetamine cultures that thrived in the 1960s? Did 
speed freaks, diet pill consuming housewives, and doping athletes disappear as a result of 
the Controlled Substances Act and its subsequent enforcement by the BNDD and DEA? 
Not quite. While Senator Birch Bayh may be credited for spearheading efforts to tighten 
controls on stimulant production and distribution by reassigning amphetamines, 
methylphenidate, and phenmetrazine to Schedule II status, he was far less successful in 
addressing the overprescription and overconsumption of diet pills. The FDA permitted 
the prescription of amphetamines for obesity as a labeled use of the medication. Concern 
began to mount following the investigations of Senator Gaylord Nelson of Wisconsin 
during the mid-1970s. During hearings in the Senate Monopoly Committee on the 
efficacy of prescription drugs, the senator took a special interest in the amphetamines and 
expressed particular concern over their application in the treatment of obesity. While 
Nelson routinely criticized the FDA for its permissive positions regarding the drugs, both 
Richard J. Crout, director for the Bureau of Drugs, and Frederick Rody, Jr., acting deputy 
administrator for the DEA, expressed similar concerns during hearings in late 1976.69 
 Despite promises to address the persistent problem of diet pill abuse, federal 
authorities had yet to act when individual states decided to take the initiative. Among the 
vanguard in this movement was the state of Wisconsin, which completely banned the use 
of amphetamines for dietary purposes in November 1977. The impetus for the state’s 
action in this matter reportedly began after David Joransen, a researcher for the state’s 
Controlled Substances Board, observed some strange patterns in the sale of 
                                                





amphetamines. Looking over the 1975 sales figures for Biphetamine 20, a drug marketed 
by the Pennwalt Company and known causally as “Black Beauties,” he observed that of 
approximately 1 million doses of the drug sold in Wisconsin that year, more than 118,000 
were dispensed by only 26 practitioners. Shockingly, while 20 of those practitioners were 
allopathic physicians, three were osteopaths, two were dentists, and one was a podiatrist. 
In short, six non-physicians were responsible for more than 20,000 dosage units being 
dispensed. Among the physicians, one doctor alone had purchased more 33,000 pills, a 
second was responsible for 28,000, and a third for 8,200. Another surprising figure 
revealed that almost half of the 118,000 pills sold by the top 26 were sold in Milwaukee 
County, while an equal number were sold in sparsely populated Dodge County, which 
had a large German community, a state prison, “and probably a lot of fat women,” 
Joransen related to a journalist from the Washington Post. 
 These findings spurred a more comprehensive study and a preliminary decision in 
June 1976 by Wisconsin’s Department of Health and Social Services to cut off funding 
for amphetamine products. Confirming that many doctors in Milwaukee had been 
prescribing large doses of amphetamines to state Medicaid patients, sales of Biphetamine 
in that city dropped from 25,000 dosage units per month to less than 2,200 units within 
just a couple months. Meanwhile, a second study revealed that, while Biphetamine may 
have been the original drug under investigation, Dexedrine, Benzedrine, and Desoxyn 
were even bigger sellers within the state. Six pharmacies in Sheboygan County, 
Wisconsin, had purchased more than 5,000 units each in 1976, for a total of 56,000 units. 





local newspaper, the Sheboygan Press, ran a headline proclaiming “Sheboygan: State 
Speed Capital.”70 
Joransen’s findings undoubtedly spurred the November 1977 ban. Perhaps the 
most notable aspect of the Wisconsin law was the fact that it targeted not only sales of the 
drugs, but their very prescription. Doctors found prescribing amphetamines as dietary 
aids faced charges of unprofessional conduct and the threat of having their licenses 
suspended by the state’s Medical Examiners Board, a power that even the FDA lacked. 
And just how effective were these efforts? By February 1978, less than four months after 
the law took effect, authorities reported a dramatic drop in sales. The state's largest 
distributor, which served the Milwaukee area, reported a drop of 97 percent in the sale of 
Biphetamine 20 pills.71  
The move by states such as Wisconsin to target overprescription by physicians 
suggests how state governments such as Wisconsin conceptualized the problem 
somewhat differently than federal authorities had up to that point in time. Rather than 
addressing the issue of distribution primarily in terms of the quantities of pills that could 
dispensed or prescribed, some state governments decided to intervene in an area that had 
long been the purview of the FDA—the actual conditions for which drugs could be 
ordered as therapies. In the case of Wisconsin, physicians could still prescribe 
amphetamines for depression, narcolepsy, and hyperkinesis, but no longer obesity, once 
the November 1977 law took effect.72  
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 The Wisconsin case was widely covered in the press and especially followed by 
the FDA. Of his own state’s efforts, Joransen noted in the Washington Post that, “We see 
ourselves at the vanguard of getting the other states and the federal government to look at 
this problem to see that there are other, just as serious, problems besides Schedule I drugs 
like heroin. These other drugs, like amphetamines, which are used regularly[,] can pose a 
greater problem because of their availability.” In response, the FDA official Stuart 
Nightingale suggested a fresh investigation of the matter: “When we found out what was 
going on in Wisconsin, it was a pleasant surprise. Only the states have the power to take 
away a doctor's license or take other disciplinary action. We can't stop a physician, but 
we can take other actions that are consistent with what has happened in Wisconsin.” 
Suggesting the role of the states in crafting effective drug policy, he added that they have 
“the power to move further than the federal government. We think it's a good idea for a 
state-level action like this to take place. It is much more effective than what we can do.”73 
Such intervention by the states helped to inform the FDA’s thinking, too, as it did when it 
held hearings in December 1977 on the issue of the overprescription of amphetamines for 
obesity. As a result of the hearings, which included testimony from Joransen, the FDA 
proposed an outright ban on the prescription of amphetamines for obesity in July 1979.74  
 Another area of concern throughout the 1970s was the persistent use of 
amphetamines among athletes. Perhaps no sport was taken more by the issue than 
football, as evidenced by a high profile drug scandal involving the San Diego Chargers in 
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1973, the only such public case in the NFL during the decade. The matter involved a San 
Diego psychiatrist named Arnold Mandell who worked for the team as an unpaid 
psychiatric consultant between 1972 and 1974, prescribing amphetamines for football 
players. When the scandal broke publicly, it resulted in a total of $40,000 in fines levied 
by the NFL Commissioner Pete Rozelle against Chargers team owner Eugene Klein, 
general manager Harland Svare, and eight players. After being implicated Mandell 
became disaffected and began to speak out publicly about his experiences with the 
Chargers. Following his 1976 publication of a book called The Nightmare Season, 
Mandell was reportedly beset with difficulties from his former employers and 
investigated for wrongdoing in the scandal. Mandell was reprimanded by the California 
Board of Medical Quality Assurance for prescribing large amounts of amphetamines for 
11 Charger players, on the evidence of prescription forms discovered by NFL security 
chief Jack Danahy. His defense in the case was that all of these players were longtime 
heavy amphetamine users who, because of new regulations imposed by the NFL in 1971 
to curtail the previously common bulk purchase and distribution of amphetamines by 
team doctors, had switched to using dangerous “street speed” from street-corner drug 
traffickers. Mandell claimed he prescribed amphetamines for these men to get them off 
impure drugs and onto chemicals he knew to be pure so that he could gradually decrease 
their dosage. Of the four counts brought against Mandell, three were dismissed, but he 
was found to have “overprescribed” amphetamines for the 11 players in question. His 
medical license was initially revoked (it was immediately reinstated, but he was placed 
on five years probation), and his federal license to write prescriptions for all scheduled 





 The incident prompted Mandell to become more publicly active about the 
problems he saw in the sport. Calling attention to a phenomenon he termed the “Sunday 
Syndrome,” Mandell interviewed 85 players on other teams within the NFL, finding 
several patterns about drug usage by players. He found that amphetamine usage in high 
doses to produce an “analgesic rage” was more common among older players than 
younger ones and more prevalent among defensive players, especially linemen, than 
those in skill positions. Breaking down patterns of usage by position among the players 
he interviewed, it was revealed that one of eight quarterbacks used between 10 and 15 
milligrams of amphetamine regularly on game days, six of 11 wide receivers consumed 5 
to 15 milligrams, ten of 14 offensive linemen were took 15 to 105 milligrams, eight of 11 
running backs used doses ranging from 5 to 25 milligrams, two of two tight ends 
consumed 10 to 30 milligrams, nine of nine defensive linemen used between 30 and 150 
milligrams, five of nine linebackers took 10 to 60 milligrams, and seven of 11 defensive 
backs used five to 20 milligrams. What the results suggested, Mandell claimed, was that 
whereas some linebackers, defensive backs, running backs and wide receivers consumed 
moderate amounts of amphetamine on game days in largely illusory attempts to increase 
quickness, fight fatigue, and reduce the pain of impact, certain offensive and defensive 
linesman and “special team” members employed the drug to help “psych” themselves 
into a belligerent frenzy.75 
 These examples, the continued overprescription of amphetamines by physicians 
and persistent use of the drugs in sports, suggests that despite serious efforts to come to 
grips with the problem, elements of the 1960s speed culture persisted at the dawn of the 
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1980s. Yet, if the NFL was unwilling to clean up its own sport, as some critics charged, 
then at least individual states were enthusiastic about moving to deal with the problem of 
physician overprescription.  
Conclusion 
In this chapter, I have discussed how lawmakers, using the newly passed 
Controlled Substances Act as a platform, moved to tighten controls on amphetamines and 
other psychostimulant drugs during the early 1970s. The main issue of concern was the 
proper scheduling of these drugs in the newly created classification system that fell under 
the jurisdiction of the BNDD and, later, the DEA. Debates over the proper level of 
controls for psychostimulant drugs during the early 1970s focused on whether they 
should be controlled according to their medical uses, a position held by the FDA, or 
according to their potential for addiction and danger of being illegally diverted for illicit 
use, the preference of the BNDD. I also consider how some physicians expressed 
opposition to the imposition of controls, using a case from Canada in 1973 as a contrast 
to those medical experts who supported the imposition of more stringent controls. 
Despite efforts at opposition, however, the forces of greater control would prevail. Yet 
the persistence of the “amphetamine cultures” explored in the previous chapter suggests 
more clearly the way consumption of drugs was, and frequently was not, affected by the 
intervention of federal authorities, particularly those in the FDA and DEA.  By the late 









 With the opening of the 1980s, the zenith of psychostimulants as therapeutic 
agents appeared to be winding down. The prior decade had seen a narrowing of 
legitimate indications for the drugs, accompanied by more stringent regulations that 
constrained their medical uses. With the introduction of newer antipsychotic agents into 
medical practice during the 1960s and 1970s, the halcyon days of stimulants for 
combination drug therapies had ended. The introduction of the tricyclic antidepressants 
for major depression and, later, the selective serotonin reuptake inhibitors (SSRIs) for 
minor depression, suggested that the psychostimulants’ heyday as a treatment for 
depression had also come to a close. The passage of the 1970 Controlled Substances Act 
and subsequent efforts by legislators and regulatory bodies, particularly the Food and 
Drug Administration (FDA) and Drug Enforcement Administration (DEA), formalized 
the diminishing medical applications of the psychostimulants. Finally, state-level 
intervention during the late 1970s attenuated the lingering problem of the amphetamine 
overprescription for obesity.  
The federal government’s designation of amphetamines and methylphenidate as 
controlled substances privileged narcolepsy and hyperkinesis as the most legitimate 
applications for the medications.1 At the time, the number of patients receiving drugs for 
both of these conditions was far less than the millions consuming amphetamines for 
weight loss alone. With this rending of psychostimulants’ indications during the 1970s, 
                                                
1 For more information about the current scheduling of amphetamine and methylphenidate, as well 
as its recognized indications, see U.S. Department of Justice, Drug Enforcement Administration, Drugs of 





the coming of a new decade portended their demise as medical therapies—a “brave new 
world” that coincided with a renewed vigor by the Reagan administration to attack 
nonmedical drug consumption.2 What these expectations failed to anticipate, however, 
was the incredible surge in the number of children who would be diagnosed with 
attention-deficit/hyperactivity disorder (ADHD) and prescribed psychostimulants for its 
management. 
ADHD and the Resurgence of Ritalin 
 “Welcome to Ritalin Nation,” declared psychologist Richard DeGrandpre in 
1998 after commenting on the staggering rise in the number of school-age children 
receiving methylphenidate for the treatment of the disorder.3 By the end of the 1970s, 
much of the initial furor over the prescription of Ritalin and other stimulants for 
hyperkinesis had diminished. With the official recognition of attention deficit disorder 
(ADD) in 1980, the disorder was given increased legitimacy. The prescription of Ritalin 
to children quietly began to escalate. It has been estimated that between 270,000 and 
541,000 school children in the United States were being prescribed methylphenidate in 
1980.4 In 1987, physicians Daniel Safer and John Krager estimated that 750,000 students 
were receiving the drug for the disorder.5 In the 1990s, the number of children prescribed 
the drug began to skyrocket. By the beginning of the twenty-first century, five million 
                                                
2 See Davenport-Hines, Pursuit of Oblivion, chaps. 13 and 14; and Musto, The American Disease, 
chs. 11 and 12. 
 
3 DeGrandpre, Ritalin Nation, 18. 
 
4 Kenneth D. Gadow, “Prevalence of Drug Treatment for Hyperactivity and Other Childhood 
Behavior Disorders,” in Psychosocial Aspects of Drug Treatment for Hyperactivity, ed. Kenneth D. Gadow 
and John Loney, eds. (Boulder, CO.: Westview Press, 1981), 13-70. 
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American children and adolescents were prescribed stimulant drugs for the treatment of 
ADHD.6 Accompanying the surge in Ritalin prescriptions during the 1990s was a steep 
rise in the media’s interest in the issue. A Google news search for “Ritalin” between the 
years 1960 and 2009 (see Figure 7.1) suggests growing media attention in 
methylphenidate consumption. A closer look at the years between 1980 and 2009 (see 




                                                
6 Greg Critser, Generation Rx: How Prescription Drugs Are Altering American Lives, Minds, and 
Bodies (Boston: Houghton Mifflin, 2005), 140. My estimate considers the total number of users. Framed 
another way, in 2001, physicians wrote 20 million prescriptions for the drug nationwide. See “ADHD 
Medication Issue Could Find National Spotlight,” Education USA, March 18, 2002, 8. 
 Utilizing a different set of sources to determine the number of children receiving pharmacotherapy 
for ADHD, Rasmussen estimates that by 1980, the number was approximately 500,000. By 1990, it had 
reached about 1 million, and by the early 2000s, it was between 4-5 million.  
 
7 I undertook a news archive search of the term “ritalin” (which presents findings both in 
lowercase and uppercase) in order to gauge growing media attention in the drug. The presentation of 
findings in Figures 7.1 and 7.2 are meant to provide a rough indication on growing media interest, and they 
make no claim for precise figures. In particular, I searched the term “ritalin” on Google News, an 
automated news aggregator service that is part of the larger web portal Google. The aggregator finds news 
stories from a large selection of scanned newspaper articles going back up to 200 years, and then presents 
trends in the form of a graph grouped decade by decade. It should be noted that the depth of coverage 
varies from source to source; however, major newspapers are well represented in the Archive Search. For 
example  
 In Figure 7.1, the frequency of the term “ritalin” or “Ritalin” at least one time in news articles 
from the years 1960 to 2009 are presented. More precisely, the number of articles in which the term 
appeared: January 1, 1960 to December 31, 1964 – 3 articles; 1965 to 1969 – 11 articles; 1970 to 1974 – 86 
articles; 1975 to 1979 – 128 articles; 1980 to 1984 -111 articles; 1985 to 1989 – 405 articles; 1990 to 1994 
– 1,050 articles; 1995 to 1999 – approximately 4,000 articles; 2000 to 2004 – approximately 8,770 articles; 
and January 1, 2005 to July 25, 2009 – approximately 11,200 articles. Figure 7.2 contains the same findings 






Figure 7.1 – News articles mentioning “ritalin” or “Ritalin” between January 1, 1960 and 





Figure 7.2 – News articles mentioning “ritalin” or “Ritalin” between January 1, 1980 and 




 In 2000, precisely three decades after its first inquiry into the use of “behavior 
modification drugs” by hyperkinetic children, Congress once again convened hearings to 
consider the escalating prescription of Ritalin to American youth for ADHD. Perhaps the 
most interesting feature of the hearings was an obliviousness demonstrated by lawmakers 
and testifying physicians about the historical dimensions of the disorder; there was not a 
single reference to the 1970 hearings. However, these latest hearings had many features 
in common with those held following the “Omaha incident.” Lawmakers expressed 
concerns about a perceived epidemic of children being prescribed powerful psychotropic 





its management with stimulant therapies. Both sides agreed that potential overdiagnosis 
and overprescription were problems to be avoided. In many ways, the hearings confirmed 
the conventional wisdom about ADHD and Ritalin. But they also revealed some notable 
historical shifts. One in particular was the emerging dominance of pediatrics over child 
psychiatry in the prescription of stimulants. In 1998, pediatricians wrote 50 percent of the 
prescriptions for ADHD; psychiatrists wrote 25 percent; family practitioners wrote 9 
percent; and neurologists wrote 7 percent.8 
“Ritalin Culture” 
The escalating incidence of ADHD and its management with stimulant 
medications since the late 1980s have not been purely medical phenomena. The ADHD 
experience has been characterized by social and cultural dimensions far surpassing the 
discourses around hyperkinesis during the 1960s and 1970s. If there were multiple 
“amphetamine cultures” during the 1960s organized around the drugs’ recreational, 
weight management, and other performance enhancing characteristics, then perhaps the 
consumption of psychostimulants (mainly methylphenidate) during the last two decades 
for ADHD may be characterized as a longstanding “Ritalin culture.” 
 ADHD’s formal introduction in 1980 marked an important shift for the disorder 
formerly known as hyperkinesis. The new diagnostic category’s inclusion within the 
DSM-III indicated something of a consensus about its validity within mainstream 
psychiatry. Coinciding with this new sense of legitimacy for ADHD was a prolific output 
of books and articles that publicized the disorder while educating a receptive public about 
the disorder and its treatment. Bestselling books such as Barbara Ingersoll’s Your 
                                                
8 House Subcommittee on Early Childhood, Youth, and Families, House Committee on Education 






Hyperactive Child, Edward Hallowell and John Ratey’s Driven to Distraction, and 
Russell Barkley’s Taking Charge of ADHD brought increased publicity to the disorder 
and its management.9 In one sense, these works were harbingers of a broader self-help 
movement that coalesced around ADHD during the late 1980s and 1990s. At the same 
time, however, they solidified public acceptance for the new diagnostic category and its 
medical treatment with stimulant drugs. Acceptance of ADHD as a valid diagnosis, 
particularly for children and adolescents, was further reinforced by the emergence of 
summer camps, workshops, and tutoring services to help youth understand and accept 
their disorder, all of which suggested the development of what Iversen has termed a “self-
aware ADHD community.”10 In some quarters, the diagnosis of ADHD has been viewed 
even more positively. Traits associated with the disorder, such as distractibility, poor 
impulse control, and emotional sensitivity, have been reconceptualized as strengths by 
advocates who contend that such individuals are better characterized as creative, 
energetic, and intuitive.11 
 Yet a strident opposition movement has developed in parallel to the ADHD-
acceptance movement. Contesting the legitimacy of the diagnosis and the associated 
prescription of Ritalin and other psychostimulant therapies, this group has been more 
vociferous in their criticism than Conrad or even Schrag and Divorky were during the 
1970s. Perhaps the best known representative of this view has been the Church of 
                                                
9 Barbara Ingersoll, Your Hyperactive Child: A Parent’s Guide to Coping with Attention Deficit 
Disorder (New York: Doubleday, 1988); Edward M. Hallowell and John J. Ratey, Driven to Distraction: 
Recognizing and Coping with Attention Deficit Disorder from Childhood to Adulthood (New York: 
Pantheon Books, 1994); and Russell A. Barkley, Taking Charge of ADHD: The Complete, Authoritative 
Guide for Parents (New York: Guilford Publications, 1995). Ingersoll and Barkley are child psychologists, 
while Hallowell and Ratey are pediatric psychiatrists. 
 
10 Iversen, Speed, Ecstasy, Ritalin, 65. 
 





Scientology, known popularly for its opposition to conventional modern psychiatry and 
pharmacotherapy.12 Through a subsidiary organization called the Citizens Commission 
on Human Rights, established in 1969 to investigate perceived psychiatric abuses, the 
Church of Scientology has waged a campaign against Ritalin, claiming the drug to be a 
“chemical straitjacket.”13 In 1987, the Commission lobbied the Republican Study 
Committee to influence Congress to investigate Ritalin. Representative Cass Ballenger 
(R-NC), then a member of the House Committee on Education and the Workforce, 
pursued the matter by requesting the FDA to investigate and report on Ritalin use and 
safety. But once the relationship between the Committee and the Church of Scientology 
became clear, Ballenger dissociated himself from the matter.14  
The Committee intensified its campaign in 2000, however, when it filed class-
action lawsuits against Novartis and the American Psychiatric Association (APA) in five 
states. Based on the rising production and prescription of Ritalin throughout the 1990s, 
the suits alleged that the plaintiffs had conspired to increase the sales of Ritalin.15 To help 
make its case, the plaintiffs sought the expertise of psychiatrist Peter Breggin, a well-
                                                
12 W. Vaughn McCall, “Psychiatry and Psychology in the Writings of L. Ron Hubbard,” Journal 
of Religion and Health 46, no. 3 (September 2007): 437-447; Gregory K. Fritz, “Awakening to 
Scientology,” Brown University Child and Adolescent Behavior Letter 22, no. 7 (July 2006): 8; and Danylo 
Hawaleshka, “A New War over Ritalin,” Maclean’s 119, no. 20 (May 15, 2006): 38-39. 
 
13 Daniel J. Safer and John M. Krager, “Treatment of Attention Deficit-Hyperactivity Disorder—
Reply,” JAMA 269, no. 18 (May 12, 1993): 2369; Daniel Smith, “Shock and Disbelief,” Atlantic Monthly 
287, no. 2 (February 2001): 79-90.  
 
14 Joel Sappell and Robert W. Welkos, “Suits, Protests Fuel a Campaign against Psychiatry,” Los 
Angeles Times, 29 June 1990. 
 
15 Barry Meier, “Suits Charge Conspiracy by Maker and Doctor’s Group to Expand Ritalin Use,” 
New York Times, 14 September 2000; Toni Locy, “Fight over Ritalin Is Headed to Court,” USA Today, 15 
September 2000; “ADHD Lawsuits,” PBS Frontline, 2001 
[http://www.pbs.org/wgbh/pages/frontline/shows/medicating/backlash/lawsuits.html]. The lawsuits in 





known critic of biological psychiatry.16 The plaintiffs contended that the defendants had 
conspired to widen the diagnostic criteria when ADD was reclassified as ADHD during 
the publication of the DSM-IV in 1994, thereby increasing the number of people 
diagnosed with the disorder and boosting the sales and profits of Ritalin’s manufacturer. 
Novartis and the APA responded with the argument that ADHD was a medically valid 
disorder and that claims to the contrary flew in the face of medical evidence and 
psychiatric consensus. Furthermore, the defendants pointed to support for their position 
by the National Institutes of Health (NIH) and its Consensus Conference on ADHD, the 
National Academy of Pediatrics’ diagnosis guidelines for the disorder, and the FDA’s 
continued approval of methylphenidate for its treatment.17 By 2002, the various lawsuits 
had been dismissed in favor of Novartis and the APA. 
 On the surface, it may appear that the Ritalin culture of the 1980s and 1990s 
consisted of two camps either in support of or opposed to ADHD as a valid medical 
condition. However, these interests occasionally intersected in unsettling ways. In 1987, a 
support and advocacy group called Children and Adults with ADD (CHADD) was 
founded in Florida by a small group of parents and psychologists. Within a decade, 
membership had grown to over 20,000 members, including 2,000 medical professionals 
providing care to ADHD patients. While CHADD may have begun as a grassroots 
movement, its eventual links to the pharmaceutical industry created a massive 
controversy. In 1995, CHADD petitioned the DEA to reclassify Ritalin from Schedule II 
                                                
16 See Peter R. Breggin, Talking Back to Ritalin: What Doctors Aren’t Telling You about 
Stimulants and ADHD (Cambridge, MA: Da Capo Press, 2001). 
 
17 “ADHD Lawsuits.” See also, National Institutes of Health, “Diagnosis and Treatment of 
Attention Deficit Hyperactivity Disorder (ADHD),” NIH Consensus Statement 16, no. 2 (November, 16-18 






to Schedule III, which would have loosened a number of controls on the drug’s 
prescription rules and production quotas. The DEA denied the request, but in the course 
of hearings, it was revealed that CHADD had received almost $1 million in funding from 
Ciba-Geigy during the early 1990s. In 1991, the drug firm donated $100,000 to the group, 
and by 1994, its contributions had grown to $398,000 annually. Given that CHADD’s 
annual budget at this time was about $2 million, these contributions were significant.18 
So, too, were the potential benefits that loosening federal controls might have for the 
pharmaceutical firm.  
 The relationship between CHADD and Ciba-Geigy prompted the Citizens 
Commission for Human Rights to name the advocacy group as a defendant in some of its 
lawsuits against the drug firm and the APA. While those cases may have been dismissed, 
the establishment of potentially unethical relationships between the parties suggests how 
the murky the issues concerning Ritalin during the last two decades have been. Further 
compounding this observation is the fact that CHADD still exists as one of the leading 
ADHD advocacy groups, and that its current partnerships include federal entities such as 
the Centers for Disease Control’s (CDC) National Center on Birth Defects and 
Developmental Disabilities (NCBDDD).19 
The prescription of Ritalin for ADHD continues to raise questions about the 
relationship between medical and extramedical use of drugs. In 1998, an article in the 
Albany, New York Times-Union first brought attention to the use of Ritalin by college 
students as a “study drug.” The story highlighted a senior art major at Skidmore College 
                                                
18 Karen Thomas, “Ritalin Maker’s Ties to Advocates Probed, Financial Link Called 
Understated,” USA Today, November 16, 1995. 
 






in Saratoga Springs, who noted that that the drug allowed her to read three times as fast 
and “soak it in quicker.” Likewise, a 21-year old economics student confessed that his 
friends long had consumed Ritalin without a prescription to help them study.20 
Throughout the early 2000s, rising extramedical consumption of methylphenidate among 
high school and college students continued to attract attention among the media, medical 
authorities, and government officials. By 2004, the Partnership for a Drug-Free America 
revealed that 2.3 million teenagers in the United States, almost ten percent, claimed to 
have used stimulants such as Adderall or Ritalin without a prescription.21 In subsequent 
studies, the organization found that over half of teenagers surveyed did not perceive a 
great risk in the taking of Ritalin or Adderall not prescribed for them.22 
Contemplating the “Fen-Phen” Debacle 
 As I have noted in my dissertation, the prescription of amphetamine drugs to 
assist patient-consumers in their efforts to lose weight comprised one of the leading uses 
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21 See Partnership for a Drug-Free America, 2004 Partnership Attitude Tracking Study, April 21, 
2005. Accessed online: 
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22 For more on the contemporary features of ADHD and stimulant use, see Diller, Running on 
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of psychostimulant drugs during the postwar era. Medical authorities and lawmakers 
voiced earnest concerns over the issue of amphetamine overprescription during the late 
1960s. Although the FDA had threatened action during the 1970s, and while states such 
as Wisconsin took preemptive measures to deal with the problem, by and large, the drugs 
were permitted to remain on the market. 
 As a result of the Drug Efficacy Study and Implementation (DESI) conducted 
during the late 1960s as part of the Kefauver-Harris Amendments, the FDA decided to 
act upon findings that placed doubts upon the effectiveness of the amphetamines in 
weight loss. In 1970, the FDA gave the manufacturers of anorectic drugs, including 
amphetamines, a year to provide substantial evidence, based on controlled clinical 
studies, of their products’ efficacy in weight loss. Were the manufacturers unable to do 
so, then the FDA threatened to revoke obesity indications for the drug or to remove them 
from the market altogether. In undertaking this endeavor, physician and FDA official Eric 
Colman noted that one of the problems faced by policymakers was the absence of 
standards to define weight-loss efficacy.23 
 In June 1972, the FDA revealed the findings from its Amphetamine Anorectic 
Drug Project, a meta-analysis of the data that had been provided to the Administration, 
which covered 10,000 patients who had participated in 200 drug studies on the efficacy 
of the amphetamine drugs for weight loss. The study found that patients who had taken 
the amphetamine drugs lost “a fraction of a pound more a week” than those patients who 
                                                






had taken placebo drugs.24 This amount of weight loss might appear to be trivial, 
especially when considered against the possible dangers of the amphetamines discussed 
in this dissertation. However small, the findings demonstrated that amphetamine drugs 
were “statistically significant” when compared to placebo, which was in line with how 
FDA officials had chosen to measure efficacy. 
 As a result, the amphetamine drugs were permitted to remain on the market for 
weight loss during the 1970s, despite occasional threats by federal officials, such as the 
one in 1979, to remove them from the market. The FDA did mandate in the late 1970s 
that prescription of these drugs were to be limited to only a few weeks and that warnings 
would be required regarding their potential for dependence. These requirements, enacted 
in 1977, coupled with the FDA’s threat of more stringent action appeared to be sufficient 
for federal lawmakers, if not necessarily for states such as Wisconsin. The 1980s would 
see an overall decrease in the prescription of amphetamine-based anorectics.25 
 The decline in the use of stimulant drugs for the treatment of obesity reversed 
dramatically in the mid-1990s with skyrocketing prescriptions of fenfluramine and 
phentermine, the combination better known as “Fen-Phen.” Fenfluramine was a 
sympathomimetic drug introduced in 1973 by Robins Pharmaceutical as Pondimin. In the 
late 1980s, Wyeth had acquired Robins, as well as the rights to Pondimin. Phentermine 
was an amphetamine-based drug introduced during in 1959, and it was marketed 
primarily under the brand Fastin, which was owned by SmithKline. 
                                                
24 See Thaddeus E. Prout, Final Report to the Director, Bureau of Drugs, in Safety and Efficacy of 
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 Of particular interest in this case was Wyeth, which owned the rights to 
fenfluramine and had begun marketing it heavily during the mid-1990s as a weight loss 
drug. At the same time, the firm introduced the dextro-isomer version of the drug, 
dextrofenfluramine, onto the market as Redux after receiving FDA approval in 1996. The 
process of approval had been rather controversial, as five members of the eleven person 
committee believed the drug’s weight-loss benefits did not outweigh its risks. 
Nevertheless, the drug was approved, with the recommendation that its prescription be 
limited to patients whose obesity posed a threat to long-term health. Despite this 
stipulation, Redux was being dispensed at a rate of 85,000 prescriptions per week within 
a year of its market introduction.26 
 The staggering success of both Fen-Phen and the newer Redux came to an abrupt 
halt when a medical technician in Fargo, North Dakota, discovered an unusual heart 
valve defect in patients taking the drug. The hospital’s cardiologist, Jack Crary, contacted 
colleagues at the Mayo Clinic, who also had noticed similar effects associated with the 
drug. In 1997, the New England Journal of Medicine published the findings of the 
researchers, which suggested that both fenfluramine and dextrofenfluramine were 
associated with heart valve degeneration.27 In September of that year, both drugs were 
pulled off of the market, bringing the “Fen-Phen” craze to a swift conclusion. As a result 
of the debacle, Wyeth was subjected to thousands of lawsuits over the drug, many of 
which remain unresolved.28 
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Phentermine,” New England Journal of Medicine 337, no. 9 (August 28, 1997): 581-588. 
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 Yet the search for drugs to help Americans lose weight has continued unabated. 
Shortly after the Fen-Phen scandal, the FDA took aim at another stimulant-like drug 
being marketed for weight loss, ephedrine. As I noted in my introduction, this 
sympathomimetic drug fueled Alles’s initial discovery of amphetamine in 1929. By the 
end of the 20th century, it was being revived as a weight loss drug. Expressing concern 
about the potential health risks that ephedrine posed for dieters, particularly elevated 
blood pressure and increased risk for heart problems, the FDA proposed a partial ban on 
the drug in 1997.29 After overcoming initial concerns about how to define safe dietary 
intake levels and duration of use, in 2004 the FDA finally imposed a ban on ephedrine 
alkaloids marketed for uses other than asthma, colds, allergies, or traditional Asian 
medical use. In effect, the FDA was targeting the advertising of non-prescription, 
ephedrine-containing supplements that had flooded the market in recent years for weight 
loss. The risks of these supplements, the FDA concluded, outweighed their potential 
benefits.30 Complementing the FDA’s action in this matter were efforts to ban the 
supplement in sports, particularly professional football, after its use had been increasingly 
linked to the deaths of athletes since the 1990s.31 
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Crystal Meth and Ecstasy 
  Despite efforts to combat methamphetamine abuse since the “speed years” of the 
1960s, illicit use of the drug has continued to persist. After a decline in illegal 
methamphetamine use in the mid-1970s, abuse of the drug began to increase during the 
early 1980s as street use of methamphetamine overtook that of amphetamine. Part of the 
reason for this increase involved new methods that allowed amateurs to synthesize the 
drug from pseudoephedrine, a common ingredient in over-the-counter cold medications.  
 Originating in the West, particularly California, Colorado, Oregon, Oklahoma, 
and Texas, illegal methamphetamine use began to rise and then spread eastward in the 
mid-1980s. Between 1983 and 1988, illicit consumption of the drug doubled, and then it 
doubled again between 1988 and 1992. However, the greatest spike in consumption came 
during the 1990s, when there was a five-fold increase in the use of methamphetamine. By 
2004, almost 1.5 million Americans had used methamphetamine, and 3 million had used 
some form of amphetamine non-medically. In addition, the percentage of admissions to 
drug abuse treatment programs for methamphetamine abuse was about nine percent in 
2005, more than double the number a decade earlier.32  
 Accompanying the rising use of methamphetamine consumption are the ways in 
which the drug is manufactured and consumed. Clandestine methamphetamine 
manufacture in the United States has become increasingly associated with small-scale 
“meth labs” capable of creating a more potent form of the drug known as crystal meth. 
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Resembling clear rock-candy, this form of the drug is commonly smoked in glass pipes. 
In addition to its cheap and easy manufacture, the drug’s fast administration into the body 
provides an immediate rush that rivals injected forms of the drug. Nicolas Rasmussen has 
suggested that one reason for the drug’s popularity may derive from its allure as an 
inexpensive alternative to cocaine.33  
In addition to the current epidemic of methamphetamine abuse has been the 
associated consumption of methylene-dioxy-methamphetamine (MDMA), commonly 
known as “ecstasy,” and a related drug called methylene-dioxy-amphetamine (MDA). In 
1930, Gordon Alles discovered MDA as part of his research. While he noted its unusual 
effects as both a stimulant and hallucinogen, Alles found no immediate use for the drug. 
Rasmussen has noted how the drug’s growing street consumption as an LSD-like 
substance during the late 1960s, partly through the efforts of the former experimental 
chemist Alexander Shulgin, led to the drug’s rapid criminalization during the early 1970s. 
However, MDMA remained legal. During the late 1970s and early 1980s, the drug 
developed a reputation within quasi-medical, alternative psychotherapeutic practices. 
Generally known as “Adam” within this particular setting, MDMA’s particular 
psychological effects—namely, its ability to reduce fear and anxiety and induce a sense 
of intimacy within users—made it a popular drug for these therapies. However, the 
growing reputation of MDMA in this setting attracted the attention of federal authorities, 
and the drug was formally outlawed as a Schedule I controlled substance in 1985. 
Nevertheless, underground consumption of MDMA continued to grow during the late 
1980s and 1990s as part of the rave-music culture, particularly in Britain. Despite 
                                                






attempts by authorities to crack down on the drug, its illicit use, especially among young 
ravers, remains popular.34 
The Past and Its Relevance for the Present 
 My brief sketches of the current debates regarding ADHD and its management 
with stimulants, ongoing controversies regarding diet drugs, and present illicit drug abuse 
only hint at the complexity of these issues. Thousands of pages have been written on each 
of these topics. My concern is less to expound on these present debates than to illuminate 
the past. However, I hope to demonstrate the ongoing relevance of the history to the 
present concerns over psychostimulant drugs in our society. 
 The subject of ADHD has been extremely controversial during the past two 
decades, and there is no indication that the disorder or its management with stimulant 
drugs will be resolved in the near future. As I have noted, scholars have endeavored to 
demonstrate that ADHD has a longer history than the current controversies would 
suggest. My aim in this study was somewhat more modest: to further our understandings 
of how clinical researchers and child psychiatrists approached the topic of stimulant 
therapy. In one sense, my task has been somewhat easier than other historians’ precisely 
because my interest was less concerned with the disorder and more focused on the 
stimulants used in its management. Nevertheless, I am mindful that this issue still 
engenders its own share of controversies, too. My only hope here is that my study 
clarifies our understandings about the history of these therapies. 
 The issue of Fen-Phen clearly has its historical antecedents. Just as Wyeth 
pursued the market potential of Redux, firms such as SKF, Geigy, and many others 
attempted to capitalize upon and profit from amphetamines for weight loss during the 
                                                





decades after World War II. The story is an old one. So, too, are the untold numbers of 
people who consumed the drugs in the hopes that they would improve their lives, only to 
learn that “magic pills” can reveal their share of unwelcome consequences.  
  Finally, crystal meth and MDMA users of the 21st century are also nothing new. 
The abuse of these drugs can be traced back to the speed freaks of Haight-Ashbury. And 
when one considers the nonmedical of ADHD medications such as Adderall among 
young people as “study drugs,” we can discern even older antecedents regarding the 
extramedical use of stimulants, not to mention their relationship to the medical uses of 
drugs. If this dissertation does not directly engage these contemporary issues, then I hope 
readers will discern the relevance of psychostimulants’ past for their present. 
Psychostimulants and the History of Psychiatry 
 My primary concern throughout this dissertation has been to document the role 
psychostimulants played in the practice of American psychiatry. Building on the 
groundbreaking scholarship of David Healy, Edward Shorter, David Herzberg, Andrea 
Tone, Jonathan Metzl, Erika Dyck, Nicolas Rasmussen, and others, I further demonstrate 
how pharmacotherapies became a defining feature of psychiatry in the postwar era. 
Whether using the major tranquilizers to alleviate the symptoms of schizophrenia 
decisively for the first time or prescribing anxiolytics to calm patients’ “nerves,” 
psychiatrists have been defined in large part by the medications that have mediated the 
ills of their patients and ensured their own legitimacy as healers.  
 Yet my study does more than confirm this broad trend toward drug-mediated 
psychiatry by complicating scholars’ assumptions about its practice. The application of 





dividing line between these two forms of psychiatric practice should not be drawn too 
solidly. Just as clinicians turned to Dexedrine and Ritalin as adjuncts to ECT for their 
most serious cases of depression within mental hospitals, psychiatrists also prescribed the 
medications for milder depressive symptoms for their private practice patients. While 
there may have been very real differences between psychosis and neurosis, the 
prescription of psychostimulants within both realms suggests that some therapeutic 
experiences were common to both realms. In doing so, I advance observations made by 
Jonathan Sadowsky, Mical Raz, and others about the interchanges between institutional 
and outpatient psychiatry during the postwar era. 
 The history of therapeutic stimulant use also complicates positivist interpretations 
of paradigm shifts within the practice of psychiatry. Historians such as Judith Swazey and 
Edward Shorter have emphasized how chlorpromazine wrought a revolution in the 
treatment of the severely mentally ill by suggesting how the major tranquilizers 
represented a major improvement over the somatic therapies documented by Joel 
Braslow, Jack Pressman, and others. Yet as innovative as these pharmacotherapies may 
have been, it was clear to many psychiatrists that they were far from perfect and helped 
only a limited number of patients. My study concludes that combination therapy served to 
rectify the therapeutic shortcomings of these new drugs, and it suggests that the shift 
toward psychiatric pharmacotherapy was less orderly than it has been commonly 
portrayed. At the same time, my analysis of how analytically oriented psychiatrists 
capitalized on amphetamine and methylphenidate’s potential to excite and agitate patients 
during psychotherapy sessions rendered the drugs ideal for pharmacologically induced 





Nicolas Rasmussen, all of whom have studied the intersection between psychodynamic 
and pharmacological approaches in outpatient therapeutics. 
Psychostimulants and Broader Trends in History 
 How is my story relevant for non-specialists whose interests may lie outside the 
history of psychiatry and psychopharmacology? The drugs that have been the focus of 
my study have been consumed by millions of Americans during the past half-century. 
Psychostimulants fulfilled a wide variety of expectations for many different Americans. 
Focusing on the clinical applications of the drugs, I probe how physicians both enabled 
and stymied these modes of consumption. In some cases, particularly where psychiatric 
applications of the drug were concerned, users of the drugs were understood explicitly as 
patients subject to medical authority and expertise. But in others, users were consumers 
as much as patients—paying customers who exhibited a higher degree of agency. 
Contrast, for example, the schoolboy placed on stimulant therapy for hyperkinesis with 
the dieting housewife seeking amphetamine to shed unwanted pounds. Both individuals 
were ostensibly under the care of physicians, but the nature of the doctor-patient 
relationship could not have been more different. 
 In sorting out the myriad uses of psychostimulants by millions of Americans, 
physicians and policymakers sometimes walked in lockstep. Witness how medical 
leaders such as David E. Smith and John Griffith worked in tandem with government 
officials to crack down on amphetamine abuse by “speed freaks.” Conversely, medical 
leaders managed to win over concerned politicians about the use of stimulants for the 
treatment of hyperkinesis. As the 1970 Congressional hearings into the use of “behavior 





stimulant therapy in hyperkinetic children. If there may have been some overzealous 
prescription of the drugs in some of the nation’s school districts, child psychiatry 
nevertheless defended the indication of stimulants for the disorder and ensured their 
continued place within the armamentarium for decades to come. Yet even as I describe 
broad trends toward the increasing acceptance of stimulant therapy for these children, I 
am also mindful of the many divergent views held by clinicians. Consider the differences 
between the clinical researchers such as Leon Eisenberg and Rachel Klein who helped 
establish the efficacy of the therapies during the 1960s, Omaha school psychiatrist such 
as Byron Oberst alleged to have overprescribed the drugs to students in his system, and 
physicians such as Benjamin Feingold who disowned stimulant therapy in favor of 
dietary changes for the treatment of hyperkinesis during the 1970s. Nevertheless, the 
cases of recreational speed junkies and hyperactive children serve to provide contrasting 
examples of the ways in which medical and political authorities demarcated the 
boundaries between illegitimate and legitimate uses for psychostimulants in postwar 
America. 
 Sometimes, however the relationship between physicians and politicians could be 
more tenuous, if not hostile. Consider how lawmakers such as Senator Birch Bayh had to 
balance bariatricians’ claims that dietary applications of amphetamines indeed constituted 
legitimate uses of the drugs against mounting concerns from other medical leaders that 
patients were become unwittingly addicted to them. Moreover, the letters his office 
received from the public both expressing support and opposition to their ready 
availability could not have helped in making the conundrum’s resolution any easier. Then 





controls in Canada, fearing that physicians would lose their ability to pursue the most 
effective courses of treatment for their patients. 
The efforts of profit-hungry pharmaceutical firms to tap the full market potential 
for their drugs further complicates the demarcation between psychostimulants’ legitimate 
and illegitimate uses. Although companies promoted these drugs for indications 
congruous with their use by psychiatrists, such as in the treatment of depressive 
symptoms, adjuncts to psychoanalysis, and hyperkinesis in children, there is no doubt 
that they also attempted to expand their markets even further. Ciba’s marketing of Ritalin 
for “environmental depression” during the late 1960s and early 1970s especially riled 
psychiatrists who believed that the company was attempt to bypass the specialty most 
associated with the treatment of depression, in favor of general practitioners who 
represented a lucrative market to be courted. There is little doubt that the pharmaceutical 
industry was seeking to widen its audience for Ritalin, Dexedrine, Dexamyl, and other 
psychostimulants during these years.  
My study reveals something about the broader political economy and culture of 
drug consumption in postwar America. These drugs were ingested by millions of 
Americans, affecting their minds, bodies, and lives in the process. My elucidation of their 
myriad clinical applications, as well as a set of discrete “amphetamine cultures” to ponder 
the association between medical and extramedical consumption, contributes to historians’ 
understanding of the relationship between physician-prescribers, patient-consumers, 
pharmaceutical firms, and policymakers. With stimulants still central to the management 
of ADHD and implicated in escalating patterns of methamphetamine abuse, among other 





Methylphenidate versus Amphetamine: A History of Ritalin? 
 Although my dissertation ostensibly focused on the clinical uses of the 
psychostimulants, it admittedly privileged the history of Ritalin. While Rasmussen 
concerned himself mainly with the history of the amphetamines, his study largely 
overlooked methylphenidate. While some researchers such as Ilina Singh have called 
attention to various facets of its past, mainly how Ciba marketed the drug for child 
hyperactivity, Ritalin’s history has remained largely obfuscated. As one of my more 
implicit contributions to the historiography on pharmaceuticals, I have endeavored 
throughout this study to illuminate the history of Ritalin. As Singh has perceptively 
observed, the cultural, political, and even scientific contexts of both Ritalin and ADHD 
are characterized by a “contemporary flavor” that have cloaked their historical 
dimensions.35 Just as scholarship by Lakoff, Singh, Mayes and Rafalovich, and Smith 
have restored some historical comprehension to ADHD and its antecedents, it is my 
ardent hope that this study has done the same for the history of Ritalin. As I have 
demonstrated, methylphenidate has enjoyed a complex clinical history characterized by 
multiple trajectories over the past half-century. 
 What of this history? How is it substantially different from amphetamine’s past? 
In many ways, the history of methylphenidate very nearly matches that of the 
amphetamines. Like Benzedrine before it, Ritalin was also used as an antidepressant, and 
like Methedrine and Dexedrine, it was marketed as a tool to aid psychoanalysis. Both 
drugs were efficacious in the management of childhood hyperkinesis. However, the 
unique pharmacological properties that made methylphenidate distinct from 
amphetamine, namely its attenuated effects on the body, limited some of Ritalin’s 
                                                





applications. In particular, methylphenidate’s lack of anorectic properties meant that it 
was not marketed for weight loss as the amphetamines were. Yet, as I observed in my 
study, psychiatrists repeatedly expressed a preference for methylphenidate over the 
amphetamines for certain applications. Ritalin’s properties as a somewhat milder 
stimulant made it preferable for clinicians who believed the drug a preferable 
complement to major tranquilizers for the treatment of schizophrenia. And while the 
weight loss properties of amphetamine made it popular among dieters, these qualities 
were viewed as undesirable among physicians treating hyperkinetic children and 
adolescents and helped to solidify methylphenidate’s place within child psychiatry. For 
its part, Ciba made the most of differences between the two drugs in its marketing of 
methylphenidate. Advertisements that referenced Ritalin as “mild, safer” and “chemically 
new, clinically different” all served to distinguish the medication from the amphetamines 
that had preceded it.36 
 Even beyond the scope of my query, methylphenidate may prove to be the more 
enduring psychostimulant, at least therapeutically, when its current dominance in the 
treatment of ADHD is taken into consideration. While amphetamine drugs are still used 
to manage the disorder, particularly Adderall, an amphetamine-dextroamphetamine 
combination produced by Shire Pharmaceuticals, it is Ritalin that remains most closely 
associated with the disorder. Methylphenidate abuse remains a documented problem, 
particularly where cognitive enhancement among high school and college students is 
concerned. But such problems are overshadowed by amphetamines’ lingering association 
as drugs of abuse, especially methamphetamine and MDMA. 
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 For all the contrasts between methylphenidate and amphetamine, however, it is 
impossible to comprehend the history of the former without considering its relation to the 
latter. Although it may emphasize the history of Ritalin as an exemplar for understanding 
the clinical applications of psychostimulants within American medicine, my dissertation 
has broadly considered the history of a class of drugs rather than any one of its 
constituents. In taking this holistic approach, I have been able to limn how medications 
within similar properties could be set against one another in the minds of the physicians 
who used them. If anything, my study reveals that not all drugs within a given 
pharmaceutical class were created equal. Discerning clinicians privileged certain 
psychostimulants over others when seeking the most efficacious treatment for depression, 
hyperkinesis, obesity, or when needing an adjunct to complement treatments for 
psychosis or to facilitate psychoanalysis. Likewise, pharmaceutical firms such as Ciba 
made the most of these clinical preferences and touted drugs such as Ritalin as more 
efficacious than rival products. 
 In one sense, my study illuminates the history of Ritalin, whose past has been 
obscured by its contemporary associations with ADHD. Yet, this dissertation has a more 
expansive interest. By considering the history of the psychostimulants as a whole, I have 
been able to further scholars’ understandings of both amphetamine and methylphenidate, 
and related issues such as therapeutic choice by clinicians. 
Future Directions 
 The topic of stimulant drugs has elicited no shortage of study and debate ever 
since Benzedrine made its debut in 1933. Just as important for the viability of such an 





a historiographical gap to be filled and, by extension, an opportunity to be fulfilled. Yet 
there have been tens of thousands, if not hundreds of thousands, of pages written on the 
subject within the clinical literature. Government documents on the issue have been 
equally as voluminous. Other archival sources waiting to be exploited for my study. In 
short, much more remains to be written about the topic at hand. Several of my chapters 
could have comprised dissertation topics all their own. This is perhaps most true of 
Chapter 4, “Brother’s Little Helper,” where much remains to be discovered regarding 
how stimulant therapy was established as efficacious for hyperkinesis. 
 Nevertheless, my study’s main concern was to illuminate how clinicians utilized 
psychostimulant drugs within their practices, as well as to understand the place of 
medicine in engaging broader issues of consumption and regulatory control of these 
drugs in postwar America. I believe that each of the chapters contributed to this overall 
theme. At the same time, I also sought to engage a number of other important 
historiographical issues in my dissertation, particularly the nature of historical change 
within the psychiatric profession and the place of pharmaceuticals in effecting that shift 
and the evolving relationship between physician-prescribers, patient-consumers, the 
pharmaceutical industry, and regulatory bodies during the postwar era. It is my ardent 
hope that my study will further illuminate historians’ knowledge about these issues, as 
well. 
 As I conclude my dissertation, I also suggest future directions for my study. First, 
there is still a need to understand just how prevalent the various medical practices I have 
charted were. The meaning of psychopharmacology can be difficult to deduce without a 





clearer understanding of this issue. Second, despite my best efforts to recover lost 
narratives regarding the clinical applications of psychostimulants, there are still others 
waiting to be rediscovered. I hope that future work will help me to discern these uses and 
to establish a more robust, patient-centered history of psychostimulants. Third, my work 
sometimes privileged medical elites in order to reveal the history of psychostimulants, 
but what of the “average” physician? Did he or she approach these drugs in the same 
way? By addressing these questions, I hope to develop a more detailed map of the clinical 
history of these drugs. At the same time, there is a need to hear more from patients and 
consumers of stimulants. I also hope to consider this issue more. Finally, there is still 
much to be learned about the interplay between the pharmaceutical industry and medical 
profession, as well as political leaders and clinicians, where psychostimulants are 
concerned. I hope to learn more about this issue, as well. 
 For now, however, I close my dissertation with the observation that 
psychostimulant drugs have altered the bodies, minds, and lives of many Americans, and 
that the various agents involved in their manufacture and marketing, prescription and 
consumption, and control and availability have all played important roles in this process. 
I hope this dissertation furthers scholars’ knowledge about this subject. 
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